Volltext - Krause und Pachernegg

Jahrestagung der Österreichischen
Kardiologischen Gesellschaft - 30.
Mai bis 2. Juni 2012, Salzburg Abstracts
Journal für Kardiologie - Austrian
Journal of Cardiology 2012; 19
(5-6), 123-194
Online-Datenbank mit
Autoren- und Stichwortsuche
Offizielles Organ des
Österreichischen Herzfonds
Member of the
ESC-Editors’ Club
Member of the
Indexed in EMBASE/Excerpta Medica/Scopus
P . b . b .
0 2 Z 0 3 1 1 0 5 M ,
V e r l a g s p o s t a m t :
3 0 0 2
P u r k e r s d o r f ,
E r s c h e i n u n g s o r t :
3 0 0 3
G a b l i t z
Journal für Kardiologie
22. Jahrgang 2015, Nummer 3–4, ISSN 1024-0098
Die meistgelesenen Artikel
Pathophysiologie und Diagnostik komplexer
angeborener Herzfehler
B. Nagel, R. Maier, S. Gasser, J. Mair
Ventrikuläre Extrasystolie bei Patienten ohne
strukturelle Herzerkrankung
B. Rotman
Member of the
ESC-Editor‘s Club
Member of the
Offizielles Organ des
Österreichischen Herzfonds
P. b . b . 0 2 Z 0 3 110 5 M
Indexed in EMBASE/Excerpta Medica/SCOPUS
Verlagsort: 3003 Gablitz, Mozartgasse 10
Preis: EUR 10,–
Ausgabe März 2015 – hier klicken
Heartbeat – das Siemens Magazin für
Kardiovaskuläre Versorgung
© Siemens AG Österreich 2015 All rights reserved.
Answers for life.
ÖKG-Jahrestagung 2012 – Abstracts
Österreichische Kardiologische Gesellschaft
Jahrestagung 2012
30. Mai bis 2. Juni 2012, Salzburg
Poster in alphabetischer Reihenfolge: Gruppe / Erstautor
Vorträge: Best Abstracts I (BAI) und II (BAII) sind rot hervorgehoben.
 Akutes Koronarsyndrom/Acute Coronary
Decreased Interleukin-33 Serum Levels After Coronary
Stent Implantation are Protective Against In-Stent
S. Demyanets, R. Jarai, K. M. Katsaros, S. Farhan, A. Wonnerth, T. W. Weiss,
G. Maurer, W. S. Speidl, J. Wojta, K. Huber
Division of Cardiology, Department of Internal Medicine II, Medical University
Vienna; 3rd Medical Department, Cardiology and Emergency Medicine,
Wilhelminenhospital, Vienna
Background Restenosis after stent deployment is an overreaction
of the wound healing response after vascular injury and is characterized
by the sequence of inflammation, granulation, and extracellular matrix remodeling. Interleukin-33 (IL-33) is a recently described member of the IL-1 family of cytokines and is a ligand for the ST2 receptor. Circulating IL-33 was increased in patients with inflammatory
disorders such as rheumatoid arthritis, systemic sclerosis, inflammatory bowel disease and liver failure. However, the predictive value of
IL-33 for the development of in-stent restenosis (ISR) is not known.
Methods We included 387 consecutive patients undergoing percutaneous coronary intervention (PCI) of whom 193 had stable angina, 93 non-ST elevation myocardial infarction (NSTEMI), and
101 ST-elevation MI (STEMI), respectively. Blood was taken directly before and 24 hours after stent implantation. Plasma levels of
IL-33 were measured by a specific ELISA. The presence of ISR was
initially evaluated by clinical means. When presence of myocardial
ischemia was suspected, coronary angiography was performed to
confirm the suspected diagnosis of ISR.
Results Bare metal stents (BMS) were used in 283 and drug eluting stents (DES) were used in 104 patients. Clinical ISR was present
in total in 34 patients (8.8%). IL-33 was detectable in 185 patients
and was below detection limit in 202 patients. In patients with
decreased IL-33 (n = 95), unchanged or non-detectable levels
(n = 210) or increased levels of IL-33 after PCI (n = 82), ISR-rate
was 2.1%, 9.5% and 14.6%, respectively (p < 0.05). Accordingly,
patients with ISR showed a significant increase of IL-33 upon PCI
(p < 0.05). This association was independent from clinical presentation and risk factors as well as numbers and type of stents.
Conclusion In patients with both stable and unstable coronary artery disease, a decrease of IL-33 serum levels after stent implantation is associated with a lower rate of in-stent restenosis.
Soluble ST2 Plasma Levels are Increased in Acute
Coronary Syndromes and Predict Long-Term Mortality
S. Demyanets, R. Jarai, K. M. Katsaros, S. Farhan, A. Wonnerth, T. W. Weiss,
G. Maurer, W. S. Speidl, K. Huber, J. Wojta
Department of Internal Medicine II, Medical University of Vienna; 3rd Medical
Department, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna
Background ST2 is an interleukin (IL)-1receptor family member
and is a receptor for IL-33. Elevated soluble ST2 (sST2) has been
associated with an adverse short-term prognosis in non-ST-elevation myocardial infarction (NSTEMI) and ST-elevation MI (STEMI),
as well as long-term prognosis in patients with NSTEMI. In the
present study we investigated a possible association of sST2 plasma
levels and different clinical stages of coronary artery disease (CAD).
In addition, we assessed the predictive value of sST2 levels in patients with stable angina, NSTEMI and STEMI.
Methods We included 373 consecutive patients with angiographically proven CAD of whom 178 had stable angina, 97 had
NSTEMI, and 98 had STEMI, respectively. Patients were followed
for a mean of 42 months for the occurrence of a combined clinical
endpoint (all cause death, MI and rehospitalisation for cardiac
causes). Plasma levels of sST2 were measured by a specific ELISA.
Results sST2 plasma levels were significantly increased in patients with STEMI (median 453, IQR 313–688 pg/mL) as compared
to patients with NSTEMI (269, IQR 157–496 pg/mL; p ≤ 0.001). In
addition, patients with acute coronary syndromes showed significantly higher levels of sST2 as compared to patients with stable
CAD (169, IQR 79–260 pg/mL; p ≤ 0.001). During follow-up, 37
(9.9%) patients died. sST2 plasma levels significantly predicted
mortality in the total cohort (p < 0.05). Cardiac events occurred in
66 (17.6%) patients. sST2 significantly predicted occurrence of the
combined endpoint in patients with STEMI (p = 0.003), but not with
NSTEMI (p = 0.35) or stable CAD (p = 0.50).
Conclusions Plasma levels of sST2 are increased in acute coronary syndromes. In addition, sST2 levels predict mortality in the
total cohort and cardiac events specifically in STEMI patients.
Prasugrel versus Clopidogrel in Daily Clinical Practice in Patients Undergoing Primary PCI in the
Austrian Acute-PCI Registry
J. Dörler, F. X. Roithinger, M. Juhasz, W. Benzer, R. Zweiker, P. Siostrzonek,
J. Auer, H. Schuchlenz, O. Pachinger, F. Weidinger
Department of Cardiology, Innsbruck Medical University; Department of Medicine,
Hospital Mödling; Department of Medicine, Hospital Barmherzige Brüder Eisenstadt; Department of Interventional Cardiology, Academic Hospital Feldkirch;
Department of Cardiology, Medical University Graz; Hospital Barmherzige
Schwestern Linz; Department of Cardiology, St. Josef Hospital Braunau; Department of Cardiology and Intensive Care Medicine, LKH Graz-West; Department of
Internal Medicine II, Rudolfstiftung Hospital Vienna
Background Prasugrel is recommended as first line drug for dual
antiplatelet therapy after primary PCI (PPCI) in ST-elevation myocardial infarction (STEMI). There are few data on its use in daily practice
of PPCI and clinical outcome in comparison with clopidogrel.
Methods 2454 consecutive patients with ST-elevation myocardial infarction undergoing PPCI between January 2010 and December 2011 and receiving either prasugrel or clopidogrel before arrival
in the catheter laboratory were enrolled. Evaluation included baseline characteristics and in-hospital outcome. In addition, logistic regression analyses were performed to determine indicators for
prasugrel treatment.
Results 2017 (82.2%) patients received clopidogrel and 437
(17.8%) received prasugrel. Patients on prasugrel were younger
(56.0 yrs [49.0–64.0] vs 64.0 yrs [53.0–74.0]; p < 0.01), more often
J KARDIOL 2012; 19 (5–6)
For personal use only. Not to be reproduced without permission of Krause & Pachernegg GmbH.
ÖKG-Jahrestagung 2012 – Abstracts
male (71.1% vs 80.8%; p < 0.01) and current smokers (58.4% vs
43.3%; p < 0.01), but had less previous PCI (9.2% vs 12.5%;
p = 0.04). Direct field triage was more common in the prasugrel
group (73.7 vs 26.2%; p < 0.01) resulting in a shorter delay to PPCI
(3.08 h [1.93–5.71] vs 3.57 h [2.23–6.69]; p = 0.01). In-hospital
mortality was lower in the prasugrel group (1.8% vs 4.7%; p = 0.01)
with no difference in TIMI major bleedings between prasugrel
(0.2%) and clopidogrel (0.9%; p = 0.24). Multivariable logistic regression analysis revealed that age (HR 0.97; 95%-CI: 0.96–0.98
per year; p < 0.01), male sex (HR 0.69; 95%-CI: 0.51–0.94; p = 0.02)
and direct field triage (HR 1.59; 95%-CI: 1.21–2.09; p = 0.01) were
independent predictors of prasugrel treatment.
Conclusion In clinical practice prasugrel is predominantly used in
younger male patients transferred directly from the field to PPCI.
These factors may result in lower in-hospital mortality with similar
TIMI major bleeding rates compared to clopidogrel.
B-Type Natriuretic Peptide and Risk of ContrastInduced Acute Kidney Injury in Acute ST-Segment
Elevation Myocardial Infarction: A Substudy from
R. Jarai, K. Huber, R. Mehran, G. Dangas, G. Stone
3rd Medical Department, Cardiology and Emergency Medicine,
Wilhelminenhospital, Vienna, Austria; Cardiovascular Research Foundation,
Lenox Hill Heart and Vascular Institute, New York, USA
Background Contrast-induced acute kidney injury (CI-AKI) after
percutaneous coronary intervention (PCI) is associated with adverse
short- and long-term outcomes. However, identification of patients
at risk for CI-AKI is challenging. Using a large contemporary randomized trial database of patients with ST-segment elevation myocardial infarction (STEMI), we therefore sought to examine whether
admission B-type natriuretic peptide (BNP) levels predict the development of CI-AKI.
Methods A total of 979 STEMI patients enrolled in the HORIZONS-AMI trial had BNP levels measured in the emergency room
prior to primary PCI as part of the study protocol. CI-AKI was defined as a relative increase in serum creatinine of ≥ 25%, or an absolute increase of ≥ 0.5 mg/dL, occurring within 48 hours after contrast administration. Logistic regression analysis was used to estimate the association of admission BNP with development of CIAKI.
Results CI-AKI occurred in 131 patients (13.3%). Baseline BNP
was a significant univariable correlate of CI-AKI (OR 1.40, 95%CI: 1.09–1.80; p = 0.009). After multivariable adjustment for clinical, laboratory and angiographic variables, BNP remained a significant independent predictor of CI-AKI (1.56 [1.16. 2.09]; p = 0.003).
Significant net reclassification improvement (NRI) was achieved
by addition of BNP to the current clinical risk prediction model
Figure 1: R. Jarai et al.
J KARDIOL 2012; 19 (5–6)
(NRI = 0.022; p = 0.03) and to the Mehran Risk Score (NRI = 0.028;
p = 0.002).
Conclusion Measurement of serum BNP at hospital admission
may help identify patients who are at risk for developing CI-AKI
after primary PCI in STEMI (Figure 1).
Prognostic Relevance and Prediction of ContrastInduced Acute Kidney Injury in Acute ST-Elevation
Myocardial Infarction: Analysis from the HORIZONSAMI Trial
R. Jarai, K. Huber, G. Dangas, R. Mehran, G. Stone
3rd Medical Department, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria; Cardiovascular Research Foundation, Lenox Hill Heart
and Vascular Institute, New York, USA
Background and Aims There are limited data available on the
short- and long-term prognostic relevance of contrast-induced acute
kidney-injury (CI-AKI) in patients with ST-elevation myocardial
infarction (STEMI) undergoing primary PCI. Identification of patients at risk of CI-AKI could be of major clinical importance, as
starting specific therapeutic interventions prior to acute coronary
angiography might prevent the development of CI-AKI.
Methods A total of 2975 STEMI patients enrolled in the HORIZONS-AMI trial had available data on serum creatinine concentrations after angiography. CI-AKI was defined as a relative increase
in creatinine of ≥ 25%, or an absolute increase in creatinine of
≥ 0.5 mg/dL within 48 hours after primary PCI. We assessed cardiac
mortality, non-fatal MI, target vessel (TVR) and target lesion revascularization (TLR), stent thrombosis, non-CABG related major
bleeding and net adverse clinical events (NACE = MACE or major
non-CABG bleeding) as a function of CI-AKI. Multivariate analyses were used to identify predictors of CI-AKI, as well predictors of
the primary and secondary endpoints.
Results Patients with CI-AKI (n; %) had significantly worse outcome than patients without CI-AKI reflected by significantly higher
rates of in-hospital cardiac death (5.8% vs 0.7%; p < 0.001), recurrent myocardial infarction (2.4% vs 1.1%; p = 0.0229) and bleeding
rates (16.8% vs 6.9%; p < 0.001). The need for TVR (3.4% vs 1.8%;
p = 0.0213) and TLR (3.4% vs 1.6%; p = 0.009) was substantially
higher among patients with CI-AKI and there was a trend for higher
rates of stent thrombosis, which was significantly different at 30
days (1.0% vs 0.2%; p = 0.0129). In multivariable Cox-regression
analyses, CI-AKI was an independent predictor of all adjudicated
endpoints with the exception of non-fatal myocardial infarction CIAKI. In multivariate logistic regression analysis, age, low hemoglobin concentrations at admission, Killip Classification, heart rate,
body mass index, creatinine clearance and history of kidney dysfunction were independent predictors of CI-AKI.
Figure 2: R. Jarai et al.
ÖKG-Jahrestagung 2012 – Abstracts
Neutrophils and NETs at the Culprit Lesion Site of
ST-Elevation Acute Coronary Syndrome
XI – 1
A. Mangold, Th. Scherz, A. Falkinger, S. Puthenkalam, K. Distelmaier,
K. Preissner, I. M. Lang
Division of Cardiology, Department of Internal Medicine II, Medical University of
Vienna, Austria; Institute for Biochemistry, Justus Liebig University, Giessen,
Figure 3: R. Jarai et al.
Conclusions CI-AKI is a serious complication of primary PCI,
which is associated with highly impaired short- and long-term outcome, including major adverse clinical events, stent-thrombosis and
bleeding complications (Figures 2, 3).
Kardiogener-Schock-Register Klagenfurt
XI – 5
C. Kaulfersch, G. Grimm
2. Medizinische Abteilung, Klinikum Klagenfurt
Einleitung Wir berichten über 261 Patienten, die in der Zeit von
April 2007 bis Jänner 2012 mit der Diagnose kardiogener Schock an
unserer Abteilung betreut wurden.
Material/Methode Retrospektive Analyse aller Patienten an unserer ICU mit der ICD-Diagnose R57.0 (kardiogener Schock). Selektion der Patienten nach der aktuellen deutsch-österreichischen
S3-Leitline „kardiogener Schock“.
Ergebnisse 167 (64 %) der Patienten waren Männer, 94 (36 %)
Frauen. Das durchschnittliche Alter betrug 68,3 Jahre. 81 % der Patienten präsentierten sich im ischämischen Schock (davon STEMI
76 %; NSTEMI 24 %). Die 30-Tage-Mortalität aller Patienten betrug 49 % (46 % bei ischämischem Schock, 58 % bei nicht-ischämischem Schock). Die Mortalität bei NSTEMI war mit 52 % höher als
bei STEMI mit 46 %. Eine IABP wurde bei 31 % der Patienten mit
kardiogenem Schock implantiert. Mit IABP verstarben 39 Patienten
(48 %). 181 (69 %) der Patienten wurden invasiv beatmet (Dauer
median: 4,8 Tage). 22 Patienten (8 %) wurden bei Schockniere dialysiert. Die durchschnittliche Aufenthaltsdauer betrug 8,1 Tage. Es
entstanden Gesamtkosten von ca. 6,372.000 Euro (ca. 24.400 Euro/
Diskussion Die Mortalität des kardiogenen Schocks bleibt trotz
neuer medikamentöser und interventioneller Therapieoptionen
weiterhin hoch. Unsere Daten sind vergleichbar mit jenen internationaler Studien/Register bezüglich des Endpunktes Mortalität
nach kardiogenem Schock mit/ohne IABP. Daten großer randomisierter Studien bezüglich Mortalitätsvorteil bei IABP fehlen
bislang (IABP-Schock-II-Studie vor Abschluss). Der kardiogene
Schock bindet erhebliche Ressourcen (Diagnostik/Therapie/Pflege/Budget). Die rasche Revaskularisierung ab Diagnosestellung
ist der Goldstandard bei ischämischem Schock, sowohl bei STEMI
als auch NSTEMI.
Background Mechanisms of acute plaque rupture and coronary
occlusion in ST-elevation acute coronary syndrome (STE-ACS) are
poorly understood. In contrast to common knowledge implicating
intralesional macrophages in the pathogenesis of acute coronary
vascular syndromes, we hypothesize that circulating innate immune
cells mediate plaque rupture and thrombotic occlusion. In former
studies, we reported the accumulation of neutrophils and related
proteins at the culprit lesion site. Neutrophil extracellular traps
(NETS) represent an efficient effector mechanism of activated neutrophils. We aimed to characterize neutrophils in the different circulatory compartments (systemic, coronary fluidic and solid aspiration
material) of STE-ACS patients.
Methods STE-ACS patients who underwent primary percutaneous coronary intervention at the Vienna General Hospital were consented (n = 70). Culprit site blood was aspirated with a thrombectomy catheter and particulate thrombus material was separated. In
parallel, blood was sampled from the femoral arterial sheath. Flow
cytometry was employed to evaluate neutrophils accumulating at
the plaque rupture site in the fluidic and solid compartment. These
results were complemented by ELISA and immunofluorescence assays.
Results Neutrophils derived from coronary thrombi are highly activated compared to systemic values (CD66b, CD11b) and form aggregates with platelets. Coronary thrombi display excessive
amounts of NETs. Neutrophil-derived degradation products are predominant in coronary thrombi. MPO in coronary plasma is significantly increased. By contrast, neutrophils in fluidic compartment of
culprit site aspirates show reduced expression of CD11b and form
fewer aggregates.
Conclusion We report the presence of activated NET-producing
neutrophils at the culprit lesion site of STE-ACS patients. NETs act
as an active scaffold for the nascent coronary thrombus.
Specific Monocyte Subsets are Increased at the
Culprit Lesion Site of ST-Elevation Acute Coronary
Syndrome Patients
XI – 2
A. Mangold, A. Falkinger, Th. Scherz, K. Distelmaier, I. M. Lang
Division of Cardiology, Department of Internal Medicine II, Medical University of
Background ST-elevation acute coronary syndrome (STE-ACS)
is the leading cause of death. Mechanisms of acute plaque rupture
and coronary occlusion are poorly understood. In contrast to common knowledge implicating intralesional macrophages in the pathogenesis of acute coronary vascular syndromes, we hypothesize that
circulating innate immune cells mediate plaque rupture and thrombotic occlusion. Monocytes are early inflammatory cells implicated
in the pathogenesis of ACS. CD16+ monocytes represent an activated and proinflammatory subtype. In the present study, we examined the distribution and activation status of these subsets in STEACS.
Methods STE-ACS patients who underwent primary percutaneous coronary intervention at the Vienna General Hospital were consented (n = 40). Culprit site blood was aspirated with a thrombectomy catheter and particulate thrombus material was separated.
In parallel, blood was sampled from the femoral arterial sheath.
Flow cytometry was employed to classify monocytes by their
CD14:CD16 ratio (CD14+CD16-, CD14+CD16+, CD14-CD16+)
at the plaque rupture site, both in the fluidic and solid compartments.
Results CD14-CD16+ monocytes were selectively increased in
the fluidic compartment at the culprit lesion site of STE-ACS patients. They express a distinct pattern of adhesion (CD49d, e, f,
J KARDIOL 2012; 19 (5–6)
ÖKG-Jahrestagung 2012 – Abstracts
CD142) and activation markers (TLR2, TLR4, HLA-DR) and aggregate with platelets.
Conclusion CD16-positive monocytes accumulate at the culprit
lesion site in STE-ACS patients. We hypothesize that interaction
with platelets induces CD16 expression initiating pro-inflammatory
downstream effects, including inflammatory cell recruitment.
Vigilanz gegenüber CX-Myokardinfarkten: Erfahrungen aus einem Schwerpunktkrankenhaus
XI – 7
D. Petener, P. Wexberg, M. Avanzini, W.-B. Winkler, F. Weidinger
2. Medizinische Abteilung, Krankenanstalt Rudolfstiftung, Wien
Einleitung Entsprechend den aktuellen ESC-Guidelines ist bei
NSTEMI eine Revaskularisation innerhalb der ersten 72 Stunden
vertretbar. Allerdings beobachten wir bei diesen Patienten ohne sofortige Revaskularisation immer wieder hohe Enzymverläufe trotz
der vermeintlich „harmloseren“ EKG-Diagnose. Wir konnten in
einer früheren Untersuchung zeigen, dass auch bei NSTEMI angiographisch häufig ein Gefäßverschluss diagnostiziert wird und der
Ramus circumflexus (RCX) dabei in einem hohen Prozentsatz das
schuldige Gefäß darstellt, das oft in den EKG-Standardableitungen
und echokardiographisch nicht eindeutig zu beurteilen ist. Ziel der
vorliegenden Studie war es daher aufzuzeigen, ob unsere oben genannten Erkenntnisse über die Zeit zu einer häufigeren Revaskularisation der CX-Myokardinfarkte an unserer Abteilung führten.
Methodik 748 Patienten wurden zwischen 2006 und 2011 an unserer Abteilung im Rahmen eines akuten Myokardinfarktes einer
angiographischen Abklärung unterzogen. Entsprechend der EKGVeränderungen wurden die akuten Koronarsyndrome in STEMI
und NSTEMI unterteilt. Die lokale Datenbank wurde retrospektiv
hinsichtlich der Gefäßverteilung und des Risikoprofils analysiert.
Die Verteilung wurde mittels Chi-Quadrat-Test statistisch ausgewertet.
Ergebnisse Das klinische Risikoprofil war zwischen STEMI und
NSTEMI vergleichbar. In der NSTEMI-Gruppe stieg der Anteil des
RCX als schuldiges Gefäß über die Jahre an (von 13,5 % im Jahr
2006 auf 17,1 % in 2007, auf 25,0 % in 2008) und pendelte sich in
diesem Prozentsatz ein (21,1 % in 2009, 20,8 % in 2010, 23,7 % in
2011). Die Häufigkeit des RCX als schuldiges Gefäß unter den
STEMIs schwankte (11,5 % in 2006, 5,4 % in 2007, 13,1 % in 2008,
17,3 % in 2009, 9,2 % in 2010, 12,0 % in 2011).
Tabelle 1: D. Petener et al.
Culprit CX
13,5 %
17,1 %
25,0 %
21,1 %
20,8 %
23,7 %
Culprit CX
11,5 %
5,4 %
13,1 %
17,3 %
9,2 %
12,0 %
Diskussion An unserer Abteilung ist in der Gruppe der NSTEMIs
der Anteil des RCX als schuldiges Gefäß unter den akut koronarangiographierten Patienten über die Jahre gestiegen. Ursache dafür
ist vermutlich die erhöhte Vigilanz gegenüber True-Posterior-Myokardinfarkten und gegenüber der in früheren Arbeiten gezeigten
Tatsache, dass viele Patienten mit NSTEMI tatsächlich Gefäßverschlüsse haben (Tabelle 1).
Patients Admitted for Acute Coronary Syndrome:
Current Prescription Rates of Antiplatelet Therapy
and Statins
XI – 4
R. Steinacher, J. Altenberger, J. Kraus, M. Pichler, U. Hoppe
Universitätsklinik für Innere Medizin II, Landeskrankenhaus Salzburg
Introduction Patients with acute coronary syndrome (ACS)
present a high prevalence of cardiovascular risk factors that have
been described in international registries. We report on currently
observed prescription rates of antiplatelet agents and treatment with
statins at time of admission within a multicenter registry upon cardiovascular risk factors in ACS patients.
Methods The Austrian ACS Survey for Cross Risk collected data
on atherosclerosis risk factors, comorbidity, acute management and
long term treatment in patients presenting with ACS in 38 medical
centers in Austria. Documented coronary artery disease (CAD) consisted of 1 or more of the following criteria: stable angina with documented CAD, history of unstable angina, history of percutaneous
coronary intervention, history of coronary artery bypass graft surgery or pervious myocardial infarction. Documented peripheral artery disease (PAD) was defined by current intermittent claudication
or a history of intermittent claudication with previous angioplasty,
stenting, peripheral arterial bypass graft or other intervention in-
Table 2: R. Steinacher et al. Patient Medical History and Treatment at Time of Presentation
n = 495
n = 123 (24.8)
n = 29 (5.9)
n = 47 (9.5)
Diabetes plus
Risk factors*
n = 120 (24.2)
No Therapy
157 (31.7)
6 (4.9)
2 (6.9)
3 (6.3)
10 (8.3)
Antiplatelet Therapy
– Acetylsalicylic Acid (%)
– Clopidogrel (%)
– Other Platelet Inhibitor (%)
– Dual Platelet Therapy (%)
177 (35.8)
43 (8.7)
6 (1.2)
38 (7.7)
96 (78.0)
34 (27.6)
2 (1.6)
30 (24.4)
18 (62.1)
5 (17.2)
1 (3.4)
3 (10.3)
32 (66.7)
10 (20.8)
1 (2.1)
9 (18.8)
58 (48.3)
12 (10.0)
3 (2.5)
12 (10.0)
VKA (%)
19 (3.8)
11 (8.9)
4 (13.8)
2 (4.2)
6 (5.0)
No VKA/Antiplatelet Therapy (%)
290 (58.6)
16 (13)
5 (17.2)
12 (25)
53 (44.2)
Statine (%)
145 (29.3)
75 (61.0)
16 (55.2)
23 (47.9)
57 (47.5)
17 (3.4)
11 (8.9)
1 (3.4)
6 (12.5)
8 (6.7)
268 (54.1)
37 (30.1)
8 (27.9)
18 (37.5)
41 (34.2)
325 (65.7)
– 343 (69.3)
– 107 (21.6)
– 45 (9.1)
– 167 (33.7)
– 260 (52.5)
– 68 (13.7)
43 (35.0)
– 70 (56.9)
– 31 (25.2)
– 22 (17.9)
– 41 (33.3)
– 65 (52.8)
– 17 (13.8)
10 (34.5)
– 14 (48.3)
– 10 (34.5)
– 5 (17.2)
– 9 (31.0)
– 16 (55.2)
– 4 (13.8)
24 (50.0)
– 31 (64.3)
– 13 (27.1)
– 4 (8.3)
– 12 (25.0)
– 28 (58.3)
– 8 (16.7)
53 (44.2)
– 71 (59.2)
– 29 (24.2)
– 20 (16.7)
– 12 (10.0)
– 60 (50.0)
– 48 (40)
Other lipid lowering agents (%)
LDL > 100 mg/dl untreated
LDL > 70 mg/dl untreated
– LDL > 100 mg/dl
– LDL 100–70 mg/dl
– LDL < 70 mg/dl
– HDL < 40 mg/dl
– HDL 40–60 mg/dl
– HDL > 60 mg/dl
* Risk factors include hypertension, hypercholesterolemia, current smoking, men aged 65 years or older, or women aged 70 years or older; CAD: coronary artery
disease; CVD: cerebrovascular disease; PAD: peripheral artey disease; VKA: vitamin k antagonist; LDL: low density lipoprotein; HDL: high density lipoprotein
J KARDIOL 2012; 19 (5–6)
ÖKG-Jahrestagung 2012 – Abstracts
cluding amputation. Cerebrovascular disease (CVD) was defined as
Carotid stenosis, a history of stroke or transient ischemic attacks.
Cardiovascular risk factors were defined as diabetes, hypertension,
hypercholesterolemia, current smoking, men aged 65 years or older,
or women aged 70 years or older. Logistic regression was used for
multivariable analysis.
Results A total of 495 ACS patients were enrolled for analysis.
Mean age was 65.5 ± 13.2 years, 67.3% of patients were male; mean
body mass index (BMI) was 27.2 ± 4.4 kg/m2. Concerning relevant
comorbidities 68.1% reported hypertension, 52.1% hypercholesterolemia, 24.2% diabetes, 11.5% renal insufficiency and 19.6% heart
failure, respectively. A history of vascular disease was reported for
a single arterial bed in 27.1% of patients, polyvascular disease in
6.3%. Prescription rates of antiplatelet therapy and statins are demonstrated in Table 2. A history of CAD, CVD, PAD or diabetes with
additional risk factors was present in 218 individuals among whom
72 (33.0%) did not receive antiplatelet or VKA therapy. Multivariable predictors for receiving either antiplatelet or VKA therapy in
the presence of overt vascular disease or diabetes with additional
risk factors were older age (p = 0.009), a history of CAD (p < 0.001)
and a history of PAD (p = 0.031). Diabetes with additional risk factors did not proof to be independently associated with use of either
antiplatelet therapy or VKA in this setting.
Conclusion A substantial proportion of ACS patients present with
a medical history warranting antiplatelet therapy and statin treatment. Our data suggests that in a significant proportion of patients
presenting with ACS these substances were under-prescribed. To
our opinion the problem exceeds compliance issues that may be reflected by low rates of patients that have refrained from all therapy.
These data has to be discussed in respect to previously published
reports on guideline adherence.
Figure 4: M. Tajsic et al.
Diagnostic Relevance of Copeptin in Addition to
High-Sensitivity Troponin I in Patients with Acute
Chest Pain – Preliminary Results of the WILCOPRegistry
M. Tajsic, R. Jarai, J. Wojta, K. Huber
3rd Medical Department, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna; Department of Cardiology, Medical University of Vienna
Introduction Recent data suggest that combined measurement of
copeptin and cardiac troponin T levels provides a reliable tool for
early identification of patients with acute myocardial infarction.
However, whether this holds true for the new high-sensitivity troponin assays is not known at present.
Material and Methods This is an ongoing prospective singlecentre study of consecutive patients admitted to the emergency department (ED) of the Wilhelminenhospital with chest pain suggestive of acute coronary syndrome (ACS). The registry started in
March 2011 and the present analysis reports the data of the first 577
consecutive patients. All patients had copeptin and hs-cTnI determinations at admission to the hospital. Copeptin concentrations were
measured using a novel, commercially available, chemiluminescence assay (Copeptin Kryptor® developed by BRAHMS AG,
Hennigsdorf, Germany).
Results Overall, 82/577 (14.2%) patients had the final diagnosis
of ACS. Copeptin and hs-cTnI concentrations at admission were
significantly higher among patients with proven ACS (p < 0.001;
respectively). Accordingly, in all patients with ACS both biomarkers had good diagnostic accuracy, although c-statistics of
hs-cTnI (AUC 0.918; 95%-CI) were significantly higher than that of
copeptin (AUC 0.678; 95%-CI). At admission, 8/82 (12.5%) patients with ACS had hs-cTnI levels under the detection limit of the
assay (0.017 ng/ml) and 15/82 (18.3%) patients had hs-cTnI within
the reference range (≤ 0.056 ng/ml). This was the group of so-called
Figure 5: M. Tajsic et al.
‘early presenters to ED’. In this ‘early presenters’ group with normal
hs-cTnI concentrations, copeptin levels had good diagnostic accuracy for ACS (AUC 0.753; 95%-CI; p = 0.001) and in fact, more
beneficial than c-statistics of hs-cTnI in the same patient group
(AUC 0.704; 95%-CI; p = 0.007). However, among patients with
already elevated levels of hs-cTnI at admission (‘late presenters’
group) copeptin had no diagnostic relevance (AUC 0.457; 95%-CI;
p = 0.06). Overall, the combination of both markers resulted in
an increase of diagnostic accuracy with an AUC of 0.932 (95%-CI;
p = 0.216), compared to the c-statistics of hs-cTnI alone (AUC
0.918; 95%-CI).
Discussion Levels of hs-cTnI at admission to ED have excellent
accuracy for early diagnosis of ACS. However, among the patients
with initially normal hs-cTnI levels, presenting in ED in early hours
after the onset of symptoms, there might be a significant diagnostic
relevance of additional determination of copeptin levels, which
could result in a rapid and reliable rule-out of ACS (Figures 4, 5).
J KARDIOL 2012; 19 (5–6)
ÖKG-Jahrestagung 2012 – Abstracts
Akut-Koronarangiographien bei Migranten und
Nicht-Migranten: Erste Ergebnisse einer prospektiven Vergleichsstudie
H. Ucar-Altenberger, D. Gündüz, E. Mulaomerovic, C. Stöllberger, W.-B. Winkler,
M. Avanzini, Ch. Wegner, E. Sekulin, F. Weidinger
2. Medizinische Abteilung, Krankenanstalt Rudolfstiftung, Wien
Einleitung Bei Akut-Koronarangiographien ist eine Häufung junger Patienten mit Migrationshintergrund aufgefallen. Eine retrospektive Analyse hat gezeigt, dass keine Unterschiede in der Häufigkeit klassischer Risikofaktoren zwischen Migranten und NichtMigranten vorliegen. Dieses Phänomen weist auf ein höheres Risiko
von Migranten hin, das seit November 2011 mittels einer prospektiven Studie untersucht wird. Wir berichten über die ersten Ergebnisse dieser Untersuchung.
Methode Eingeschlossen wurden konsekutive Patienten, die seit
September 2011 an unserer Abteilung wegen eines akuten Koronarsyndroms akut koronarangiographiert wurden. Während des Krankenhausaufenthaltes wurden Alter, Geschlecht, Koronarangiographie-Befund, klassische Risikofaktoren und ethnische Herkunft erhoben. Als „Migranten“ wurden Patienten definiert, deren Geburtsort außerhalb Österreichs lag.
Ergebnis Bisher haben wir 54 Patienten (26 % weiblich) mit einem
mittleren Alter von 59 Jahren eingeschlossen. Die Koronarangiographie zeigte eine Eingefäßerkrankung bei 27 %, eine Zweigefäßerkrankung bei 24 %, eine Drei- oder Mehrgefäßerkrankung bei
41 % und keine Koronarstenosen bei 7 %. Hypertonie fand sich bei
83 %, Hypercholesterinämie bei 85 %, Nikotinkonsum bei 37 % und
Diabetes mellitus bei 24 %. 23 Patienten (43 %) waren Migranten:
14 kamen aus dem ehemaligen Jugoslawien, 4 aus Nordosteuropa,
2 aus Zentraleuropa und je einer aus der Türkei, aus Bangladesh und
aus Uruguay. Migranten waren jünger als Nicht-Migranten (55 vs.
61 Jahre; p < 0,05), waren häufiger Raucher (52 vs. 26 %; p < 0,05)
und hatten tendenziell häufiger Hypertonie (91 vs. 77 %). Keine Unterschiede zwischen Migranten und Nicht-Migranten gab es bei Hypercholesterinämie (86 vs. 83 %), Diabetes mellitus (26 vs. 23 %)
und in der Geschlechtsverteilung (Frauenanteil: Migranten 22 % vs.
Österreicher 29 %). Sowohl eine koronare Eingefäßerkrankung als
auch eine Zweigefäßerkrankung fand sich bei Österreichern etwas
häufiger als bei Migranten (35 vs. 17 % bzw. 25 vs. 21 %) und eine
Drei- oder Mehrgefäßerkrankung hatten mehr Migranten als Österreicher (52 vs. 32 %).
Schlussfolgerung Migranten, die akut koronarangiographiert
werden, sind jünger als Nicht-Migranten, leiden häufiger unter koronarer Drei- oder Mehrgefäßerkrankung, unterscheiden sich aber
wenig in Hinblick auf klassische Risikofaktoren, außer Nikotinkonsum. Dieses Phänomen weist auf ein höheres, möglicherweise genetisches Risiko von Migranten hin.
Infarction (STEMI-) Netzwerkes Wien ist das Katheterlabor der
Universitätsklinik für Kardiologie primärer Anlaufpunkt an Wochenenden und Feiertagen. Zusätzlich kann während der Kernarbeitszeit die NFA auf Anfrage angefahren werden. Für selbstkommende
Patienten besteht ein Interventionsdienst in Rufbereitschaft.
Methoden Zur retrospektiven und deskriptiven Darstellung kommen im Folgenden prospektiv gesammelte Daten aller MCI-Patienten, die im Jahr 2011 an der NFA vorstellig wurden. Die Registrierung patientenbezogener und medizinischer Daten erfolgt logisch
und physikalisch streng getrennt. Entsprechend den Cardiology
Audit and Registration Data Standards (CARDS) der European
Society of Cardiology (ESC) werden demographische Daten, Risikofaktoren, kardiovaskuläre Anamnese und Heimtherapie, klinische
Präsentation und EKG, präklinische Therapie, Laborparameter, klinische Therapie und eventuelle Komplikationen sowie die Ergebnisse der Herzkatheteruntersuchung falls durchgeführt, gesammelt.
Ergebnisse (Tabelle 3, Abbildungen 6–12) Im Jahr 2011 wurden insgesamt 615 Patienten mit MCI an der NFA versorgt. Das
Alter der Patienten lag bei einem Mean von 63 ± 14 Jahren. Nur
32 % waren weiblich (siehe demographische Information). In 75 %
war die NFA die primäre Anlaufstelle für die Patienten. Die 326 (53
%) STEMIs wurden in 88 % durch den Rettungsdienst hospitalisiert. 4 % der STEMIs wurden präklinisch und 1 % innerklinisch
lysiert. In 83 % wurde eine primäre perkutane Koronarintervention
(PCI) durchgeführt. In 11 % der STEMIs wurde keine primäre
Reperfusion angestrebt. 49 % zeigten eine Vorderwandischämie, in
46 % war die Hinterwand betroffen.
Die 274 (45 %) Non-ST-Myocardial Infarctions (NSTEMI) wurden
zu 69 % durch den Rettungsdienst hospitalisiert. 45 % wurden über
die NFA einem Herzkatheter zugeführt. In 2 % der MCIs konnte
retrospektiv keine Zuteilung mehr in STEMI/ NSTEMI vorgenommen werden.
Zu innerklinischen Reanimationsmaßnahmen an der NFA kam es in
6 % der Fälle. Hierfür waren in 80 % Kammerflimmern oder eine
Patienten mit akutem Myokardinfarkt an der
Universitätsklinik für Notfallmedizin – Jahresrückblick 2011
XI – 3
R. van Tulder, D. Roth, B. Heidinger, Ch. Havel, H. Herkner, W. Schreiber
Universitätsklinik für Notfallmedizin, Medizinische Universität Wien
Einleitung Die Universitätsklinik für Notfallmedizin (NFA) am
Allgemeinen Krankenhaus Wien (AKH) versorgt gemeinsam mit
der Universitätsklinik für Kardiologie die Patienten mit akutem
Myokardinfarkt (MCI). Im Rahmen des ST-Elevation-Myocardial-
Tabelle 3: R. van Tulder et al. Demographische Daten und Risikofaktoren
63 ± 14
Diabetes mellitus
20,6 %
32,4 %
27,5 ± 4,8
25,4 %
Anamnestisch MCI
18,7 %
29,6 %
Anamnestisch PCI
18,7 %
50,0 %
Anamnestisch CABG
5,2 %
J KARDIOL 2012; 19 (5–6)
Abbildung 6: R. van Tulder et al.
Abbildung 7: R. van Tulder et al.
ÖKG-Jahrestagung 2012 – Abstracts
Abbildung 8: R. van Tulder et al.
Abbildung 11: R. van Tulder et al.
Abbildung 9: R. van Tulder et al.
Abbildung 12: R. van Tulder et al.
Lipid Parameters in Acute Coronary Syndromes
versus Stable Coronary Artery Disease in Subjects
With and Without Metabolic Syndrome
XI – 6
A. Vonbank, Ch. H. Saely, Ph. Rein, H. Drexel
Innere Medizin, Landeskrankenhaus Feldkirch
Abbildung 10: R. van Tulder et al.
ventrikuläre Tachykardie ursächlich. Die Gesamtmortalität an der
NFA betrug für das Jahr 2011 2 %.
Zusammenfassung Im Jahr 2011 wurden 615 MCIs an der NFA
versorgt. Das entspricht einem Zuwachs von 0,5 % im Vergleich
zum Vorjahr. 53 % waren STEMIs. Insgesamt wurden 89 % einer
primären Reperfusion zugeführt. Die Gesamtmortalität für den Aufenthalt an der NFA betrug für das Jahr 2011 2%.
Background Differences in lipid parameters between patients
with acute coronary syndromes and patients with stable coronary
artery disease (CAD) are unclear and are addressed in the present
Methods We enrolled 582 patients with angiographically proven
stable CAD (of whom 37.2% had the diagnosis of the MetS according to NCEP-ATPIII criteria and 182 patients with acute coronary
syndromes (of whom 33.9% had MetS according to NCEP ATPIII
Results When compared to patients with stable CAD, HDL cholesterol and apolipoprotein A1 were significantly lower in patients
with acute coronary syndromes among subjects with the MetS (38 ±
9 mg/dl vs 48 ± 13 mg/dl; p < 0.001 and 139 ± 30 mg/dl vs 14 ±
25 mg/dl; p < 0.001, respectively) as well as among subjects without
the MetS (52.4 ± 17 mg/dl vs 60.3 ± 15 mg/dl; p = 0.001 and 147.3 ±
31 mg/dl vs 157.2 ± 26 mg/dl; p = 0.003, respectively). Analysis of
covariance (ANCOVA) adjusting for age, gender, smoking, BMI,
and hypertension confirmed an independent impact of the acute
coronary syndrome state on these lipid parameters both among patients with the MetS and among subjects without MetS.
J KARDIOL 2012; 19 (5–6)
ÖKG-Jahrestagung 2012 – Abstracts
Total cholesterol, LDL cholesterol and apolipoprotein B neither in
subjects with the MetS (182 ± 41 mg/dl vs 197 ± 48 mg/dl; p = 0.583
vs 120 ± 43 mg/dl vs 130 ± 42 mg/dl; p = 0.884 and 84 ± 23 mg/dl
vs 83 ± 24 mg/dl; p = 0.834 respectively) nor among subjects without MetS (191 ± 50 mg/dl vs 193 ± 47 mg/dl; p = 0.583 vs 124 ±
42 mg/dl vs 124 ± 45 mg/dl; p = 0.884 and 84 ± 23 mg/dl vs 83 ±
24 mg/dl; p = 0.834 respectively), differed significantly between
acute coronary syndromes and stable CAD patients. Furthermore,
there were no significant differences in triglycerides between patients
with acute coronary syndromes and patients with stable CAD, neither
among subjects with the MetS (187 ± 85 mg/dl vs 184 ± 99 mg/dl;
p = 0.160) nor among subjects without the MetS (114 ± 49 mg/dl vs
111 ± 67 mg/dl; p = 0.891).
Conclusion Both among patients with the MetS and among nonMetS individuals, HDL cholesterol and apolipoprotein A1 are lower
in the acute coronary syndrome state than with stable CAD.
 Basic Science
Impact of Endothelin-A Receptor Blockade on
Neutrophil Activation in Patients with ST-Elevation
Acute Coronary Syndrome
MMP-9 Released Angiogenesis Inhibitors Prevent
Adaptive Capillary Growth in Hypertrophy and
Contribute to Progression to Heart Failure
XII – 5
R. Wurm, Ch. Adlbrecht, I. Lang
Division of Cardiology, Department of Internal Medicine II, Medical University
K. Ablasser, A. Nikolova, P. del Nido, F. Fruhwald, B. Pieske, R. Gasser, I. Friehs
Klinische Abteilung für Kardiologie, Medizinische Universität Graz; Children’s
Hospital, Harvard Medical School, Boston, USA
Background Endothelin (ET) is a pro-fibrotic vasoconstrictor
and a mediator of microvascular dysfunction and cardiac remodeling. Animal studies investigating ET receptor blockade in acute
myocardial infarction have led to conflicting results regarding ventricular remodeling. In-vitro, ET-A receptor blockade decreases
neutrophil activation. As part of a randomized clinical trial where
we assessed the effect of the ET-A receptor blocker BQ-123 on
myocardial perfusion in patients with ST-elevation acute coronary
syndrome (STE-ACS), we assessed the effect of BQ-123 treatment
on neutrophil activation
Methods Patients with posterior-wall STE-ACS were randomly
assigned to receive intravenous BQ-123 at 400 nmol/minute or placebo over 60 minutes, starting immediately prior to primary percutaneous coronary intervention (PCI, n = 54). Peripheral blood samples
were drawn upon arrival in the catheterization laboratory (baseline)
and at 24 hours after PCI. Myeloperoxidase (MPO), a marker of
neutrophil activation, was measured in plasma using a commercially
available ELISA assay (eBioscience, San Diego, CA, USA).
Results MPO levels at 24 hours after PCI of patients randomized
to the placebo group were significantly correlated with the time
Purpose In left ventricular pressure-overload hypertrophy, lack of
adaptive capillary growth contributes to progression to heart failure.
Remodeling of the hypertrophied myocardium requires proteolysis
of extracellular matrix (ECM) carried out by matrix metalloproteinases (MMPs). MMPs, specifically MMP-9, are known to cleave
ECM components which generate angiogenesis inhibitors (angiostatin, endostatin, tumstatin). We hypothesized that MMP-9 released anti-angiogenic factors during compensated hypertrophy,
which resulted in lack of adaptive capillary growth and progression
to heart failure.
Methods Newborn rabbits underwent aortic banding. At compensated hypertrophy (4 weeks) and systolic heart failure (7 weeks)
myocardial tissue from banded and sham operated control animals
was analyzed by immunoblotting for angiostatin, endostatin and
tumstatin. MMP-9 activity was determined by zymography. A MMP9 specific inhibitor (N- ([1,1-biphenyl]-4-ylsulfonyl)-D-phenylalanine) was administered intrapericardially to hypertrophied animals
and tissue was analyzed by immunoblotting and zymography as
stated above. Rabbit were followed by weekly echocardiography to
determine mass/volume ratio and fractional shortening.
Results MMP-9 was activated in hypertrophied myocardium vs
controls (23 ± 1 vs 17 ± 1; p = 0.04), which resulted in significantly
increased levels of angiostatin (86 ± 7 vs 115 ± 10; p = 0.03), endostatin (28 ± 1 vs 33 ± 1; p = 0.02) and tumstatin (17 ± 4 vs 35 ± 6;
p = 0.03). Zymography confirmed inhibition of MMP-9 (hypertrophy: 17 ± 1 vs hypertrophy+MMP-9 inhibitor: 14 ± 0.6; p = 0.01)
and angiostatin, endostatin and tumstatin were down-regulated,
accompanied by up-regulation of capillary density (hypertrophy:
2.99 ± 0.07 vs hypertrophy+MMP-9 inhibitor: 2.7 ± 0.05; p = 0.002).
Mass/volume ratio by echocardiography, as a measure of hypertrophy, showed a significant increase in the banded group vs the sham
group at week 4 (40.84 ± 0.08 vs 1,02 ± 0.04; p < 0.05), but declined
significantly when the hearts dilated and went into systolic heart
failure in week 7 (0.88 ± 0.04 vs 0.77 ± 0.05; p < 0.05). Inhibition of
MMP-9 prevented the dilation of the left ventricle and, as confirmed
by echocardiographic measurements of fractional shortening, prevented systolic heart failure after 7 weeks.
Conclusions Remodeling resulted in activation of MMP-9 which
enhanced the release of angiogenesis inhibitors, angiostatin, endostatin and tumstatin. Up-regulation of angiogenesis inhibitors prevented adaptive capillary growth in pressure-overload hypertrophied myocardium. Therapeutic interventions aimed at inhibition of
angiogenesis inhibitors were useful in maintaining capillary density
and thereby preventing heart failure.
Figure 13: R. Wurm et al. Reduction of myeloperoxidase (MPO)
plasma levels over the first 24 hours after percutaneous coronary
intervention in patients with STE-ACS receiving an endothelin A receptor antagonist (BQ-123) or placebo.
J KARDIOL 2012; 19 (5–6)
from symptom onset to first balloon inflation (r = 0.455; p = 0.023),
the number of affected myocardial segments assessed by magnetic
resonance imaging (r = 0.572; p = 0.005) and the myocardial blush
grade at the end of PCI (r = –0.524; p = 0.006). Patients randomized
to receive BQ-123 demonstrated a greater reduction of MPO levels
compared to placebo-treated patients (177 ng/mL reduction [IQR
103–274] for BQ-123 vs 108 ng/mL [74–147] for placebo, p = 0.006;
Figure 13).
Conclusion Short-term administration of BQ-123 reduces MPO
plasma levels and possibly neutrophil activation in patients with
STE-ACS. In trials with larger patient numbers this observation
may translate into improved blush grade and smaller infarct size.
ÖKG-Jahrestagung 2012 – Abstracts
Influence of MicroRNA-223 Deficiency in Myocardial
Ischemia-Reperfusion Injury
III – 3
K. Bader, K. Streil, M. Reiner, B. Haubner, S. Leierseder, St. Engelhardt,
O. Pachinger, B. Metzler
Klinische Abteilung für Innere Medizin III/Kardiologie, Medizinische Universität
Innsbruck, Österreich; TU München, Deutschland
Introduction MicroRNA-223 (miR-223) is a specific microRNA
which acts as a negative modulator of neutrophil activation and degradation. As upregulation of neutrophil activation is associated with
increased inflammatory response, we aim to investigate the contribution of miR-223 in the regulation of neutrophil infiltration in the
myocardial infarct zone following myocardial ischemia-reperfusion
injury. To our knowledge, no in vivo ischemia/reperfusion model
has been applied to study the detailed role of miR-223.
Material and Methods MiR-223 knockout (KO) and control wild
type (WT) mice were subjected to experimental myocardial ischemia
and reperfusion (m I/R). For histological evaluation of cardiac tissue
damage paraffin embedded heart sections were stained with Haematoxylin and Eosin. Blood of all animals were collected from the renal
vein for measurement of plasma levels of Troponin T, a marker of cardiac cellular damage. Total RNA was extracted from the area at risk
(AAR) and the remote zone, respectively, and RNA quantification of
TNF-alpha and IL-6 was performed by real-time PCR.
Results After 30 min ischemia and 48 h reperfusion, serum Troponin T levels were significantly increased (3306 vs 1024 pg/ml,
p = 0.001, n = 9) in miR-223 KO rodents compared to WT mice.
Histological analysis showed that ischemia-reperfusion resulted in
marked myocardial injury in all groups of animals, but the cardiac
damage was more severe in miR-223-deficient mice after 48 h of reperfusion following 30 min of ischemia. Furthermore, serum Troponin T levels were significantly increased (5476.0 vs 3250.5 pg/ml,
p = 0.017, n = 9) in miR-223 KO rodents compared to WT mice after
3 h of reperfusion following 30 minutes of ischemia. Quantitative
RT-PCR analysis revealed that gene expression of TNF-alpha and
IL-6 was significantly higher (both, p ≤ 0.05) in the AAR compared
to the remote zone.
Discussion So far, our preliminary data indicate that mice lacking
miR-223 exhibit an enlarged infarct size following myocardial I/R
injury and suggest a contribution of miR-223 in the regulation of
neutrophil infiltration in the myocardial infarct zone.
Continued Ventilation During Open Heart Surgery
Attenuates Inflammatory Response
II – 4
L. Beer, Th. Sezerafin, A. Mitterbauer, P. Altmann, Th. Haider, B. Seinlechner,
M. Dworschak, G. Lang, W. Klepetko, H. J. Ankersmit
Universitätsklinik für Chirurgie, Abteilung für Thoraxchirurgie; Universitätsklinik
für Anästhesie, Medizinische Universität Wien, Österreich; University of
Debrecen, Hungary
Background Cardiopulmonary bypass, utilized in on-pump coronary artery bypass graft procedure (CABG) is known to affect cytokine release leading to a generalized endogenous immune suppression and the release of inflammation markers. We investigated
whether continued ventilation on cardiopulmonary bypass induces
attenuation of immune response.
Material and Methods 30 patients undergoing conventional
CABG operation were randomized into a ventilated on CPB (VG)
and non-ventilated (NVG) group. Venous blood was drawn preoperative, postoperative and 24, 48, 72, 96 and 120 hours after initiation of CABG operation. sST2, IL-4, IL-10, IL-13, MIP-1beta, MCP1, Endotoxin, IgM, and IgG were measured by ELISA. An unpaired
t-test or Mann-Whitney-U-test was used for statistical analysis.
Results Serum levels of sST2 increased within 24 hrs after NVGCABG procedure. sST2 levels were significantly lower in VG group
(1366.4 ± 111.9 vs 2296.3 ± 463.6 pg/ml; p = 0.033) at 24 hrs.
Endotoxin levels correlated with sST2 levels (24 hrs post CABG,
r = 0.723, p < 0.0001), whereas no correlation between endotoxin
and IL-10 concentration was found. The mean MIP-1beta levels
(pg/ml) measured 24, 48, 72 hours after CABG were significantly
Figure 14: L. Beer et al.
Figure 15: L. Beer et al.
lower in VG: 10.9 ± 10.0 vs 153.2 ± 153.2; p = 0.005, 16.7 ± 9.5 vs
147.9 ± 42.7 p = 0.019 and 14.2 ± 6.2 vs 97.8 ± 22.5; p = 0.005
compared to VG. NVG patients showed significantly higher MCP-1
concentration after CPB compared to VG (72 hrs, 96 hrs, 120 hrs;
p < 0.05). Moreover, IL-10 levels were significantly lower in the
VG as compared to NVG (10.5 ± 1.0 vs 15.3 ± 1.7 pg/ml; 24 hrs post
CABG; p = 0.038). IL-13, IL-4, IgM and IgG showed now difference between the 2 groups.
Conclusion Continued lung ventilation during CABG results in a
significant reduction of sST2 and IL-10 24 hours after surgery and
attenuates macrophage chemotactic and inflammatory response
(Figures 14, 15).
LQTS Associated Caveolin-3 Mutations Differentially Regulate the Hyperpolarization-Activated
Cyclic Nucleotide Gated Channel 4
II – 7
T. Darabi, D. Rottlaender, L. J. Motloch, M. Wolny, R. Larbig, S. Reda,
U. C. Hoppe
Department of Internal Medicine II, Paracelsus Medical University, Salzburg,
Austria; Center for Molecular Medicine, University of Cologne, Germany
Background The congenital long-QT syndrome (LQTS) is an inherited arrhythmogenic disorder. In some patients with LQTS mutaJ KARDIOL 2012; 19 (5–6)
ÖKG-Jahrestagung 2012 – Abstracts
tions of CAV3-encoded caveolin-3 were identified. In heterologeous expression these mutants increased the late sodium current. Carries of CAV3 mutants present with distinct clinical symptoms and
ECG abnormalities, i. e. the CAV3 mutant T78M can be correlated
to nonexertional syncope and sinus bradycardia, A85T to cardiac
arrest in sleep, F97C to shortness of breath and chest pain, and
S141R to nonexertional syncope. Hyperpolarization-activated cyclic nucleotide gated (HCN) channels underlie the If current and
play a central role in cardiac pacemaker activity. HCN4 is known to
associate with caveolin-3 to form a macromolecular complex.
Objectives To examine the effects of human LQTS-associated
caveolin-3 mutations on HCN4 ion channel function and possibly
indentify a link to clinical symptoms such as bradycardia.
Methods HEK293-cells were co-transfected with HCN4, and
wildtype caveolin-3, a LQTS-associated CAV3 mutant (T78M,
A85T, S141R or F97C) or an empty control plasmid, respectively.
HCN4 currents were recorded by hyperpolarization steps from
–40 mV to –170 mV for 5 seconds using the whole-cell patch-clamp
Results Wildtype caveolin-3 significantly decreased HCN4 current density (–6.3 ± 1.5 pA/pF at –130 mV, n = 11) vs HCN4 alone
(–20.61 ± 1.71 pA/pF, n = 10). Compared to wildtype caveolin-3 the
different human LQTS-associated CAV3 mutants displayed distinct
effects on HCN4 current properties. While the T78M mutation
(–5.8 ± 0.9 pA/pF, n = 8) did not alter the caveolin-3 effect on HCN4
current size, the other CAV3 mutations to a various extend undermined the diminishing action of caveolin-3 on HCN4 current density (A85T –13.7 ± 2.4 pA/pF, n = 10; S141R –35.0 ± 10.4 pA/pF,
n = 9; F97C –15.5 ± 3.5 pA/pF, n = 8). Moreover, the CAV3 mutants
differentially modified activation kinetics of HCN4. While caveolin-3 alone had only a minor effect on HCN4 current activation (tau
at –130 mV 2478 ± 441 ms and 2948 ± 355 ms without and with
caveolin-3, respectively), LQTS-associated CAV3 mutants accelerated HCN4 current activation (tau at –130 mV: T78M 1653 ± 280 ms;
A85T 1450 ± 339 ms; S141R 1119 ± 55 ms; F97C 1176 ± 484 ms).
Conclusions Our results indicate that HCN4 channel function is
modulated by caveolin-3. LQTS-associated mutations of caveolin-3
may differentially influence pacemaker current properties, which
might play a pathophysiological role in clinical manifestations of
the disease.
Gene Expression of 1SLC8A1 (Solute Carrier Family
8, Member 16 – NCX1) is not Regulated During
Experimental Myocardial Ischemia, but Regulation
can be Elicited by Cardioprotective Drugs
III – 2
R. Gasser, S. Pätzold, E. Holzwart, H. Mächler
Department of Internal Medicine, Medical University Graz
Cellular Ca++-homeostasis is largely maintained by the transmembrane Na+/Ca++-exchanger (NCX; 1SLC8A1 [Solute Carrier Family
8, member 16; NCX1]). NCX is a bidirectional transporter that normally extrudes Ca++ from the cell (forward mode), but also brings
Ca++ into the cell (reverse mode) under special circumstances such
as intracellular Na+-accumulation or membrane depolarization.
Changes in NCX function may cause abnormal Ca++-release from
the sarcoplasmic reticulum (SR) and increase the propensity to abnormal cardiac electrical activity and arrhythmias of all kinds.
Here, using microarray gene expression profiling technique, validated by real-time PCR, we find that NCX1 gene expression is significantly down-regulated by nebivolol compared to atenolol in
simulated ischemic/hypoxic (N2-perfused) preparations. In the
microarray preliminary analyses we found that NCX1 gene expression is significantly down-regulated by nebivolol compared to
atenolol both in O2-perfused preparations and simulated ischemia/
hypoxia (N2-perfused) preparations. In the presence of atenolol,
however, down-regulation of NCX1 is only minimal (Table 4).
Using real-time PCR, we have validated whether or not NCX1 gene
expression is significantly down-regulated by nebivolol compared
to atenolol in simulated ischemia/hypoxia (N2-perfused) preparations. It can be seen that, without the influence of beta-blockers,
J KARDIOL 2012; 19 (5–6)
Table 4: R. Gasser et al.
Nebivolol : Control
Atenolol : Control
Nebivolol : Control
Atenolol : Control
there is no significant regulation of NCX1-expression during myocardial ischemia. There is, however, a significant difference between the expression of NCX1 during myocardial ischemia in the
presence of atenolol (18.0 + 0.6) and nebivolol (13.6 + 0.3; +SEM;
p < 0.05): NCX1-expression is decreased during ischemia in the
presence of nebivolol.
Here, confirmed by real-time PCR, the finding that NCX1 gene expression is significantly down-regulated by nebivolol compared to
atenolol in simulated ischemia/hypoxia (N2-perfused) preparations
may argue for a higher protective, anti-ischemic but also anti-arrhythmic potential of nebivolol compared to standard beta-blockers
like atenolol. Especially patients with ischemia-triggered arrhythmias – patients with ischemic cardiomyopathy, not revascularized
ischemia, large myocardial scars may profit from this particular
property of nebivolol over atenolol.
Percutaneous Intramyocardial Delivery of Secretome
of Apoptotic White Blood Cells (APOSEC) Improves
Myocardial Viability and Left Ventricular Function in
Experimental Ischemic Cardiomyopathy
XII – 6
M. Gyöngyösi, M. Zimmermann, N. Pavo, M. Lichtenauer, G. Maurer,
H. J. Ankersmit
Division of Cardiology, Department of Internal Medicine II, Medical University
Background Despite promising preclinical and clinical results of
the cell-based therapy in chronic ischemic heart failure, the achievable benefit still remains suboptimal. We have previously shown the
regenerative capacity of the secretome of the apoptotic white blood
cells (APOSEC, containing a mixture of regenerative paracrine factors, such as cytokines and growth factors) in acute myocardial infarction (AMI).
Purpose In the present experiment we have investigated the effect
of APOSEC on the ventricular function and myocardial ischemia in
experimental ischemic cardiomyopathy.
Methods Porcine APOSEC was produced by collecting peripheral white blood cells (WBCs), followed by apoptosis induction
via Caesium-137 irradiation and incubation for 24 h. Supernatants
were frozen and lyophilized. Closed chest reperfused AMI was induced by 90-min occlusion of the mid LAD in 14 domestic pigs,
followed by baseline cardiac magnet resonance imaging (MRI) with
late enhancement (LE) at day 3. One moth later (day 30), the animals
were randomized and received either porcine APOSEC (resuspended supernatant of totally 11.5× 10^12 irradiated apoptotic
WBCs) (n = 7) or Medium (cell culture medium) (n = 7) using the
3D NOGA percutaneous intramyocardial injection technique in the
periinfarction areas (10–13 treatment points). After 1-month followup (FUP) (day 60), control cardiac MRI+LE and measurements of
myocardial viability via diagnostic electroanatomical mapping were
performed. Gene expression of the infarction border zone and the
necrotic areas were evaluated and post hoc validation of genes identified by microarray was performed by using quantitative real-time
polymerase chain reaction (PCR).
ÖKG-Jahrestagung 2012 – Abstracts
Results APOSEC led to an improvement of left ventricular ejection fraction (45 ± 6% vs 38 ± 9%), cardiac output, cardiac index
(4.1 ± 0.4 vs 3.32 ± 0.3 L/min) and to decrease in infarct size (14 ±
4% vs 20 ± 5%) (p < 0.05). FUP NOGA mapping revealed an increase in myocardial viability in the injected myocardial area (10.1 ±
3.0 mV vs 8.7 ± 7.1 mV; p < 0.05). Gene profiling analysis revealed
robust significant upregulation of stem cell homing (cadherin,
CXCR4 and stromal-derived factor-1) and some angiogenic factors
(such as cathepsin) and myogenic genes expressing myosin and
actin in the injected areas of the APOSEC, as compared with the
Medium group. The angiogenic growth factor gene expression (vascular endothelial, fibroblast or insulin-like growth factor) was similar in both groups (probably due to the open infarct-related artery in
both groups confirmed by FUP angiography). In the infarcted area,
gene expression of troponin, myosin and actin were significantly
elevated in APOSEC group, as compared with the Medium group,
suggesting a regenerative process in the ischemic injured myocardium.
Conclusion “Cell-less cell therapy” proved to be effective in improvement of experimental chronic myocardial ischemia and left
ventricular dysfunction, leading to a significant overexpression of
myogenic and stem cell homing genes, therefore might be a promising tool in treatment of ischemic cardiomyopathy. The observed
effect might be attributed to the much higher concentration of the
locally acting paracrine factors as compared to that of the cell-based
myocardial regenerative therapies.
Complete Cardiac Regeneration in a Mouse Model
of Myocardial Infarction
XII – 4
B. J. Haubner, B. Metzler, J. Penninger
IMBA Penninger Lab Innsbruck, Universitätsklinik für Innere Medizin III/Kardiologie, Medizinische Universität Innsbruck
Background Cardiac remodeling and subsequent heart failure remains a critical issue after myocardial infarction despite improved
treatment and reperfusion strategies. Recently, it has been demonstrated that newborn mice retain the capacity of cardiac regeneration
in an apical resection model. However, the regeneration potential of
newborn hearts following myocardial infarction leading to a complex cardiac injury needs to be addressed.
Methods We established a protocol for left anterior descending
artery (LAD) ligation in one-day-old mice. Using hypothermia anesthesia, the LAD was irreversibly ligated and subsequent tissue remodeling and regeneration were assessed using serial histological
sectioning of the hearts combined with hematoxylin eosin (HE),
Masson trichrome, immunohistochemical staining, and lineage
Results Following 24 hours of LAD ligation we found massive
cardiac injury in the left ventricle. Immunohistochemical analysis
demonstrated cleaved caspase 3 positive cells in the border zone of
the area of infarction, confirming massive cell death. Ischemia-induced cardiomyocyte death translated in a visible area of infarction
at day 4 after LAD ligation. Amazingly, hearts harvested more than
7 days of LAD ligation displayed complete regeneration and we
failed to observe any obvious signs of tissue damage or scarring.
Moreover, tissue regeneration translated into normal and long-term
heart function as assessed by echocardiography. In contrast, LAD
ligations in 7-day-old mice resulted in extensive scarring comparable to adult mice, indicating that the regenerative capacity for
complete cardiac healing after heart attacks can be traced to the first
week after birth.
Conclusion Here, we present for the first time a mammalian
model of complete cardiac regeneration following irreversible LAD
ligation. This model system provides the unique opportunity to uncover molecular and cellular pathways that can induce cardiac regeneration after ischemic injury, findings that one day could be
translated to human heart attack patients.
Mitogen-Activated Protein Kinase Kinase 7 (MKK7)
Couples Myocardial Ischemia/Reperfusion Stress to
Necro(pto)tic Cell Death
B. J. Haubner, M. Reiner, K. Streil, K. Bader, J. Voelkl, I. Kozierdazki,
O. Pachinger, J. Penninger, B. Metzler
IMBA Penninger Lab Innsbruck, Universitätsklinik für Innere Medizin III/Kardiologie, Medizinische Universität Innsbruck
Background Apoptosis has long been considered the sole form of
programmed cell death during development and disease. Lately,
necroptosis has been implemented as a novel mode of necrotic cell
death that is executed in a regulated manner. We have previously
demonstrated the benefit of muscle-restricted loss of MKK7 during
myocardial ischemia and reperfusion (mI/R). However, the form of
cell death that is regulated by MKK7 upon mI/R is largely unknown.
Methods Therefore, we subjected muscle-restricted MKK7 knockout (MKK7fl/fl;Mck Cre, termed MKK7MKO hereafter) compared
to MKK7 control (MKK7fl/fl) mice to experimental mI/R and analyzed the cardiac samples using electron microscopy (EM) and immunohistochemistry. In addition, immunoblotting was utilized in
order to monitor the kinetics of MKK7 activation.
Results After 30 minutes of ischemia and 24 hours of reperfusion,
MKK7fl/fl cardiac EM samples displayed large areas of damaged
cardiomyocytes with a typical necrotic phenotype, including rupture of the plasma membrane and an increasingly translucent cytoplasm. In contrast, MKK7MKO EM specimen showed hardly any
damaged cells within the area at risk. Typical ultrastructural characteristics found in MKK7MKO cardiomyocytes were changes of
single mitochondria, previously described in the borderzone of the
infarcted area. Furthermore, immunohistochemical stainings and
immunoblotting for cleaved caspase 3 revealed the caspase independent cell death in our model.
Finally, c-Jun NH2-terminal protein kinase (JNK) phosphorylation,
as a marker of MKK7 activity, was significantly increased in the
MKK7fl/fl mice after 30 minutes of ischemia and 20 minutes of
reperfusion. This mI/R stress induced JNK activation is completely
lost in the MKK7MKO animals.
Conclusion Here, we demonstrate that in vivo mI/R leads to a
caspase independent type of cell death with ultrastructural characteristics of necrosis. Moreover, this form of tissue injury can be experimentally regulated via the conditional knock-out of MKK7.
Recruitment and Migration of Endothelial Progenitor
Cells Induced by Low Energy Shock Wave Treatment
XII – 7
J. Holfeld, W. Mathes, C. Tepeköylü, K. Albrecht-Schgör, R. Kirchmair, M. Grimm
Universitätsklinik für Herzchirurgie, Medizinische Universität Innsbruck
Background Shock wave therapy (SWT) was shown to enhance
the recruitment of endothelial progenitor cells (EPCs) in chronic hind
limb ischemia in rats. This mechanism is crucial for vasculogenesis
in ischemic myocardium.
Methods The lower compartment of a transwell was filled with
supernatant of hypoxic SWT treated or untreated cardiomyocytes
and endothelial cells. The upper compartment was filled with EPCs.
Migrated cells within the membran were stained and counted by
fluorescence microscopy. ELISA of supernatant was performed for
several kinds of growth factors and chemokines to detect chemotactical signals for cell recruitment.
Results Significantly higher numbers of endothelial cells were
found in the lower compartment of the treatment group. Hypoxic
endothelial cells secreted numerous chemokines and growth factors
as stimuli for cell recruitment and homing.
Discussion SWT stimulates hypoxic endothelial cells to recruit endothelial progenitors for vasculogenesis in ischemic myocardium.
J KARDIOL 2012; 19 (5–6)
ÖKG-Jahrestagung 2012 – Abstracts
Shock Wave Treatment Enhances the Differentiation of
Monocytes into M2 Macrophages Which are Crucial
for Angiogenesis in Ischemic Myocardium
XII – 8
J. Holfeld, C. Tepeköylü, R. Kozaryn, A. Falkner, L. Loacker, M. Grimm
Universitätsklinik für Herzchirurgie, Medizinische Universität Innsbruck
Background Cardiac shock wave treatment (SWT) induces angiogenesis in ischemic heart failure. In a previous experiment our
group found high numbers of macrophages in treated ischemic myocardium as shown by RM-4 immunostaining. M2 macrophages play
a crucial role in angiogenesis.
Methods Peripheral blood mononuclear cells (PBMCs) were
separated from donor blood by Ficoll gradient. Human umbilical
vein endothelial cells (HUVECs) were isolated from umbilical cord
donors. Hypoxia was induced in HUVECs for 16 hours. Thereafter
cells were treated with SWT. The supernatant of treated cells was
added to monocytes. Both groups were incubated with interleukin4
over 7 days. Number of M1 and M2 macrophages was determined
by FACS and PCR. All other blood cells were counted with FACS
or immunostaining.
Results 7 days after shock wave treatment of hypoxic endothelial
cells there are significantly more macrophages in the treatment
group. Surprisingly, we also found higher numbers of immune cells,
e. g. natural killers, in the treatment group.
Discussion SWT stimulates ischemic endothelial cells to release
growth factors that activate monocytes to differentiate into M2 macrophages which attenuate inflammation. It thereby enhances tissue
regenerative processes and angiogenesis. This findings clearly explain the mechanism of increased angiogenesis after cardiac SWT in
Levosimendan Exhibits Anti-Inflammatory Effects
on Human Endothelial Cells by Attenuating the Expression of Pro-Inflammatory Adhesion Molecules
in vitro
III – 6
K. A. Krychtiuk, L. Watzke, Ch. Kaun, S. Demyanets, J. Pisoni, St. P. Kastl,
K. Huber, G. Maurer, J. Wojta, W. S. Speidl
Division of Cardiology, Department of Medicine II, Medical University Vienna;
3rd Med. Department of Internal Medicine, Cardiology and Emergency Medicine,
Wilhelminenhospital, Vienna
Purpose Levosimendan is a positive inotropic drug for the treatment of acute decompensated heart failure (HF). In clinical trials,
levosimendan was shown to be effective in particular in HF due to
acute myocardial infarction (AMI) and it has been demonstrated that
levosimendan reduces infarct size in animal models. Neutrophil recruitment is a crucial step in tissue damage due to ischemia reperfusion injury. The aim of the present study was to examine whether
levosimendan reduces the expression of adhesion molecules on
endothelial cells.
Methods Human umbilical vein endothelial cells (HUVECs)
were treated with 200 U/ml interleukin-1β (IL-1β) and incubated
with or without levosimendan (10 µM). Expression of E-selectin,
vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) was measured by flow cytometry
after 8 h and by real-time PCR after 2 h, 4 h, 8 h and 24 h of incubation. HUVECs treated with IL-1β with or without co-treatment
with levosimendan for 4 h were incubated with polymorphonuclear cells (PMNs) for 5 and 30 minutes to examine cell adhesion in vitro.
Results Treatment of HUVECs with IL-1β for 8 h increased expression of E-selectin, ICAM-1 and VCAM-1 (15-fold, 45-fold and
80-fold, respectively; p < 0.05 for all). Preincubation with levosimendan for 30 minutes down-regulated the expression of E-selectin
by 65% (p < 0.05), ICAM-1 by 60% (p < 0.01) and VCAM-1 by
30% (n. s.), respectively. mRNA levels of E-selectin, ICAM-1 and
VCAM-1 were highly upregulated by IL-1β treatment after 2 h, 4 h,
8 h and 24 h (p < 0.01). Co-treatment with levosimendan lead to a
J KARDIOL 2012; 19 (5–6)
downregulation of adhesion molecules after 2 h (by 75%, p < 0.001
for E-selectin; by 44%, p < 0.01 for ICAM-1; no change for VCAM1; respectively), 4 h (by 40%, p < 0.05 for E-selectin; by 17%, n. s.
for ICAM-1; no change for VCAM-1; respectively) and 8 h (by 55%,
p < 0.01 for E-selectin; by 42%, p < 0.001 for ICAM-1; by 32%, n. s.
for VCAM-1; respectively). In vitro cell adhesion experiments
showed increased adhesion of PMNs to HUVECs after treatment
with IL-1β, pre-treatment with levosimendan lead to a markedly decreased number of PMNs bound to HUVECs (1130 vs 732 after
30 mins, p < 0.01; 302 vs 161 after 5 mins, p < 0.001; all values
represent mean of cells that adhered to HUVECs per 250 µm2 after
washing 3 times for IL-1 vs IL-1 + levosimendan treatment).
Conclusions Levosimendan down-regulates expression of adhesion molecules in endothelial cells and decreases adhesion of PMNs.
This could explain, at least in part, the beneficial effects of levosimendan after myocardial infarction due to a decrease of ischemia
reperfusion injury.
Erhalt der linksventrikulären Funktion durch AntiThymozyten-Globulin (ATG) im Modell des experimentellen Myokardinfarkts an der Ratte durch
Induktion von pro-angiogenetischen und antiapoptotischen Mechanismen
III – 8
M. Lichtenauer, G. Werba, M. Mildner, A. Baumgartner, K. Hoetzenecker, S. Nickl,
L. Beer, B. K. Podesser, H. J. Ankersmit
Christian-Doppler-Labor für Diagnose und Regeneration von Herz- und Thoraxerkrankungen, Abteilung für Thoraxchirurgie, Medizinische Universität Wien
Einleitung Das ventrikuläre Remodelling nach einem Myokardinfarkt (MI) stellt ein bedeutendes medizinisches und volkswirtschaftliches Problem dar. Vorangegangene Studien zeigten, dass die
Verabreichung apoptotischer Leukozyten oder Anti-LymphozytenSerum die kardiale Funktion nach Ischämie bewahren kann. Ziel
dieser Studie war es zu evaluieren, ob Anti-Thymozyten-Globulin
(ATG), als klinisch langbewährtes Medikament welches Apoptose
von T-Zellen auslöst, ein vergleichbares therapeutisches Potenzial
im experimentellen MI-Modell in der Ratte besitzt.
Material und Methode Herzinfarkte wurden mittels Ligatur
des Ramus interventricularis anterior (RIVA) in Sprague-DawleyRatten induziert. Anschließend wurden 10 mg ATG pro Tier intravenös verabreicht. Drei Tage und 6 Wochen nach Induktion des
Infarkts wurde das infarzierte Myokard der Tiere histologisch und
immunhistologisch untersucht. Weiters wurden nach 6 Wochen
kardiale Funktionsparameter erhoben. Die Ausdehnung der Infarktareale wurde mittels Planimetriesoftware berechnet. In In-vitroAssays wurde der Einfluss von ATG auf die Sekretion diverser
Zytokine, Chemokine und Wachstumsfaktoren mittels ELISA
Ergebnisse In vitro zeigt sich, dass ATG in Zell- und Vollblutkulturen eine hoch-signifikante Induktion der Sekretion von pro-angiogenetischen Faktoren auslöste (u. a. IL-8 und MCP-1, Abbildung
16a, b). Weiters fand sich eine höhere Gefäßdichte in der PeriInfarktregion 6 Wochen nach ATG Behandlung (52 vs. 37 Gefäße
pro Mikroskopfeld, p < 0,04). In Micro-Arrays konnte gezeigt werden, dass Kardiomyozyten, die mit ATG-konditioniertem Zellkulturüberstanden koinkubiert wurden, eine deutliche Herabregulierung von p53 zeigten.
Ratten, die mit ATG behandelt wurden, präsentierten eine signifikant
geringere Infarktgröße (25 % vs. 11 %; p < 0,01, Abbildung 16c–e).
Echokardiographisch konnte gezeigt werden, dass ATG-behandelte
Tiere eine bessere linksventrikuläre Ejektionsfraktion aufwiesen als
Tiere aus der Kontrollgruppe (53 % vs. 43 % EF; p < 0,01, n = 13
pro Gruppe, Abbildung 16f).
Diskussion Die vorliegenden Daten zeigen, dass ATG, ein klinisch in der Transplantationsmedizin gut erprobtes Medikament,
Neo-Angiogenese induzieren, den Infarktschaden nach experimenteller Ischämie reduzieren und die kardiale Funktion erhalten
ÖKG-Jahrestagung 2012 – Abstracts
Abbildung 16: M. Lichtenauer et al.
Continued Lung Ventilation During Open Heart Surgery attenuates Systemic Heat-Shock Protein 70
II – 3
A. Mitterbauer, Th. Sezerafin, L. Beer, P. Altmann, Th. Haider, B. Seinlechner,
G. Lang, M. Dworschak, W. Klepetko, H. J. Ankersmit
Abteilung für Thoraxchirurgie, Universitätsklinik für Chirurgie; Universitätsklinik
für Anästhesie, Medizinische Universität Wien, Österreich; University of
Debrecen, Hungary
Background Cardiopulmonary bypass, utilized in on-pump coronary artery bypass graft procedures (CABG) induces generalized
immune suppression and release of heat shock proteins (HSP) and
cc-CK18. We hypothesized that continued ventilation on cardiopulmonary bypass (CPB) induces attenuation of immune response.
Methods 30 patients undergoing conventional CABG operation
were randomized into a ventilated on CPB (VG) and non-ventilated
(NVG) group. Venous blood was drawn before as well as 0, 24, 48,
72, 96 and 120 hours after surgery. HSP27, HSP70, ICAM-1, IL-6,
IL-8 and cc-CK18 were measured by ELISA. An unpaired t-test or
Mann-Whitney-U-test was used for statistical analysis.
Results Serum levels of HSP70 were significantly lower in VG
compared to NVG after the end CABG procedure (1629.2 ± 157.1
vs 5203.5 ± 549.6 pg/ml; p < 0.0001). Furthermore, significant
lower HSP-70 concentrations were measured 24 hours (p < 0.0001),
48 hours (p = 0.007), 72 hours (p = 0.021) and 96 hours (p = 0.007)
after surgery. L-6 levels were significantly reduced in VG as compared to control group (83.1 ± 13.5 vs 110.2 ± 10.3 pg/ml, 24 hrs;
p = 0.033). Serum IL-6 increment after CABG operation does not
correlate with HSP27, 70, ICAM-1 and cc-CK18 levels indicating
that HSP release and the described pro-inflammatory response after
CABG were two independent events. HSP27, ICAM-1, IL-8 and
cc-CK18 concentrations showed now differences between the 2
Conclusion Significantly less HSP70 was detectable in patients
receiving uninterrupted lung ventilation on CPB, possibly indicating a difference in inflammatory responses, cellular stress or damage between the ventilated and non-ventilated group. These date
suggest that inter-operative ventilation has a protective effect on
HSP70 secretion in CABG patients (Figure 17).
Two Voltage-Gated Calcium Channels Regulate Calcium Uptake in Murine Cardiac Mitochondria II – 8
L. J. Motloch, D. Rottlaender, T. Gebing, M. Wolny, R. Larbig, S. Reda,
U. C. Hoppe
Department of Internal Medicine II, Paracelsus Medical University, Salzburg,
Austria; Center for Molecular Medicine, University of Cologne, Germany
Figure 17: A. Mitterbauer et al.
J KARDIOL 2012; 19 (5–6)
Background Mitochondrial Ca2+ handling controls the rate of
mitochondrial energy (ATP) production, modulates the spatial and
temporal profile of intracellular Ca2+ signaling, regulates mitochondrial ROS generation, and may trigger cell death. Mitochondrial Ca2+
uptake is thought to be mediated by the Ca2+ uniporter (MCU) and
other non specific Ca2+ pathways. Recently, a MCU and a non-MCUtype mitochondrial Ca2+ uptake channel were documented in human
myocardium. However, existence and electrophysiological properties
of calcium channels in murine cardiac mitochondria remain unclear.
Methods We isolated cardiac mitoplasts (mitochondria lacking
the outer membrane) of mice and performed mitoplast-attached
single-channel recordings.
Results By patch-clamping the inner membrane of these cardiac
mitochondria we identified 2 different murine voltage-gated Ca2+
channels, i. e. mCa1 and mCa2. Both channels differed in electro-
ÖKG-Jahrestagung 2012 – Abstracts
physiological gating parameters. In the presence of Ca2+ 105 mM in
the pipette solution the unitary single-channel amplitude of mCa1
(–1.16 ± 0.03 pA, at –100 mV) was higher than the amplitude of
mCa2 (–0.90 ± 0.03 pA). mCa1 showed 3–5 subconductance levels,
while mCa2 had only one open state. Moreover, the open probability of mCa1 (0.35 ± 0.05%) was significantly lower compared to
mCa2 (0.97 ± 0.17%). Both channels could be inhibited by high
concentrations of Ruthenium 360 (10 µM), while they were insensitive to blockers of other possibly Ca2+-conducting mitochondrial
Conclusions Single-channel properties suggest that mCa1 underlies the murine MCU. Besides the classical MCU, mitochondrial
Ca2+ uptake in mouse heart is mediated via a second voltage-gated
Ca2+ channel (mCa2) with distinct properties.
JAK3 Tag Single Nucleotide Polymorphism
rs3212780 is Significantly Associated With Diabetes-Related Metabolic Phenotypes
III – 4
A. Muendlein, C. Saely, S. Geller-Rhomberg, A. Leiherer, P. Rein, A. Vonbank,
H. Drexel
Landeskrankenhaus Feldkirch
Background Janus kinase (JAK) 3 is involved in cytokine receptor-mediated intracellular signal transduction. Inhibition of JAK3
protects beta-cells from cytokine toxicity and has been shown to
delay the onset of diabetes in the mouse model. The influence of
JAK3 single nucleotide polymorphisms (SNPs) on diabetes risk or
on diabetes-related metabolic traits is unknown.
Methods We therefore investigated the association of JAK3 tagging SNP rs3212780 (C > T) with metabolic phenotypes and type 2
diabetes (T2DM) in a cohort of coronary patients including 1220
non-diabetic subjects and 375 patients with T2DM, totally comprising 1595 individuals.
Results Among non-diabetic subjects SNP rs3212780 was significantly associated with HbA1c (CC: 5.8 ± 0.4, CT: 5.7 ± 0.4, TT: 5.6 ±
0.4%; p = 0.001), fasting glucose (CC: 5.4 ± 0.7, CT: 5.3 ± 0.7, TT:
5.5 ± 1.1 mmol/L; p = 0.010), and HDL-cholesterol (CC: 55 ± 17,
CT: 55 ± 16, TT: 51 ± 16 mg/dL; p = 0.009), as well as with total
cholesterol (CC: 212 ± 44, CT: 206 ± 46, TT: 196 ± 48 mg/dL;
p = 0.002) and LDL-cholesterol (CC: 134 ± 37, CT: 131 ± 40, TT:
124 ± 42 mg/dL; p = 0.013). In patients with T2DM, the JAK3 variant was significantly associated with fasting glucose (CC: 8.3 ± 2.7,
CT: 8.7 ± 2.8, TT: 7.4 ± 1.9 mmol/L; p = 0.036). The association
between SNP rs3212780 and T2DM did not reach statistical significance (allelic odds ratio = 1.18 [0.98–1.40]; p = 0.076).
Conclusion We conclude that JAK3 tagging SNP rs3212780 is
significantly associated with phenotypes conferring an increased
cardiometabolic risk, at least in non-diabetic coronary patients. The
association between rs3212780 and the risk of T2DM warrants further investigation.
Effect of Paclitaxel-Eluting Balloon on Vasomotor
and Endothelial Function of Porcine Peripheral Arteries, Combined with Safety and Efficacy Preclinical Studies
XII – 1
C. Plass, M. Pavone-Gyöngyösi
Division of Cardiology, Department of Internal Medicine II, Medical University
Introduction Drug-eluting balloon (DEB) prevents neointimal
hyperplasia in coronary arteries. In contrast to the muscular type
coronary vessels, the peripheral (femoral and iliac) arteries are large
elastic arteries, differing from coronaries by size, relative composition of elastic and muscle tissue and by physiologic functional properties. The present study was conducted to prove the safety and efficacy of the use of the paclitaxel (PTX)-coated peripheral percutaneous balloon FREEWAY (Eurocor, Germany) in prevention of
neointimal hyperplasia and to investigate the vasomotor response of
the peripheral arteries to DEB use.
Methods 26 domestic pigs underwent percutaneous FREEWAY
overstretch balloon dilation (1.3: 1 balloon/artery ratio) for 1 min of
both iliac (6–7 mm of size, 40 mm of length) and femoral (5-6 mm of
size, 40 mm of length) arteries using carotid access. Measurements
of tissue PTX concentration (pre-clinical safety study) were performed by harvesting of the dilated arteries at 15 min, 1 h, 3 and 9
days follow-up (FUP). The development of neointimal hyperplasia
was measured by computerized planimetry 1 month after overstretch injury in a randomized pre-clinical efficacy study. The vasomotor response of the iliac and femoral arteries was determined after
5 h, 1 and 7 days. During the FUP, the animals were treated with per
os clopidogrel and aspirin.
Results The achieved tissue PTX concentration showed a significant correlation with the applied balloon inflation pressure 1 h post
delivery in femoral arteries (r = 0.597; p < 0.05). The tissue PTX
concentration was 433 ± 122, 185 ± 20, 4 ± 1 and 1.4 ± 0.5 ug/g in
iliac arteries, and 131 ± 26, 54 ± 8, 30 ± 6 and 5.2 ± 1.7 ug/g in
femoral arteries at 15 min, 1 h, 3 days and 9 days post-dilation, respectively. The injury score was similar in all arteries. The degree of
neointima was small in all arteries after overstretch injury, but the
difference in neointimal area was significant: 0.24 ± 0.03 vs 1.51 ±
0.48 mm2 in femoral arteries dilated with FREEWAY or plain balloon, and 0.62 ± 0.24 vs 1.21 ± 0.04 mm2 in iliac arteries treated with
FREEWAY or plain balloon, respectively. In contrast to coronary
arteries, use of DEB did not lead to addiction to vasoconstriction of
the vessels, and no difference between the FREEWAY and plain
balloon was observed regarding the impaired endothelium-dependent vasodilation capacity.
Conclusions FREEWAY DEB reduces effectively the neointimal
hyperplasia in peripheral (iliaca and femoral) arteries, and does not
lead to worse vasodilatory capacity as compared to plain balloon.
Cardiac Morphology and Function in Migfilin Deficient
Mice Due to Experimental Pressure Overload II – 2
M. Reiner, K. Streil, B. J. Haubner, K. Bader, D. Moik, R. Fässler, O. Pachinger,
B. Metzler
Department of Internal Medicine III/Cardiology, Innsbruck Medical University;
Institute of Molecular Biotechnology Vienna, Austria; Department of Molecular
Medicine, Max-Planck-Institute of Biochemistry, Martinsried, Germany
Background Migfilin, a protein associated with cell adhesions
and the cytoskeleton, translocates Ca++ dependent to the nucleus
and interacts with the cardiac transcription factor Csx/Nkx2-5,
which is involved in cardiac development and hypertrophy by inducing gene expression of atrial natriuretic peptide (ANP) and brain
natriuretic peptide (BNP), among others. The in vivo role of
migfilin in cardiac hypertrophy and function is unknown.
Material and Methods Migfilin wild type (WT) and knock out
(KO) mice were examined at baseline and further after one and three
weeks of pressure overload, induced by transverse aortic constriction (TAC). To assess cardiac morphology and function, transthoracic echocardiography was performed, mean cross-sectional area
of cardiomyocytes was measured in histological sections and
mRNA of the cardiac hypertrophy genes ANP and BNP was quantified by rt-PCR.
Results Echocardiography at baseline showed significantly smaller
hearts but normal cardiac function in migfilin KO mice. After 1 and
3 weeks of TAC, cardiac function was reduced in KO mice (FS, 1
week: 51.99% vs 55.21%, p = 0,01; 3 weeks: 49.79% vs 51.93%,
p = 0,02) and murine hearts appeared to be more dilated after 3
weeks of pressure overload (End Diastolic Diameter, 3.95 mm vs
3.75 mm, p = 0,005). Mean cross-sectional area of cardiomyocytes
after 1 and 3 weeks of TAC was significantly decreased in KO compared to WT mice (both, p < 0.05). Additionally, migfilin deficient
mice showed decreased mRNA levels of ANP and BNP at baseline
and after TAC (both, p < 0.05).
Discussion These data suggest that migfilin plays an essential
role in cardiac hypertrophy since loss of migfilin in mice results in
smaller hearts at baseline and reduced myocardial hypertrophy and
function in association to pressure overload.
J KARDIOL 2012; 19 (5–6)
ÖKG-Jahrestagung 2012 – Abstracts
Cx43 Hemichannels of the Inner Mitochondrial
Membrane Mediate Ischemic Preconditioning in
Murine Cardiomyocytes
II – 5
D. Rottländer, L. Motloch, M. Wolny, R. Sara, R. Larbig, U. Hoppe
Universitätsklinik für Innere Medizin II, Universitätsklinikum Salzburg, Österreich;
Zentrum für Molekulare Medizin Köln, Deutschland
Background Ischemic preconditioning involves activation of
multiple signaling pathways with mitochondrial ion channels as an
end-effector. Recently, we demonstrated that connexin 43 (Cx43)
found in the inner mitochondrial membrane, is essential for
cytoprotective signal transduction onto mitoKATP channels. Since
inhibition of mitoKATP channels via Cx43 by carbenoxolone and
43GAP27 implicated that Cx43 functions as a channel in mitochondria, we sought to directly record Cx43 channels in isolated mitoplasts.
Methods and Results We identified single-channel currents,
which were clearly distinct from mitoKATP channels, with a mean
open probability (Po, total) of 2.6 ± 0.4% (at –80 mV, n = 16) and a
unitary conductance of 102.5 ± 7 pS. Notably, these channels were
activated by RRNYRRNY, but not RRPPYN, with an increase of
Po, total to 26.1 ± 4.7% (p < 0.05 vs control) without affecting channel conductance (106.1 ± 9 pS), and inhibited by 43GAP27 which
suppressed Po, total and single-channel conductance to 49.1 ± 5 pS
(p < 0.05 vs control). Single-channel properties thus supported the
notion that we were recording mitochondrial Cx43 channels.
We therefore reasoned that Cx43 might be a promising target for
cardioprotection circumventing possible secondary effects on other
cellular functions occurring when activating multiple kinases of the
upstream pathway. Thus, we determined whether the Cx43 C-terminal binding peptide RRNYRRNY confers protection in isolated
cardiomyocytes or when administered systemically by intraperitoneal injection into mice. To facilitate rapid biodistribution and in
vivo transduction into cardiomyocytes the peptide was conjugated
to TAT47–57 as an intracellular carrier. Under normoxic conditions
RRNYRRNY had no effect on the viability of isolated cardiomyocytes compared to the control peptide RRPPYN or no peptide. However, under simulated ischemia-reperfusion RRNYRRNY markedly
reduced cell death versus the control peptide or no peptide. This
indicated that RRNYRRNY provided protection at the single cell
level independent of cell-cell coupling, i. e. gap junctions. Consistent
with these in vitro results, intraperitoneal delivery of RRNYRRNY
(20 nmol) 20 min prior to 30 min coronary artery ligation and subsequent 120 min reperfusion significantly reduced infarct size in
wildtype mice; this protection was even more pronounced than that
by ischemic preconditioning with one cycle of 10 min coronary occlusion and 10 min reperfusion. The effect of RRNYRRNY was
specific, since injection of the control peptide (RRPPYN) resulted
in no cardioprotection against ischemia-reperfusion injury.
Discussion For the first time we directly recorded mitochondrial
Cx43 channels which were activated by RRNYRRNY. Moreover,
RRNYRRNY rendered isolated cardiomyocytes in vitro and the
heart in vivo resistant to ischemia/reperfusion injury, indicating that
mitoCx43-mediated reduction of infarct size was not undermined by
RRNYRRNY-related opening of sarcolemmal Cx43 channels. Our
results demonstrate that Cx43 functions as a channel in mitochondria being an attractive target for drug development against
cardiomyocyte injury.
β Transfers Cytoprotective Signaling Through
Connexin 43 onto Mitochondrial ATP-Sensitive
K+ Channels
II – 6
D. Rottländer, L. Motloch, R. Sara, M. Wolny, K. Boengler, R. Schulz, G. Heusch,
U. Hoppe
Universitätsklinik für Innere Medizin II, Universitätsklinikum Salzburg, Österreich;
Zentrum für Molekulare Medizin Köln; Universität Essen; Universität Giessen,
Background Ischemic preconditioning involves activation of signaling pathways, including activation of protein kinase C (PKC) and
J KARDIOL 2012; 19 (5–6)
inhibition of glycogen synthase kinase 3beta (GSK3β). Opening of
mitochondrial ATP-sensitive K+ (mitoKATP) channels has been
proposed to play a critical role in ischemic preconditioning. Recently, we demonstrated that connexin 43 (Cx43) found in the inner
mitochondrial membrane, is essential for cytoprotective signal
transduction onto mitoKATP channels.
Objectives To dissect signal transduction targeted at mitoKATP
channels and to possibly identify a functional link between
mitoKATP channel activation, mitochondrial Cx43 and GSK3β activity.
Methods We used direct single-channel patch-clamp recordings
of cardiac mitoplasts from C57/Bl6J mice and homozygous GSK3βS9A mice with cardiac-specific expression of a constitutively active
form of GSK3β, and performed Western blots and co-immunoprecipitation of isolated mitochondria.
Results MitoKATP channel activity was stimulated by the GSK3β
small molecule inhibitor SB216763 (5 µM), which increased the
open probability compared to control. The Cx43 inhibitor carbenoxolone (10 µM) and the Cx43 mimetic peptide 43GAP27 (250 µM)
significantly reduced mitoKATP channel activation by SB216763,
supporting the notion that GSK3 transfers cytoprotective signaling
via Cx43 onto mitoKATP channels. In GSK3β-S9A mitoplasts
mitoKATP currents could be recorded with similar single-channel
properties as in wildtype mitochondria. Single-channel activation of
mitoKATP by the PKC activator PMA was significantly attenuated
in GSK3β-S9A mitoplasts. Western blot analysis revealed reduced
phosphorylation of mitochondrial Cx43 at the PKC phosphorylation
site Ser368 upon PMA application in mitochondria from GSK3βS9A mice versus wildtype. Furthermore Immunoprecipitation of
Cx43 from isolated mitochondria revealed a signal for GSK3β,
while immunoprecipitation of GSK3β also showed a signal for
Cx43, indicating an association of these proteins.
Conclusions PKC transmits a signal onto mitoKATP channels
through GSK3β. This GSK3β signal transduction on mitoKATP
channels is transferred via Cx43 within a multiprotein signaling
Angiotensin II Induces Ca2+- and IP3-Dependent
Depolarisations in Mouse and Human Ventricular
II – 1
M. Sacherer, S. Ljubojevic, P. Stiegler, M. Sereinigg, B. Pieske, F. Heinzel
Klinische Abteilung für Kardiologie; Klinische Abteilung für Transplantationschirurgie, Medizinische Universität Graz
Background Angiotensin II (ATII) is a potent vasoconstrictor associated with cardiac remodeling, progression of heart failure and
arrhythmia. ATII signals primarily via the Gq-coupled ATII receptor type 1 (AT1) and activates phospholipase C (PLC) signaling
pathway including IP3-mediated Ca2+ release and diacylglycerol
(DAG) activation of protein kinase C. Recent data suggest that DAG
can directly regulate members of transient receptor potential cation
(TRPC) channels family. TRPC3 was shown to form a functional
complex with NCX, and its activation may lead to alterations in subcellular Na+ and Ca2+ homeostasis. On the other hand acute ATII
induced IP3- mediated Ca2+ release from the SR may also play a
critical role on Ca2+ hoemeostasis in cardiomyocytes (CMs). Although dysbalance in Na+ and Ca2+ concentration can lead to
arrythmogenic events, no direct evidence is provided whether ATII
may induce triggered cellular depolarisations and increase diastolic
Ca2+ leak from the SR. Therefore, we investigated the acute effect
of ATII on Ca2+ homeostasis in CMs isolated from mouse and human ventricular tissue.
Methods Cytosolic [Ca2+] (Fluo4-AM, confocally) was measured in electrically stimulated CMs from mouse (n = 41–72 cells
per group) and human (n = 4 cells per group) hearts not suitable for
transplantation. Amplitude of [Ca2+] transients (CaTs) and caffeine
transients (CaffTs)were calculated as F/F0 and diastolic SR Ca2+
leak as frequency of sparks (SparkF, in s-1*pL-1). Arrhythmic
depolarisations were identified by synchronized SR Ca2+ release
(syncCR, in number*s-1) during diastole. Action potentials (Aps)
ÖKG-Jahrestagung 2012 – Abstracts
were recorded in whole cell patch clamp mode. Cells were kept in
elevated [Ca2+]o (mouse: 3 mM, human: 5 mM) and ATII (100 nM)
was applied for 15 min.
Results In human CMs ATII increases the incidence of arrhythmogenic diastolic Ca2+ release (SparkF: ATII vs CTRL, 292 ± 89
vs 37 ± 21; p < 0.05). In mouse cells, ATII tended to increase APD90
from 53.4 ± 6.4 to 92.4 ± 34.2 ms (p = 0.1). ATII increased CaTs
amplitude from 2.7 ± 0.2 to 4.1 ± 0.3 (p < 0.05), while SparkF increased from 46 ± 21 to 269 ± 29 (p < 0.05). The incidence of
syncCR increased by ATII application (0.81 ± 0.14) as compared to
CTRL (0.10 ± 0.03; p < 0.05). Ouabain in combination with Na+-free
external solution also lead to increased diastolic leak (SparkF: 154 ±
31; p < 0.05), but not syncCR during diastole (syncCR: 0.06 ± 0.02;
n. s. vs CTRL). ATII did not change SR Ca2+ content (CaffTs: ATII
vs CTRL, 6.2 ± 0.3 vs 5.5 ± 0.5; p = n. s.; subset of cells). 2-APB, a
blocker of the IP3-receptor, decreased both SparkF (103.7 ± 29.29)
and syncCR (0.04 ± 0.02; both p < 0.05 vs ATII alone). In cells
matched for SparkF, 2-APB decreased syncCR (ATII vs ATII+2APB; 0.63 ± 0.14 vs 0.06 ± 0.03; p < 0.05).
Conclusion ATII increases Ca2+ mediated arrhythmias in both
mouse and human CM. IP3-receptor mediated signaling promotes
depolarisations induced by ATII independent of SR Ca2+ leak.
Lack of Tenascin-C does not Affect Hemodynamics
in Cardiac Remodeling
III – 5
D. Santer, K. Trescher, F. Nagel, J. Krynicka, Ch. Kaun, M. Krssak, K. Plesch,
M. Wolfsberger, B. Podesser
LBC f. kardiovaskuläre Forschung. Bes. Einrichtung für biomedizinische Forschung
Vienna; Department of Cardiac Surgery, Landesklinikum St. Pölten; Division of
Cardiology, Department of Medicine II; Centre of Excellence High Field MR,
Department of Radiology, Medical University Vienna; Department of Paediatrics
and Adolescent Medicine, Landesklinikum Wr. Neustadt
Background The extracellular matrix (ECM) protein Tenascin-C
(TNC) is expressed within 24 h after myocardial infarction (MI) in
the border zone between vital and infarcted myocardium. TNC
affects cell attachment for reorganization in infarcted tissue. Our
goal was to describe hemodynamic impacts of TNC and associations
to relevant ECM proteins in cardiac remodeling using a MI model in
TNC knockout mice.
Methods In A/J (WT, n = 12) and TNC-Knockout (TNC-KO,
n = 13) mice left lateral thoracotomy was accomplished under isoflurane and the left anterior descending coronary artery was ligated.
Ten weeks after surgery animals underwent cardiac magnetic resonance imaging (MRI). After MRI mice were anesthetized, beating
hearts were rapidly excised and evaluated on the isolated working
heart (WH) device for further hemodynamic measurements. Additionally, real-time PCR of TIMP 1, 2, MMP-9, and OPN expression
in remodeled myocardium of WT (n = 6) and TNC-KO (n = 6) was
Results MRI analyses ten weeks after MI showed no significant
differences between WT and TNC-KO: Heart Rate (WT: 465 ±
13 bpm vs TNC-KO: 499 ± 10 bpm, n. s.), Ejection Fraction (WT:
34 ± 5% vs TNC-KO: 30 ± 4%, n. s.), Enddiastolic Volume (WT:
99 ± 15 µl vs TNC-KO 89 ± 13 µl, n. s.), Endsystolic Volume (WT:
73 ± 14 µl vs TNC-KO: 68 ± 13 µl, n. s.) and Stroke Volume (WT:
27 ± 2 µl vs. TNC-KO: 22 ± 2 µl, n. s.). Cardiac output and aortic
flow were not significantly different in working heart mode. OPN
(p < 0.01), TIMP-1 (p < 0.01), TIMP-2 (p < 0.01) and MMP-9
(p < 0.05) were downregulated in TNC-KO compared to WT.
Conclusion Our observations do not confirm direct hemodynamic
effects neither in MRI nor in WH due to the lack of TNC. Future
investigations have to illustrate compensatory pathways that seem
to at least partially preserve TNC induced mechanisms.
Veränderung der Natriumregulation in Herzmuskelzellen im frühen Stadium der Herzinsuffizienzentwicklung der Maus
XIII – 4
P. Schoenleitner, F. R. Heinzel, G. Jin, G. Unterer, B. Pieske, P. Wakula
Klinische Abteilung für Kardiologie, Ludwig-Boltzmann-Institut für Translationale
Herzinsuffizienzforschung, Medizinische Universität Graz
Einleitung Erhöhte sympathische Aktivierung trägt zur Herzinsuffizienzentwicklung bei. Mäuse mit kardiospezifischer Überexpression des β1-adrenergen Rezeptors (β1-TG) entwickeln nach
mehreren Monaten eine progressive Herzinsuffizienz. Eine frühe
Störung der Kalziumhomöostase ist an der Entwicklung des Phänotyps ursächlich beteiligt. Schon vor dem Auftreten signifikanter kardialer Funktionsstörungen ist das zytosolische [Ca+] in β1-TG-Kardiomyozyten erhöht. Wir konnten zeigen, dass die erhöhte [Ca+]
durch eine Erhöhung des zytosolischen [Na+] in Verbindung mit veränderter Na-Ca-Austauscher-Funktion verursacht wird. Der Grund
für die [Na]-Erhöhung im Frühstadium des kardialen Remodellings
ist unbekannt. In einem späteren Stadium wurde eine erhöhte Expression des Na+-H+-Austauschers (NHE1) beschrieben. Wir untersuchten die Expression und Regulation von Natriumtransportproteinen im Frühstadium der Herzinsuffizienzentwicklung in der
Methoden Proteinkonzentrationen von Natrium-Kalium-ATPase(NKA-) Untereinheit α1 und α2, deren regulatorische Untereinheit
Phospholemman (PLM), NHE1 und TRPC3 wurden in Ganzventrikelhomogenaten (GH) und Zelllysaten (ZL) von 8–12 Wochen alten
β1-TG-Mäusen und deren WT-Wurfgeschwistern mittels WesternBlot bestimmt. Die Phosphorylierung von Phospholemman (Ser68)
wurde via phosphorspezifischen Antikörpern in GH bestimmt und
gegen GAPDH und CSQ normalisiert (arbiträre Einheiten ± SEM).
Zur statistischen Auswertung der Daten wurde der t-Test verwendet.
Ein Wert p < 0,05 wurde als signifikant definiert.
Ergebnisse Die Expression der physiologisch dominierenden
Untereinheit NKA α1 war in jungen β1-TG- vs. WT-Mäusen sowohl in GH als auch in ZL unverändert. NKA α2 war in den GH der
β1-TG-Tiere signifikant verringert (0,87 ± 0,09, n = 5 vs. 1,24 ±
0,08 in WT, n = 4; p < 0,05), in ZL zeigt sich ein ähnlicher Trend
(0,76 ± 0,18, n = 4 in β1-TG vs. 1,21 ± 0,19, n = 5 in WT; p = 0,11).
PLM-Expression war vermindert (0,71 ± 0,08, n = 5 vs. 1,23 ± 0,18,
n = 4; p < 0,05), die Phosphorylierung von PLM signifikant erhöht
(1,3 ± 0,05, n = 5 vs. 0,748 ± 0,06, n = 4; p < 0,001). Die Expression
von NHE1 war in den β1-TG-Tieren, sowohl in den ZL als auch in
den GH, unverändert. Die Proteinexpression des Transit-ReceptorPotential-Canonical-3- (TRPC3-) Kanals, als mögliche Ursache eines sarkolemmalen Na+-Einwärtsstroms, war in den GH signifikant
verringert (0,97 ± 0,04, n = 5 vs. 1,33 ± 0,06, n = 4; p < 0,001), in
den ZL konnte diese Veränderung nicht nachgewiesen werden.
Diskussion NKA-α2-Expression ist bei β1-TG-Tieren mit chronischer beta1-adreneger Stimulation frühzeitig vermindert exprimiert und könnte zur erhöhten [Na] beitragen. Die verminderte Expression und erhöhte Phosphorylierung von PLM lassen jedoch eine
begleitende De-Inhibierung von NKA erwarten, die die verminderte
NKA-α2-Expression kompensieren könnte.
Die unveränderte Expression der physiologischen Veränderungen
der NHE1- und TRPC3-Expression können nicht als Erklärung für
das erhöhte zytostolische Natrium herangezogen werden.
Deregulation of SUMO-1 and Ubc-9 Expression in
Lungs from Pulmonary Hypertensive Rats
XIII – 7
C. Schreiber, A. Panzenböck, M. Strobl, St. Hubmer, J. Jakowitsch,
H. Bergmeister, A. Pichler, I. M. Lang, D. Bonderman
Division of Cardiology, Department of Internal Medicine II, Medical University
Vienna, Austria; Max Planck Institute of Immunobiology and Epigenetics Freiburg,
Background Pulmonary arterial hypertension (PAH) results from
obstruction of the pulmonary vasculature due to uncontrolled proliferation of pulmonary artery endothelial cells. On a molecular basis,
reduced levels of signaling molecules that inhibit cell proliferation
J KARDIOL 2012; 19 (5–6)
ÖKG-Jahrestagung 2012 – Abstracts
have been shown. Most importantly, defective SMAD-4 signaling
has been demonstrated in lungs from PAH patients and monocrotaline (MCT)-treated pulmonary hypertensive rats. SMAD-4
concentration in the nucleus is regulated via Small Ubiquitin-like
Modifier-1 (SUMO-1), a posttranslational modifier of intracellular
proteins. Conjugation of SUMO-1 to SMAD-4 is mediated via the
enzyme Ubc-9. The aim of the present study was to study SUMO-1
and Ubc-9 expression in a rat model of pulmonary hypertension.
Methods 12 male Sprague-Dawley rats were studied before and
28 days after left unilateral pneumonectomy and MCT-exposure.
Hemodynamic parameters were monitored by an implantable telemetry system (DSI Datascience, St. Paul, MN, USA). Healthy (left)
and pulmonary hypertensive (right) lungs were compared with respect to SMAD-4, SUMO-1 and Ubc-9 RNA levels.
Results While there was a clear trend towards SMAD-4 downregulation in diseased lungs (–1.1314 ± 0.509 vs 0.0 ± 0.388;
p = 0.000), SUMO-1 (0.0 ± 0.608 vs 15,600 ± 1509; p = 0.015) and
Ubc-9 (0.0 ± 0.639 vs 1524 ± 1461; p = 0.015) were significantly
up-regulated. We found a strong negative correlation between mean
pulmonary artery pressure (mPAP) and SMAD-4 (R2 = -0.490;
p = 0.033) and a positive correlation between mPAP, SUMO-1
(R2 = 0.482; p = 0.027) and Ubc-9 (R2 = 0.558; p = 0.009).
Conclusion SUMO-1 and Ubc-9 expression are deregulated in
lungs from pulmonary hypertensive rats and may represent novel
therapeutic targets.
Mild Hypothermia Prevents Sympathetic Activation
but Preserves Vascular Tone During Experimental
Endotoxemia in Pigs
XII – 2
M. Schwarzl, S. Seiler, St. Huber, P. Steendijk, H. Mächler, M. Truschnig-Wilders,
B. Pieske, H. Post
Klinische Abteilung für Kardiologie, Klinisches Institut für Medizinische und
Chemische Labordiagnostik, Medizinische Universität Graz, Österreich; Leiden
University Medical Center, Leiden, The Netherlands
Background Clinical data imply that reduced heart rate variability (HRV) predicts mortality during sepsis. Mild hypothermia (MH,
33 °C) accelerates the recovery of autonomic function after experimental cardiac arrest and resuscitation in pigs. Here, we tested the
effect of MH on HRV during experimental sepsis.
Methods Acutely instrumented pigs (65 ± 2 kg) were exposed to
lipopolysaccharide (LPS) infusion at 0.5 µg/kg/h for 1 h, 1 µg/kg/h
for further 3 h, and followed for a total of 8 h. With the beginning of
LPS infusion, pigs were assigned to either normothermia (NT, 38 °C,
n = 7) or MH (33 °C, n = 6, intravascular cooling). HRV was analysed
in 15-minute ECG-samples. *: p < 0.05 vs baseline, †: p < 0.05 vs
Results At 8 h after onset of LPS infusion vs baseline, heart rate
(bpm) increased in NT (128 ± 6* vs 97 ± 4), but decreased in MH
(79 ± 4*,† vs 98 ± 4). Systemic vascular resistance decreased in NT
Figure 18: M. Schwarzl et al.
J KARDIOL 2012; 19 (5–6)
(6.6 ± 0.4* vs 11.6 ± 0.3), but was preserved in MH (11.1 ± 1.0 † vs
12.7 ± 0.6). Time-domain parameters of HRV (SDNN, SDdeltaNN,
triangular index) did not change over time and were not different
between groups. However, spectral analysis of HRV revealed a different composition of underlying frequency bands: the high-frequent fraction (HF, = parasympathicus) increased in MH, but decreased in NT, whereas the ratio between low-frequent fraction and
HF (LF/HF, = sympathicus) increased in NT, but not in MH (Figure
Conclusion The induction of MH prevents sympathetic activation
during experimental sepsis and preserves vascular tone. MH may
have therapeutic potential in the treatment of sepsis.
The Induction of Mild Hypothermia Prevents Acute
Pulmonary Failure During Endotoxemia in Pigs
XII – 3
M. Schwarzl, S. Seiler, St. Huber, P. Steendijk, H. Mächler, M. Truschnig-Wilders,
B. Pieske, H. Post
Klinische Abteilung für Kardiologie, Klinisches Institut für Medizinische und
Chemische Labordiagnostik, Medizinische Universität Graz, Österreich; Leiden
University Medical Center, Leiden, The Netherlands
Background Acute respiratory failure is a major component of
multi-organ dysfunction during sepsis. The induction of mild hypothermia (MH, 33 °C) reduces whole body oxygen demand (WBVO2) and exerts anti-inflammatory effects in experimental settings.
We tested effects of MH during endotoxemia in pigs.
Methods Anesthetized pigs (65 ± 2 kg) were acutely instrumented
(closed chest) with a series of catheters including an intravascular
cooling device, and were ventilated in a volume controlled mode
(tidal volume = 10 ml/kg, FiO2 = 50%). Respiratory rate was adjusted to keep end-tidal pCO2 at 40–45 mmHg. Endotoxemia, a
model of septic shock, was induced by lipopolysaccharid (LPS) infusion at 0.5 µg/kg/h for 1 h and 1 µg/kg/h for further 3 h. With the
beginning of LPS infusion, pigs were assigned to either normothermia (NT, 38 °C, n = 7) or MH (33 °C, n = 6). Data are reported at
8 h after onset of LPS-infusion vs baseline. *: p < 0.05 vs baseline,
†: p < 0.05 vs NT.
Results Heart rate (bpm) increased in NT (128 ± 6* vs 97 ± 4), but
decreased in MH (79 ± 4*,† vs 98 ± 4). Mean aortic pressure
(mmHg) decreased in NT (53 ± 4* vs 86 ± 2) and MH (58 ± 1* vs 85
± 2). WB-VO2 and respiratory minute volume (RMV) increased in
NT but fell markedly in MH. Arterial oxygen saturation (sO2,art)
fell significantly in NT but not in MH. Mixed venous sO2, a strong
predictor of mortality during sepsis, decreased in NT but was preserved at baseline levels in MH.
Conclusion MH prevents acute respiratory failure during
endotoxemia. This may relate to (i) reduced systemic oxygen demand with subsequently less ventilation-associated mechanical pulmonary stress and (ii) an anti-inflammatory effect of MH that preserves the lungs capability to oxygenate blood. MH may be a therapeutic option for acute pulmonary failure during sepsis (Figure 19).
Figure 19: M. Schwarzl et al.
ÖKG-Jahrestagung 2012 – Abstracts
Modified Exhaled Nitric Oxide Measurement in
Monocrotaline-Exposed Rats to Monitor Pulmonary
XIII – 6
M. S. Strobl, C. Schreiber, St. Hubmer, H. Bergmeister, I. M. Lang, D. Bonderman
Division of Cardiology, Department of Internal Medicine II, Medical University
Background and Aims Rats exposed to monocrotaline (MCT)
are broadly used as animal model for pulmonary arterial hypertension (PAH). In analogy to human disease, right heart catheter (RHC)
is the established gold standard for pulmonary pressure monitoring.
Although exhaled nitric oxide (ENO) levels have been shown to
correlate with pulmonary pressures in humans with pulmonary vascular disease, no link between ENO and pulmonary pressures could
be established in rats. The aim of the present study was to test
whether a technical modification of the NO measurement process
could help generate reliable ENO values that correlate with pulmonary pressures as assessed by simultaneous RHC.
Methods 33 male Sprague-Dawley rats were studied 28 days after
MCT-exposure and unilateral pneumonectomy. Hemodynamic parameters were monitored by an implantable telemetry system (DSI
Datascience, St. Paul, MN, USA). ENO was measured by means of
chemiluminescence (CLD 66, Eco Physics, Duernten, Switzerland)
in single, conscious, spontaneously breathing rats. ENO values
measured by a standard accumulation method (ENO standard) and
those obtained after process modification (ENO modified) were correlated with mean pulmonary arterial pressures (mPAP).
Results After process modification, measuring errors were diminished and potential influencing factors eliminated. There was a clear
correlation between ENO modified and mPAP (p = 0.007; r = –0.459),
while no correlation was observed between ENO standard and mPAP
(p = 0.236; r = –0.212).
Conclusion Modified non-invasive ENO measurement may be
used to monitor PAH in monocrotaline-exposed rats.
Abbildung 20: M. Wallner et al.
Milde Hypothermie verbessert die myokardiale
β -adrenerge Ansprechbarkeit und Kraft-FrequenzBeziehung während experimentell-induzierter
Sepsis im Großtiermodell
XIII – 5
M. Wallner, M. Schwarzl, S. Seiler, St. Huber, P. Steendijk, H. Mächler,
M. Truschnig-Wilders, B. Pieske, D. von Lewinski, H. Post
Klinische Abteilung für Kardiologie, Medizinische Universität Graz, Österreich;
Medical University Leiden, The Netherlands
Einleitung Experimentell wirkt die milde Hypothermie (MH)
anti-inflammatorisch. Wir prüften den Effekt der MH auf die
myokardiale Kraftentwicklung in einem Modell der Sepsis bei
Material und Methode Unter Vollnarkose wurden 13 Hausschweine (65 ± 2 kg) mit einer Reihe von verschiedenen Kathetern
(SwanGanz-Katheter, linksventrikulärer Druck-Volumen-Katheter,
intraaortale Ballonpumpe und intravaskulärer Kühlkatheter) bei geschlossenem Thorax akut instrumentiert. Durch Infusion von Lipopolysaccharid (LPS) mit 0,5 µg/kg/h für 1 Stunde und 1 µg/kg/h für
3 weitere Stunden wurde ein Endotoxin-Schock induziert. Mit Beginn der LPS-Infusion wurden die Tiere entweder einer Normothermie-Gruppe (NT, 38 °C, n = 7) oder einer milden Hypothermie
Gruppe (MH, 33 °C, n = 6) zugeteilt. Der Beobachtungszeitraum
erstreckte sich über 8 Stunden. Im Anschluss wurden ventrikuläre
Muskelstreifen isoliert, optimal vorgedehnt, mit einer modifizierten
Tyrodelösung (2,5 mmol Ca2+) umspült und mit 1 Hz stimuliert.
Alle Muskelstreifen wurden bei 38 °C gemessen. Nach Messung der
Kraftfrequenzbeziehung (KFB; 0,5–3 Hz) wurden die Muskelstreifen steigenden Isoproterenol-Konzentrationen ausgesetzt.
Ergebnisse Die hämodynamischen Analysen zeigten in beiden
Gruppen eine ähnliche Beeinträchtigung der linksventrikulären
Kontraktilität (dP/dt, Analyse der Druck-Volumen-Kurven), wobei
in MH eine sympathische Aktivierung anders als in NT ausblieb. In
vitro zeigten Muskelstreifen aus MH einen höhere Kraftentwick-
Abbildung 21: M. Wallner et al.
lung als solche aus NT: KFB: 116 ± 12 % (NT) vs. 153 ± 44 % (MH),
p < 0,05; 10–16 mol/l Isoproterenol: 284 ± 21 % (NT) vs. 404 ± 41 %
(MH); p < 0,05. Die logED50 % für Isoproterenol unterschied sich
zwischen NT und MH nicht. Die Zeit von der maximalen Kraftentwicklung bis zur halbmaximalen Relaxation (RT50 %) war zwischen den Gruppen in beiden Protokollen nicht unterschiedlich.
Diskussion Die Ergebnisse zeigen eine verbesserte Kraftentwicklung von zuvor gekühlten Muskelstreifen. Da weder die logED50 %
für Isoproterenol noch Parameter der Relaxation zwischen den
Gruppen verschieden waren, nehmen wir eine besser erhaltene myofibrilläre Kraftentwicklung (Ca2+ activated force) als Mechanismus
der Protektion an. MH könnte eine therapeutische Option bei septischer Kardiomyopathie darstellen (Abbildungen 20, 21).
Levosimendan Modulates Inflammatory Response
of Human Cardiac Myocytes in vitro
III – 7
L. Watzke, K. Krychtiuk, Ch. Kaun, S. Demyanets, J. Pisoni, St. Kastl, K. Huber,
G. Maurer, J. Wojta, W. Speidl
Division of Cardiology, Department of Internal Medicine II, Medical University
Vienna; 3rd Med. Department of Internal Medicine, Cardiology and Emergency
Medicine, Wilhelminenhospital, Vienna
Purpose Levosimendan is a positive inotrope drug for the treatment of acute decompensated heart failure (HF). HF is associated
with an inflammatory activation of the failing myocardium. The aim
of the present study was to examine whether levosimendan has antiinflammatory effects on human adult cardiac myocytes (HACM).
J KARDIOL 2012; 19 (5–6)
ÖKG-Jahrestagung 2012 – Abstracts
Methods Primary HACM were isolated from ventricular tissue
from explanted human hearts of patients undergoing heart transplantation. HACM were treated with tumor necrosis factor-α (TNF-α)
(2000 U/ml) or interleukin-1 (IL-1b) (200 U/ml) and incubated with
or without levosimendan (10 µM). Specific mRNA levels of IL-6
and IL-8 were determined by real-time PCR. IL-6 and IL-8 protein
was measured by specific ELISA.
Results Treatment with TNF-α and IL-1-beta significantly increased mRNA and protein levels of IL-6 and IL-8 in HACM. Cotreatment with levosimendan significantly downregulated mRNA
expression of IL-6 (p < 0.05) and IL-8 (p < 0.05). In addition,
levosimendan decreased the effects of TNF-α on protein levels of
IL-6 and IL-8 by 35% (p < 0.05) and 48% (p < 0.02). Levosimendan
also reduced IL-1-beta-induced IL-6 and IL-8 by 51% (p < 0.05) and
60% (p < 0.001), respectively.
Conclusions Levosimendan downregulates expression of mRNA
and protein of inflammatory modulators in cardiac myocytes in
vitro. This may explain, at least in part, cardioprotective effects of
Methylene Blue Reduces Myocardial Contractility
XIII – 3
H. Weiler, O. Moeller, M. Wohlhoefer, C. Bening, A. Abugameh, Ch.-F. Vahl
Klinik für Herz-, Thorax- und Gefäßchirurgie, Universitätsmedizin Mainz, Deutschland
Objectives Methylene blue (MB) is a dye derived from phenothiazine with pleiotropic effects. MB is administered for rescue therapy
in septic shock and severe vasoplegic syndrome (VS) occurring occasionally after cardiac surgery. VS is characterized by low systemic pressure, low vascular resistance and a normal to high cardiac
index neccessiting administration of vasopressors and cristalloids.
Currently a controversial discussion on role of MB is ongoing.
While circulatory effects are quite well examined, little is known
about the influence of MB on myocardial contractility. The present
study aims to evaluate the influence of MB on myocardial contractile responsiveness in an animal model excluding any preload-,
afterload or humoral-related influences.
Methods The experiments were performed using isolated ventricular myocytes obtained from male, adult Wistar rats. After enzymatic isolation, cardiac myocytes were placed on the stage of an inverted microscope in a temperature regulated bath of 37 °C. The
observation of cell shortening and shortening velocity – provoked by
field stimulation (0,1 Hz, 20 mA) – was made by using a line camera. Cells were superperfused with carbogenated Krebs Henseleit
solution (KHL). Following an equilibration period (KHL-perfusion
for 2× 10 mins), MB was then added to the superperfusionsolution
in clinically relevant concentrations (10-7M MB)
Results During the equilibration period cells showed constant
measured parameters (cell shortening 97.9% ± 3.2%, shortening
velocity 100% ± 3.6% and relaxation rate of 102.5% ± 10.6% compared to baseline). After MB treatment, we could document an
early-onset decrease of cell shortening to 77.5% ± 7.5% (p < 0.01)
after a treatment time of 20 mins compared to baseline. Shortening
velocity of 83.0% ± 5.5% (p < 0.01) and relaxation velocity of
95.1% ± 14.8% (n. s., p = 0.56) diminished as well.
Conclusion Isolated administration of MB to the cardiac myocyte
has important negative inotropic and lusitropic effects. When administered in septic patients MB has the potential to worsen the underlying septical cardiomyopathy as demonstrated by present data.
Further evaluation is needed to identify the cellular pathways.
The Effect of the Multi Purpose Drug Tolonium
Chloride on Myocardial Contractility
XIII – 2
H. Weiler, O. Moeller, C. Bening, J. Jungbecker, A. Abugameh, Ch.-F. Vahl
Klinik für Herz-, Thorax- und Gefäßchirurgie, Universitätsmedizin Mainz, Deutschland
Objectives Tolonium chloride (TC) is a well-established pharmacological agent commonly used for the detection of insufficient surgical sutures as well as for exposition of body cavities. TC offers a
J KARDIOL 2012; 19 (5–6)
distinct redox potential allowing the administration for therapy of
methemoglobinemia. However, several case reports stressed serious
cardiovascular adverse reactions, following TC application, mainly
severe hypotension and cardiac arrhythmias. The study was designed, to analyze potential causes of the adverse events based on
the experimental model of the isolated cardiomyocyte.
Methods Hearts of male, adult Wistar rats were rapidly excised
and mounted on a Langendorffapparatus. Following enzymatic isolation, the myocytes were placed on the stage of an inverted microscope in a temperature regulated bath. The measurement of cell
shortening and shortening velocity – provoked by field stimulation
(0,1 Hz, 20 mA) – was made using a line camera. Measurements
were performed at baseline and following TC administration. Cells
were superperfused with carbogenated Krebs Henseleit solution
(KHL). Following an equilibration period (KHL-perfusion for
2× 10 minutes), TC was added to the superperfusion-solution in
clinically relevant concentration (10-7M TC). Proportional effects
were measured (expressed as percentage).
Results During the equilibration period cells showed under steady
state conditions constant measurements (cell shortening 96.7% ±
8.6%, shortening velocity of 96.9% ± 9.1% and relaxation rate of
95.4% ± 9.9% compared to baseline). Regarding the treatment effect, an early-onset decrease to 61.3% ± 17.2% (p < 0.01) compared
to baseline of cell-shortening could be documented. Shortening velocity 77.0% ± 8.6% (p < 0.01) and relaxation velocity of 82.8% ±
15.5% (n. s., p = 0.03) decreased. Spontaneous contractions following TC treatment after a perfusion period of 20 minutes could be
observed in 42.9% of all cases.
Conclusion The data shows a negative inotropic and lusitropic
influence of TC on cardiac contractility. Moreover, the data demonstrates that TC administration led to spontaneous contractions/fibrillation in a subset of cases. These effects, determined without any
systemic influences are in accordance with the reported clinical evidence. Further studies will analyze the underlying cellular pathways.
Schlüsselrolle von TRPC3 in der Angiotensin-II-vermittelten kardialen Dysfunktion
XIII – 1
St. Wolf, B. Doleschal, M.-S. Huber, G. Wölkart, K. Groschner
Institut für Pharmazeutische Wissenschaften, Pharmakologie und Toxikologie,
Karl-Franzens-Universität Graz
Hintergrund Während die Bedeutung von TRPC3 bei kardialer
Hypertrophie mehrfach gezeigt wurde, ist das proarrhythmische
Potenzial dieses Kationenkanals bislang unklar. Unter Verwendung
eines transgenen TRPC3-überexprimierenden Mausmodells wurde
die Beteiligung von TRPC3 an der Wirkung von Angiotensin II
(AngII) auf das Herz untersucht.
Methoden Die Wirkung von AngII auf den linksventrikulären
Druck (LVP) und das Elektrokardiogramm (EKG) wurde am
Langendorff-perfundierten Herzen unter konstantem Druck untersucht. AngII-Effekte auf die zelluläre Ca2+-Homöostase und Kontraktilität („sarcomer shortening“) wurden an isolierten ventrikulären Kardiomyozyten unter 1-Hz-Stimulation bei 37 °C auf einem
Epifluoreszenzsetup charakterisiert.
Ergebnisse Vergleich der Wirkung von AngII (100 nM) auf kardiale Funktionen von TRPC3- (n = 5) und Wildtyp- (WT-) Mäusen
(n = 5) zeigte, dass TRPC3-Überexpression die durch AngII-induzierten Störungen der Herzfunktion massiv verstärkt und auch qualitativ verändert. AngII reduzierte den LVP in TRPC3-Herzen innerhalb von 2 min auf 64 %, +dP/dt auf 50 % und -dP/dt auf 55 %,
während in WT-Herzen ein positiv inotroper Effekt beobachtet werden konnte. TRPC3-Herzen (n = 6) zeigten auf AngII-Gabe (100 nM)
im ECG eine akute arrhythmische Reaktion, während der Rhythmus
der WT-Herzen unverändert blieb. Bei TRPC3 konnten die AngIIinduzierten Arrhythmien im ECG mit Pyr3 (30 µM) unterdrückt
Einzelzellmessung zeigten deutliche Unterschiede hinsichtlich der
zellulären Ca2+-Transienten. Die Amplitude der Ca2+-Transienten
in TRPC3-Myozyten ([Ca2+] F/F0 0,354 ± 0,024) waren signifikant
ÖKG-Jahrestagung 2012 – Abstracts
höher (p < 0,05; n = 60) als die von WT-Zellen ([Ca2+] F/F0 0,262 ±
0,021). Hinsichtlich der Kontraktilität („sarcomer shortening“)
zeigte sich kein signifikanter Unterschied (3,8 ± 0,69 % vs. 3,52 ±
0,65 %; n = 10). Die Beladung des sarkoplasmatischen Retikulums
wurde durch raschen Verabreichung von Koffein getestet und war
bei TRPC3-Myozyten im Vergleich zu WT-Myozten um 40 % signifikant (p < 0,05; n = 43) gesteigert.
AngII-induzierte arrhythmische Aktivität und eine Erhöhung des
diastolischen Ca2+-Spiegel ausschließlich in TRPC3-Myozyten.
Während TRPC3-Zellen einen Anstieg des diastolischen Ca2+ F/F0
von 0,24 ± 0,019 und 38,67 arrhythmische Ereignisse zeigten, waren bei der WT-Kontrolle keine Arrhythmien und nur ein geringer
Anstieg des diastolischen Ca2+ F/F0 (0,24 ± 0,019) festzustellen.
Pyr3 (10 µM) unterdrückte AngII-induzierte Anstiege des diastolischen Ca2+-Spiegels und Arrhythmien auf das Niveau einer WTZelle (p < 0,05; n = 16). Die TRPC3-abhängige Erhöhung des
diastolischen Ca2+ wurde durch SEA 0400 (1 µM; n = 14) und KN93 (1 µM; n = 12) signifikant inhibiert, wobei nur SEA0400 auch die
arrhythmische Ereignisse signifikant reduziert.
Konklusion Unsere Befunde zeigen, dass die kardiale Wirkung
von AngII eng an die Expression von TRPC3 gebunden ist und dass
TRPC-Ionenkanäle mit großer Wahrscheinlichkeit eine Schlüsselrolle in der Entstehung AngII-induzierter Arrhythmien spielen.
Frühes atriales Remodelling in einem neuen experimentellen Tiermodell des Vorhofflimmerns
III – 1
D. Zweiker, M. Schwarzl, St. Huber, J. Verderber, A. Alogna, B. Pieske, H. Post,
A. Lueger
Klinische Abteilung für Kardiologie, Medizinische Universität Graz
Einleitung Vorhofflimmern (VHF) kann experimentell nur an
Großtieren nachgestellt werden. Wir präsentieren ein neues Modell
des VHF beim Schwein und charakterisieren Parameter des frühen
atrialen Remodellings.
Methoden Bei 6 Schweinen (Ausgangsgewicht 24 ± 2 kg) wurde
eine 6-wöchige atriale Tachystimulation durchgeführt. Hierzu konstruierten wir ein Schrittmacheraggregat, mit welchem wir über Telemetrie (Funkstrecke 5 Meter) sowohl die Schrittmacherfunktion
kontrollieren als auch ein atriales EKG übertragen konnten. Das
Auftreten eines anhaltenden VHF („sustained atrial fibrillation“)
nach temporärem Abschalten des Aggregates wurde 3×/Woche bei
wachen Tieren über einen Zeitraum von 1 Stunde überprüft. Die
atriale Dimension wurden nach 2, 4 und 6 Wochen Tachystimulation durch Herzultraschall in der parasternalen Längsachse ermittelt
und mit Kontrolltieren verglichen. Die atrio-ventrikuläre Überleitung wurde durch Digoxin (5 µg/kg/Tag p. o.) gebremst.
Ergebnisse Das Auftreten eines VHF stieg proportional zur Stimulationsdauer an (Abbildung 22). Bereits nach 2 Wochen kam es
zu einer deutlichen Dilatation der Atrien (Abbildung 23). Keines
der Tiere zeigte klinische Zeichen einer Herzinsuffizienz.
Abbildung 22: D. Zweiker et al.
Abbildung 23: D. Zweiker et al.
Diskussion Das vorgestellte Modell erlaubt die engmaschige Abfrage des atrialen Rhythmus ohne Sedierung in tierschonender Art
und Weise. Eine atriale Dilatation ist bereits nach 2 Wochen Stimulation apparent. Das Potenzial möglicherweise protektiver pharmakologischer Interventionen kann detailliert durch eine Verschiebung der Dosis-Wirkungs-Beziehung zwischen Stimulationsdauer
und VHF überprüft werden. Somit ermöglicht unser Modell die systematische Testung neuer Therapieansätze zur Behandlung früher
Stadien des Vorhofflimmerns.
 Bildgebung/Imaging
Diastolic Retrograde Flow in the Descending Aorta
by Cardiac Magnetic Resonance Imaging is Useful
for the Quantification of Aortic Regurgitation IV – 2
R. Badr Eslam, St. Pfaffenberger, B. A. Marzluf, M. Frey, P. Bartko, J. Babayev,
G. Maurer, J. Mascherbauer
Division of Cardiology, Department of Internal Medicine II, Medical University
Background Echocardiography is the current clinical routine for
assessing the severity of aortic regurgitation (AR). In addition to
other semiquantitative parameters, the strongest indicator for severe
AR is the presence of holodiastolic retrograde flow in the descending aorta. However, bad acoustic windows frequently limit diagnostic reliability.
The aim of the present study was to compare echocardiographically
assessed retrograde flow in the descending aorta with measurements
by cardiac magnetic resonance imaging (CMR), which is superior in
terms of image quality and reproducibility.
Methods and Results 22 consecutive patients with moderate
and severe AR by echocardiography who additionally underwent
CMR assessment of AR severity were included.
Patients were 53 ± 8 years old and predominantly male (18 vs 4).
14 patients were diagnosed with severe AR by echocardiography,
8 with moderate AR. In only 7 patients, pressure half times were reported (mean, 326 ± 72 ms), in the other patients pressure half times
were not estimable due to jet eccentricity. In all patients the regurgitant flow in the descending aorta was assessed by echo and used
for quantification of AR.
In 32% of patients, echocardiography underestimated the degree of
retrograde flow, in only 5% echocardiography overestimated the
severity of retrograde flow in the descending aorta.
Conclusion The assessment of diastolic retrograde flow by CMR
is feasible and should complement echocardiographical workup in
AR cases with unclear AR severity.
J KARDIOL 2012; 19 (5–6)
ÖKG-Jahrestagung 2012 – Abstracts
Cardiac Magnetic Resonance Imaging versus Echocardiography for Assessment of Cardiac Involvement in Pulmonary Sarcoidosis
IV – 1
T. Fandl, St. Pfaffenberger, K. Vonbank, B. Marzluf, J. Mascherbauer, Th. Binder
Division of Cardiology, Department of Internal Medicine II, Medical University
Study Objectives Sarcoidosis is a systemic granulomatous disease primarily affecting the lung. Cardiac involvement plays a major
role for treatment decisions and prognosis, since it accounts for a
majority of deaths associated with sarcoidosis. Data on prevalence
of cardiac involvement in sarcoidosis patients varies depending on
the patient population and diagnostic modality studied. We aimed to
compare cardiac involvement diagnosed by cardiac magnetic resonance imaging (CMR) with standard echocardiography and speckle
tracking echocardiography for detection of cardiac sarcoidosis in
patients with pulmonary sarcoidosis.
Methods 41 patients (mean 47 years) with biopsy-proven pulmonary sarcoidosis underwent echocardiography and CMR imaging.
Cardiac involvement was diagnosed if a positive late gadolinium
enhancement (LE) pattern not typical for coronary artery disease on
CMR was found. LE was compared to regional wall motion abnormalities on standard echocardiography and to global longitudinal
peak systolic strain (GLPSS) on speckle tracking echocardiography.
Additionally NT-proBNP was measured.
Results No (0%) patient revealed cardiac involvement by echocardiography while 14 (34%) patients showed a positive LE on CMR
(p < 0.001). 4 (10.5%) patients with positive LE showed a reduced
GLPSS compared to 3 (7.9%) patients without LE (p = 0.245). Mean
NT-proBNP was higher in patients with positive LE (127 pg/ml ±
130), when compared to subjects without LE (87 pg/ml ± 80)
(p = 0.20).
Conclusion Cardiac involvement in pulmonary sarcoidosis patients
was detected in more cases by CMR than by standard echocardiography. Speckle tracking echocardiography was also more sensitive
than standard echocardiography. However, cardiac involvement in a
caucasian population was rare compared to previously published data
based on a predominantly black-american population.
Therapeutische Konsequenzen der kardialen
Magnetresonanztomographie bei koronarangiographierten Patienten
IV – 8
B. Freudenthaler, P. Wexberg, A. Bastovansky, F. Weidinger, M. Avanzini
2. Medizinische Abteilung, Krankenanstalt Rudolfstiftung, Wien
Einleitung Die kardiale Magnetresonanztomographie (MRT) hat
in den vergangenen Jahren wesentlich an Bedeutung gewonnen.
Zahlreiche Daten belegen v. a. die Relevanz der Erfassung des Narbenausmaßes im Zuge des Revaskularisierungsmanagements, aber
auch die höhere Genauigkeit hinsichtlich Thrombusdiagnostik und
belastungsinduzierter Ischämie. Auf dieser Grundlage basierend
befasst sich die nachstehende Analyse mit der therapeutischen Konsequenz im klinischen Kontext einer kardiologischen Schwerpunktabteilung.
Methoden Retrospektive Analyse von Patienten aus der lokalen
MRT-Datenbank, die zwischen 2008 und 2012 an einem 1,5-TeslaScanner einer MRT-Untersuchung und einer Koronarangiographie
zugeführt wurden. Die Befunde wurden hinsichtlich Indikationsstellung zur MRT und therapeutischer Konsequenz aufgeschlüsselt.
Als therapeutische Konsequenz wurde eine Therapieentscheidung,
die direkt in Folge der MRT-Untersuchung gefällt wurde, angesehen, also bei Stressuntersuchung Entscheidung zur Angiographie
bzw. Revaskularisation vs. konservatives Management, bei Thrombussuche Einleiten vs. Absetzen einer oralen Antikoagulation, bei
Vitalitätsfrage Planung vs. Verzicht auf Revaskularisation.
Ergebnisse In 41 Monaten wurden insgesamt 104 Patienten in
unsere Studie eingeschlossen. 18 Patienten wurden (17,3 %) einem
Adenosinstresstest unterzogen, davon führten 15 Untersuchungen
(83,3 %) zu einer therapeutischen Konsequenz. 82 Patienten (78,8 %)
J KARDIOL 2012; 19 (5–6)
wurden hinsichtlich Myokardvitalität untersucht (einschließlich 15
[18,3 %] Verlaufskontrollen), hier zeigt sich eine therapeutische
Konsequenz bei 43 Untersuchungen (58,7 %). Die interkavitäre
Thrombussuche (3,8 %) beeinflusste bei 3 (75 %) von 4 Patienten
das weitere therapeutische Procedere.
Zusammenfassung Die Adenosinstressuntersuchungen zeigten
die höchste therapeutische Relevanz, da 83,3 % der Patienten interventionell oder operativ versorgt wurden oder durch einen negativen Stresstest von einer Revaskularisierung abgesehen wurde. Im
kleinen Patientenpool der interkavitären Thrombussuche wurde bei
75 % eine orale Antikoagulation eingeleitet. Aufgrund des großen
Anteils an Verlaufskontrollen oder nicht-konklusiver Therapieentscheidungen ergab die Vitalitätsdiagnostik kein eindeutiges Ergebnis hinsichtlich therapeutischer Konsequenz. Hier zeigt sich,
dass zahlreiche weitere Faktoren (z. B. Allgemeinzustand, Patientenwunsch, etc.) das therapeutische Vorgehen mit beeinflussen.
Intraoperative New Generation C-Arm Imaging During Cardiac Interventional Procedures: A Bridging
Solution to a Hybrid Operating Room?
IV – 7
G. Friedrich, Th. Schachner, L. Müller, S. Müller, O. Pachinger, Th. Bartel,
M. Grimm, N. Bonaros
Universitätsklinik für Herzchirurgie, Medizinische Universität Innsbruck
Objective Transcatheter valve interventions, hybrid coronary and
aortic disease procedures require angiographic intraoperative imaging supporting the heart team approach. Considering limited financial and logistic possibilities of many medical centers, alternative
strategies should be investigated.
Methods and Results Between 2/2001 and 7/2011, 392 patients
were evaluated and treated using 4 different types of mobile c-arms:
GE OEC 9800 (325), Siemens Arcadis (5), Philips Veradius (17),
Ziehm RFD (45). We observed a steady increase of this imaging procedure for major cardiac procedures from 23 to 43 cases per year during the last decade (p = 0.002). There were 3 cases (0.8%) of system
crashes, one procedure therefore deviated from a transcatheter valve
implantation (TAVI) to an open surgical procedure. All other 52
TAVI procedures were completed without valve malposition or coronary obstruction. Coronary artery bypass grafts were assessed in 318
patients during implementation of new procedures (endoscopic grafting). Anastomotic or graft revision was required in 11/375 anastomoses (3%). Nitroglycerin sensitive target vessel or graft spasm was
detected in 122 (33%) and 18 (5%) cases respectively. Emergency
coronary intraoperative coronary angiography for signs of myocardial
ischemia was performed in 14 cases (4 patients after CABG, 2 patients
after AVR, 7 patients after MVR and 1 cardiac transplant recipient), in
all but two patients at least one additional graft was needed. Bail out
aortic stenting was needed in 7 patients and performed using conventional and digital subtraction angiography and roadmapping. Median
procedure duration for coronary evaluation was 22 (10–110) minutes,
fluoroscopy time was 413 (89–2282) sec, cumulative radiation (dose
area product) was 46,261 (9,381–429,787) mGy/cm2. The amount of
contrast agent used was 150 (20–600) ml.
Conclusion The use of new generation mobile c-arms in the cardiac operation room is very useful for transcatheter valve and aortic
interventions as well as coronary artery graft evaluation. Furthermore bail-out procedures can be successfully performed. This imaging approach may represent a bridging solution to a fully equipped
hybrid interventional room.
Impact of Aortic Stiffness on NT-pro BNP Levels
4 Months After Acute STEMI
IV – 5
G. Klug, M. Kremer, H.-J. Feistritzer, A. Mayr, L. Krauter, M. Schocke,
Ch. Kremser, W. Jaschke, O. Pachinger, B. Metzler
Department of Internal Medicine III, Medical University Innsbruck
Objectives Chronic maladaptive remodeling of the left ventricular (LV) myocardium is associated with a significant worsening of
prognosis after acute myocardial infarction (AMI) aortic pulse wave
velocity (PWV) was linked to LV-geometry and -function in pa-
ÖKG-Jahrestagung 2012 – Abstracts
tients with kidney disease and non-ischemic cardiomyopathy. The
role of aortic compliance after acute STEMI is so far unknown.
Methods AMI patients reperfused by primary angioplasty (n = 51,
mean age: 58.0 ± 1.0 yrs, 5 female) underwent contrast enhanced
cardiac MRI at a median of 2.7 days (range: 0–7 days) after the index event. Furthermore aPWV as well as aortic distensibility (DC)
and compliance coefficients (CC) were determined by velocity encoded, phase contrast CMR (retrospectively ECG-gated, temporal
resolution: 20 ms). Blood samples were routinely drawn. Follow-up
was conducted after 4 months (median: 140, range: 92–239 days)
following the same protocol (cardiac MRI, ECG, laboratory tests,
Results Baseline aortic aPWV (r: 0.672; p < 0.001), aDC (r: –0.407;
p < 0.03) and aCC (r: –0.443; p < 0.02) showed moderate to good
correlations to NT-pro-BNP values 4 months after STEMI. Multivariate analysis revealed aPWV beside LVEF as an independent
predictor of 4-month NT-pro BNP levels after correction for age and
myocardial infarct size (model r: 0.781; p < 0.001). Increased aPWV
correlates moderately with diminished LV stroke volumes (SV,
r: –0.368; p < 0.02) after 4 months but not with LVEF, EDV, ESV or
LV-myocardial mass (all p > 0.05).
Conclusion Aortic stiffness (PWV, DC and CC) is associated
with NT-pro-BNP levels 4 months after STEMI, suggesting a role
for aortic stiffness in chronic LV-remodeling. Longer follow-up
periods will show if our results translate in morphological and functional changes of the left ventricle.
Impact of Cardiovascular Risk Factors on Aortic
Pulse Wave Velocity: A Comparison of Healthy
Volunteers and Patients After STEMI
IV – 6
G. Klug, H.-J. Feistritzer, M. Kremer, A. Mayr, L. Krauter, N. Riegler, M. Schocke,
W. Jaschke, O. Pachinger, B. Metzler
Department of Internal Medicine III, Medical University Innsbruck
Objectives Aortic pulse wave velocity (aPWV, m/s) is associated
with traditional cardiac risk factors and an independent prognostic
parameter for future cardiac events. The association of cardiac risk
factors with aPWV in patients with STEMI is not yet evaluated.
Methods 115 subjects were enrolled in this study (n = 43 controls
without significant coronary heart disease CHD, n = 72 STEMI patients within 7 days of index event). Aortic aPWV was determined
with velocity encoded, phase contrast cardiac MRI (retrospectively
ECG-gated, temporal resolution: 20 ms). Medical history was obtained to determine pre-existing cardiovascular risk factors (hypertension, smoking, hypercholesterinaemia, family history of CVD).
Blood pressure (BP) and lipid profiles were determined and ESC
SCORE was calculated to quantify total cardiovascular risk.
Results In controls aPWV was correlated with age (r: 0.883,
p < 0.001), systolic BP (sBP, r: 0.530; p < 0.002) and ESC SCORE
(r: 0.683; p < 0.001) but not with diastolic BP (dBP; p > 0.05).
In patients with recent STEMI aPWV correlated with age (r: 0627;
p < 0.001) and ESC SCORE (r: 0.312; p < 0.01) but not with sBP or
dBP (p > 0.05). In controls hypertension (5.0 ± 0.4 vs 11.1 ± 3.4 m/s;
p < 0.001) and hypercholesterolemia (5.9 ± 2.3 vs 10.9 ± 3.8 m/s;
p < 0.001) were associated with higher aPWV, but smoking, diabetes and positive family history were not (all p > 0.05). In contrast
in STEMI patients subjects with hypertension and hypercholesteremia did not show higher aPWV (all p > 0.05). Smoking, diabetes
and family history had no impact on aPWV in STEMI patients (all
p > 0.05).
Conclusion We observed differences in the association of cardiac
risk factors with aortic stiffness (aPWV) between healthy subjects and
patients after acute STEMI. These results may reflect more aggressive
treatment in STEMI patients and should be considered when choosing
aortic stiffness as a potential therapeutic target after STEMI.
J KARDIOL 2012; 19 (5–6)
Use and Limitations of Cardiac Magnetic Resonance
Derived Measures of Local Aortic Elasticity in Patients
After Acute ST-Elevation Myocardial Infarction IV – 9
G. Klug, H.-J. Feistritzer, M. Kremer, U. Hecker, A. Mayr, Ch. Kremser,
M. Schocke, W. Jaschke, B. Metzler
Department of Internal Medicine III, Medical University Innsbruck
Objectives Directly after acute ST-elevation myocardial infarction (STEMI), altered hemodynamics might hamper the use of Cardiac Magnetic Resonance (CMR) flow-based measures of local aortic elastic parameters. We compared the value of CMR-derived measures of aortic stiffness in healthy young volunteers, patients with
coronary heart disease and patients directly after first STEMI.
Methods We performed velocity encoded, phase contrast CMR in
24 healthy volunteers as well as in 17 patients with coronary artery
disease (CAD) and 29 patients with recent acute STEMI. Measurements were performed at the levels of the ascending and abdominal
aorta. Regional PWVTT was determined by the established transittime method and served as a reference standard. Local distensibility
coefficients (DCascending) were determined as the product of the
relative area change during systole and the pulse pressure (mmHg).
Local PWVQA was determined as the ratio between the flow (Q)
and area (A) variations. We evaluated hemodynamic parameters of
the ascending aorta (maximal flow and flow velocities). Furthermore phase contrast CMR images were scored for their quality
(from “1: good” to “5: non-diagnostic”).
Results Healthy volunteers showed higher aortic elasticity determined by DCascending than patients with CHD or STEMI (7.81 ±
4.02 vs 2.76 ± 1.21 vs 4.48 ± 2.60 [10–3* mmHg]; p < 0.001) but
did not differ form the other groups with respect on their PWVQA
(3.59 ± 1.73 vs 3.06 ± 3.19 vs 2.25 ± 1.50 [m/s]). DCascending correlated inversely with age (r: –0.605; p < 0.001) and with the reference standard PWVTT (r: –0.538; p < 0.005) indicating good agreement between the 2 methods. Local PWVQA did not correlate with
age (r: –0.159; p = n. s.) or PWVTT (r: –0.055; p = n. s.).
Interobserver agreement was high for the reference standard PWVTT
(r: 0.915; p < 0.001) and for DCascending (r: 0.863; p < 0.001) but
and only moderate for PWVQA (r: 0.398; p = 0.003).
STEMI and CHD patients differed from healthy volunteers in
maximal achieved flow velocities (46.3 and 38.6 vs 70.8 [cm/s];
p < 0.001). In STEMI and CHD patients we achieved a significantly
lower image quality than in healthy volunteers (3.4 and 3.4 vs 1.1;
p < 0.001). Scored images quality correlated inversely with
PWVQA (–0.326; p < 0.01).
Conclusion Local aortic DCascending but not PWVQA is a robust
method for the assessment of local aortic parameters in STEMI patients. Reasons might be altered hemodynamics and lower image
quality achieved in STEMI patients.
Diffuse Myocardial Fibrosis by Post-Contrast T1-Time
is Closely Related to the Degree of Heart Failure in
Heart Failure with Normal Ejection Fraction
B. Marzluf, D. Bonderman, St. Pfaffenberger, E. Ringelspacher, M. Hülsmann,
C. Tufaro, I. M. Lang, G. Maurer, R. Pacher, J. Mascherbauer
Division of Cardiology, Department of Internal Medicine II, Medical University
Introduction Myocardial fibrosis is a histological hallmark of
heart failure and an independent predictor of adverse outcome. Late
gadolinium enhancement (LGE) by cardiac magnetic resonance
(CMR) is a standard noninvasive tool for the identification of focal
fibrosis. Diffuse fibrosis, however, cannot be quantified by LGE.
Recently it was shown that diffuse myocardial fibrosis is strongly
related to post-contrast longitudinal relaxation (T1) time. The aim of
our study was to assess diffuse myocardial fibrosis by CMR T1
mapping in patients with serum NT-proBNP levels > 125 pg/ml and
preserved left ventricular ejection fraction (EF ≥ 50%).
Methods 68 heart failure patients with normal ejection fraction
and 4 healthy controls were prospectively evaluated. CMR studies
ÖKG-Jahrestagung 2012 – Abstracts
included the assessment of cardiac function and dimensions by standard cine sequences. Myocardial T1 mapping was performed 10
minutes after a gadolinium bolus using an inversion recovery sequence.
Results Serum NT-proBNP levels in patients ranged from 126 to
4239 pg/ml (mean 763 ± 864 pg/ml). Areas with LGE indicating
local fibrosis in 5 patients were excluded from T1 analysis. Postcontrast T1 was significantly related to NT-proBNP (r = –0.49;
p < 0.0001), EF (r = 0.29; p = 0.013) and cardiac output of the left
ventricle (r = 0.23; p = 0.049). In patients with NT-proBNP levels
> 500 pg/ml mean T1 was significantly shorter than in patients with
NT-proBNP < 500 pg/ml (383.4 ± 55.5 vs 410.7 ± 31.0 ms; p = 0.012)
and controls (494.0 ± 48.9 ms; p < 0.001). Furthermore, T1 was
strongly related to degree of diastolic dysfunction by echocardiography (p = 0.006) and NYHA-functional class (p = 0.003) but independent of age, heart rate or renal function.
Conclusion Post-contrast T1 is highly correlated with NTproBNP, cardiac function, and symptoms. Our data suggest that T1
mapping is a promising tool for the assessment of diffuse myocardial fibrosis. It appears to be closely linked to important prognostic
parameters in heart failure patients.
Galectin-3: Relation to Infarction Scar and Myocardial Function After STEMI
IV – 4
A. Mayr, G. Klug, K. Streil, B. Harrasser, M. Kremer, H.-J. Feistritzer, J. Mair,
M. Schocke, O. Pachinger, B. Metzler
Radiologie I; Klinische Abteilung für Kardiologie, Medizinische Universität Innsbruck
Objectives Fibrosis after acute myocardial infarction (AMI) is the
leading cause of heart failure and results in late enhancement of scar
by cardiac magnetic resonance imaging (CMR). Galectin-3 is suggested to be involved in the development of heart failure appearing
to directly mediate profibrotic pathways. The relationship between
galectin-3 and the extent of myocardial infarction scar is unknown.
Methods 29 AMI patients (n = 29, mean age: 58.1 ± 10.1 yrs, 3
female) successfully reperfused by primary angioplasty underwent a
4-month (4-mo) follow-up CMR at a median of 125 days (range:
92–200 days) after the index event. Blood samples were routinely
drawn at baseline and follow-up. Galectin-3 was determined from
serum samples drawn at the follow-up.
Results 4-mo galectin-3 values (mean 12.29 ± 4.56 ng/ml) correlated significantly with 4-mo infarct size (r: 0.406; p = 0.036), with
4-mo NT-proBNP concentrations (r: 0.420; p = 0.023) as well as
with 4-mo creatinin levels (r: 0.486; p = 0.016).
Patients with 4-mo galectin-3 concentrations above the median level
of 10.86 ng/ml presented significant impaired 4-mo left ventricular
ejection fractions (57.9 ± 8.3% vs 65.1 ± 5.8%; p = 0.011), larger
mid-term infarct sizes (15.6 ± 7.8% vs 8.9 ± 6.1%; p = 0.022) as well
as higher 4-month NT-proBNP concentrations (642.6 ± 666.0 ng/l
vs 261.4 ± 183.1 ng/l; p = 0.042) than patients with galectin-3 concentrations below 10.86 ng/ml.
Conclusion Elevated galectin-3 levels 4 months after AMI are
associated with larger infarct sizes, lower global myocardial function as well as with higher concentrations of NT-proBNP, highlighting the potential of galectin-3 as a biomarker of adverse remodeling
after AMI.
Wertigkeit der Akut-Echokardiographie bei Patienten mit NSTEMI
IV – 10
W. Weihs, V. Weihs, H. Schuchlenz, St. Harb, D. Botegal, G. Waltl, P. Zechner
Department für Kardiologie und Intensivmedizin, Landeskrankenhaus Graz-West
Einleitung Die Beurteilung des kardiovaskulären Risikos bei Patienten mit akutem Koronarsyndrom (ACS) ohne anhaltende STHebung (NSTE) erfolgt in der Regel anhand des klinischen Status,
der Anamnese, des Elektrokardiogramms (EKG) sowie der Biomarker. Die Durchführung einer Echokardiographie wird von der European Society of Cardiology (ESC) bei allen Patienten mit NSTEACS empfohlen. Die Wertigkeit der Echokardiographie ist jedoch
zum gegebenen Zeitpunkt nicht eingehend untersucht bzw. validiert.
Das Ziel der retrospektiven Studie war, die Ergebnisse der Echokardiographie bei Patienten mit erstem NSTEMI (NSTE-ACS +
Troponinerhöhung) zu analysieren und mit den Ergebnissen der
Koronarangiographie zu korrelieren.
Material und Methode Im Zeitraum 13 Monaten wurden von
insgesamt 193 konsekutiven Patienten mit NSTEMI 51 Patienten
aufgrund einer kardialen Vorerkrankung (14 PCI, 23 CABG, 14
STEMI/NSTEMI) und 24 aufgrund einer auswärts durchgeführten
Echokardiographie ausgeschlossen. Bei den verbleibenden 118 Patienten wurden die Ergebnisse der Echokardiographie, des EKGs
und der Koronarangiographie retrospektiv analysiert. Die echokardiographische Wandbewegungsanalyse (WMA) erfolgte anhand des
17-Segmentemodells, welche entweder dem anterioren, lateralen
oder inferioren Versorgungsgebiet zugeordnet wurden. Die EKGVeränderungen (ST-Senkung, T-Negativierung) wurden ebenfalls
der anterioren (V1-V4), lateralen (V5, V6, I, aVL) und inferioren
(II, III, aVF) Versorgung zugeordnet.
Ergebnisse Unter den 118 Patienten im Alter von 66,8 ± 10,3 Jahren (38–90 Jahre) befanden sich 42 Frauen und 76 Männer. Die
Koronarangiographie erfolgte in 71 % < 24 h und in 91 % < 48 h nach
dem Erstkontakt, wobei 56 Patienten (47 %) eine Ein-, 25 (21 %)
eine Zwei-, 23 (19 %) eine Dreigefäßerkrankung, 10 (8 %) eine
Hauptstammstenose und 4 (3 %) eine diffuse Koronarsklerose hatten. Bei 43 Patienten (36 %) fand sich der Verschluss zumindest
eines Koronargefäßes. In 91 Fällen erfolgte eine PCI (davon in 29
Fällen > 1 Gefäß), in 16 Fällen ein CABG und in 11 Fällen eine
konservative Behandlung.
Das EKG war bei 67 Patienten (57 %) unauffällig bzw. nicht interpretierbar (SM, LSB). Bei den übrigen Patienten gelang die Zuordnung der EKG-Veränderungen zum Versorgungsgebiet der betroffenen Koronargefäße lediglich in 55 %.
Die Echokardiographie wurde in 81 % < 24 h und in 96% < 48 h
nach dem Erstkontakt und in 95 % < 24 h vor der Koronarangiographie vorgenommen. Die WMA war bei 34 Patienten (29 %) normal,
bei 76 (64 %) pathologisch und bei 8 (7 %) nicht beurteilbar. Die
regionalen Wandbewegungsstörungen zeigten in 83 % eine Übereinstimmung mit dem Versorgungsgebiet der betroffenen Koronargefäße. Bei Vorliegen von regionalen Wandbewegungsstörungen in
mehreren Versorgungsgebieten fand sich in 77 % und bei Vorliegen
einer hochgradig reduzierten Linksventrikelfunktion (LVEF < 30 %)
in 95 % eine koronare Mehrgefäßerkrankung und/oder Hauptstammstenose.
Diskussion Patienten mit NSTEMI weisen ein sehr heterogenes
kardiales Risiko auf, welches mit den herkömmlichen diagnostischen Tools, wie Klinik, EKG oder Biomarker, nur unzureichend
abgeschätzt werden kann. Die Echokardiographie erlaubt eine Beurteilung des Ausmaßes und Lokalisation der Ischämie und stellt damit eine wertvolle Information vor der Intervention dar. Eine orientierende Echokardiographie sollte daher bereits zu einem sehr frühen Zeitpunkt, beispielsweise in der Notaufnahme, vorgenommen
Does the Integration of Personalized Ultrasound
Change Patient Management in Critical and Acute
Care Medicine?
IV – 3
P. Zechner, M. Campo dell’ Orto, H. V. Groesdonk, F. H. Seeger, W. Weihs,
R. Breitkreutz
Department of Internal Medicine, LKH Graz-West, Austria; Department of Cardiology, Kerckhoff Heart Centre Bad Nauheim; Critical Care Unit, Department of
Cardiovascular Surgery, Department of Anaesthesiology, Intensive Care and Pain
Therapy University of the Saarland, Medical Faculty Homburg (Saar); Department
of Cardiology, Johann Wolfgang Goethe University Hospital Frankfurt am Main,
Objective The aim of our study was to test the influence of personalized ultrasound (PersUS) on patient management in critical
and acute care medicine.
Materials and Methods This was a prospective multicentre
study in acute and critical care medicine with a total of 640 patient
J KARDIOL 2012; 19 (5–6)
ÖKG-Jahrestagung 2012 – Abstracts
ultrasound exams including 548 focused diagnostic exams and 92
interventional procedures. Five distinct sub-studies were conducted.
Sub-study 1 tested, if the availability of PersUS increases the frequency of use during work shifts in an intensive care environment.
The access to the PersUS device was determined randomly and the
implementation pattern of PersUS, the types of indications and estimated duration of use during all work shifts were analyzed. Substudy 2 investigated if PersUS is comparable to a high-quality mobile ultrasound device in terms of image quality and planning of selected interventions (puncture of pleural, pericardial or abdominal
effusions or the urinary bladder) in intensive care patients. Substudy 3: Four critical care physicians studied PersUS for planning an
execution of ultrasound-guided needle punctures such as pleural,
pericardial, abdominal or urinary bladder punctures for evacuation
of fluid or inserting catheters (pleurocath, pigtail or suprapubic).
They used linear analogue self-assessment to obtain semi-quantitative data of the physician’s impression of (i) diagnostic quality and
(ii) visual support in ultrasound-guided interventions. Sub-study 4
assessed the influence of PersUS integration on the duration of a
quick-check physical examination in the emergency department. A
single emergency physician used PersUS after randomisation in patients with dyspnea, thorax pain, abdominal pain or hypotension.
Finally, any influence on patient management or additional information obtained due to PersUS was noted. Sub-study 5 analyzed the
influence of the availability of a PersUS device during ward rounds.
The PersUS device was available during wards rounds on a random
basis and time between beginning and end of ward rounds was measured as well as the number of patients seen, type and length per
ultrasound exam. All data was then sorted into Group A (control
group) or Group B (examination with PersUS).
Results The randomized availability of PersUS increased its application in ICU work shifts more than twofold from 33 to 68 exams
mainly for the detection and therapy of effusions (Figure 24). Image
quality and decision making was as effective as when using highquality mobile ultrasound in a variety of intensive care patients. Diagnostic and procedural quality was rated as excellent/very good in
PersUS-guided puncture in 95% of cases. In an initial quick-check
physical examination of 48 randomized cases in an emergency department, PersUS extended the examination time by 100 seconds
(Figure 25a). However, a change of management in 6/22 (27%)
cases as well as valuable additional information for immediate recognition of underlying disease in 19/22 (86%) patients was registered by the examiner. PersUS integration into 53 randomized regular ward rounds reduced average contact time per patient by 103 seconds from 8.9 to 7.2 minutes and lowered the patient referral rate to
an echo lab from 20% to 2% within the study population (Figure
Conclusion PersUS can be easily integrated into daily routine
work of acute and critical care medicine with high diagnostic and
procedural quality with few time constraints.
Figure 24: P. Zechner et al.
J KARDIOL 2012; 19 (5–6)
Figure 25: P. Zechner et al.
 Chirurgie/Surgery
Institutional Experience with the Heartware and
Heartmate II Left Ventricular Assist Device
St. Mahr, F. Eskandary, J. Horvath, A. Rajek, G. Laufer, H. Schima, D. Zimpfer
Abteilung für Herzchirurgie, Medizinische Universität Wien
Background Left ventricular assist device (LVAD) implantation
has become a routine therapy for patients with end-stage heart failure. This study was designed to evaluate our institutional experience
with the Heartware (HVAD) and Heartmate II (HMII) LVAD in
patients with end-stage heart failure.
Patients and Methods From March 2006 to January 2012 a total of 83 (male 84.1%) patients (mean age 52 ± 12 yrs.) with terminal
heart failure received either a HVAD LVAD (n = 56) or a HMII
LVAD (n = 27) at our department as bridge to transplant or chronic
implant. Study endpoints were 30-day and in-hospital mortality.
Long-term survival on the LVAD and bridge to transplant success as
well differences between the 2 systems were calculated by KaplanMeier analysis.
Results Patients receiving a HVAD and HMII LVAD were comparable with regard to patient characteristics. Mean support time
was 353 ± 400 days. Of the 83 patients included in the present analysis, 29.3% underwent cardiac transplantation, 14.6% expired on the
LVAD and 56.1% continue to receive LVAD support. Thirty day
(overall 6.1%; HVAD 3.6% vs HMII 13%, p = 0.149) and in-hospital
mortality (overall 7.3%; HVAD 5.7% vs HMII 13%, p = 0.359) were
comparable between the 2 systems. Survival or bridge to transplant
success was 90% at 12 (HVAD 83.4% vs HMII 91%, log-rank =
0.114) and 85% at 24 months (HVAD 81.3% vs HMII 91%, logrank = 0.114) respectively.
Conclusion Left ventricular assist devices have developed as an
excellent treatment option for patients with terminal heart failure.
The observed survival rates at 1 and 2 years challenge the results of
cardiac transplantation.
ÖKG-Jahrestagung 2012 – Abstracts
 Diverse/Miscellaneous
Pulswellengeschwindigkeitsmessung als prädiktiver
Marker für die Entwicklung einer koronaren Herzkrankheit bei gesunden Probanden mit mindestens
einem vorbekannten kardiovaskulären Risikofaktor
(Comet-K-Projekt „BioPersMed“)
C. Colantonio, G. Steiner, S. Pätzold, E. Kraigher-Krainer, A. Schmidt, B. Pieske
Klinische Abteilung für Kardiologie, Medizinische Universität Graz
Hintergrund Die Risikostratifikation asymptomatischer Patienten mit erhöhtem kardiovaskulären Risiko ist nach wie vor unzureichend. Etablierte Score-Systeme (z. B. EuroSCORE) stützen sich
großteils auf klassische Risikofaktoren wie arterielle Hypertonie,
Hyperlipidämie, Adipositas, chron. Nikotinabusus, Diabetes mellitus etc. Die Pulswellengeschwindigkeit („pulse wave velocity“,
PWV) an A. carotis und A. femoralis – als potenzieller prädiktiver
Marker für die Früherkennung einer koronaren Herzkrankheit –
wurde bislang unzureichend evaluiert.
Methodik In der K-Projekt-Kohorte (Comet-Projekt, „BioPersMed“)
werden seit Ende 2010 prospektiv 1000 Probanden mit kardiovaskulären Risikofaktoren, aber noch keinem atherosklerotischen
Ereignis eingeschlossen und longitudinal nachbeobachtet. Neben
einer umfassenden kardiovaskulären Phänotypisierung (u. a. Echokardiographie, Spiroergometrie) erfolgt die Erfassung der Endothelfunktion und der Mikrozirkulation mittels Pulswellenanalyse (A.
radialis) und Pulswellengeschwindigkeitsmessung (A. carotis und
A. femoralis) mittels SphygmoCor-Gerät.
Ergebnisse In einer Pilotstudie zu Zeitaufwand, Untersuchungsablauf und Compliance wurden seit Dezember 2010 240 Probanden
eingeschlossen (105 Männer, 135 Frauen, Alter zwischen 45 und 75
In der Rangkorrelation nach Spearman zeigten sich signifikante
Zusammenhänge zwischen klassischen Risikofaktoren, Parametern
in Spiroergometrie sowie Echokardiographie und erhöhten Pulswellengeschwindigkeiten (p < 0,05 = signifikant).
Probanden mit einem BMI > 25,0 (p < 0.001) sowie Probanden mit
einer HBA1c > 6,0 (p = 0,001) zeigten erhöhte Pulswellengeschwindigkeiten im Vergleich zu Probanden mit BMI < 25,0 und
HBA1c-Werten < 6,0.
Manifeste Diabetiker (p = 0,018) sowie manifeste Hypertoniker
(p = 0,002) haben eine deutlich höhere Pulswellengeschwindigkeit
als gesunde Probanden.
Probanden mit diastolischer Ventrikelfunktionsstörung hatten signifikant erhöhte Pulswellengeschwindigkeiten (p = 0,015). Je größer E/é, desto schneller wurde auch die Pulswellengeschwindigkeit.
Insbesondere konnte eine signifikante Korrelation zwischen E/é
bzw. Vorhofgröße und Pulswellengeschwindigkeit beobachtet werden (p = 0,012).
Schlussfolgerung Unsere Daten an vermeintlich gesunden Probanden zeigen, dass die Pulswellengeschwindigkeit an den großen
Gefäßen bereits in erheblichem Maße pathologisch verändert ist.
Dies deutet auf einen direkten Zusammenhang zwischen „Steifigkeit des Herzens“ und „Steifigkeit der Gefäße“ hin.
Die Wertigkeit der PWV als Frühmarker zur Detektion kardiovaskulärer Ereignisse ist Gegenstand aktueller Studien.
Pulswellengeschwindigkeitsmessung, Echokardiographie und Spiroergometrie als Frühmarker zur
Detektion eines kardiovaskulären Remodellings
C. Colantonio, G. Steiner, S. Pätzold, E. Kraigher-Krainer, A. Schmidt, B. Pieske
Klinische Abteilung für Kardiologie, Medizinische Universität Graz
Hintergrund Bisher findet die Spiroergometrie ihren Platz zur
Beurteilung der Ausdauerleistungsfähigkeit, zur Messung des Energiestoffwechsels während körperlicher Belastung und zur Untersu-
chung der Leistungsfähigkeit des kardiopulmonalen Systems, inklusive Abklärung einer möglichen koronaren Herzkrankheit.
Die Evaluierung, ob sich kardiovaskuläre Risikofaktoren, Gefäßsteifigkeit und subklinisches kardiovaskuläres Remodelling bereits
im Frühstadium in der kardiopulmonalen Leistungsfähigkeit widerspiegeln, erfolgte bisher unzureichend.
Hierzu wird der Zusammenhang zwischen Spiroergometrie und Pulswellengeschwindigkeit („pulse wave velocity“, PWV) an A. carotis
und A. femoralis untersucht.
Methodik Seit Dezember 2010 werden prospektiv 1000 Probanden mit kardiovaskulären Risikofaktoren (art. Hypertonie,
Hyperlipidämie, Diabetes mellitus, chron. Nikotinabusus etc.), aber
noch ohne manifeste koronare Herzkrankheit eingeschlossen und
longitudinal nachbeobachtet. (K-Projekt-Kohorte; Comet-Projekt,
Im Rahmen der Einschluss-Untersuchungen erfolgt eine umfassende kardiovaskuläre Phänotypisierung (u. a. Echokardiographie, Intima/Media-Messung an Karotiden), die Erfassung der Endothelfunktion und der Mikrozirkulation mittels Pulswellenanalyse (A. radialis)
und Pulswellengeschwindigkeitsmessung durch das SphygmoCorGerät sowie die Evaluierung der Leistungsfähigkeit mittels Spiroergometrie.
Ergebnisse Seit Dezember 2010 konnten im Rahmen einer Pilotstudie 240 Probanden (105 Männer, 135 Frauen, Alter zwischen 45
und 75 Jahren) untersucht werden.
Die Pulswellengeschwindigkeit (PWV) korrelierte positiv mit dem
VE/VCO2-Slope (r = 0,287; p = 0,010) und negativ mit der maximalen Sauerstoffaufnahme (peakVO2; r = –0.470; p < 0,001). Das bedeutet je höher VE/VCO2-Slope, desto schneller die PWV und je
höher die peakVO2, desto langsamer die PWV.
In der Echokardiographie zeigte sich, dass Probanden mit diastolischer Ventrikelfunktionsstörung höhere Pulswellengeschwindigkeiten haben als diejenigen mit normaler diastolische Ventrikelfunktion (r = 0,241; p = 0,015).
Je größer E/é, desto schneller auch die PWV und desto höher der
Augmentationsindex (p = 0,011).
Zwischen der Dicke der posterioren Wand des linken Ventrikels und
der PWV fand sich ebenfalls eine positive Korrelation (r = 0,228;
p = 0,021).
Schlussfolgerung Unsere Daten an vermeintlich gesunden Probanden zeigen, dass sich die „Steifigkeit des Herzens“ und die „Steifigkeit der Gefäße“ bereits lang vor der Manifestation einer KHK
zeigen und dass sich dies auch in der kardiopulmonalen Leistungsfähigkeit widerspiegelt.
Die Wertigkeit der PWV in Kombination mit der Spiroergometrie
als Frühmarker zur Detektion einer Veränderung der kardiopulmonalen Leistungsfähigkeit sowie als Zeichen eines subklinischen kardiovaskulären Remodellings ist Gegenstand aktueller Studien.
Health-Related Quality of Life, Anxiety and Depression After PCI: Restoring a State of Equilibrium
O. Friedrich, G. Gaul, S. Höfer, J. Sipötz
Klinik für wissenschaftliche Forschung in der interventionellen Kardiologie,
Hanusch-Krankenhaus, Wien
Purpose Our study aims to describe the relation of Health-Related
Quality of Life (HRQoL) and Anxiety and Depression after PCI in
NSTEMI patients over a 24-month follow-up period. In order to
explore the potential of HRQoL and Depression/Anxiety scores as
prognostic tools for adverse outcome or monitoring instruments we
focus on the change in individual patients.
Methods 159 NSTEMI PCI patients (73.0% men; age: 63.8, SD:
9.2) at 7 centers in Austria completed the HADS anxiety/depression
and the MacNew HRQoL questionnaire before discharge and 1, 6,
12 and 24 months after discharge.
Results MacNew HRQoL and HADS Anxiety and Depression
scores are negatively correlated. Over the whole observational peJ KARDIOL 2012; 19 (5–6)
ÖKG-Jahrestagung 2012 – Abstracts
riod this correlation could be well described by a linear regression
with MacNew Global score as dependent and HADS Total score
(= HADS Anxiety + HADS Depression) as independent variable
(p < 0.001). The coefficient of determination (R^2) of the regression
equation increases drastically from 0.43 at the baseline to a level
between 0.66 and 0.77 in the follow-up period (1M: 0.68; 6M: 0.77;
12M: 0.66; 24M: 0.70), which means that while at the baseline
HADS Total score could explain 43% of the variance of MacNew
Global score in the follow-up period between 66% and 77% could
be explained.
To understand the drastic increase of the coefficient of determination it is helpful to refer to the fact that clinically relevant increase in
MacNew Global score of more than 0.5 takes place in 50–60% of the
patients. About one third of the patients remain stable and in about
10% a decrease of 0.5 or more is found.
Looking at the development of the regression equation for clinically
relevant improving and stable patients separately it becomes clear
why the increase of the explanatory power of the linear regression
equation takes place: Figure 26 shows the situation at the baseline
(a) and the situation after 6 months (b). The smaller R^2 at the
baseline results from a merging of 2 distinct groups, the (i) clinically
relevant improving patients (brown) and (ii) stable patients (green).
The coefficient of determination R^2 increases in the follow-up period because the improving patients move towards the stable patients.
Conclusion Our data suggest that the regression equation in the
follow-up period describes a state of equilibrium: a certain degree of
Quality of Life is reflected by a certain degree of mental distress. At
the baseline, the manifestation of the coronary disease and/or the
conditions of treatment cause an imbalance between these variables
– maybe because of different temporal patterns of change in HRQoL
and Anxiety and Depression scores. But not all patients experience
this imbalance: it seems obvious that the improving patients must
have deteriorated in the first place. We assume that the stable patents
have not experienced such deterioration and are therefore not improving in the follow-up period.
In order to use MacNew and HADS as monitoring and/or prognostic
tools it seems promising to refer to the state of equilibrium to define
expectancy values for single patients. This approach combines
MacNew and HADS and takes in consideration that more than a
third of the patients seem to experience no clinically relevant change
in HRQoL after PCI.
The High-Sensitive Cardiac Troponin T (hs-cTnT)
Assay is Superior to its Previous Assay Generation
for the Prediction of 90-Day Clinical Outcome in
Ischemic Stroke
XIV – 1
M. Furtner, Th. Ploner, A. Hammerer-Lercher, St. Kiechl, O. Pachinger, J. Mair
Universitätsklinik für Neurologie; Universitätsklinik für Innere Medizin III/Kardiologie; Zentralinstitut für Labordiagnostik, Medizinische Universität Innsbruck
Background Cardiac troponin T (cTnT) has been shown previously to be a predictor of stroke outcome with decision limits in the
low measuring range of the assay. Recently a new high-sensitivity
assay generation (hs-cTnT) has been introduced which is characterized by improved analytical sensitivity and better precision at the
low measuring range. Because of more accurate measurement of
low troponin concentrations, we hypothesized that this assay may be
superior to its previous assay generation for prediction of stroke
Figure 26: O. Friedrich et al.
J KARDIOL 2012; 19 (5–6)
Figure 27: M. Furtner et al. Receiver operating characteristics curves
for prediction of 90-day outcome in ischemic stroke.
ÖKG-Jahrestagung 2012 – Abstracts
Materials and Methods cTnT was measured by assays from
Roche Diagnostics® on emergency department admission in 60 consecutive patients (35 males, age 69.4 ± 13.9 years) with ischemic
stroke who were subsequently admitted to our hospital’s stroke unit
from beginning of March to end of April 2010. The clinical 90-day
outcome of ischemic stroke patients was analyzed using the Austrian stroke registry. We used the modified Rankin scale (mRS) and
Barthel index (BI) as outcome measures and defined adverse outcomes as mRSe ≥ 3 (indicating dependence or death) and/or BI < 75
Results Stroke etiology was microangiopathy in 3, macroangiopathy in 17, cardiac embolism in 26, dissection in 1 and unknown in
13 patients. At 90-day follow-up, 16 (27%) patients had an adverse
outcome. Receiver operating characteristic curve (ROC) analysis of
the predictive performances yielded a significant better performance
of hs-cTnT vs cTnT (Figure 27; area under curve: 0.80 vs 0.70;
p = 0.017). The optimal discriminator values were 11 ng/L (detection
limit of the old cTnT assay 10 ng/L) and 5.1 ng/L (detection limit of
the hs-cTnT assay 5 ng/L), respectively, with the following characteristics: sensitivity 56 vs 94%, specificity 84 vs 57%, positive predictive value 57 vs 45%, and negative predictive value 84 vs 96%.
Conclusion The improvements in cTnT assay analytical sensitivity and assay precision at the low measuring range resulted in a significant improvement of cTnT as a predictor of outcome in ischemic
stroke, particularly in respect of negative predictive value, for ruling
out worse outcome.
Mitochondriopathie als seltene Ursache eines kardialen hypertrophen Phänotyps – ein Fallbericht
XIV – 2
P. Hörmann, Ch. Fauth, J. Zschocke, S. Bösch, O. Pachinger, G. Pölzl
Abteilung für Innere Medizin III, Humangenetik, Neurologie, Medizinische Universität Innsbruck
Der Patient wurde im Alter von 36 Jahren zur Abklärung einer
hypertrophen Kardiomyopathie vorgestellt, welche anlässlich einer
kürzlich vorausgegangen kardialen Dekompensation erstmalig diagnostiziert wurde. Es bestand bereits seit ca. 3 Jahren eine zunehmende Leistungseinschränkung. An Vorerkrankungen konnte eine
bilaterale Innenohrschwerhörigkeit mit Hörgerätversorgung seit
dem 24. Lebensjahr, ein relativer Kleinwuchs sowie ein insulinpflichtiger Diabetes mellitus (ED mit 21 Jahren) erfasst werden.
Weiters bestand eine okuläre Apraxie, eine mehrmals wöchentlich
auftretende Cephalea sowie Z. n. fraglicher TIA. Klinisch fand sich
kein Hinweis auf eine Myopathie. Die Mutter des Patienten verstarb
relativ jung an einem Schlaganfall, ein Bruder des Patienten hat
ebenfalls einen insulinpflichtigen Diabetes mellitus.
Echokardiographisch zeigte sich eine asymmetrische linksventrikuläre Hypertrophie ohne nachweisbare intrakavitäre Obstruktion. Die
systolische LVF war deutlich eingeschränkt. In der Koronarangiographie fand sich eine wirksame Stenose eines diagonalen Astes, die
Füllungsdrücke waren normal. Eine kardiale Amyloidose konnte
bioptisch ausgeschlossen werden.
Die Befundkonstellation – Kardiomyopathie, insulinpflichtiger
Diabetes mellitus, okuläre Apraxie, relativer Kleinwuchs, erhöhtes
Laktat im Serum und Laktatpeaks in der zerebralen MRT-Spektroskopie – war hinweisend auf eine Mitochondriopathie. Die histopathologische Aufarbeitung der Endomyokardbiopsie unterstützte
diese Vermutung. Die molekulargenetische Mutationsanalyse der
aus dem Herzmuskelgewebe gewonnenen mitochondrialen DNA
ergab eine Mutation im Gen der t-RNA für Leucin (MTTL1-Gen),
m.3243A > G. Diese Mutation ist in Zusammenhang mit verschiedenen syndromalen und nicht-syndromalen Mitochondriopathien
(insbesondere MELAS, Mitochondrial Encephalomyopathy, Lactic
acidosis, Stroke-like episodes) beschrieben. Da die diagnostischen
Kriterien für ein MELAS-Syndrom nur teilweise erfüllt waren, wurde die Diagnose einer Mitochondriopathie mit Kardiomyopathie,
Schwerhörigkeit, Diabetes mellitus und okulärer Apraxie gestellt.
Eine ursächliche Therapie für diese Erkrankung ist derzeit nicht verfügbar. Manche Patienten profitieren von einer medikamentösen
Therapie mit Coenzym Q10. Die Gabe bestimmter Medikamente ist
kontraindiziert bzw. sollte nur unter entsprechenden Vorsichtsmaßnahmen erfolgen (z. B. Propofol, Valproin-Säure). Nach Verbesserung der LV-Funktion unter neurohumoraler Therapie ist der
Patient dzt. in einem klinisch stabilen Zustand.
Der präsentierte Fall unterstreicht die Notwendigkeit einer exakten
syndromologischen Charakterisierung von Patienten mit kardial
hypertrophem Phänotyp sowie die Wichtigkeit der interdisziplinären Zusammenarbeit zur Diagnosefindung.
Furosemide-Induced Severe Hypokalemia with
Rhabdomyolysis Without Dysrhythmia
W. Ruisz, C. Stöllberger, J. Finsterer, F. Weidinger
2. Medizinische Abteilung, Krankenanstalt Rudolfstiftung, Wien
Background and Objectives Hypokalemia induced by diuretic
abuse is a life-threatening emergency.
Case Report A 22-year-old female nurse with a BMI of 18 suffered from myalgias, vomiting and diarrhea. Blood tests revealed
hypokalemia with a lowest value of 1.1 mmol/l, moderate hyponatremia, metabolic alkalosis, mild renal insufficiency and CK
elevation. The electrocardiogram showed ST-segment abnormalities and a prolonged QT interval. Since hypokalemia and alkalosis
were unexplained, she was asked for diuretic-intake. She confessed
that she has taken 250 mg furosemide/day for the last 4 months to
improve the shape of her muscles, which she received from a physician attending the gym where she exercised. After electrolyte substitution, laboratory and electrocardiographic abnormalities regressed
and no dysrhythmias were observed. Psychiatric investigation diagnosed an adjustment disorder.
Conclusion Furosemide abuse has to be considered even in underweight individuals, especially if they have a psychiatric instability or work in health care institutions. Gym-operators should be informed about the possibility of severe side effects from chronic furosemide abuse and non-indicated uncontrolled misuse has to be
prohibited by responsible authorities.
Diagnostic and Therapeutic Yield of a Geriatric
Assessment in Elderly Patients with Severe Aortic
Stenosis Considered for Endovascular Valve Replacement: Filling Hidden Gaps of Care
Th. Schickmaier, F. Landertshammer-Gugler, J. Aichinger, Ch. Ebner, V. Eder,
R. Steringer-Mascherbauer, J. Niel, W. Tkalec, Th. Sturmberger, H.-J. Nesser,
H. Koller
Abteilung für Kardiologie, Krankenhaus der Elisabethinen, Linz
Background Aortic stenosis is almost exclusively a disease of the
elderly. Older age is also associated with a significant burden of
comorbidity and specific geriatric care issues. These often called
“geriatric syndromes” interfere with older adults’ abilities to perform basic daily activities, threaten their independence and lower
their quality of life. A geriatric assessment might identify coexisting
health problems and support cardiologists in treatment decisions
and managing these patients.
Methods The goal of the study was to evaluate the diagnostic and
therapeutic yield of a geriatric assessment through a standardized,
evidence based protocol in elderly patients with severe aortic stenosis considered for aortic valve replacement for so far undetected
geriatric care issues. The test instruments used included the MNA©,
ADLs, IADLs, GDS, Timed Get up&Go, Chair Rising Test, the
Mini Cog©, Frieds Frailty criteria and the Carlson Morbidity score.
Based on the assessment, a geriatric problem list and treatment plan
was developed using a standardized intervention plan, and patients
were stratified into performance categories defined as Healthy/
‘GoGo’, Vulnerable/‘SlowGo’ or Frail/‘NoGo’.
Results and Discussion The median number of interventions
based on the geriatric assessment of 117 patients (age 81.7 ± 5.6)
was 2 ± 1.4 (range 0–6), with 75 (63%) patients receiving 2 or more
J KARDIOL 2012; 19 (5–6)
ÖKG-Jahrestagung 2012 – Abstracts
interventions. Interventions most commonly suggested were medication modification (38%), physical therapy (23%) and neurocognitive evaluation (17%), followed by psychiatric evaluation (7%),
dietology referral (7%), social services referral (3%) and incontinence evaluation (3%).
27 (22%) patients were classified as Frail/‘NoGo’, 39 (33%) as
Healthy/‘GoGo’ and 51 (45%) as Vulnerable/‘SlowGo’.
Conclusion In our cohort of geriatric patients with severe aortic
stenosis considered for endovascular valve replacement, geriatric care
issues and the need for interventions identified by a geriatric assessment were common. Based on the assessment 22% of the patients
were stratified as physically ‘frail’. Although the effects of multidisciplinary interventions have not been evaluated in this study, our findings underline the burden of geriatric care issues in patients considered for endovascular valve replacement and suggest that a specialist
team approach is more likely to reach optimal treatment outcomes.
Bestehen zwischen Labortests und Schnelltests
zum Nachweis von D-Dimeren Unterschiede der
Produktsicherheit? – Analyse der bis Ende 2010 vom
BfArM erhaltenen Meldungen
R. Siekmeier, D. Wetzel
Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Deutschland
Einleitung Seit Implementierung der Richtlinie 98/79/EG zu Invitro-Diagnostika (IVD) müssen Vorkommnisse und korrektive
Maßnahmen zu IVD den zuständigen Behörden gemeldet werden.
Für fast alle IVD ist dies das BfArM (einige Produkte aus Anhang II
A und B der Richtlinie 98/79/EG fallen in die Zuständigkeit des
Paul-Ehrlich-Instituts). Ziel der Studie war die Analyse der Meldungen zu D-Dimertests.
Material und Methoden Analysiert wurden alle von Anfang
1999 bis Ende 2010 eingegangenen Meldungen bezüglich Meldequelle, Patientenschädigung (PS), Häufigkeit/Art von Produktfehlern bzw. korrektiven Maßnahmen.
Ergebnisse Von 2851 Meldungen zu IVD betrafen 190 IVD zur
Untersuchung der Gerinnung (6,7 % aller Meldungen zu IVD), davon 99 Tests, Kits und Reagenzien zum Gebrauch durch professionelle Anwender (3,5 %), 26 Analysengeräte und deren allgemeines
Verbrauchsmaterial (0,9 %) sowie 65 Gerinnungsselbsttests (Geräte
und Teststreifen, 2,3 %). Von den 99 Meldungen zu Gerinnungstests zum Gebrauch durch professionelle Anwender betrafen 14
Schnelltests (ST) und 11 Labortests (LT) zur Bestimmung von DDimeren. Meldungen zu ST kamen meist von Herstellern (12), seltener Behörden (1) und Anwendern (1). Auch bei LT überwogen Herstellermeldungen (6/4/1). Ein PS lag in 3 Fällen (alle ST) vor. Bei
ST fand sich nur in 1 Fall (7,1 %) ein Produktfehler (Materialfehler).
Kein Produktfehler bzw. Anwenderfehler fanden sich in 3 bzw. 2
Fällen. In 8 Fällen (57,1 %) blieb die Ursache unklar, da ST der
Anwender nicht mehr zur Verfügung standen und Rückstellmuster
eine normale Funktion zeigten. Bei LT fanden sich in 10 Fällen
(90,1 %) Produktfehler, meist Produktionsfehler (6); in 1 Fall lag
kein Produktfehler vor. Korrektive Maßnahmen erfolgten bei ST
nur in 1 Fall (7,1 %; u. a. Rückruf). Bei LT erfolgten in 5 Fällen
(45,5 %) korrektive Maßnahmen in D (5 weitere nur außerhalb D, da
Produkt dort nicht im Verkehr). Bei den Maßnahmen in D handelte
es sich (Mehrfachnennungen) meist um Kundeninformationen (5,
obligat bei Rückruf), Änderungen in Produktion/Qualitätsmanagement (5) und Rückruf (4).
Diskussion Meldungen zu D-Dimertests stellen eine wichtige
Untergruppe der Meldungen zu Gerinnungstests und -reagenzien
zum Gebrauch durch professionelle Anwender dar. Die Untersuchung auf mögliche Fehlerursachen wird vor allem bei ST durch das
Fehlen von Patientenproben und Teststreifen der Anwender erschwert. Als Folge der geringen Häufigkeit nachgewiesener Produktfehler finden sich bei ST seltener korrektiver Maßnahmen. Art
und Häufigkeit von Produktfehlern und korrektiven Maßnahmen
J KARDIOL 2012; 19 (5–6)
bei LT zur Bestimmung von D-Dimeren sind wesentlich häufiger
und entsprechen denen anderer Labortests zur Gerinnungsdiagnostik. Die erhaltenen Ergebnisse zeigen deutliche Unterschiede zwischen ST und LT und belegen die Notwendigkeit und Funktion des
bestehenden Systems der Marktüberwachung zur Sicherstellung
und Verbesserung der Produktsicherheit von IVD.
Häufigkeit und Art von Produktfehlern und Patientenschädigungen bei Systemen zur Gerinnungsselbstmessung – Analyse der 1999 bis 2010 vom BfArM
erhaltenen Meldungen
R. Siekmeier, D. Wetzel
Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Deutschland
Einleitung Seit Implementierung der Richtlinie 98/79/EG zu Invitro-Diagnostika (IVD) sind Vorkommnisse und korrektive Maßnahmen zu IVD den zuständigen Behörden zu melden. In Deutschland ist dies für fast alle IVD das BfArM (einige Produkte der Immunhämatologie und Infektiologie aus Anhang II A und B der Richtlinie
98/79/EG fallen in die Zuständigkeit des Paul-Ehrlich-Instituts [PEI];
zuständige Behörde für alle IVD in Österreich: BASG). Ziel dieser
Studie war die Analyse der Meldungen zu Gerinnungsselbsttests (Geräte und Teststreifen) zum Gebrauch durch Patienten.
Material und Methoden Analysiert wurden sämtliche im Beobachtungszeitraum von Anfang 1999 bis Ende 2010 beim BfArM
eingegangenen Meldungen in Hinblick auf Meldequelle, Patientenschädigung sowie Häufigkeit/Art von Produktfehlern bzw. korrektiven Maßnahmen.
Ergebnisse Von 2851 Meldungen zu IVD betrafen 190 IVD zur
Untersuchung der Gerinnung (6,7 % aller Meldungen zu IVD),
davon 99 Tests, Kits und Reagenzien zum Gebrauch durch professionelle Anwender (3,5 %), 26 Analysengeräte und deren allgemeines
Verbrauchsmaterial zum Gebrauch durch professionelle Anwender
(0,9 %) sowie 65 Gerinnungsselbsttests (Geräte und Teststreifen,
2,3 %) zum Gebrauch durch Patienten. Meldungen zu letzteren kamen meist von Herstellern (56; 86,2 %), seltener von Anwendern (8;
12,3 %) und Behörden (1; 1,5 %). In 31 Fällen (47,7 %) wurde eine
Patientenschädigung (PS; Blutung, Apoplex, Thrombose, Embolie
etc.) thematisiert. In 31 Fällen (47,7 %, davon 24 mit PS) wurde ein
Produktfehler ausgeschlossen. In 16 Fällen (24,6 %, alle ohne PS)
wurden Produktfehler identifiziert, meist Produktionsfehler (3),
Materialfehler (2), Softwarefehler (2), Verfehlen der Spezifikation
(2) und fehlerhafte Gebrauchsanweisungen (2), seltener Verpackungsfehler, Interferenzen, Kennzeichnungsfehler, mechanische
und elektrische Fehler (je 1). Weiteren 2 Fällen (3,1 %, ohne PS)
lagen Anwenderfehler zugrunde. In den übrigen 16 Fällen (24,6 %,
davon 7 mit PS) blieb die genaue Fehlerursache unklar, da die Produkte nicht oder nur teilweise (z. B. fehlende Teststreifen des Anwenders) zur Verfügung standen und die von den Herstellern untersuchten Produkte (z. B. Rückstellmuster der betroffenen Teststreifencharge) keine Auffälligkeiten zeigten. Korrektive Maßnahmen
erfolgten in 16 Fällen (24,6 %, 1 Fall mit PS) und waren meist Kundeninformation (15, obligat bei Rückruf), Rückruf (11) sowie Änderungen in Produktion/Qualitätskontrolle (6), Software (3), Gebrauchsanweisung (3), Design (2) und Kennzeichnung (1).
Diskussion Seit Beginn 1999 nimmt die Anzahl der Meldungen
zu IVD kontinuierlich stark zu, was auf eine zunehmende Etablierung des Systems der Marktüberwachung hinweist. Die Analyse der
Meldezahlen zu IVD zeigt, dass Gerinnungsselbsttests eine wichtige Produktgruppe innerhalb dieser Gruppe darstellen. Im Vergleich
zu anderen IVD finden sich bei Gerinnungsselbsttests – evtl. als
Folge der Sensibilisierung der Hersteller – häufiger Meldungen mit
PS, die bei späterer Untersuchung jedoch keinen Zusammenhang zu
Produktfehlern und korrektiven Maßnahmen aufweisen. Die erhaltenen Ergebnisse zeigen die Notwendigkeit und Funktion des bestehenden Systems der Marktüberwachung zur Sicherstellung und
Verbesserung der Produktsicherheit von IVD.
ÖKG-Jahrestagung 2012 – Abstracts
Figure 28: M. Sponder et al.
Sex Matters! Influence of Sex and Etiology on
Endostatin Serum Levels in Patients with Chronic
Heart Failure (CHF)
XIV – 4
M. Sponder, R. Pacher, M. Hülsmann, M. Gwechenberger, J. Knoth, St. Kampf,
M. Fritzer-Szekeres, B. Litschauer, J. Strametz-Juranek
Division of Cardiology, Department of Internal Medicine II, Medical University
Background Endostatin, a potent angiostatic factor, inhibits endothelial cell proliferation and migration and stimulates endothelial
nitric oxide synthase (e-NOS). Chronic heart failure (CHF) is a
vasoconstictive state associated with a significant upregulation of
neurohumeral factors such as brain-natriuretic peptide (BNP), predicting morbidity and mortality in CHF patients. Therefore, the aim
of the present study was to investigate the impact of sex, etiology
and functional heart class in CHF on serum endostatin levels.
Material and Methods Endostatin levels were measured (ng/ml)
at rest in 75 individuals, divided into 2 groups: 30 CHF-patients (17
dilatative, 13 ischemic; 9 NYHA I, 9 NYHA II, 12 NYHA III) and a
control group consisting of 45 “elderly” non smokers (female vs
male). In the CHF group also BNP was measured.
Results In contrast to the control group, which showed no gender
specific difference in mean endostatin levels (female: 112.33 ±
23.59; male: 116.55 ± 16.65), male CHF-patients (263.00 ± 115.39)
had much higher endostatin levels compared to female CHF-patients (191.36 ± 52.94). Endostatin levels in dCHF were 192.25 ±
44.85 compared to iCHF 260.69 ± 116.02. Endostatin also showed a
positive correlation to BNP-levels in the CHF group (p < 0.003).
1. CHF is associated with upregulation of endostatin levels, especially in female patients
2. CHF based on ischemic heart disease is associated with higher
Endo serum levels compared to DCHF
3. Furthermore, Endostatin serum levels correlate to BNP levels in
CHF patients. Further studies are warranted, to investigate the impact of Endo as prognostic marker in CHF patients (Figure 28).
Transitioning from Subcutaneous to Intravenous
Treprostinil Administered by the Implantable Infusion Pump LenusPro®: A Single-Center Pilot Study
XIV – 6
R. Steringer-Mascherbauer, V. Eder, C. Huber, S. Wittrich, R. Függer, U. Fröschl,
H. J. Nesser
Abteilung für Kardiologie, Krankenhaus der Elisabethinen, Linz
Introduction Parenteral Treprostinil is a mainstay in the therapy
of pulmonary arterial hypertension (PAH). However, administration
of parenteral prostanoids with external pump systems is technically
challenging and associated with significant side effects such as infusion site pain with subcutaneous (s. c.) and possibly life-threatening
catheter-related infections with intravenous (i. v.) administration.
The Lenus Pro® implantable infusion pump was specifically developed to overcome the drawbacks of s. c. administration of Treprostinil. In 2010, we reported the first implantation of a Lenus Pro®
pump with a filling interval of 28 days.
Methods We performed a retrospective chart analysis to assess
safety and efficacy of i. v. Treprostinil delivered by Lenus Pro®. The
study was approved by the local ethics committee.
Results Between September 2010 and October 2011, 14 patients
underwent implantation at our center. All patients had experienced
significant clinical benefits with s. c. Treprostinil but reported serious site pain associated with the change of the infusion site. Under
general anesthesia, a catheter was placed in the Vena subclavia, or
cephalica, according to the decision of the implanting surgeon. After
preparation of the pump pocket in the abdominal wall, the pump was
connected to the central venous access. To avoid overlap effects,
s. c. Treprostinil was stopped one hour after connection. No intraoperative complications occurred. Postoperatively two patients developed a mild seroma, one requiring puncture. No other complications especially no infections, were observed. We have performed
more than 60 refill procedures. To date one patient died during follow-up, the remaining patients are clinically stable and report an
increased quality of life.
Conclusion This first pilot study demonstrates that i. v. Treprostinil, delivered by the implantable pump Lenus Pro®, is safe, effective and feasible in PAH patients transitioned from s. c. Treprostinil.
Filling intervals of 28 days ensure optimal compliance and patient
management. The absence of side effects such as infusion site pain is
associated with a dramatic increase in quality of life.
Neurological Comorbidity Affects Prognosis in Left
Ventricular Hypertrabeculation/Noncompaction
XIV – 3
C. Stöllberger, G. Blazek, Ch. Wegner, J. Finsterer
2. Medizinische Abteilung, Krankenanstalt Rudolfstiftung, Wien
Objective Left ventricular hypertrabeculation/noncompaction
(LVHT) is a cardiac abnormality which is frequently associated with
neuromuscular disorders (NMD). It is unknown, if there are differences between LVHT-patients with and without NMD. Aim of the
study was to compare baseline characteristics and prognosis of
LVHT-patients with and without NMD.
Methods Included were patients in whom LVHT was diagnosed in
one echocardiographic laboratory between June 1995 and June 2011.
They underwent a baseline cardiologic examination and were invited
for a neurological investigation. In June 2011, the patients were contacted by telephone and assessed if the patient was alive or not.
Results LVHT was diagnosed in 172 patients (53 female, mean
age 53 ± 16 years). 123 patients (72%) were investigated neurologically. A specific NMD was diagnosed in 25: Metabolic myopathy
n = 16; Leber’s hereditary optic neuropathy n = 3; myotonic dystrophy n = 3; Becker muscular dystrophy n = 1; post-poliomyelitis syndrome n = 1, and Duchenne muscular dystrophy n = 1. A NMD of
J KARDIOL 2012; 19 (5–6)
ÖKG-Jahrestagung 2012 – Abstracts
unknown etiology was diagnosed in 79 patients, and the neurological investigation was normal in 19 patients. During a follow-up of
64 months the mortality was 4.84%/year. Baseline data did not differ between patients with and without NMD. No death occurred
among the patients without NMD although they had a longer observation period (8 vs 4 years, p = 0.01) than patients who were not
investigated neurologically.
Conclusions Presence or absence of NMD influences prognosis
of LVHT-patients, why LVHT-patients should be referred to the
neurologist. Presence or absence of a NMD should be considered in
therapy-planning of LVHT-patients.
The proANP Increase During Exercise may Predict
the PAP Increase in Connective Tissue Disease
Patients at Risk of PAH
XIV – 5
M. Tscherner, G. Kovacs, F. Fruhwald, R. Maier, B. Obermayer-Pietsch, V. Foris,
H. Olschewski
Abteilung für Pulmologie; Abteilung für Kardiologie; Abteilung für Endokrinologie,
Universitätsklinik für Innere Medizin, Medizinische Universität Graz; LudwigBoltzmann-Institut für Lungengefäßforschung, Graz
Background Natriuretic peptides (brain natriuretic peptide (BNP)
and atrial natriuretic peptide [ANP]) are produced in cardiomyocytes of different myocardial regions. In case of dilation of the heart,
BNP and ANP are excessivly released into the circulation. BNP is
used as a biomarker in patients with chronic heart failure and pulmonary hypertension (PH). ANP is a marker of acute cardiac stress and
may reflect actual hemodynamic changes during exercise. In connective tissue disease an excessive increase of pulmonary pressure
may represent an early stage of pulmonary vascular disease and may
be clinically relevant.
Patients and Methods We investigated plasma levels of
proANP and NT-proBNP during right heart catheterization at rest
and exercise in patients with connective tissue disease without PH.
The levels at rest and during exercise were compared by Wilcoxon
signed rank test. The correlations between the changes of mean PAP
and NT-proBNP as well as mean PAP and proANP were calculated
by Spearman’s Rho test.
Results 47 patients (resting mean PAP: 16 ± 3 mmHg, mean PAP
at maximal exercise: 37 ± 8 mmHg) were included. NT-proBNP and
proANP significantly increased from rest to exercise (NT-proBNP
rest: 91 ± 102 pg/mL, maximal exercise: 96 ± 96 pg/mL, p < 0.001;
proANP rest: 2.43 ± 1.22 pg/mL, maximal exercise: 2.92 ± 1.33 pg/mL,
p < 0.001). The increase in proANP levels between rest and maximal
exercise significantly correlated with the increase in meanPAP
(p = 0.007, r = 0.404), but there was no significant correlation for
NT- proBNP (p = 0.606).
Conclusion Our results suggest that the exercise induced increase
of proANP in patients with connective tissue disease may indicate
the exercise-induced increase in PAP.
Compression-Only-CPR in Telephone-Assisted Bystanders: Is “To Push as Hard as You Can” Superior
in Achieving 5–6 cm Chest Compression Depth than
the Current Guideline Recommendation? A Double
Randomized-Parallel-Group-Simulation-Study V – 2
Figure 29: R. van Tulder et al. Participant estimations of compression
Table 5: R. van Tulder et al. Demographic data of voluntary participants
(n = 13)
(n = 13)
Female – n (%)
7 (58)
5 (38)
Age – mean ± SD
40 ± 14
33 ± 13
BMI – mean ± SD
27 ± 4
26 ± 4
FFB-Mot – mean ± SD
105 ± 14
111 ± 14
Right hander – n (%)
12 (92)
12 (92)
Smoking history – n (%)
4 (31)
8 (62)
Pack years – median (IQR)
0 (0–10)
0 (0–10)
SD = standard deviation; BMI = body mass index; FFB-Mot = physical
fitness questionnaire; IQR = interquartile range
outcome was defined as compression depth. Secondary outcomes
were defined as drawn estimation of 5 cm by every participant, exertion measured by BORG scale, modified Nine Hole Peg Test (NHPT),
provider’s systolic and diastolic blood pressure and the quality values
measured by the Resusci® Anne skillmeter manikin.
Results 13 participants were each allocated to control and intervention. 1 participant of the intervention group dropped out after
minute 7 for exhaustion. Primary outcome showed a mean compression depth of 44.1 mm with an interindividual standard deviation
(SDb) of 13.0 mm and an intraindividual standard deviation (SDw)
of 6.7 mm for the control group versus 46.1 mm and a SDb of 9.0 mm
and a SDw of 10.3 mm for the intervention group (Difference: 1.9
[–6.9 to –10.8]; p = 0.66). For secondary outcome participants estimated a mean of 43 ± 13 mm in control group versus 45 ± 15 mm in
the intervention group (p = 0.99). Secondary outcome investigating
exhaustion and COCPR quality values did not show any difference.
Conclusion There is no difference in compression depth, quality
of COCPR or physical strain on lay-rescuers when advising “push as
hard as you can” versus the standard AMPDS instruction “push
down firmly 5 cm” (Figure 29, Table 5, 6).
 Herzinsuffizienz/Heart Failure
R. van Tulder, D. Roth, Ch. Havel, Ph. Eisenburger, B. Heidinger, Ch. C. Chwojka,
H. Novosad, F. Sterz, H. Herkner, W. Schreiber
Universitätsklinik für Notfallmedizin, Medizinische Universität Wien; Notruf NÖ,
St. Pölten
Schlafbezogene Atemstörungen bei Patienten mit
chronischer Herzinsuffizienz und optimierter medikamentöser Therapie
VI – 5
Background In telephone-assisted, advanced medical priority dispatch system (AMPDS) driven, lay-rescuer, compression only cardiopulmonary resuscitation (COCPR) it remains unclear whether the
instruction “push as hard as you can” improves compression depth.
Methods This was a prospective, experimental, double-blinded,
randomized, controlled, parallel group study to investigate chest compressions following the instruction “push as hard as you can”. Primary
P. Dolliner, P. Ubl, L. Ringhofer, L. Stiebellehner, G. Steurer
Abteilung für Nuklearmedizin, Medizinische Universität Wien
J KARDIOL 2012; 19 (5–6)
Einleitung Ein Fortschreiten von chronischer Herzinsuffizienz
(HI) kann durch wiederholt auftretende nächtliche Atemstörungen
begünstigt werden. Das insuffiziente Myokard wird zusätzlich
durch ein Ansteigen der Vorlast, Nachlast und des Sympathikotonus
sowie durch vermehrt auftretende Arrhythmien beeinträchtigt. Aus
ÖKG-Jahrestagung 2012 – Abstracts
Table 6: R. van Tulder et al. Secondary outcomes: Performance data measured with Resusci® Anne Skillmeter
Total External Chest Compressions (ECC)* – (n per minute)
ECC – accurate* – (n per minute)
ECC – too shallow* – (n per minute)
ECC – too deep* – (n per minute)
ECC – correct hand position* – (n per minute)
ECC – incomplete recoiling* – (n per minute)
ECC – mean frequency* – (n per minute)
ECC – compression/relaxation ratio* (%)
Mean hands off – (seconds per minute)
BORG scale – at study end
HR – last minute (bpm)
SBP at study end (mmHg)
DBP at study end (mmHg)
NHPT – at study end (seconds)
mean ± SDb (SDw)
mean ± SDb (SDw)
(95 % CI)
94.5 ± 5.3 (27.6)
2,8 ± 5,5 (12,3)
57,1 ± 40,3 (30,2)
33,8 ± 33,8 (16,1)
37,3 ± 34,3 (29,3)
70,6 ± 42,8 (26,1)
100,6 ± 18,0 (17,4)
46,4 ± 7,6 (7,2)
2,0 ± 7,3
15 ± 2
103 ± 16
159 ± 10
92 ± 6
25 ± 4
88.1 ± 16.0 (28.3)
0,34 ± 0,20 (2,0)
52,6 ± 38,2 (29,0)
18,8 ± 32,9 (18,0)
40,2 ± 30,6 (30,2)
80,4 ± 34,9 (92,8)
92,8 ± 9,1 (18,3)
47,9 ± 9,3 (7,4)
1,9 ± 7,2
15 ± 3
98 ± 17
156 ± 15
96 ± 10
27 ± 4
6.4 (–5.0 to 17.8)
2,4 (–1,2 to 6,1)
4,4 (–26,5 to 35,5)
–0,3 (–26,3 to 25,7)
–2,8 (–28,9 to 23,2)
–9,8 (–44,1 to 24,5)
7,7 (–4,0 to 19,5)
–1,4 (–8,2 to 5,3)
0,1 (–1,6 to 1,8)
0,1 (–1,6 to 1,8)
5,2 (–4,2 to 14,7)
3,4 (–4,0 to 10,7)
–1,3 (–6,8 to 4,3)
–1,2 (–4,1 to 1,6)
* Estimates are adjusted for panel data structure with repeated measurements. SDb denotes between (interindividual) standard deviation of the random
intercepts; SDw denotes within cluster (intraindividual) standard deviation. Measurements denoted as “at study end” were performed immediately after participants stopped chest compression.
ECC = external chest compression; BORG = Scale of perceived exertion; HR = heart rate; bpm = beats per minute; SBP = systolic blood pressure; mmHg =
millimeters mercury; DBP = diastolic blood pressure; NHPT = Nine Hole Peg Test
früher durchgeführten Studien ist eine hohe Prävalenz von Schlafapnoe bei Kardiomyopathie-Patienten bekannt. In diesen Arbeiten
fanden allerdings die leitliniengerechten medikamentösen Therapieschemen kaum Beachtung. Das Ziel unserer Arbeit war die Erfassung der Häufigkeit des Schlafapnoe-Syndroms bei Patienten mit
chronischem Herzversagen und optimierter medikamentöser Langzeitbehandlung.
Methoden Wir untersuchten 177 konsekutive Patienten ohne klinischen Hinweis für Schlafapnoe und zumindest mittel- bis höhergradig reduzierter linksventrikulärer Auswurfleistung und einer Erhöhung der natiuretischen Peptide (NT-pro BNP > 300 pg/ml). Patienten mit Zeichen einer dekompensierten HI oder instabilem Zustand wurden ausgeschlossen. Die Teilnehmer wurden mit nächtlicher Polygraphie, einem 5-Kanal-Aufzeichnungssystem (Embletta
X10®), untersucht.
Ergebnisse 151 (85,3 %) Teilnehmer waren männlich und 26
(14,7 %) weiblich. Das mediane Alter betrug 65,1 Jahre (Spannbreite 33,1–88,2 Jahre). Etwa 2/3 der Patienten (66,3 %) hatten eine
ischämische und die verbleibenden 36,7 % eine dilatative Kardiomyopathie. Die linksventrikuläre Auswurfleistung errechnete sich
mit durchschnittlich 24,6 ± 13,1 %. Bei den Teilnehmern wurde ein
medianes NT-pro BNP von 3320,5 pg/ml (Spannbreite 305,1–
35.000 pg/ml) gemessen.
172 (97,2 %) Teilnehmer wurden mit einem ACE-Hemmer oder
AT2-Blocker behandelt, 160 (90,4 %) standen unter medikamentöser Betarezeptorenblockade und 106 (60 %) nahmen regelmäßig
Spironolacton ein.
Bei 88 (49,7 %) Patienten wurde ein Apnea-Hypopnea-Index (AHI)
≥ 15/Stunde Aufzeichnungszeit festgestellt. Bei diesen Patienten lag
die mittlere Sauerstoffsättigung bei 92,2 %, die mittlere ereignisassoziierte Sauerstoffentsättigung betrug 7,3 % und die minimale
Sauerstoffsättigung errechnete sich mit durchschnittlich 78.7 %.
Durchschnittlich 72 Minuten (16,3 % der Aufzeichnungszeit) lag
die Sauerstoffsättigung bei diesen Patienten unter 90 %.
Bei 61 (69,3 %) Patienten bestand das pathologisch vorherrschende
Atemmuster hauptsächlich aus zentralen Ereignissen und bei den
verbleibenden 26 (29,6 %) Patienten handelte es sich überwiegend
um obstruktive Apnoen oder Hypopnoen im Sinne eines obstruktiven Schlafapnoe-Syndroms. Bei einem (1,1 %) Patienten konnte die
Atemstörung nicht weiter klassifiziert werden.
Diskussion Bei chronischem Herzversagen ist die Prävalenz von
schlafbezogenen Atemstörungen trotz evidenzbasierter optimierter
medikamentöser HI-Therapie hoch. Weitere Untersuchungen sind notwendig, um Erkenntnisse über die Auswirkungen der repetitiven nächtlichen Sauerstoffabfälle auf das insuffiziente Myokard zu erlangen.
The MitraClip System in Patients after Resynchronization Therapy and Persistent Significant Mitral
Regurgitation and Concomitant Heart Failure VI – 6
Ch. Ebner, Th. Sturmberger, W. Tkalec, J. Aichinger, R. Steringer-Mascherbauer,
V. Eder, G. Kabicher, J. Niel, H.-J. Nesser
Abteilung für Kardiologie, Krankenhaus der Elisabethinen, Linz
Background Despite cardiac resynchronization therapy (CRT)
significant functional mitral regurgitation (FMR) frequently persists
and may lead to sustained heart failure (HF) symptoms. Surgery in
most of these patients is of limited value due to high perioperative
risks whereas medical treatment may fail to compensate HF symptoms. The percutaneous repair with the MitraClip system offers an
additional therapeutic option in selected CRT-patients.
Methods and Results Between August 2009 and March 2012
MitraClip treatment was performed in 13 patients after previous device implantation (CRT-P or CRT-D). Indication of percutaneous
catheter-based mitral valve repair with the MitraClip system was
significant MR ≥ grade 3 and persistent symptoms of Heart Failure
NYHA ≥ 3.
Patients mean age was 72.2 ± 7.2 yrs, 61% were male. Median time
after resynchronization therapy was 53.5 months (IQR: 29–71). In
5/13 patients a CRT-D system was in place and in 30% an ischemic
cardiomyopathy was the underlying pathology of mitral regurgitation. LVEF was markedly reduced in all patients (mean LVEF
26.1 ± 5.4%) and 6/13 patients even had a LVEF ≤ 25%. Accordingly the log. EuroScore was markedly elevated (mean 28.9 ± 14.2%).
A single clip was successfully implanted in 11 patients (84%)
whereas 1 patient received 2 clips. In one patient the clip could not
be positioned appropriately, so treatment was feasible in 12/13 patients. Reduction of mitral regurgitation was obtained from grade
3.5 ± 0.3 to grade 1.4 ± 0.4. In12/13 pts. we had no major complications, only 1 patient developed cardiac tamponade treated by conservative means. ICU mean duration of stay was 2 days and total
hospitalization was median 9,5 days (IQR; 7–13 days). In-hospital
and 30 days mortality was zero and 12 month mortality was only
20% in this group of patients with multiple co-morbidities and without further treatment options. One patient underwent successful heart
transplantation due to deterioration of heart failure even reduction
of mitral regurgitation was consistent. Stage of heart failure could be
reduced from mean NYHA class 3.6 to class 2.5 and also distinct
reduction in NT-pro BNP levels was possible.
Conclusion Residual significant mitral regurgitation after CRT in
HF patients can be treated successfully by the MitraClip system to
reduce regurgitant volume. Mitral valve repair with the MitraClip
J KARDIOL 2012; 19 (5–6)
ÖKG-Jahrestagung 2012 – Abstracts
system is an attractive option in patients with significant mitral regurgitation and persistent heart failure symptoms over time despite
previous cardiac resynchronization therapy.
Endomyocardial Biopsy in Unexplained New-Onset
Heart Failure: Time Matters!
M. Frick, F. Kellner, S. Kellner, S. Pankuweit, B. Maisch, O. Pachinger, G. Pölzl
Universitätsklinik für Innere Medizin III/Kardiologie, Medizinische Universität
Innsbruck, Österreich; Universitätsklinik für Innere Medizin und Kardiologie,
Universität Marburg, Deutschland
Background The role of endomyocardial biopsy (EMB) in the
evaluation of patients with non-ischemic cardiomyopathy (CMP) is
still under debate. A recent AHA/ESC consensus document suggests to perform EMB in “unexplained new-onset heart failure of
2 weeks to 3 months duration”, although the scientific evidence for
this recommendation is scarce. The objective of this retrospective
study was to evaluate the impact of this time frame and to identify
prognostic parameters in patients with suspected inflammatory cardiomyopathy.
Methods 272 patients (mean age 45 ± 13 years), who underwent
EMB between March 2001 and November 2010 at the Department
of Cardiology at Innsbruck Medical University, were enrolled in
this study. Patients with a history of heart transplantation and those
suffering from systemic diseases (amyloidosis, sarcoidosis) were
excluded. Work up of biopsy specimens included immunohistology
for the assessment of myocardial inflammation and PCR for the detection of virus persistence. The combined endpoint was defined as
death for any reason, heart transplantation, assist device implantation or hospitalization for acute heart failure Mean follow-up was
32 ± 26 months.
Results Time from diagnosis of CMP to EMB was significantly
higher in patients with events compared to those without (18 months
vs 6 months; p < 0.001). Patients with NYHA-class III and IV suffered significantly more often from a cardiovascular event compared to those in NYHA-class I and II (33% vs 16%; p = 0.007).
Presence of bundle branch block (rate of events 32% vs 19%;
p = 0.047) and unspecific ST segment changes at time of first presentation (80% vs 63%; p = 0.016) were associated with poor outcome.
In multivariate analyses evidence of inflammation alone (p = 0.038)
or in combination with viral persistence (p = 0.025) was associated
with worse outcome only in patients presented within 3 months of
unexplained new-onset heart failure. On contrast, EMB results did
not impact on outcome in patients who presented after 3 months of
new-onset heart failure.
Conclusion Our data suggest, that time from diagnosis to EMB,
NYHA class as well as ECG changes are associated with worse outcome. In multivariate analyses we found that EMB-results had only
an impact on prognosis if patients underwent biopsy within 3 months
after new-onset of heart failure symptoms. Consequently, our study
supports the time frame suggested by the AHA/ESC consensus statement on EMB.
Outcome ein Jahr nach CRT-Implantation in
F. Fruhwald, B. Strohmer
Universitätsklinik für Innere Medizin, Medizinische Universität Graz; Paracelsus
Medizinische Privatuniversität Salzburg
Einleitung Entsprechend der europäischen HerzinsuffizienzGuidelines von 2008 ist die Cardiale Resynchronisationstherapie
(CRT) ein etabliertes Verfahren zur Behandlung von Herzinsuffizienz in den NYHA-Stadien III und IV bei Patienten mit vergrößertem
Durchmesser des linken Ventrikels (LVEDD > 55 mm) und eingeschränkter linksventrikulärer Auswurffraktion (LVEF < 35 %). Das
CRT-Survey, eine gemeinsame Initiative der Heart Failure (HFA)
sowie der Heart Rhythm Association (EHRA) der ESC, hat in den
Jahren 2008/2009 die in Europa gelebte Wirklichkeit im Hinblick
J KARDIOL 2012; 19 (5–6)
auf diese Therapieform abgebildet und nach 1 Jahr das Outcome der
Patienten erhoben. Wir berichten hier über die Daten der österreichischen Zentren.
Methodik Alle zwischen 1.11.2008 und 30.6.2009 an den 10 teilnehmenden Zentren implantierten CRT-Systeme wurden zusammen
mit den Ausgangs- sowie Outcomedaten erhoben. Es wurden lediglich Patienten dokumentiert, die ihr Einverständnis dazu gegeben
Ergebnisse 155 Patienten (117 männlich, 38 weiblich) mit einem
mittleren Alter von 68 ± 10 Jahren (31–86) wurden inkludiert, wovon sich 144 Patienten einem elektiven Eingriff unterzogen haben.
Es fanden sich folgende NYHA-Klassen: NYHA 1/2/3/4 bei 3/31/
110/11 Patienten. 96 Patienten hatten Sinusrhythmus, Vorhofflimmern wurde bei 58 Patienten (37 %) dokumentiert. Die Breite des
QRS-Komplexes betrug 158 ± 34 ms (80–250). Eine echokardiographische Untersuchung war bei 146 Patienten vorhanden, wobei
der LVEDD 65 ± 9 mm (45–98) und die LVEF 27 ± 8 % (10–50)
Die Eingriffe wurden überwiegend von Chirurgen durchgeführt (n =
109), Elektrophysiologen und interventionelle Kardiologen waren
ca. zu 1/3 (n = 35 resp. n = 21) die Implanteure. Es wurden überwiegend CRT-D (n = 120) implantiert, lediglich 35 Patienten (23 %)
erhielten einen CRT-P. Post implantationem betrug die Breite des
QRS-Komplexes 141 ± 27 ms (80–204). 148 Patienten (95 %) wurden mit einem ACE-Hemmer oder Angiotensin-Rezeptor-Blocker
entlassen, 133 (86 %) mit einem Betablocker, 125 (81 %) mit einem
Diuretikum und 71 (46 %) mit einem Aldosteron-Antagonisten.
Nach 12 ± 3 Monaten waren 15 Patienten (10 %) verstorben, 53
(37 %) wurden rehospitalisiert, überwiegend wegen Herzinsuffizienz. Komplikationen am Device waren bei 18 Patienten (13 %) dokumentiert, wobei Sondendislokationen (n = 5), Sondenmalfunktionen (n = 5) und Phrenikusstimulation (n = 6) am häufigsten auftraten. Erfreulicherweise wurde keine Infektion beobachtet. Appropriate Schocks waren in 6 Fällen, inappropriate in 5 Fällen sowie
appropriates antitachykardes Pacing (ATP) in 13 Fällen nachweisbar. Die NYHA-Klassen zeigten einen eindeutigen Shift in Richtung leichtere Herzinsuffizienz: NYHA 1/2/3/4 fand sich bei 49/73/
13/7 Patienten. 96 Patienten wurden durch das CRT-Gerät stimuliert, überwiegend im DDD- (n = 61) oder im VVI-Modus (n = 28).
Die LVEF war im Mittel auf 38 ± 10 % (10–50) angestiegen, der
Ventrikeldurchmesser auf 60 ± 9 mm (42–91) zurückgegangen.
Das mediane NT-pro-BNP war von 2203 vor der Implantation auf
997 pg/ml gesunken.
Schlussfolgerung Die österreichischen Daten des CRT-Survey
zeigen, dass die Indikation zur Implantation großzügig und nicht
immer im Gleichklang mit den Guidelines gestellt wird. Die Herzinsuffizienz konnte durch die CRT in Kombination mit einer optimalen medikamentösen Therapie deutlich gemildert werden, dies
wurde sowohl subjektiv (NYHA-Klasse) als auch objektiv (NT-proBNP). Nichtsdestotrotz ist bei diesen chronisch kranken Patienten
mit einer beträchtlichen Rehospitalisierungsrate sowie einer 1-Jahres-Mortalität von 10 % zu rechnen.
Institutional Experience with Extracorporeal Membrane Oxygenation Support for Right Ventricular
Failure After Left Ventricular Assist Device Implantation
VI – 9
St. Mahr, F. Eskandary, J. Horvath, A. Rajek, G. Laufer, H. Schima, D. Zimpfer
Abteilung für Herzchirurgie, Medizinische Universität Wien
Background Right ventricular failure complicating left ventricular assist device implantation (LVAD) has a poor outcome. This
study was designed to determine the success of extracorporeal membrane oxygenation support (ECMO) for the treatment of right ventricular failure after LVAD implantation.
Methods From December 2008 to August 2011 13 patients (mean
age 56 yrs, male 92,3%) undergoing LVAD implantation at our department received an ECMO for therapy refractory right ventricular
failure. In 11 patients the ECMO was implanted at the time of
LVAD implantation due to inability to wean from CPB. In 2 patients
ÖKG-Jahrestagung 2012 – Abstracts
the ECMO was implanted preoperatively for therapy refractory
biventricular failure and continued postoperatively for right ventricular failure.
Results After recovery of right ventricular function, the ECMO
was successfully explanted in 10 of 13 patients (77%). Three patients
(23%) expired while on ECMO support. Mean duration of ECMO
support was 3 days. On patient died despite successful ECMO
weaning as a consequence of non-device related sepsis. Interestingly, mortality was higher in those patients receiving the ECMO
prior to LVAD implantation (50%), as compared to those receiving
the ECMO after inability to wean from cardiopulmonary bypass
(27%, p < 0.05). Overall in-hospital mortality was 30.7%.
Conclusion ECMO facilitates recovery of right ventricular function after LVAD implantation complicated by perioperative right
ventricular failure. Nevertheless, perioperative mortality remains
high, especially in those patients receiving the ECMO preoperatively for biventricular support.
Häufigkeit, Relevanz und Prognose von Elektrolytstörungen bei Herzinsuffizienzpatienten
VI – 4
M. Niederau, L. Stadlmüller, C. Colantonio, F. Fruhwald
Abteilung für Kardiologie; Institut für Medizinische Informatik, Statistik und
Dokumentation, Medizinische Universität Graz
Einleitung Die Niere spielt bei Herzinsuffizienz im Elektrolythaushalt die zentrale Rolle was Regulation und Aufrechterhaltung
von konstanten Elektrolytspiegeln betrifft. Hier greifen auch einige
für Herzinsuffizienz verwendete Medikamente an.
Methoden Es wurden die lokalen Daten aus dem Herzinsuffizienzregister der Arbeitsgruppe Herzinsuffizienz (AG-HI) der Österreichischen Kardiologischen Gesellschaft (ÖKG) herangezogen.
Patienten, die erstmalig in einer Spezialambulanz vorstellig wurden,
wurden nach Einholen des Einverständnisses in diesem Register
dokumentiert. Nach 12 Monaten wurde ein Follow-up erhoben.
Anhand der Natrium- und Kaliumwerte der Erstuntersuchung wurden die Patienten in Gruppen eingeteilt: Normalgruppe, Hypo-/
Hypernatriämie, Hypo-/Hyperkaliämie sowie deren Kombinationen. Die Hypokaliämie, Hypernatriämie und Hyperkaliämie mit
gleichzeitiger Hypernatriämie wurden aufgrund des geringen Vorkommens (n = 1) nicht berücksichtigt.
Resultate Das Patientenkollektiv bestand im Zeitraum von 2006–
2010 aus 228 Patienten (189 Männer, 39 Frauen, mittleres Alter
60 ±13 Jahre). Die medikamentöse Therapie bei Erstuntersuchung
bestand aus ACE-Hemmer bei 175 Patienten (77 %), AngiotensinRezeptor-Blocker bei 36 Patienten (16 %), Angiotensin-RezeptorBlocker oder ACE-Hemmer bei 207 Patienten (91 %), Diuretika bei
166 Patienten (73 %), Aldosteron-Antagonisten bei 132 Patienten
(58 %) und Betablocker bei 205 Patienten (90 %). Der Großteil der
Patienten war mit NYHA-Klasse II (44 %) und III (37 %) klassifiziert.
Insgesamt wiesen 43 Patienten (19 %) eine Elektrolytstörung bei
Erstuntersuchung auf. Ein statistisch signifikanter Zusammenhang
zwischen NYHA-Stadium und dem Vorhandensein von Elektrolytstörungen konnte nicht gefunden werden (p = n. s.).
Nach 12 Monaten waren 17 Patienten verstorben, 15 aus der Gruppe
mit normalen Elektrolyten und 2 aus der Gruppe mit Elektrolytstörungen (p = n. s.), wobei letztere aus der Gruppe mit Hyponatriämie sowie Hyponatriämie plus Hyperkaliämie stammten. Insgesamt wurden 111 Patienten rehospitalisiert, wobei mit 48 % aus
der Normalgruppe und 51 % aus der Gruppe mit Elektrolytstörungen kein signifikanter Unterschied zu finden war (p = n. s.). Die
Patienten mit Elektrolytstörungen waren im Mittel länger rehospitalisiert als Patienten mit normalen Elektrolyten.
Ein möglicher Zusammenhang einer Niereninsuffizienz (eGFR < 50)
und der Entwicklung einer Hyperkaliämie ließ sich statistisch nicht
belegen (p = n. s.).
Im Hinblick auf Medikamentendosierungen mit möglichem Einfluss auf die Elektrolyte konnte folgendes beobachtet werden:
Spironolacton wurde in der Gruppe der kombinierten Elektrolyt-
störungen in einer höheren Dosierung verordnet als in der Normalgruppe (59 mg/d vs. 38 mg/d), dieser Unterschied war allerdings
nicht statistisch signifikant. Dagegen wurde Furosemid in der Gruppe der Hyponatriämie wesentlich höher dosiert als in der Normalgruppe (69 mg/d vs. 43 mg/d; p = 0,0064).
Diskussion Elektrolytstörungen sind ein relativ häufiger Befund
bei Patienten mit Herzinsuffizienz. Solche Patienten sind länger
rehospitalisiert als Patienten mit normalen Elektrolyten, vor allem,
wenn eine Hyperkaliämie oder eine kombinierte Hyponatriämie/
Hyperkaliämie vorliegt. Ein möglicher Zusammenhang mit der medikamentösen Therapie der Erkrankung liegt nahe, da einzelne
Elektrolytstörungen mit signifikant höheren Dosierungen von Diuretika einhergehen als in der Normalgruppe.
Why Heart Failure Treatment Is Not Prescribed to
Heart Failure Patients. Data from the EuroHeart Failure Survey-III at an Austrian University Heart Failure
VI – 8
V. Platzer, K. Ablasser, F. Fruhwald
Universitätsklinik für Innere Medizin, Medizinische Universität Graz
Introduction The number of patients with heart failure is growing
steadily in the Western world. Although the European Society of
Cardiology (ESC) has published guidelines for the optimal treatment of heart failure it can be difficult to put this recommendation
into practice. Therefore, the ESC has initiated the EuroHeart Failure
Survey (EHFS)-III with the aim to get information about real world
reasons for not prescribing recommended heart failure therapies
Patients and Methods After giving written informed consent
patients with chronic heart failure have been asked in accordance
with the structured case report form provided by the ESC at baseline. After 12 months a follow-up is planned. Here we report the first
data from an Austrian university heart failure clinic taking part in
Results 33 patients (8 female, 25 male; median age: 56 years) have
been included in the EHFS between October 2011 and February
2012. 25 patients (76%) are treated with ACE-inhibitors (ACEI), 8
patients (24%) with Angiotensin-receptor-blockers (ARB), 31 patients (94%) with beta-blockers (BB) and 27 patients (82%) were
treated with Aldosteron-antagonists (AldoA).
Of the 25 patients treated with an ACEI 8 (32%) were on recommended daily dose while 9 (36%) could not be further uptitrated due
to symptomatic hypotension.
Of the 8 patients treated with an ARB 3 (38%) had reached maximum dose while another 3 (38%) could not undergo further optimisation due to hypotension. Of the 31 patients treated with a BB 7
(23%) were on ESC-recommended daily dose while 16 (52%) could
not be further uptitrated due to bradyarrhythmia or symptomatic
hypotension. Of the 27 patients treated with AldoA 8 (30%) had
reached optimal dose while 6 (22%) could not attain target dose due
to hyperkalemia and in 13 (48%) patients no reason was specified.
Conclusion Only a minority of chronic heart failure patients is on
ESC-recommended daily dose of medication. The reasons for not
reaching target dose can mostly be attributed to specific side effects
of the drugs used.
Auswirkung verschiedener Stimulationsvektoren
bei der CRT auf echokardiographische und vektorkardiographische Parameter
VI – 3
G. Saurer, B. Anelli-Monti, W. Koglek, W. Weihs
Department für Kardiologie und Intensivmedizin, LKH Graz-West; Klinikum
Klagenfurt am Wörthersee, Klagenfurt
Einleitung Die CRT weist eine hohe Nonresponderrate von bis zu
30 % auf. Eine Ursache liegt in der suboptimalen Lage der linksventrikulären Sonde (Koronarvenenmorphologie, Narbe, Phrenikusstimulation, hohe Reizschwelle). Mit einer quadripolaren linksventrikulären Sonde (Quartet™ von St. Jude Medical), die im AbJ KARDIOL 2012; 19 (5–6)
ÖKG-Jahrestagung 2012 – Abstracts
Abbildung 30: G. Saurer et al.
stand von 47 mm 4 Pole aufweist, können bis zu 10 unterschiedliche
Stimulationsvektoren bzw. -orte programmiert werden. Dadurch erhöhen sich die Möglichkeiten einer optimaleren biventrikulären Stimulation im Vergleich zur klassischen bipolaren linksventrikulären
In einer Studie untersuchen wir, ob sich unterschiedliche Vektoren
echokardiographisch abbilden lassen und ob eine Korrelation des
besten echokardiographisch bestimmten Vektors zum Time Intervall (TI) der Vektorkardiographie (VKG) besteht. Mit der VKG
lässt sich die elektrische Dyssynchronie zeitlich und räumlich darstellen. Ein TI > 65 ms im Ausgangs-EKG (ohne Stimulation) korreliert mit einem positiven CRT-Respons. Eine Verkürzung des TI
nach Resynchronisation stellt einen Parameter für eine erfolgreiche
CRT dar.
Methode An einem Fallbeispiel bestimmen wir echokardiographische Parameter (LV-Ejektionsfraktion in %; LV-enddiast. Volumen [LVEDV] in ml; LV-endsyst. Volumen [LVESV] in ml; „septal
to posterior wall motion delay“ [SPWMD] in ms;) von 5 unterschiedlichen Stimulationvektoren der quadripolaren Sonde und korrelieren sie mit dem TI (in ms) der Vektorkardiographie. Die echokardiographischen und vektorkardiographischen Daten wurden geblindet ausgewertet.
Ergebnis Der optimalste echokardiographisch bestimmte Stimulationsvektor in diesem Fallbeispiel war V3. Bei dieser Einstellung
ergab sich eine Verbesserung der LVEF um 18 % im Vergleich zum
nichtstimulierten linken Ventrikel und eine Verbesserung um 17 %
im Vergleich zum schlechtesten Stimulationsvektor V0. Der Dyssynchronieparameter SPWMD verbesserte sich um 250 ms im Vergleich zum Ausgangswert und um 85 ms zu V0.
Das beste TI wies ebenso V3 mit einer Verbesserung auf 55 ms auf.
Die geringste Verbesserung wies der Vektor V1 mit 100 ms auf. Im
Vergleich zum Ausgangswert zeigte sich eine Abnahme des TI um
35 ms.
Diskussion Bei unserem Fallbeispiel kam es zu einer Verbesserung der echokardiographischen Parameter unterschiedlichen Ausmaßes bei Verwendung unterschiedlicher Stimulationsvektoren
einer quadripolaren Sonde.
Es zeigte sich eine gute Übereinstimmung der mechanischen mit der
elektrischen Resynchronisation. In einer Studie wird diese Beobachtung überprüft. Sollte sich die Korrelation bestätigen, könnte die
Vektorkardiographie als einfache und rasche Methode zur Bestimmung des optimalen Stimulationsvektors angewendet werden
(Abbildung 30).
Single Center Experience with Percutaneous Edge
to Edge Mitral Valve Repair in High-Risk Patients
Th. Sturmberger, Ch. Ebner, W. Tkalec, J. Aichinger, R. Steringer-Mascherbauer,
G. Kabicher, V. Eder, J. Niel, H.-J. Nesser
Abteilung für Kardiologie, Krankenhaus der Elisabethinen, Linz
Background Patients with severe symptomatic mitral regurgitation (MR) have poor prognosis in the absence of surgery. An European survey established that more than half of patients with symptomatic significant MR are not referred for surgery or are refused by
cardiac surgeons, mainly due to poor LV-function and multiple
comorbidities. Clinical trials with the MitraClip system showed
J KARDIOL 2012; 19 (5–6)
promising results regarding feasibility and safety of this device and
functional improvement of patients. We report outcomes of our patients in a so called high risk group.
Methods We included patients with symptomatic heart failure
(NYHA class ≥ 3), poor LV-function (LVEF ≤ 35%) and significant
MR ≥ 3, who were declined for surgery. Transthoracic echocardiography was performed before, at discharge and 3 and 6 months after
the procedure. Differences in 6-min-walk test (6-MWT), NT-pro
BNP, New York Heart Association (NYHA) functional class and
Echoparameter were reported.
Results MitraClip procedure was performed in 21 patients with a
mean age 69.6 ± 10.1 years, mean log. EuroScore 24.4 ± 13.6%,
mean NYHA class 3.7 ± 0.3 and a median NT-pro BNP 4910 pg/dl
(IQR 1617–12425). Mean LVEF was 26.6 ± 6.4% and mean 6-MWT
distance was 208 ± 159 m. In 11 patients ischemic cardiomyopathy
was the underlying pathology of MR.
The MitraClip procedure was successful in 20/21 patients. In one
patient the clip could not be placed. A single clip was implanted in
18 patients (90%), whereas two clips were placed in 2 patients
(10%). Severity of MR was reduced significantly in the successfully
treated patients and 19/20 patients were discharged with a MR grade
≤ 2. No procedure related death occurred and only 1 patient died
within 3 months.
Clinical and echocardiographic 6-month follow-up data could be
obtained in 13 patients.
At 6 months, MR ≤ 2 was present in all 13 patients, and 8/13 patients
were in NYHA functional class I or II. The vast majority of the latter
had a LVEF ≥ 25% at baseline. Six-minute walk distance improved
significantly and distinct reduction in NT-pro BNP plasma levels
and LA-Index were observed.
Conclusion Percutaneous edge-to-edge valve repair with the
MitraClip system in high surgical-risk patients with severe MR and
poor LV-function is feasible and safe. Successful procedures lead to
an improvement in functional capacity after 6 months. However,
careful patient selection seems mandatory, especially in case of very
advanced heart failure.
Associations of Methylarginines and Homoarginine
with Diastolic Dysfunction in Patients at Cardiovascular Risk with Preserved Left Ventricular Ejection
VI – 2
A. Tomaschitz, F. Edelmann, St. Pilz, A. Meinitzer, A. Schmidt, E. Ritz, G. Gelbrich,
H.-D. Düngen, K. Kienreich, R. Stahrenberg, R. Wachter, W. März, B. Pieske
Klinische Abteilung für Kardiologie; Klinische Abteilung für Endokrinologie und
Stoffwechsel; Clinical Institute of Medical and Chemical Laboratory Diagnostics,
Medizinische Universität Graz Österreich; Department of Cardiology and Pneumology, University of Goettingen; Department of Nephrology, University of
Heidelberg; Coordination Center for Clinical Trials, University of Leipzig; Department of Cardiology, Charité-Universitätsmedizin Berlin; Synlab Centre of Laboratory Diagnostics Heidelberg, Germany
Introduction ADMA, SDMA and homoarginine are considered
to modulate nitric oxide synthesis that is crucial for cardiovascular
and myocardial health. We evaluated whether asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and homoarginine are associated with biochemical markers and echocardiographic measures of diastolic dysfunction and with glomerular filtration rate (GFR).
Materials and Methods We investigated primary care patients
at cardiovascular risk with preserved left ventricular ejection fraction from the multicentre, prospective, observational DIAST-CHF
study. We measured serum concentrations of ADMA, SDMA and
homoarginine and performed standardized echocardiographic examinations.
Results Among 1396 patients (mean age: 65.3 ± 8.3 years; 54.6%
women), diastolic dysfunction was ruled out in 261 patients
(18.7%). Mild, and moderate or severe grade of diastolic dysfunction was present in 900 (64.5%), and 235 (16.8%) study participants,
respectively. After adjustments for cardiovascular risk factors,
ÖKG-Jahrestagung 2012 – Abstracts
Table 7: A. Tomaschitz et al. Binary logistic analyses for presence
and grade of diastolic dysfunction according to the standard deviation of ADMA, SDMA or homoarginine.
(per SD)
(per SD)
(per SD)
Entire study cohort (n = 1396)
Odds ratios (with 95%-CI) for diastolic dysfunction
1.17 (1.01–1.34)*
1.24 (1.05–1.46)*
0.83 (0.73–0.94)#.
Model 1
1.00 (0.86–1.15)
0.90 (0.77–1.05)
0.94 (0.82–1.08)
Model 2
0.97 (0.83–1.14)
0.91 (0.75–1.10)
0.86 (0.73–1.01)
Model 3
1.00 (0.84–1.18)
0.95 (0.77–1.16)
0.84 (0.72–0.99)*
Model 4
1.01 (0.85–1.19)
0.95 (0.76–1.22)
0.84 (0.72–0.99)*
Model 5
1.04 (0.87–1.25)
0.93 (0.72–1.21)
0.84 (0.71–0.99)*
Patients with diastolic dysfunction (n = 1135)
Odds ratios (with 95%-CI) for moderate or severe
diastolic dysfunction
1.14 (0.99–1.31)
1.03 (0.90–1.18)
1.20 (1.04–1.38)*
Model 1
1.21 (1.05–1.39)#
1.17 (1.02–1.34)*
1.12 (0.96–1.31)
Model 2
1.27 (1.09–1.49)#
1.26 (1.09–1.47)#
1.09 (0.92–1.29)
Model 3
1.19 (1.01–1.40)*
1.21 (1.03–1.42)*
1.06 (0.89–1.27)
Model 4
1.21 (1.03–1.43)
1.39 (1.14–1.69)
1.05 (0.88–1.25)
Model 5
1.11 (0.93–1.33)
1.33 (1.07–1.64)#
1.03 (0.86–1.23)
Logistic regression analyses with diastolic dysfunction as the outcome variable and ADMA, SDMA, and homoarginine (per SD) as the explanatory variable and cummulative adjustments.
Model 1 adjusted for age and sex.
Model 2 additionally adjusted for body mass index, systolic blood pressure,
diabetes mellitus, LDL- and HDL-cholesterol and active smokers.
Model 3 additionally adjusted for heart rate, left ventricular hypertrophy and
history of myocardial infarction.
Model 4 additionally adjusted for glomerular filtration rate.
Model 5 additionally adjusted for ADMA, SDMA, and homoarginine.
ADMA: asymmetrical dimethylarginie; SD: standard deviation; SDMA: symmetrical dimethylarginine. * p < 0.05; # p < 0.01
ADMA and SDMA were positively and homoarginine was negatively associated with N-terminal pro-B-type natriuretic peptide
(NT-proBNP) and mid-regional pro-adrenomedullin (MR-proADM)
(p < 0.05 for all). Lower homoarginine levels were an independent
predictor for the presence of diastolic dysfunction and higher
ADMA and SDMA levels were associated with the severity of diastolic dysfunction (p < 0.05 for all). ADMA was moderately and
SDMA was highly significantly associated with GFR.
Discussion Our findings suggest that higher levels of ADMA and
SDMA as well as lower levels of homoarginine may be associated
with an adverse cardiovascular risk profile and in particular with
diastolic dysfunction. Further studies should clarify the potential of
these amino acids derivates for the therapy of cardiovascular diseases (Table 7).
A Risk Factor-Based Porcine Model of Heart Failure
with Preserved Ejection Fraction (HFPEF)
VI – 1
J. Verderber, M. Schwarzl, S. Seiler, P. Steendijk, B. Pieske, H. Post
Klinische Abteilung für Kardiologie, Medizinische Universität Graz, Österreich;
Leiden University Medical Center, Leiden, The Netherlands
Background Heart failure with preserved ejection fraction
(HFPEF) results from the accumulation of cardiovascular risk factors. So far, no therapeutic intervention has shown to decrease mortality in HFPEF, which in part relates to the lack of suitable animal
models. We aimed to model HFPEF in pigs by induced hypertension
and western diet.
Methods and Results Eight landrace pigs were implanted with
subcutaneous 90-day release DOCA pellets (an aldosterone
Flgure 31: J. Verderber et al.
analogon), and subsequently fed a high salt/high lipid/high sugar
diet for 90 days (DOCA). Eight weight-matched pigs (no DOCA,
regular diet) served as controls. After 90 days, tail-cuff systolic
blood pressure during light sedation was 139 ± 11 mmHg in DOCA
vs 95 ± 6 mmHg in control (p < 0.05). Echocardiography demonstrated pronounced concentric hypertrophy in DOCA. LV function
was assessed during deep anesthesia by pressure-volume (PV)
analysis. In DOCA vs control, baseline cardiac output (6.0 ± 0.2 vs
6.6 ± 0.5 l/min) and heart rate (95 ± 5 vs 84 ± 6 bpm) were not different, while LV ejection fraction (68 ± 3 vs 51 ± 3%) was higher
(p < 0.05). The end-systolic and end-diastolic PV relationships
(ESPVR and EDPVR) were markedly shifted leftwards in DOCA
(Figure 31). Right atrial pacing both at baseline and during lowdose dobutamine infusion (2.5 µg/kg/h) revealed a lower increase of
cardiac output in DOCA.
Conclusion This risk factor based animal model for the first time
reproduces two major characteristics of HFPEF: (i) a leftward shift
of the ESPVR and EDPVR and (ii) a limited cardiac reserve.
Venous Congestion Rather than Low Output Predicts Hepatic and Renal Failure in CHF
VI – 7
A. Von der Heidt, G. Goebel, M. Frick, G. Poelzl
Department of Internal Medicine III, Cardiology, Medical University Innsbruck
Purpose Secondary organ dysfunction such as renal and hepatic
failure is an integral part of the heart failure syndrome. The underlying pathomechanisms, however, are still not well-defined. In this
study we sought to investigate the impact of hemodynamic perturbations on liver and kidney function in a large cohort of chronic heart
failure (CHF).
Methods Hemodynamic parameters from right heart catheterization along with liver (AP, T-Bil, GGT, GOT, GPT) and renal (serum
creatinine [SCr], eGFR) function tests and clinical parameters were
evaluated in a cohort of 293 patients (median age 47, NYHA class I
28,8%, II 34,8%, III/IV 35,4%; median LV-EF 28%) with CHF.
Bivariate correlations and partial correlations adjusted for age and
gender were performed to assess associations between hemodynamic and laboratory parameters. Univariate and multivariate regression models adjusted for age, gender, BMI, ischemic etiology,
hypertension and NYHA class were created to estimate the contribution of congestion and forward failure on hepatic and renal failure.
Results Prevalence of elevated liver and kidney functions tests
were as follows: AP 4,8%, T-Bil 9,2%, GGT 32,1%, GOT 23,5%,
GPT 57,3%, SCr 19,1%, eGFR 16%. GGT, eGFR and SCr were
strongly associated with RAP and CI (p < 0.001) whereas bilirubin
was only correlated with RAP (p < 0.001). By contrast, only weak
correlations were found for GPT and GOT with CI (p < 0.05) and AP
with RAP and CI (p < 0.05). In multivariate regression models RAP
J KARDIOL 2012; 19 (5–6)
ÖKG-Jahrestagung 2012 – Abstracts
rather than CI was independently associated with T-Bil (RAP β =
0.232, p = 0.001; CI β = –0.025; p = 0,728), GGT (RAP β = 0.177;
p = 0.012; CI β = –0.143; p = 0.058), eGFR (RAP β = –0.144;
p = 0.015; CI β = 0.080; p = 0.220), and SCr (RAP β = 0.152;
p = 0.013; CI β = –0.082; p = 0.225). Models for AP, GOT, and GPT
were not significant.
Conclusion Our data suggest that venous congestion rather than
forward failure is the hemodynamic pathomechanism contributing
to hepatic and renal failure in CHF. This association holds true independent of epidemiologic and clinical parameters including etiology
and severity of HF. Hence, meticulous volume management is of
utmost importance in CHF.
 Interventionelle Kardiologie/
Interventional Cardiology
Inzidenz von kardialen Reizleitungsstörungen und
Schrittmacher-Implantation nach transfemoralperkutanem Aortenklappenersatz (Core Valver®)
VII – 8
H. Blessberger, Th. Lambert, M. Grund, K. Kerschner, A. Kypta, B. Hartenthaler,
J. Kammler, C. Steinwender, F. Leisch
I. Medizinische Abteilung mit Kardiologie, AKH Linz; Landeskrankenhaus
Hintergrund Neu aufgetretene Schenkelblöcke oder höhergradige
AV-Blockierungen zählen zu den bekannten postinterventionellen
Komplikationen nach transfemoral-perkutanem Aortenklappenersatz
(PAKE). Die Inzidenz von postinterventionellen Schrittmacher-Implantationen aufgrund dieser neu aufgetretenen Reizleitungsstörungen wird in der Literatur mit 3–40 % angegeben.
Material und Methode Im Rahmen einer retrospektiven Beobachtungsstudie wurde die Inzidenz neu implantierter Schrittmacher an unserer Abteilung nach PAKE zwischen November 2008
und Februar 2012 erhoben. Alle Patienten wurden nach Klappenersatz mindestens 48 Stunden intensivmedizinisch mit EKGMonitoring überwacht. Bei Neuauftreten einer höhergradigen
postinterventionellen Reizleitungsstörung (Linksschenkelblock,
AV-Block II.°, AV-Block III.°) wurde die Indikation zur Schrittmacher-Versorgung gestellt (Symphony®, Sorin®). Bei Patienten
mit permanentem AV-Block III.° erfolgte eine DDD-/VVI-Stimulierung. Bei Patienten mit intermittierend intakter AV-Überleitung erfolgte eine Programmierung im AAI-SafeR®-Modus, der
eine Eigenüberleitung erlaubt und erst bei Vorliegen eines AVBlocks automatisch in einen vorhofgesteuerten Ventrikelstimulationsmodus wechselt. Hierbei werden ein AV-Block II.° als 3 blockierte atriale Impulse innerhalb von 12 Zyklen und ein AV-Block
III.° als 2 konsekutiv nicht übergeleitete Impulse definiert. Die
AV-Block-Episoden werden im Ereignisspeicher des Schrittmachers erfasst und zur Beurteilung des Vorliegens selbiger Rhythmusstörungen herangezogen.
Ergebnisse Im Beobachtungszeitraum wurden 59 Patienten mit
höhergradiger Aortenklappenstenose mit einer Core Valve®-Klappe
versorgt (mittleres Alter 81,8 ± 5,4 Jahre, 54 % Frauen). Der mittlere Nachbeobachtungszeitraum war 12 Monate (Interquartilen-Abstand: 3–24 Monate). Die 30-Tages-Mortalität betrug 6,8 % (4 Patienten), die 6-Monats-Mortalität 13 % (6 Patienten). Kein Patient
verstarb an einem suspekt arrhythmogenen Ereignis. Sechs Patienten hatten bereits vor PAKE einen Schrittmacher erhalten und wurden von der Analyse ausgeschlossen. Von den verbleibenden 53 Patienten erhielten 27 Patienten (51 %) einen Schrittmacher (18 Patienten wegen eines höhergradigen AV-Blocks, 9 Patienten aufgrund
eines neu aufgetretenen Linksschenkelblocks). Vier Patienten wurden bei AV-Block III.° und Vorhofflimmern im VVI-Modus stimuliert, von den übrigen 23 Patienten im AAI SafeR®-Modus wurden
5 Patienten (22 %) zu nahezu 100 % ventrikulär stimuliert bei permanentem AV-Block III.°, 9 Patienten (39 %) zeigten wiederholt
AV-Block II.°- und -III.°-Episoden (2314 bzw. 193 Episoden). Bei
J KARDIOL 2012; 19 (5–6)
3 Patienten (13 %) mit eigener AV-Überleitung wurden im Nachbeobachtungszeitraum keine höhergradigen AV-Blockierungen
vom Schrittmacher aufgezeichnet. Von den restlichen 6 Patienten
waren oder sind noch keine Schrittmacherdaten verfügbar. Bei Patienten mit postinterventionell unauffälliger Reizleitung, die keinen
Schrittmacher erhielten, traten auch bei weiteren Kontrollen keine
AV-Blockierungen neu auf.
Diskussion Reizleitungsstörungen während der unmittelbar postinterventionellen Überwachung erlauben eine Vorhersage bezüglich
höhergradiger AV-Blockierungen: Bei normalen Reizleitungsverhältnissen traten im Verlauf keine höhergradigen AV-Blockierungen
neu auf. Auch bei nur intermittierend auftretendem AV-Block II.°
oder III.° sollte aufgrund der nachgewiesenen häufigen Rezidive der
Leitungsstörungen ein Schrittmacher implantiert werden.
Early Changes of Pulse Wave Velocity and Central
Aortic Blood Pressure Parameters Following Renal
Sympathetic Nervous Denervation
M. C. Brandt, S. Reda, F. Mahfoud, J. Schuler, P. Grüner, M. Böhm, U. C. Hoppe
Universitätsklinik für Innere Medizin II, Paracelsus Medizinische Privatuniversität
Salzburg, Österreich; Klinik für Innere Medizin III, Universitätsklinikum des
Saarlandes, Homburg/Saar, Deutschland
Background Therapy refractory hypertension causes significant
structural and functional alterations not only in the heart but also in
the central and peripheral vasculature. Recently, a novel technique
using a tonometer sensor connected to a computer has been established to measure vascular stiffness by calculating the central aortic
blood pressure curve and the pulse wave velocity from peripheral
pulse recordings of the radial, carotid and femoral artery (Atcor
Medical Pty Ltd., West Ryde, Australia). Clinical studies have
shown prognostic relevance of the augmentative pressure and pulse
wave velocity in patients with arterial hypertension. Our aim was to
study the effect of sympathetic renal denervation (RDN) on central
aortic pulse wave parameters and pulse wave velocity.
Results A total of 26 patients were enrolled consecutively and
RDN was performed. Before and 1 month after the procedure, pulse
wave studies were done. The mean age in the cohort was 64 ± 2 years,
males were a majority of 69.4%. As early as 1 month post RDN, the
mean blood pressure was significantly reduced (177 ± 4/95 ± 2 mmHg
systolic/diastolic at baseline vs 156 ± 4/87 ± 3 mmHg at 1; p = 0.003;
n = 26). The blood pressure reduction was accompanied by distinct
changes of pulse wave parameters and pulse wave velocity.
The calculation of the central aortic blood pressure curve from the
radial pressure recording showed a significant reduction in aortic
systolic (159 ± 5 mmHg vs 144 ± 4 mmHg; p = 0.042), diastolic
(95 ± 2 mmHg vs 87 ± 3 mmHg, p = 0.001) and pulse pressure (68
± 4 mmHg vs 57 ± 3 mmHg, p = 0.036). The mean systolic pressure (141 ± 3 mmHg vs 127 ± 4 mmHg; p < 0.0001) and mean
diastolic pressure (110 ± 3 mmHg vs 100 ± 3 mmHg, respectively;
p < 0.0001) were also significantly reduced. Furthermore, the augmentative pressure showing early or increased pulse wave reflections causing increased cardiac workload, was significantly reduced 1 month after RDN, before (augmentative pressure 22.1 ±
2.0 mmHg vs 18.6 ± 1.8 mmHg; p = 0.042) and after correction for
heart rate (augmentation index at heart rate 75/min 25.1 ± 1.5 vs
23.8 ± 1.6; p = 0.045). Consistently, an improvement of cardiac
function was evident in a small but significant decrease of the ejection duration in relation to cardiac cycle length (34.6 ± 0.7 % vs
33.1 ± 0.7 %; p = 0.007).
The pulse wave velocity from the carotid to the femoral artery
showed a significant reduction from 11.7 ± 0.6 m/s to 10.5 ± 0.6 m/s;
p = 0.021).
Conclusion Our results show for the first time that RDN not only
facilitates better peripheral blood pressure control but also causes
distinct changes of central aortic blood pressure parameters. Together with better blood pressure reduction novel parameters of arterial stiffness and vascular remodeling with important clinical prognostic implications for the individual patients are improved at an
early stage after RDN.
ÖKG-Jahrestagung 2012 – Abstracts
Inhibition of Platelet Aggregation by Intracoronary
Bolus-Only Administration of Abciximab: Time
Course and Influence of Clopidogrel versus
Prasugrel Loading
G. Christ, Th. Hafner, Th. Chatsakos, E. Wilhelm, M. Francesconi, A. PodczeckSchweighofer
5. Medizinische Abteilung – Kardiologie SMZ-Süd/KFJ, Wien
Background Current acute coronary syndrome (ACS) guidelines
recommend a bolus and infusion administration of the GP IIbIIIa
inhibitor abciximab on top of dual antiplatelet inhibition in high risk
patients undergoing percutaneous coronary intervention (PCI). Recent data suggest that an abciximab bolus-only regimen with high
loading dose clopidogrel does not impair platelet inhibition throughout 24 h.
Objectives To evaluate the time course and extent of platelet inhibition by a single intracoronary abciximab bolus and the relation to
co-medication with clopidogrel or prasugrel.
Patients and Methods 56 consecutive high-risk ACS patients
(70% STEMI, 30% NSTEMI with visible thrombus) and intracoronary abciximab bolus administration (0.25 mg/kg) were included
(55% loaded with 600 mg clopidogrel, 45% with 60 mg prasugrel).
Thrombin receptor-activating peptide (TRAP) and ADP induced
platelet reactivity was measured by Multiple Electrode Aggregometry (MEA; Multiplate®), at 4 h, 24 h, 3 and 6 days. Clinical outcome was evaluated at 30 days.
Results Overall platelet reactivity, measured by TRAP induced
aggregation, was significantly suppressed for more than 24 h (45 ±
17 U) and returned to normal (> 84 U) only after 6 days (90 ± 26 U;
p < 0.001). Co-medication with prasugrel significantly reduced
ADP-induced (p = 0.002), as well as TRAP-induced (p = 0.02),
platelet aggregation compared to clopidogrel throughout the observation period. Six patients in the clopidogrel group (19 %) were
classified as nonresponder (> 49 U ADP) and switched to prasugrel
(2 on day 4 and 4 on day 7; ADP pre-switch: 88 ± 25 U vs postswitch: 22 ± 10 U; p < 0.001). During 30 days no stentthrombosis or
repeat myocardial infarction and two deaths (4%) in cardiogenic
shock occurred. Significant bleeding complications were low (4%,
only puncture site related: one TIMI major with red blood cell transfusion in the clopidogrel group and one TIMI minor in the prasugrel
Conclusion A single intracoronary abciximab bolus in combination
with high loading dose of thienopyridines effectively inhibits overall
platelet reactivity for more than 24 hours, suggesting no need for continuous abciximab infusion. Co-medication with prasugrel compared
to clopidogrel not only reduces ADP induced platelet aggregation, but
also overall platelet reactivity via a so far not known mechanism.
Single Center Experience with Paravalvular Leak
Closure After Recurrent Mitral Valve Surgery XV – 7
Ch. Ebner, W. Tkalec, J. Aichinger, Th. Sturmberger, V. Eder, H.-J. Nesser
Abteilung für Kardiologie, Krankenhaus der Elisabethinen, Linz
Background Paravalvular leak (PVL) is a common complication after surgical valve replacement with reported incidence up to
17% for prosthetic valves in the mitral position. Although most of
these leaks are clinically silent, in up to 3% of these patients
reoperation is needed due to heart failure symptoms or hemolysis.
Percutaneous closure of periprosthetic paravalvular leaks has been
proposed as an attractive alternative to surgical closure particularly in high risk patients. Herewith we present our experience using this technique.
Methods and Results The first procedure as the first in Austria
was performed in our institution on June 2010. Until November 2011
we performed 5 procedures in 4 patients (50% male) with a mean
age of 65 ± 8.8 years. All of them had bileaflet mechanical prostheses and signs and/or symptoms of heart failure. Additionally hemolysis criteria were evident: hemoglobin ≤ 10 g/dl (mean 8.5 ± 1),
Lactat Dehydrogenase: ≥ 600 mg/dl (median 2114, IQR 1275–
4495), and haptoglobin: ≤ 10 mg/dl (mean 1 ± 1.7). All of them had
at least ≥ 2 previous redo-operations of their prostheses due to
paravalvular leaks and ≥ 2 blood transfusions in the past to correct
The procedure was performed under fluoroscopy and guided by
2D/3D transesophageal echocardiography (Philips IE 33) to determine the size and location of the PVLs. Duration of he procedure
was mean 165 ± 49 minutes. 4/5 procedures were done using an
antegrade approach via the V. fem. dext. with consecutive transseptal puncture. In 1 procedure a retrograde approach via the A.
fem. dext. was choosen and passing the aortic valve. In all of the
patients 2 Amplatzer Vascular Plugs III were placed followed by
significant reduction of the regurgitant flow in 3/4 patients. No
periprocedural complications occurred and all patients are still
alive. In one of the patient a second PVL could not be closed due to
anatomic conditions (introduction of the guide wire but not catheter passage ); nevertheless need of blood transfusions could be
reduced. 2/4 patients had an excellent result disclosing only trivial
residual paraprosthetic regurgitation, significant reduction of
hemolysis criteria and clinical improvement. In 1/4 patient significant paravalvular regurgitation remained and finally this patient
underwent redo mitral valve replacement at risk due to symptomatic heart failure.
Conclusion Transcatheter closure of PVL after previous valve
surgery can be attempted with acceptable success rates and in our
series without complications. This procedure seems to be an attractive alternative in patients after previous surgical valve procedures complicated by paravalvular leaks combined with distinct
hemolysis or significant mitral regurgitation. In our series this
technique was exclusively performed in patients with distinct
comorbidities or high surgical risk of the redo due to failed previous leak repair.
Optische Kohärenztomographie zur Beurteilung
des Stentergebnisses – ein klinischer Erfahrungsbericht bei 20 Patienten
VII – 6
C. Gangl, Th. Neunteufl, G. Delle-Karth, G. Kreiner, I. Lang, Ch. Roth, N. Lajic,
M. Vertesich, L. Krenn, D. Bonderman, R. Berger
Klinische Abteilung für Kardiologie, Universitätsklinik für Innere Medizin II,
Medizinische Universität Wien
Einleitung Die Kontrolle des Stent-Ergebnisses wird allgemein
vor allem mittels angiographischer Beurteilung durchgeführt. Pathologien, die die angiographische Kontur nicht oder nur in geringem
Ausmaß beeinflussen, können so nur schwer festgestellt werden.
Mittels Optischer Kohärenztomographie (Frequency-Domain OCT)
– einem Verfahren zur intravaskulären Bildgebung – können hochauflösende Bilder von der Koronararterienwand bzw. dem Inneren
der Koronararterie erstellt werden, die dem intravaskulären Ultraschall im Bezug auf die Auflösung um bis zu Faktor 10 überlegen
sind. Somit können Stent-Anomalien noch exakter beurteilt werden,
um diese gegebenenfalls adäquat korrigieren zu können.
Material und Methoden Es wurden deskriptiv Daten von 20 Patienten ausgewertet, welche sich zwischen Mai 2010 und Mai 2011
einem interventionellen Herzkatheter-Eingriff am AKH Wien unterzogen haben. Dabei wurden die Patienten durch Randomisierung
entweder mittels Xience Prime (Everolimus) oder Biomatrix Flex
(Biolimus) behandelt. Nach erfolgtem Stenting und eventueller
Nachdilatation nach der Entscheidung des Interventionalisten wurde abschließend von einem ausgewählten Stent eine OCT durchgeführt. Die dabei gewonnen Aufzeichnungen wurden anschließend
durch einen erfahrenen Analysten mithilfe der auf dem OCT-Gerät
installierten Software auf die in Tabelle 8 angeführten Phänomene
hin ausgewertet.
Ergebnisse Die Charakteristika der beiden Kohorten sind in
Tabelle 9 angeführt.
Wie in Tabelle 8 aufgeschlüsselt, konnten bei insgesamt 11 Stents Malappositionen festgestellt werden (Biomatrix 5/Xience 6). Stent-Underexpansions konnten in insgesamt 4 (Biomatrix 2/Xience 2), asymmetrisch expandierte Stentsegmente in insgesamt in 9 implantierten
J KARDIOL 2012; 19 (5–6)
ÖKG-Jahrestagung 2012 – Abstracts
Tabelle 8: C. Gangl et al. Ergebnisse
(n = 10)
(n = 10)
(n = 20)
Most asym. Exp.
Edge-Diss. (prox./dist.)
1 Segment
2 Segmente
3 Segmente
4 Segmente
1 Segment
2 Segmente
3 Segmente
4 Segmente
1 Segment
2 Segmente
3 Segmente
4 Segmente
5 Segmente
Tabelle 9: C. Gangl et al. Kohorten-Charakteristika
(n = 10)
Geschlecht (m/w)
(n = 10)
(IQR 50,5–58) (IQR 54–67,5)
Indikation (elektiv/ACS)
R. intermedius
Direct Stenting
(n = 20)
(IQR 51,5–62,3)
Stents (Biomatrix 4/Xience 5) detektiert werden. Fünf Stents zeigten
nach Implantation eine Edge-Dissection (Biomatrix 4/Xience 1).
Wie weiters in Tabelle 8 ersichtlich, konnten in einer Vielzahl (16
von 20) der untersuchten Stents Plaque-Protrusionen (Vorwölbungen des Plaques über die Stent-Struts hinaus, ohne Kontinuitätsunterbrechung der Intima oder Plaquekappe) festgestellt werden. In
19 von 20 Patienten konnten Plaque-Prolapse in unterschiedlichen
Größen und Anzahl pro Stent gefunden werden.
Konklusion Mittels OCT können viele morphologische Auffälligkeiten nach der Stent-Implantation detektiert werden, die klinische
Bedeutung dieser Auffälligkeiten muss erst in Verlaufskontrollen
bzw. bei größeren Patientenkollektiven untersucht werden.
Long-Term Follow-Up of Patients Treated with Combined Delivery of Intracoronary and Intramyocardial
Bone-Marrow Mononuclear Cells
XV – 1
E. Gieseking, B. Syeda, H. Sochor, S. Charwat, J. Bergler-Klein, G. Maurer,
M. Gyöngyösi
Division of Cardiology, Department of Medicine II, Medical University Vienna
Background Between 2002 and 2006, patients with recent acute
myocardial infarction (AMI) and ejection fraction (EF) between 30
J KARDIOL 2012; 19 (5–6)
and 45% were included into the MYSTAR prospective randomized
study, and received combined delivery of bone-marrow mononuclear
cells (BM-MNC) either 3–6 weeks (mean 32 ± 12 days, early group)
or 3–4 months (mean 93 ± 15 days, late group) post AMI. The BMMNC therapy resulted in an improvement in mean ejection fraction
of 3.5% and infarct size of 3.7%.
Aim The aim of the present follow-up (FUP) study was to evaluate
the long-term effect (mean 5 years) of the cardiac stem cell therapy
on clinical outcome and on ventricular function and size of infarction.
Methods and Results Six patients died during the follow-up
due to cardiac reasons (heart failure). Five patients were lost to FUP
or refused the investigations. Patients were invited to undergo gated
99m-Tc-MIBI perfusion scintigraphy to evaluate infarct size and global EF (primary endpoint of the MYSTAR study). The further 5-year
clinical follow-up (FUP) included the records of major adverse cardiac events (MACCE, defined as all-cause mortality, re-AMI, reintervention of the infarct-related artery and stroke), implantation of
automatic cardioverter-defibrillators (ICD) and hospitalization due
to angina pectoris or acute or chronic heart failure.
Results Infarct size decreased non-significantly from 24.3 ±
11.6% (3 months post-stem cell therapy) to 21.0 ± 12.2% (p =
0.266) during the mean 5 years FUP. Trend towards decrease in enddiastolic volume was observed (from 209 ± 76 ml to 182 ± 69 ml;
p = 0.126), suggesting reverse remodeling. EF increased significantly during the 5 years FUP (from post-stem therapy value of
41.5 ± 8.4% to 45.4 ± 9.2% at 5 years FUP) (p = 0.028). AICD was
implanted in 5 patients, repeated hospitalization was necessary in 20
patients. Cumulative MACCE occurred in 10 patients, including
cardiac death and reintervention (n = 4). Stroke or reinfarction did
not occur.
Conclusion Combined intramyocardial and intracoronary delivery of BM-MNC led to a significant increase in global EF, and a
trend towards decrease in infarct size and end-diastolic volume over
a 5 years FUP, in patients with a low (30–45%) EF post-AMI.
75-jährige Patientin mit Pulmonalstenose und ausgedehnter Verkalkung an Trikuspidalring und -klappe
mit resultierender hochgradiger Trikuspidalstenose
VII – 1
M. Hammerer, P. Maister, K. Hergan, U. Hoppe
Universitätsklinik für Innere Medizin II; Universitätsklinik für Radiodiagnostik,
Salzburger Landeskrankenhaus
Einleitung Wir berichten über eine 75-jährige Patientin mit Z. n.
perkutaner Valvuloplastie der Pulmonalklappe (PK) vor 19 Jahren
sowie perkutaner Valvuloplastie der Trikuspidalklappe (TK) vor
3 Jahren. Aufgrund chronisch-progredienter rechtskardialer Insuffizienz (periphere Ödeme, Hepatopathie, NYHA II–III) wurde die Indikation zu einem neuerlichen perkutanen Interventionsversuch gestellt.
Aktuelle Befunde Die Transthorakale Echokardiographie (TTE)
zeigte eine Trikuspidalstenose (TS) III° (Abbildung 32 a, c) bei
massiven para-/valvulären Verkalkungen mit exzessiver rechtsatrialer Dilatation, sowie ein kombiniertes Vitium der nur mäßig
sklerosierten PK mit führender Pulmonalstenose (PS II°–III°)
(Abbildung 32 d). Der linkskardiale Befund war altersentsprechend unauffällig.
Die Multislice-Computer-Tomographie (CT) bestätigte die massive
Verkalkung des TK-Ringes mit Fortsetzung auf den Halteapparat
und die Mitralklappe (MK) (Abbildung 32 b).
Die Invasivdiagnostik ergab: mittlerer Gradient über TK: 5 mmHg;
mittlerer/maximaler Gradient über PK: 21/55 mmHg.
Perkutane Intervention Zunächst 2-malige PK-Valvuloplastie
(Abbildung 33 a). Da sich im rechtsventrikulären Ausflusstraktes
(RVOT) der Eindruck einer zusätzlichen Stenosierung ergab, wurde
hier diagnostisch mit sehr geringem Druck eine Ballonentfaltung
ausgeführt, welche eine exzentrische kalzifizierte Obstruktion bestätigte (Abbildung 33 b). In der Trikuspidalklappe erfolgte eine
ÖKG-Jahrestagung 2012 – Abstracts
Percutaneous Coil Embolization of a Perforated Side
Branch of the Right Coronary Artery 3 Weeks After
Abdominal Surgery
XV – 5
R. Hemetsberger, N. Schulze-Waltrup, T. Nitschke, H. Heuer
Innere Medizin I Kardiologie, Rhythmologie, Nephrologie, St. Johannes Hospital
Dortmund, Deutschland
Figure 32: M. Hammerer et al.
Figure 33: M. Hammerer et al.
weitere Valvuloplastie (Abbildung 33 c). Von einer Doppel-Ballon-Valvuloplastie wurde aufgrund der massiven Verkalkungen Abstand genommen.
Ergebnisse Eine TTE-Kontrolle nach 2 Monaten zeigte deutlich
geringere Gradienten über der PK (Abbildung 33 d) ohne Zunahme
des Insuffizienzgrades, aber einen unveränderten Schweregrad der
hämodynamisch führenden TS. Auch klinisch-anamnestisch kam es
leider zu keiner relevanten Besserung. Nach multidisziplinärer Diskussion im Heart-Team wurde für ein konservativ-palliatives Vorgehen entschieden.
Diskussion TS und PS sind seltene Herzklappenerkrankungen.
Eine TS ist in den allermeisten Fällen postrheumatischer Genese
und ist dann in der Regel mit einer Mitralstenose assoziiert. Zweithäufigste Ätiologie einer TS und häufigste einer PS ist eine kongenitale Stenosierung oder Atresie. Wir beschreiben den äußerst ungewöhnlichen Fall einer ausgedehnten Verkalkung im Bereich der TK
(mit resultierender TS III°), des TK-Ringes und des RVOT mit Ausläufern bis an die MK sowie die subvalvulären Apparate von TK
und MK. Bisher beschriebene seltene Fälle ähnlicher TK-Ring-Verkalkungen (allerdings meist ohne funktionelle Beeinträchtigung)
waren nahezu immer mit einer langjährig vorbestehenden chronischen Rechtsherzbelastung im Rahmen kongenitaler Vitien (PS
oder ASD) assoziiert. Ein postulierter kausaler pathogenetischer
Zusammenhang bleibt hypothetisch. In Anbetracht der Seltenheit
dieser Entität ist jedenfalls anzunehmen, dass eine rechtskardiale
Druckbelastung im Rahmen einer pulmonalen oder pulmonalarteriellen Hypertonie keine ausreichende Prädisposition darstellt.
Auch bei unserer Patientin ist von einer primären (wohl kongenitalen) PS als auslösendem Faktor auszugehen.
Introduction Iatrogenic pericardial tamponade after abdominal
surgery is a rare and severe complication caused by laceration of the
heart through the diaphragm. Here we describe for the first time a
case using percutaneous coil embolization for a perforated coronary
side branch after abdominal surgery.
Methods and Results A 75-year-old female presented to our
emergency department with abdominal pain 3 weeks after a laparoscopic cardiomyotomy.
The physical examination showed paleness, cold sweat, hypotension
with a blood pressure of 70/50 mmHg, sinus tachycardia of 130 bpm,
muffled heart sounds and hardly palpable peripheral pulses. The
blood analysis revealed anemia with hemoglobin of 7.6 g/dl.
With an urgent suspicion of blood loss, first an abdominal sonography was performed and excluded free liquid in the abdominal cavity
but showed a dilated vena cava (2.7 cm). A subsequent echocardiography revealed a pericardial tamponade with approximately 19 mm
effusion in front of the right ventricle with typical right ventricular
compression in the diastole. She was promptly transferred to our
intensive care unit.
A pericardiocentesis drained initially 550 ml of hemorrhagic effusion with a hemoglobin of 12 g/dl. A pigtail-catheter was retained in
order to drain the fluid. After 8 h the blood pressure decreased rapidly and an echocardiography showed a re-tamponade. The catheter
was occluded with clots. A second pericardiocentesis was performed and collected 500 ml with a hemoglobin of 9 g/dl.
An emergency cardiac-CT showed a small cloud of contrast agent
extravasating into the pericardial fluid. In a subsequent coronary
angiogram free contrast agent extravasation from a side branch of
the right coronary artery was seen, following the diagnosis of coronary artery perforation. The leakage corresponded to the inferior
contrast agent dissemination at the cardiac-CT.
We decided to embolize the side branch with a fibred platinum coil
using a microcatheter and a coil pusher. After exact positioning at
the leakage the coil was released and 2 minutes later no extravasation was further more detected. The remaining liquid was drained
and the pigtail-catheter was removed.
The patient was monitored for 2 days and was discharged at the 4th
day in a stable condition.
Conclusion In this case a cardiac tamponade caused by a perforated
RCA-side branch after abdominal surgery, manifested clinically after
3 weeks, was drained by pericardial puncture and treated successfully
by percutaneous coil embolization of the perforated artery.
This case reflects that even 3 weeks after abdominal or oesophagogastric surgery shock symptoms should hint at a cardiac tamponade.
Patienten mit Interventionen an chronischen Koronarverschlüssen (CTO): Hohe Strahlenakkumulation
durch radiologische und nuklearmedizinische
Untersuchungen innerhalb eines Jahres
Ch. Köllerer, C. Seelmaier, J. Schuler, U. Hoppe
Universitätsklinik für Innere Medizin, Kardiologie und Internistische Intensivmedizin, Universitätsklinikum LKH Salzburg
Einleitung Die effektive Strahlendosis einer diagnostischen Koronarangiographie beträgt durchschnittlich 3–4 mSv. Bei einer unkomplizierten Intervention erhöht sich diese Dosis um weitere 10 mSv.
Bei komplexen Prozeduren (Bifurkationen, CTOs) und adipösen
Patienten kann sich die Strahlendosis massiv erhöhen. Berichte von
3 Sv und mehr sind publiziert. Zusätzlich werden oft Koronar-CT
(3–10 mSv) und Myokardszintigraphien (10–15 mSv) zum Vitalitätsnachweis durchgeführt. Insbesondere bei Patienten mit chroniJ KARDIOL 2012; 19 (5–6)
ÖKG-Jahrestagung 2012 – Abstracts
schen Koronarverschlüssen (CTO) kann die Strahlendosis in der
Vor- und Nachsorge erheblich akkumulieren.
Anhand eines ausgewählten CTO-Patientenkollektivs soll deren kumulative Strahlenbelastung innerhalb von 12 Monaten abgeschätzt
Methodik Retrospektive Analyse aller klinischen Patientendaten
aus einem monozentrischen CTO-Register hinsichtlich strahlenbelastender Untersuchungen (Röntgen-Thorax, CT, Angiographien,
Szintigraphien). Es wurden alle Untersuchungen gezählt, die zum
Zeitpunkt der CTO-Intervention (Indexaufenthalt) und in den nachfolgenden 12 Monaten an der Klinik durchgeführt wurden.
Ergebnisse Insgesamt wurden im Zeitraum von 04/07 bis 04/11
die Daten von 70 Patienten, die einer CTO-Katheterintervention
unterzogen wurden, gesammelt und analysiert.
Beginnend vom Indexaufenthalt und in den darauffolgenden 12 Monaten wurden bei 68 Patienten (97,1 %) insgesamt 174 RöntgenThorax-Untersuchungen durchgeführt (durchschnittlich 2,5). Bei
15 Patienten (21,4 %) erfolgte postinterventionell eine Kontrollkoronarangiographie. 41 Patienten (58,6 %) erhielten eine Myokardszintigraphie, 2 Patienten (2,9 %) eine Lungenszintigraphie.
Bei 33 Patienten (47,1 %) wurde ein Koronar-CT durchgeführt.
7 Patienten (10 %) erhielten mindestens einmal ein CT einer anderen
Körperregion (11 Untersuchungen). Bei 4 Patienten (5,7 %) erfolgte
eine Röntgenaufnahme einer anderen Körperregion. Insgesamt wurden bei den 70 Patienten 391 unterschiedlich strahlenbelastende Untersuchungen zusätzlich zur CTO-Intervention durchgeführt (Mittelwert 5,6).
Diskussion Bei Koronarpatienten, die eine komplexe Koronarintervention wie eine CTO-Rekanalisation erhalten, sollte nicht nur
auf die Strahlenbelastung während der Intervention geachtet werden. Während eines einjährigen Follow-up wurde eine CTO-Kohorte durchschnittlich 5,5 weiteren radiologischen bzw. nuklearmedizinischen Untersuchungen ausgesetzt. Im Einzelfall kann es somit zu
einer sehr hohen kumulativen Strahlenbelastung kommen.
Alle Behandelnden sollen daher jede einzelne strahlenintensive Untersuchung streng indizieren und strahlenfreie Alternativen nutzen.
Die Patienten müssen in jedem Fall über die möglichen Risiken der
Strahlenbelastung hingewiesen werden und die Aufzeichnung der
einzelnen Untersuchungen in einem Röntgenpass ist mehr denn je
Incidence of Coronary Stent Fractures in Patients at
High Risk
VII – 5
L. C. Krenn, V. Berger-Kulemann, P. Krisai, F. Wolf, G. Delle-Karth, G. Kreiner,
Ch. Roth, C. Gangl, I. Lang, H. Sochor, Th. Neunteufl, Ch. Löwe, R. Berger
Klinische Abteilung für Kardiologie, Universitätsklinik für Innere Medizin II;
Universitätsklinik für Radiodiagnostik, Medizinische Universität Wien
Background Fracture of drug-eluting stent (DES) is regarded to
play a significant role in several cases of stent thrombosis, in-stent
restenosis, target lesion revascularization, myocardial infarction as
well as sudden death. The rates of stent fracture diagnosed by coronary angiography (CA) seem to be underestimated (1–7%), as significantly higher rates are reported at autopsy (29%). Coronary
computered tomography (CCT) may be a more accurate method for
the detection of stent gaps than CA.
Aim This is the first study to prospectively evaluate the incidence
of stent gaps in patients at high risk for stent fracture.
Methods Patients with two or more risk factors for stent fracture
defined as (1) stent length ≥ 28 mm, (2) stent overlapping, (3) localization in the right coronary artery or saphenous vein graft and (4)
vessel angulation of ≥ 75° before implantation or ≥ 45° stent angulation after implantation were invited to undergo a coronary CT angiography 6 months after the procedure. A coronary angiography including optical coherence tomography was recommended in patients with a partial or total stent gap.
Results In eleven (46%) out of 24 patients (70.8% male, mean age
63.2 ± 10 years) coronary CT revealed a stent gap. Stent fracture
was suggested in 7 patients (29%), whereas a stent-gap between not
J KARDIOL 2012; 19 (5–6)
exactly overlapped stents (identified by measurement of the stentlengths) was diagnosed in 4 patients (17%). In the following CA all
stent gaps were confirmed by optical coherence tomography. In
3 patients (13%) stent gap was associated with an instent-restenosis
(n = 2.8%) and a chronic total occlusion (n = 1, 4%), respectively.
Conclusion Stent gaps are a frequent phenomenon in patients at
risk (46%). A stent fracture was diagnosed in 29% of patients with
43% of these patients requiring revascularisation. A larger patient
population and a longer follow-up time is needed to further elucidate the clinical impact of CCT for evaluation of patients at high risk
for stent fracture.
A HEART Team Approach for TAVI: Clinical Outcome
of the First 32 Patients as Compared with Results
of the PARTNER Trial and with the Austrian TAVI
VII – 2
M. Leibl, G. Unger, A. Geppert, E. Wessely, J. Falkensammer, A. Bambazek,
F. Waldenberger, A. Assadian, B. Gustorff, M. Grabenwöger, K. Huber
3. Medizinische Abteilung, Kardiologie, Gefäßchirurgie, Anästhesie,
Wilhelminenspital, Wien; Herzchirurgie Krankenhaus Hietzing, Wien
Background In the past, transcutaneous aortic valve implantation
(TAVI) has shown to restore valvular function in inoperable highrisk patients with severe aortic valve stenosis resulting in clinical
improvement and patient survival as compared to a conservative
strategy. This method has been investigational for many years and
was usually associated with a learning curve in the early phase of
implementation of this method in the departments offering TAVI.
We report results of the first 32 patients of our TAVI program,
which started 8/2010 after extensive education of the responsible
interventionists at specialized centers and with the help of an experienced proctor for the first 15 patients to avoid complications in the
“learning phase”. Moreover, optimized techniques and surroundings (e. g. preparation and closure of the femoral artery by a vascular
surgeon, presence of an anesthesiologist and a cardiac surgeon during the whole procedure, stand-by of a mobile heart lung unit with
technician) were organized from the very beginning of this method.
Our peri-procedural, short- and long-term results are compared with
those achieved in larger patient cohorts (PARTNER Trial, PT; and
Austrian TAVI Registry, ATR), respectively.
Methods Between 8/2010 and 1/2012, 32 high-risk patients (Euro
SCORE 26.6 ± 12.4%) with a mean age of 83 ± 5 years, who were
not eligible for cardiac surgery by decision of the cardiac surgeon
(MG), received a Medtronic CoreValveTM at our department. We
analyzed the clinical outcome during the peri-procedural phase as
well as at 30 days and after one year.
Results Baseline echocardiographic parameters before implantation of the CoreValveTM revealed a mean transvalvular pressure of
45.4 ± 14.3 mm Hg (PT: 44.5 mm Hg; ATR: 53.6 mmHg), a mean
aortic valve area (AVA) of 0.7 ± 0.2 cm2 (PT: 0.6 cm2; ATR: 0.6 cm2),
and a mean LVEF of 48.9 ± 10.2% (PT: 53.9 %; ATR: not available). Echocardiographic assessment after TAVI revealed a mean
transvalvular pressure of 8,7 ± 3,9 mm Hg (PT: 11,1 mm Hg; ATR:
9.67 mm Hg), a mean AVA of 2.2 ± 0.9 cm2 (PT: 1.5 cm2; ATR:
1.94 cm2), and a mean LVEF of 50,7 ± 8,8% (PT: 57,9; ATR: not
available]. Major bleeding from the femoral artery (n = 3; 9.4%; PT:
16.2%, ATR: 6%), stroke or TIA (n = 1; 3.1%; PT: 6.7%, ATR: 3.2%)
and post-procedural complete AV block requiring pacemaker implantation (n = 2; 6.3%; PT: 3.4%, ATR: 23.2%) represented periprocedural complications. Moreover, 11 additional patients (34.4%),
who developed post-procedural left or right bundle branch block,
also received a pacemaker as a precaution (total PM rate after TAVI:
40.6%). No patient died during or immediately after the procedure.
Short-term all-cause mortality at 30 days was 6.3% (PT: 3.4%; ATR:
not available). All-cause mortality after 1 year (5/11 patients) was
45.5%. Of all deaths about 2/3 were non-cardiovascular indicating
the specific high-risk and multimorbid population included for TAVI
procedures at our institution.
Conclusion These data confirm experience from other groups that
TAVI can be successfully initiated and performed without a “learn-
ÖKG-Jahrestagung 2012 – Abstracts
ing curve” if a close cooperation within a HEART team including
different specialties is organized. This success encourages to further
extending our program.
Post-Procedural Atrial Fibrillation After Transcatheter
Aortic Valve Implantation versus Surgical Aortic
Valve Replacement
XV – 6
L. J. Motloch, D. Rottländer, S. Reda, R. Khatib, R. Larbig, U. C. Hoppe
Department of Internal Medicine II, Paracelsus Medical University, Salzburg
Background Transcatheter aortic valve implantation (TAVI) represents an alternative option for elderly with severe aortic valve
stenosis who are denied surgical aortic valve replacement (SAVR)
due to high perioperative risk. The impact of TAVI on post-procedural atrial fibrillation is undefined.
Methods In a single-centre analysis we assessed clinical data, preoperative risk scores (STS-Score, logistic EuroSCORE), pre-procedural ECGs and 72-hour post-procedural rhythm monitoring of 170
patients undergoing TAVI (n = 84) or SAVR (n = 86). In a subanalysis transapical (n = 43) and transfemoral TAVI (n = 41) were
Results Expectedly, TAVI patients were significantly older, presented with more severe symptoms, had higher STS-Scores, higher
logistic EuroSCOREs and revealed more frequently intermittent
atrial fibrillation compared to SAVR patients. Despite this more
compromised health state, prevalence of post-procedural atrial fibrillation was significantly lower in the TAVI group (6.0% vs 33.7%
after SAVR; p < 0.05). More than 2/3 of TAVI patients but no
SAVR patient with atrial fibrillation in pre-procedural ECGs had
stable sinus rhythm during 72 hour post-procedural monitoring.
Notably, no atrial fibrillation was observed after transfemoral TAVI.
While atrial fibrillation onset in the SAVR group predominantly
occurred on postoperative day 3, atrial fibrillation onset after transapical TAVI was obtained within the first 24 hours after the intervention.
Conclusion Our results indicate that TAVI compared to SAVR
reduces the risk of peri-procedural atrial fibrillation. Furthermore,
pre-procedural atrial fibrillation may be converted into sinus rhythm
particularly after transfemoral TAVI suggesting an impact of decreased intracardiac pressures in the absence of adverse peri-procedural factors that might promote atrial fibrillation.
Drug-eluting Stent versus Bare-metal Stent nach
koronarer Rotablation
XV – 9
L. Pilgerstorfer, H. Kratzer, E. Zeindlhofer, A. Winter, M. Gattermeier, K. Höllinger,
D. Kiblböck, D. Szücs, A. Gierlinger, M. Schmid, Ch. Steiner, P. Siostrzonek
Interne II, KH Barmherzige Schwestern, Linz; Landesklinikum Mostviertel,
Waidhofen a. d. Ybbs
Einleitung Die Rotablation (RA) stellt bei starker koronarer Gefäßverkalkung eine wichtige interventionelle Therapieoption dar.
Die Behandlung langer Gefäßsegmente mittels RA ist mit einer hohen
Restenoserate assoziiert. Drug-eluting Stents (DES) könnten gerade
nach RA gegenüber Bare-metal Stents (BMS) vorteilhaft sein.
Material und Methoden Wir erfassten alle Patienten, die in unserem Katheterlabor in den Jahren 2000–2010 einer RA mit StentImplantation unterzogen worden waren und bei denen eine Reangiographie nach 6 Monaten verfügbar war. Von diesen insgesamt 91
Patienten hatten 52 Pat. DES und 39 Pat. BMS erhalten. Als primärer Endpunkt wurden die Instent-Restenose und die Target-VesselRestenose nach 6 Monaten gewählt, sekundäre Endpunkte waren
Myokardinfarkt und Tod nach 6 Monaten.
Ergebnisse DES- und BMS-Patienten waren in Hinblick auf Alter
(71,0 ± 9,6 vs. 72,1 ± 8,8 a), Geschlecht (Männer: 69,2 % vs. 69,2 %)
und kardiovaskuläre Risikofaktoren (Diabetes: 40 % vs. 26 %;
p = 0,17) vergleichbar. Die Stentlänge betrug bei Pat. mit DES und
BMS 31 ± 15,9 und 25,1 ± 13.9 mm (p = 0,078), der mittlere
Stentdiameter 3,1 ± 0,28 und 3,5 ± 0,4 mm (p < 0,001). In der angiographischen 6-Monats-Kontrolle hatten 26,5 % der Pat. mit DES
und 46,8 % der Pat. mit BMS eine Instent-Restenose (p = 0,06).
Die Target-Vessel-Restenose betrug 40,8 % für Pat. mit DES und
65,6 % für Pat. mit BMS (p = 0,011). Restenosen außerhalb des
Stent-Segmentes traten bei Pat. mit DES und BMS in 14,2 % bzw.
18,8 % (p = 0,59) auf.
Sekundäre Endpunkte traten selten auf und waren in den Gruppen
nicht-signifikant unterschiedlich (Infarkt 2/51 nach DES und 2/39
nach BMS, Tod bei 1/51 nach DES und 2/39 nach BMS.
Diskussion Die klinische Ereignisrate 6 Monaten nach RA ist bei
Verwendung von DES und BMS niedrig. Restenosen sind nach
langstreckiger RA und Stentimplantation häufig und nicht nur auf
die gestenteten Segmente beschränkt. DES reduzieren gegenüber
BMS nach RA die Rate an Instent-Restenosen, aber nicht die Stenoserate in Segmenten ohne Stentabdeckung.
Mesh Covered Stents and Myocardial Blush in
STEMI Patients
XV – 3
N. Preis, J. Sipötz, O. Friedrich, M. Winkler, G. Gaul
2. Medizinische Abteilung, Hanusch-Krankenhaus, Wien
Background Our single centre retrospective trial sets out to examine the outcome of PCI in STEMI patients using a mesh covered
stent device designed to provide embolic protection compared to a
control group in with conventional stent devices. Endpoints were
myocardial blush measured by a quantitative method, TIMI after
PCI, ST-segment elevation resolution, and 6 months mortality.
Method Our trial included 58 single vessel interventions after
acute STEMI. In 24 patients the mesh covered stent was deployed,
the control group included 34 patients.
Myocardial reperfusion after PCI was assessed by Myocardial Blush
Grade (MBG) and by using the Quantitative Blush Evaluator
(QuBE) a computer program created by Vogelzang et. al. (2009)
providing a quantitative measure for myocardial blush. To apply the
QuBE to our angiographic data we modified the method calculating
the increase in grey value in the filling phase of the vessel, only.
The modified QuBE value is significantly correlated with MBG
(p < 0.001) and ST-elevation resolution (p = 0.02). Complete STsegment resolution was defined as a resolution of more than 70%
60–90 minutes after PCI.
Results We found a non-significant trend of better TIMI flow
grade and MBG after PCI in patients treated with mesh covered
stents (TIMI 2: 8.3%, 3: 91.7%; MBG 2: 8.3%, 3: 91.7%) compared
to the control group (TIMI 1: 2.9%; 2: 17.7%, 3: 79.4%; MBG 1:
8.8%; 2: 17.7%; 3: 73.5%). Quantitative measured myocardial blush
was significantly better (median: 5, q1/q3: 4/7 vs median: 3.5, q1/q3:
2/6; p < 0.001). No significant difference was found with respect to
ST-segment elevation resolution and 6 months.
Table 10: N. Preis et al. Outcome Parameters
Mesh covered stent
(n = 24)
Conventional stent
device (BMS or DES)
(n = 34)
0.0 %
8.3 %
91.7 %
2.9 %
17.7 %
79.4 %
0.0 %
8.3 %
91.7 %
8.8 %
17.7 %
73.5 %
Modified QuBE
* TIMI 3 vs TIMI 1/2 (Fisher Exact Test); ** MBG 3 vs MBG 1/2 (Fisher Exact
Test); *** Mann-Whitney-U-Test
J KARDIOL 2012; 19 (5–6)
ÖKG-Jahrestagung 2012 – Abstracts
Conclusion At the current stage our trial suggests, the deployment
of mesh covered stents results in better myocardial reperfusion in
STEMI-patients compared to conventional stent devices. It may be
assumed that covering a stent with a mesh may protect against distal
embolization in thrombus burden. Further randomized research is
needed (Table 10).
Local versus General Anesthesia for Transfemoral
Aortic Valve Implantation
VII – 9
S. Reda, L. J. Motloch, D. Rottländer, R. Larbig, J. Strauch, T. Wahlers,
U. C. Hoppe
Klinik für Innere Medizin II/Kardiologie, Universitätsklinikum Salzburg, Österreich;
Universitätsklinik für Herz- und Thoraxchirurgie, Bochum; Universitätsklinik für
Herz- und Thoraxchirurgie, Köln, Deutschland
Background Transcatheter aortic valve implantation (TAVI) represents a novel option for elderly with severe aortic valve stenosis who
are denied surgical aortic valve replacement due to high perioperative
risk. While transfemoral TAVI generally is being performed in general anesthesia (GA), TAVI under local anesthesia plus mild sedation
(LAPS) might be an effective and safe alternative.
Methods In a 3 year single-centre analysis we assessed clinical
data, preoperative risk scores (STS-Score), echocardiography, periprocedural data and labor costs in 74 patients undergoing transfemoral TAVI under GA (n = 33) and LAPS (n = 41).
Results Patients who underwent TAVI in LAPS presented significantly more often with pulmonary hypertension and impaired renal
function, and tended to have a higher STS-Score and more severe
symptoms (higher NYHA class) versus the GA group. There were
no significant differences in procedure-related 30-day mortality or
complications between groups. The peak systolic and mean central
aortic pressure were significantly higher in the LAPS group, while
at the same time these patients required significantly less often
periprocedural adrenergic support. There was no significant difference between intervention time and fluoroscopy time. However, total procedure time was significantly shorter and labor costs were
lower in the LAPS group. Patients who underwent TAVI in LAPS
could be mobilized significantly earlier.
Conclusion Our study indicates that TAVI under LAPS is as effective and safe as TAVI under GA. Furthermore total procedure
time and labor costs could be reduced by LAPS. Mobilization of
patients could be achieved earlier. We therefore consider LAPS to
be favorable in patients undergoing transfemoral TAVI.
Contrast Agent and Radiation Exposure in Revascularization of Chronic Total Occlusions: Magnetic
Navigation versus Conventional Percutaneous
Coronary Intervention
VII – 3
S. Scherzer, R. Berger, L. Krenn, A. Kaider, G. Delle Karth, Th. Neunteufl
Division of Cardiology, Department of Internal Medicine II, Medical University
Introduction Aim of this trial was to compare magnetic navigation system (MNS) and conventional approach in revascularization
of coronary chronic total occlusions (CTO).
Methods Forty symptomatic patients with CTO were randomized
to MNS or conventional approach for antegrad crossing of the occluded vessel. Crossing success, crossing time, radiation exposure,
and contrast media usage were directly compared using intentionto-treat and per protocol analysis. In the per protocol analysis each
study group included patients with cross over after failing wirecrossing in the original group.
Results In the intention-to-treat analysis wire-crossing and revascularization were successful in a comparable number of CTOs using
MNS (n = 9/9) and the conventional approach (n = 13/12). Crossing
time was significantly shorter in the MNS group (415.5 sec; IQR
211.5–497.5 sec) than in the conventional group (1131 sec; IQR
275.5–2630 sec; p = 0.03). Also radiation exposure was significantly
lower in the MNS group (513.5 mGy; IQR 313–837 mGy) than in
J KARDIOL 2012; 19 (5–6)
the conventional group (1346.5 mGy; IQR 520.5–4053.5 mGy;
p = 0.02). Usage of contrast agent was in trend lower in the MNS
group (42.4 ml; IQR 28.55–56.3 ml) than in the conventional group
(116 ml; IQR 21.25–313.6 ml). However, four previously failed
MNS cases were successfully crossed with a wire and revascularized using the conventional approach. Accordingly, in the per-protocol the wire-crossing rate was in trend higher using the conventional approach (17 of 31) compared to the MNS (9 of 28; p = 0.08).
Conclusion The use of MNS for wire-crossing and revascularization is feasible and can reduce crossing-time, radiation exposure,
and the use of contrast agent. However, due to a better selection of
crossing wires the conventional approach enables wire-crossing in
cases failed by MNS and seems to be the more successful choice.
The Course of NT-proBNP in Patients who Underwent Percutaneous Transcatheter Aortic Valve
VII – 4
S. Scherzer, R. Rosenhek, Th. Binder, G. Maurer, S. Sandner, G. Kreiner,
W. Wisser, Th. Neunteufl, J. Bergler-Klein
Division of Cardiology, Department of Internal Medicine II, Medical University
Background Natriuretic peptides have been shown to predict outcome in patients with severe aortic stenosis before and after aortic
valve replacement. The aim of this study was to evaluate the course
of N-terminal pro B-type natriuretic peptide (NT-proBNP) in patients who underwent percutaneous transcatheter aortic valve implantation (TAVI).
Methods Between May 2007 and January 2012, 78 symptomatic
pts with severe aortic stenosis successfully underwent TAVI (55 pts
received a Edwards Sapiens valve, 23 pts a CoreValve). NT-proBNP
(Roche Elecsys) was assessed before and 30 days, 3, 6, and 12
months, 2 and 3 years after TAVI.
Results Patients had an age of 83 ± 6 years, the logistical EuroScore
was 24.7 ± 12%, the baseline aortic valve area 0.6 ± 0.1 cm2, and the
mean gradient 59 ± 18 mmHg. Baseline NT-proBNP was significantly correlated to the logistical EuroScore (rho = 0.3; p = 0.008),
but not to age. After TAVI NT-proBNP decreased in trend from
2401 pg/ml (n = 71; IQR 1223–5789) to 1593 pg/ml (n = 22; IQR
783–3505; p = 0.35) after 7 days, to 1743 pg/ml (n = 42; IQR 769,8–
3945,5; p = 0.134) after 30 days, to 1525 pg/ml (n = 42; IQR 902–
3714; p = 0.356) after 3 months, to 1166 pg/ml (n = 39, IQR 569–
2342; p = 0.019) after 6 months, to 1451 pg/ml (n = 23, IQR 770–
3971; p = 0.164) after 12 months, to 1354 pg/ml (n = 13, IQR 356–
4034; p = 0.111) after 2 years and to 1186 pg/ml (n = 10; 309–2072;
p = 0.690) after 3 years. The Cox regression analysis suggests baseline NT-proBNP to be a predictive marker for survival (HR 1.3;
p = 0.1).
Conclusion After TAVI, NT-proBNP levels tended to decrease.
Baseline NT-proBNP seems to be a predictor for outcome after
TAVI. These data should be confirmed in larger patient populations.
Low-Speed Rotational Atherectomy with Substantial
Debulking Improves Long-Term Outcome
XV – 2
J. Sipötz, M. Winkler, O. Friedrich, G. Gaul
2. Medizinische Abteilung – Kardiologie, Hanusch-Krankenhaus, Wien
Aims Our retrospective trial aims to evaluate the longterm outcome in PCI patients undergoing a modified protocol of Rotational
Atherectomy using a lower burr speed of 135 krpm in short runs,
intermittent ablation and minimal deceleration (pecking technique)
relative to a non-debulked control group.
Methods Out of a 6 year period we selected all patients (i. e.:
1033) treated with single vessel interventions in our cath-lab. 144
patients were excluded because of incomplete data sets. Of the resulting 889 patients 40% (i. e.: 356 patients) underwent substantial
debulking. To compare long time survival between debulked and
non-debulked patients we calculated Kaplan Meyer curves up to 80
ÖKG-Jahrestagung 2012 – Abstracts
Results Comparing the baseline data, the non-debulked group (n =
533) was significantly younger than the debulked group (n = 356),
other clinical variables did not differ significantly. The lesions in the
debulked group were morphologically more severe (lesion length:
13.5 ± 10.6 mm vs 10.0 ± 7.1 mm, p < 0.001; % stenosis: 71.0 vs
68.6, p = 0.007; % ostial lesions: 17.4 vs 7.2, p < 0.001; ACC class
C: 62% vs 35%, p < 0.001). The intervention resulted in a substantially greater lumen increase in the debulked group (2.3 ± 0.5 mm vs
2.2 ± 0.6 mm, p < 0.001) with a burr-to-artery ratio of 0.64 ± 0.14.
Kaplan-Meier survival analysis up to 80 months between the 2 groups
was identical.
To address selection bias, we used propensity-score matching based
on 26 prognostically important clinical and angiographic variables
resulting in the formation of 279 matched pairs (i. e.: 578 patients).
Lumen gain after intervention was significantly greater in the debulked group (2.3 ± 0.6 mm vs 2.2 ± 0.5 mm, p = 0.009). In the
matched group treated with rotational atherectomy survival was
substantially improved (hazard ratio 0.52, confidence interval 0.32–
0.85, p < 0.01).
Conclusion We have redefined the protocol of the technique of
rotational atherectomy with a platform speed of 135 krpm, pecking
technique and a step-up burr sizing up to a debulking burr-to-artery
ratio of greater than 0.6. We hypothesize this modification might
explain the equal long-term outcome in patients with worse baseline
endorsed by a significant improvement when analyzed by propensity for rotational atherectomy. We explain these data by the
debulking effect of atherectomy with a greater lumen gain compared
to matched patients and by the introduction of a less damaging protocol.
Outcome of Left Main Percutaneous Coronary Interventions – A Single-Centre Retrospective Study
XV – 4
M. Unterhuber, N. Moes, O. Pachinger, H. Alber
Universitätsklinik für Innere Medizin III/Kardiologie, Medizinische Universität
Background The SYNTAX study has demonstrated that percutaneous coronary interventions (PCI) of left main (LM) stenoses are
feasible in patients with stable coronary artery disease. However,
there is ongoing controversy about the optimal patient selection for
LM-PCI. Hence, the aim of this retrospective study was to determine prognostic factors for LM-PCI which may improve patient selection in the future.
Methods 90 patients (age 69 ± 11 years) were enrolled, in whom
LM-PCI was performed at our department (until march 2011). All
baseline clinical characteristics as well as important laboratory values were analyzed retrospectively. Also, all cardiovascular events
(all cause death, myocardial infarction, stroke, bypass-operation and
repeat coronary intervention) were documented after contacting patients by letter as well as phone call. The median follow-up time was
54 months.
Results In univariate analyses several parameters (e. g. arterial
hypertension, chronic kidney disease, ST-elevation myocardial infarction, EuroSCORE, stent size and type, no use of intravascular
ultrasound) were associated with increased risk for cardiovascular
events. In a multivariate analysis chronic kidney disease (p < 0.01),
ST-elevation myocardial infarction (p < 0.01), EuroSCORE (p < 0.01),
use of bare-metal stents (p = 0.05) and no use of intravascular ultrasound (p = 0.02) remained significantly associated with cardiovascular events. After publication of the SYNTAX trial the proportion
of stable patients with LM-PCI significantly increased (67% vs
95%; p < 0.01) and no peri-interventional event occurred.
Conclusion Our data suggest that LM-PCI in patients with chronic
kidney disease, a high EuroSCORE or during acute myocardial infarction is associated with increased cardiovascular events in the
long term. The results also support the use of drug-eluting stents as
well as intravascular ultrasound for post-implantation control.
Finally, we could demonstrate a clinically relevant impact of the
SYNTAX trial in our daily practice.
J KARDIOL 2012; 19 (5–6)
Erfolgsrate und periphere Gefäßkomplikationen
nach Implementation eines transradialen Katheterprogramms
XV – 8
A. Winter, D. Kiblböck, K. Höllinger, E. Zeindlhofer, L. Pilgerstorfer, U. Brunhuber,
A. Schiller, D. Szücs, Ch. Steiner, L. Pilgerstorfer, A. Winter, A. Gierlinger,
P. Siostrzonek
Interne II/Kardiologie, Krankenhaus der Barmherzigen Schwestern, Linz
Einleitung Wir berichten über unsere Erfahrungen bei Implementation eines transradialen (TR) Katheterprogramms in unserem
Herzkatheterlabor. Die Umstellung von der transfemoralen (TF) zur
TR-Technik wurde durch Untersuchungen zur Ergebnisqualität begleitet. Der vorliegende Bericht beschreibt Erfolgsrate und Häufigkeit von peripheren Gefäßkomplikationen nach TR-Gefäßzugang.
Material und Methode Die TR-Technik wurde in unserem Labor
seit Jänner 2011 systematisch eingeführt. Unser standardisiertes
Vorgehen umfasst die Durchführung eines Allen-Tests, die Punktion
mit einer 20G-Kanüle, das Einbringen einer hydrophil beschichteten
6F-Schleuse (Radifocus II, Terumo Europe N.V., Leuven, Belgien)
in Seldinger-Technik, die Applikation von 5000 E Heparin und
5 mg Verapamil, und die Verwendung von Standarddrähten und
Koronarkathetern wie beim TF-Vorgehen. Nach Schleusenentfernung wird ein TR-Band (Terumo Europe N.V., Leuven, Belgien) für
4 h appliziert. Nach einem Jahr verfügen nunmehr alle 5 Katheterärzte über eine TR-Erfahrung aus über 200 Untersuchungen, davon
mindestens 50 Koronarinterventionen. Zur Qualitätskontrolle wurden nun prospektiv Daten aller TR-Untersuchungen vom 1.11.2011
bis 31.1.2012 ausgewertet. Inkludiert war bei allen Patienten eine
Pulskontrolle mit Duplex- und Doppler-Sonographie der A. radialis
24 h und 4 Wochen nach der Katheterprozedur.
Ergebnisse Im Zeitraum von 3 Monaten wurden 482 Pat. einer
Katheteruntersuchung unterzogen, davon wurde bei 318 Pat. (66,2 %;
Alter: 66,6 ± 10,8 Jahre, 70 % Männer) primär der TR-Zugang und
bei 164 Pat. (33,8 %) primär der TF-Zugang verwendet. Ursachen
für einen primären TF-Zugang waren eine Angiographie im Bereitschaftsdienst (n = 49), die geplante Abklärung oder Intervention bei
Vitium (n = 17), ein pathologischer Allen-Test (n = 21) bzw. Arztoder Patientenpräferenz (n = 78). Bei 79 (34,3 %) Pat. mit TR-Zugang erfolgte eine Koronarintervention. Bei 24 Pat. (7,5 %) mit primär geplantem TR-Zugang musste auf einen TF-Zugang gewechselt
werden. Ursache waren Probleme bei der Punktion bei 16 Pat., beim
weiteren Vorgehen über die Armarterie bei 6 Pat. und bei der Sondierung der Koronararterien bei 2 Patienten.
Bei 2 Pat. (0,6 %) mit TR-Zugang trat eine akute gefäßbezogene
Komplikation auf. Ein Pat. mit Nachblutung entwickelte ein inkomplettes Kompartmentsyndrom am Unterarm, das jedoch keiner chirurgischen Intervention bedurfte, weitere Nachblutungen waren selten und durchwegs oberflächlich und begrenzt. Die Sonographie der
A. radialis nach 24 h und 4 Wochen konnte bei 222 bzw. 190 Pat.
durchgeführt werden. Der Gefäßdiameter an der Punktionsstelle betrug nach 24 h 2,48 ± 0,05 mm und nach 30 Tagen 2,47 ± 0,05 mm
(p = n. s.). Ein Verschluss der A. radialis wurde nach 24 h bei 4 Pat.
(1,3 %; davon 1 Pat. symptomatisch) und nach 30 Tagen bei 1 Pat.
(0,3 %; asymptomatisch) festgestellt.
Diskussion Die Implementation der TR-Untersuchung in unserem Herzkatheterlabor erzielte rasche Akzeptanz durch Ärzte, Pflegepersonal und Patienten. Nach Durchführung von 200 Prozeduren
pro Untersucher ist die TR- Technik mit einer akzeptablen Erfolgsrate und einer geringen Komplikationsrate durchführbar.
Interventionelle Behandlung eines großen Aneurysmas der rechten Koronararterie
VII – 7
E. Zeindlhofer, A. Winter, K. Höllinger, M. Schmid, P. Siostrzonek
Interne II/Kardiologie, Krankenhaus der Barmherzigen Schwestern, Linz
Wir berichten über einen 60-jährigen männlichen Patienten, der wegen einer seit 3 Monaten bestehenden Crescendo-Angina zur Koronarangiographie zugewiesen wurde. An kardiovaskulären Risikofaktoren waren eine arterielle Hypertonie, eine Hypercholesterinämie, sowie ein mehrere Jahre zurückliegender Nikotinkonsum zu
ÖKG-Jahrestagung 2012 – Abstracts
Austrian TAVI Registry: One-Year Experience
D. Zweiker, R. Zweiker, E. Maurer, G. Lamm, M. Heigert, Th. Neunteufl, M. Leibl,
E. Zeindlhofer, M. Grund, J. Pollak, W. Tkalec, O. Luha, R. Maier
Klinische Abteilung für Kardiologie, Medizinische Universität Graz; Klinische
Abteilung für Innere Medizin II, Klinikum Wels-Grießkirchen; 3. Medizinische
Abteilung, Landesklinikum, St. Pölten; Universitätsklinik für Innere Medizin II,
Salzburger Universitätsklinikum; Klinische Abteilung für Kardiologie, Medizinische
Universität Wien; Interne II/Kardiologie, Krankenhaus Barmherzige Schwestern,
Linz; Interne 1, Allgemeines Krankenhaus, Linz; 4. Medizinische Abteilung mit
Kardiologie, Krankenhaus Hietzing, Wien; 2. Interne/Kardiologie, Krankenhaus
der Elisabethinen, Linz
Figure 34: E. Zeindlhofer et al.
erheben. An Vorerkrankungen bestand eine operiertes abdominelles
Aortenaneurysma sowie ein operiertes N. prostatae.
Die transradiale Koronarangiographie zeigte das Vorliegen einer
koronaren Eingefäßerkrankung mit proximaler 90 %-RCA-Stenose
sowie ein unmittelbar anschließendes poststenotisches 20 × 22 ×
30 mm messendes Aneurysma (Abbildung 34a). Nach Diskussion
verschiedener therapeutischer Optionen sowie Aufklärung und Zustimmung des Patienten wurde ein interventioneller Therapieversuch geplant. Eine Gerinnungstherapie mit Prasugrel und Acetylsalicylsäure wurde eingeleitet. Die Intervention gestaltete sich vor
allem wegen der proximalen Gefäßkrümmung schwierig. Letztlich
gelang es unter Verwendung eines Guideliner-Katheters (Vascular
Solutions Inc., Minneapolis, USA), 3 Stents in die proximale Stenose
(Skylor 3,5 × 13 mm; Invatec, Roncadelle, Italien) und in das Aneurysma (Aneugraft 3,5 × 23 mm; ITGI Medical, Or-Akiva, Israel und
M-Guard 3,5 × 18 mm; Inspire MD, Tel Aviv, Israel) vorzubringen.
Allerdings erwies sich der Versuch, das Aneurysma mittels Graftstents abzudecken, nur teilweise erfolgreich, da eine distale Verankerung der Stents im Ausgang des Aneurysmas nicht erreicht werden konnte (Abbildung 34b). Erst bei einer zweiten interventionellen Sitzung konnte eine komplette Überbrückung des Aneurysmas durch Implantation eines zweiten M-Guard-Stents 4,0 × 19 mm
in den distalen Aneurysmateil erreicht werden (Abbildung 34c).
Die duale Plättchenhemmertherapie wurde fortgeführt. Der Patient
ist seither kardial beschwerdefrei, die geplante Kontrollangiographie nach 3 Monaten zeigte eine vollständige Ausschaltung des Aneurysmas ohne Vorliegen von Re-Stenosen (Abbildung 34d).
Verbesserungen der interventionellen Technik ermöglichen selbst
bei schwierigen anatomischer Gegebenheiten die erfolgreiche
Katheterbehandlung eines großen Koronararterienaneurysmas.
Objective Transcatheter aortic valve implantation (TAVI) is a
new, minimally invasive intervention for treatment of severe aortic
stenosis. However, there is limited data concerning mid- and longterm outcome in a routine clinical setting. Beginning with January 1,
2011, the Austrian TAVI registry has been launched to document
and assess procedure details, risks and outcome. 10 centers in Austria
are currently participating in the registry.
Design and Methods In 2011, 315 patients (202 female, 113
male) were included in the registry (age 82 ± 5 years). The logistic
EuroSCORE was 19.9 ± 13.5%, and the STS Risk Score (available
for 123 patients) was 16.1 ± 11.1% for the female and 8.9 ± 8.7% for
male patients, respectively. After baseline data assessment and
documentation of the procedure itself (valve type, access site, duration, complications), follow-up visits at 1, 3, 6 and 12 months after
the procedure were scheduled.
Results 282 CoreValve and 33 Sapien prostheses were implanted.
Preferred access site was transfemoral (n = 285). A transapical
(n = 18) or transsubclavian (n = 12) approach were used less frequently. Acute procedural success rate was 99.4%. Complications
were observed in 29% of patients. Use of CoreValve was accompanied by less complications (48% vs 26%). Need for pacemaker implantation was the most common complication (n = 55, 17% overall), followed by unplanned surgery (5.4%) and peripheral vascular
major bleeding (4.8%). The follow-up examinations (baseline vs 30day follow-up) showed significant improvement of hemodynamic
parameters (Vmax 4.5 ± 0.7 m/s vs 1.9 ± 0.5 m/s, mean gradient 53 ±
17 mmHg vs 9 ± 4 mmHg, and AVA/BSA 0.4 ± 0.1 cm2 vs 1.1 ±
0.3 cm2; p < 0.001), as assessed by echocardiography. Additionally,
frailty was assessed using the Karnofsky index, which showed significant improvement from 60 ± 10% to 80 ± 20%; p < 0.001). Periprocedural mortality was 1% (3 patients). The 30-day survival was
Conclusion Data of this registry prove that study results of TAVI
concerning patient selection and outcome being transferred successfully into routine clinical settings. The major limitation of the presented registry is that a considerable number of patients was not included into the registry due to various reasons. To overcome this
bias, the Task Force TAVI of the Austrian Society of Cardiology
and the Austrian Society of Thoracic and Cardiovascular Surgery
proposes a nationwide Austrian Aortic Valve Registry, which could
probably start with 2013.
J KARDIOL 2012; 19 (5–6)
ÖKG-Jahrestagung 2012 – Abstracts
 Koronare Herzkrankheit (KHK)/Coronary
Heart Disease (CHD)
Erfolgreiche und nachhaltige Modifizierung kardiovaskulärer Risikofaktoren durch ambulante kardiologische Rehabilitation
XVI – 4
J. Niebauer, K. Mayr, H. Harpf, A. Philippi, E. Huber, G. Zenker, B. Ebner,
M. Wonisch, R. Pokan, W. Benzer
Universitätsinstitut für präventive und rehabilitative Sportmedizin, Paracelsus
Medizinische Privatuniversität Salzburg; Cardiomed – Ambulante kardiologische
Rehabilitation, Linz; Krankenanstalt Institut für Bewegungstherapie Graz; RehaSport-Institut Feldkirch; Ambulatorium Nord, Salzburg; Physikalisches Ambulatorium der Stadtwerke Bruck a. d. Mur; Institut für Präventiv- und Rehabilitationsmedizin Cardio-Vital-Wels; Hansa Privatklinikum Graz; Institut für Sportwissenschaften, Universität Wien; Institut für Interventionelle Kardiologie, Landeskrankenhaus, Feldkirch
Ziel Es war das Ziel dieser Studie, die Wirksamkeit der ambulanten
kardiologischen Rehabilitation Phase II und Phase III nach dem
Modell der Arbeitsgemeinschaft für ambulante kardiologische Rehabilitation (AGAKAR), folgend den Guidelines der Österreichischen Kardiologischen Gesellschaft (ÖKG), zu untersuchen.
Methodik Alle Ambulatorien, die Vertragspartner der Österreichischen Sozialversicherungen sind, gaben die Daten der Patienten der
ambulanten kardiologischen Rehabilitation Phase II und III prospektiv in die von der AGAKAR installierte, webbasierte Datenbank
ein. Insgesamt gelangten im Zeitraum 1.1.2009–30.11.2011 für die
Phase II 1432 und für die Phase III 1390 vollständige Datensätze zur
Ergebnisse Die Patienten in der ambulanten kardiologischen Rehabilitation der Phase II konnten ihre Leistungsfähigkeit am Fahrradergometer während des 4–6-wöchigen Rehabilitationsprogramms
um durchschnittlich 20,56 ± 27,72 Watt verbessern. Des Weiteren
erreichte der überwiegende Teil der Patienten einen systolischen
Blutdruck von < 140 mmHg (85,9 %), ein LDL < 100 mg/dl (66,8%),
Triglyzeride < 150 mg/dl (70,0 %) und bei den Männer 60,8 % einen
Bauchumfang < 102 cm. Am Ende der Phase III wurden die Zielwerte
von einem noch größeren Teil der Patienten erreicht, wobei die Ergebnisse dann am besten waren, wenn der Phase III eine ambulante
anstelle einer stationären Phase II vorausging. Bei den Frauen blieb
der Bauchumfang und bei beiden Geschlechtern der Body-massIndex beim Großteil der Patienten außerhalb der Zielwerte. Die Ergebnisse des Hospital Anxiety and Depression Scale- (HADS-) Fragebogens zeigten, dass bereits zu Beginn der ambulanten Phase II
die Werte für Ängstlichkeit (HADS-A: 84,8 %) und Depressivität
(HADS-D: 89,0 %) beim größten Teil der Patienten im Zielbereich
lagen und im Rahmen des Rehabilitationsprogramms sich weiter
verbesserten (HADS-A: 86,4 %, HADS-D: 90,8 %). Die gesundheitsbezogene Lebensqualität der Rehabilitanden verbesserte sich in
allen 4 Skalen des MacNew-Fragebogens.
Schlussfolgerung Diese Daten beweisen einmal mehr und in
dieser speziellen Ergebnisanalyse erstmals auch für Österreich die
Wirksamkeit und Nachhaltigkeit sowohl der ambulanten kardiologischen Rehabilitation der Phase II als auch der Phase III nach dem
Modell der AGAKAR und folgend den Guidelines der ÖKG. Diese
Ergebnisse sollten dazu Anlass geben, die in Österreich praktizierte,
evidenzbasierte und leitlinienkonforme ambulante Rehabilitation
lückenlos, flächendeckend, berufsbegleitend und wohnortnah anzubieten und nicht mehr nur auf wenige Zentren zu beschränken.
Das Ausmaß der koronaren Herzkrankheit ist ein
starker, unabhängiger Prädiktor der Langzeitmortalität
XVI – 3
M. Rammer, T. Weber, A. Haiden, M. Porodko, E. Laßnig, M. Suppan, B. Eber
Abteilung für Innere Medizin 2, Klinikum Wels-Grieskirchen
Hintergrund Historische Studien zeigten einen Zusammenhang
zwischen dem Ausmaß der koronaren Herzkrankheit (KHK), mittels
Koronarangiographie (CAG) bestimmt, und der Prognose. Neuere
J KARDIOL 2012; 19 (5–6)
Daten dazu stammen vorwiegend aus CT-angiographischen Studien. Die prognostische Wertigkeit der konventionellen CAG vor dem
Hintergrund einer modernen Therapie der KHK ist nicht bekannt.
Wir evaluierten den prognostischen Wert des Ergebnisses einer diagnostischen CAG hinsichtlich der Langzeit-Sterblichkeit von Patienten mit klinischem Verdacht auf eine KHK.
Methodik Das untersuchte Kollektiv umfasste 1334 konsekutive
Patienten (64,7 ± 11,1 Jahre, 61 % männlich), die mit Verdacht auf
KHK zwischen Juli 2001 und Februar 2002 einer CAG unterzogen
wurden. Die CAG-Ergebnisse wurden kategorisiert als signifikante
(≥ 50%ige) Stenose in 1 (KHK 1), 2 (KHK 2), 3 (KHK 3) epikardialen Gefäßen, signifikante (≥ 50%ige) Stenose des linken Hauptstammes (HS), nicht-signifikante (< 50%ige) Stenose in zumindest
einem Gefäß (Sklerose) oder unauffällige Koronarien. Endpunkt
war die Gesamtsterblichkeit, die Erfassung der Endpunkte erfolgte
über Krankengeschichten, telefonische Hausarzt-Interviews sowie
über Daten der Statistik Austria. In multivariablen Cox-Regressions-Analysen erfolgte eine Adjustierung für Alter, Geschlecht,
Cholesterin, Hypertonie, Diabetes, Kreatinin und Raucherstatus.
Ergebnisse 18,9 %, 15,9 %, 26,4 %, 20,0 %, 18,8 % der Patienten
hatten unauffällige Koronarien, eine Sklerose, eine KHK 1, KHK 2
oder KHK 3/HS. Während der mittleren Nachbeobachtungszeit von
8,0 ± 2,5 Jahren betrug die Sterblichkeit 8,7 %, 17,0 %, 19,6 %,
30,7 % und 41,4 % für Patienten mit unauffälligen Koronarien,
Sklerose, KHK 1, KHK 2 und KHK 3/HS. Auch nach Adjustierung
für klassische Risikofaktoren blieb das KHK-Ausmaß ein unabhängiger Mortalitäts-Prädiktor (p < 0,0001).
Schlussfolgerung Auch vor dem Hintergrund einer aktuellen
Therapie sind das Vorhandensein sowie das Ausmaß CAG-definierter atherosklerotischer Veränderungen Prädiktoren für die LangzeitMortalität unabhängig von klassischen Risikofaktoren.
Full Arterial Revascularization as a Second CABG
XVI – 5
E. Ruttmann, V. Mühlberger, N. Fischler, A. Sakic, M. Grimm, O. Chevtchik
Department of Cardiac Surgery; Department of Cardiolgy, Innsbruck Medical
Introduction A 67-year-old male patient presents with severe
angina CCS III–IV since June 2011.
Material and Methods He underwent a CABG procedure in
January 1988 receiving 2 saphenous vein grafts (SVG) to the LAD
and RCA with thromb-end-arterectomy of both vessels. Due to recurrence of symptoms and occluded grafts at repeated cardiac catheterization he underwent a CABG-reoperation with 3 SVG grafts to
all major coronary arteries.
He lived uneventfully until June 2011. At repeated cardiac catheterization all native coronary arteries were occluded except a 90%
stenosis of a diagonal branch that failed a re-intervention. The SVG
graft to the RCA was occluded, the other SVGs to LAD and CX
were severely calcified with high grade stenosis. The RCA was occluded but showed excellent collaterals, ventricular function was
preserved (EF = 69%).
Result In November 2011 he underwent a 2nd re-operation. Intraoperative TEE diagnosed a grade III tricuspid regurgitation that was
repaired using a CE MC3 annuloplasty ring. In the previous re-operation in 1988 the left internal thoracic artery was violated in the
middle segment, however, due to skeletonization reached enough
length to be “recycled” as an in-situ graft to the diagonal branch.
Furthermore, he received the right internal thoracic artery as an insitu graft to the LAD and a radial graft to the CX.
The postoperative course was uncomplicated.
Conclusion Full arterial revascularization for CABG re-operations
is feasible and safe and prevents from long-term SVG graft failure.
ÖKG-Jahrestagung 2012 – Abstracts
Angiopoietin-Like 4 is Elevated in Type-2 Diabetes
But is Not Associated With Angiographically Determined Coronary Artery Disease
XVI – 1
 Pulmonale Hypertonie/Pulmonary Hypertension
Ch. H. Saely, A. Muendlein, A. Vonbank, K. Geiger, P. Rein, H. Drexel
VIVIT-Institute, Innere Medizin, Landeskrankenhaus, Feldkirch
Prevalence and Clinical Impact of Atrial Fibrillation
Among Patients with Pulmonary Hypertension BAI
Background Angiopoietin-like 4 (ANGPTL4, fasting-induced
adipose factor), a protein inhibitor of lipoprotein lipase, is synthesized and secreted during fasting in adipose tissue and the liver. Its
associations with metabolic syndrome traits are uncertain, and it is
not known whether it is associated with type 2 diabetes (T2DM) or
coronary artery disease (CAD).
Methods We therefore measured serum ANGPTL4 in 493 patients undergoing coronary angiography for the evaluation of established or suspected stable CAD; significant CAD was diagnosed
when coronary stenoses ≥ 50% were present.
Results ANGPTL4 was significantly positively correlated with
age (r = 0.177; p <0.001) and fasting glucose (r = 0.112; p = 0.013)
but was not correlated with waist circumference, triglycerides, HDL
cholesterol, systolic blood pressure or diastolic blood pressure.
ANGPTL4 was significantly higher in patients with T2DM (n = 115)
than in non-diabetic subjects (28 ± 32 vs 25 ± 38; p = 0.032); however, it was not significantly different between patients with significant CAD (n = 246) and individuals without significant CAD
(p = 0.112).
Conclusion We conclude that ANGPTL4 is positively correlated
with fasting glucose and elevated in T2DM but is not significantly
associated with angiographically determined CAD.
D. Rottländer, L. Motloch, R. Sara, D. Schmidt, R. Larbig, U. Hoppe
Universitätsklinik für Innere Medizin II, Universitätsklinikum Salzburg, Österreich;
Universitätsklinikum Köln, Deutschland
Chemerin is Associated with the Metabolic Syndrome But is Not Linked to Angiographically
Determined Coronary Artery Disease
XVI – 2
Ch. H. Saely, A. Muendlein, A. Vonbank, K. Geiger, P. Rein, H. Drexel
VIVIT-Institute, Innere Medizin, Landeskrankenhaus, Feldkirch
Background The novel adipocytokine chemerin has been suggested to be linked to insulin resistance and to the metabolic syndrome (MetS). Its association with coronary artery disease (CAD) is
unclear. We hypothesized that chemerin is associated with both
angiographically determined CAD and with the MetS.
Methods We measured serum chemerin in 498 patients undergoing coronary angiography for the evaluation of established or suspected stable CAD; the MetS was defined according to NCEPATPIII criteria; significant CAD was diagnosed when coronary
stenoses ≥ 50% were present.
Results Chemerin was higher in MetS patients (n = 150) than in
subjects without the MetS (184 ± 77 vs 150 ± 62 ng/ml; p < 0.001).
It did not differ significantly between patients with significant CAD
(n = 250) and those without significant CAD (p = 0.327). When both,
MetS and CAD status were considered, chemerin was higher in MetS
patients both among those who had significant CAD (182 ± 80 vs
152 ± 60 ng/ml; p = 0.002) and among those who did not have significant CAD (187 ± 73 vs 148 ± 63 ng/ml; p < 0.001); it did not
differ significantly between patients with significant CAD and subjects without significant CAD among MetS patients (p = 0.248) nor
among subjects without MetS (p = 0.263). Analysis of covariance
(ANCOVA) showed that from the NCEP-ATPIII metabolic syndrome traits a large waist circumference as well as elevated trigylcerides were independent predictors of elevated serum chemerin
(F = 12.5; p < 0.001 and F = 8.5; p = 0.004).
Conclusion We conclude that chemerin is significantly associated
with the MetS but not with angiographically determined CAD. The
overall association of chemerin with the MetS is carried by its association with visceral obesity and elevated triglycerides.
Background Pulmonary hypertension (PH) is associated with progressive impairment of right ventricular function, reduced exercise
capacity and a poor prognosis. Little is known about the prevalence,
clinical manifestation and impact of atrial fibrillation (AF) on cardiac function in PH.
Objective To investigate the prevalence of AF in various forms of
PH, and to assess the clinical manifestation and hemodynamic parameters in PH with AF. In a subanalysis PH due to chronic left
heart failure and PH due to any other cause in the absence and presence of AF were separately compared.
Methods and Results In a 4-year single-centre retrospective
analysis of 225 patients with confirmed PH of various origins, AF
was prevalent in 31.3%. In patients with PH and AF, parameters of
clinical deterioration (NYHA/WHO functional class, 6-minute walk
distance, NT-proBNP levels) and renal function were significantly
compromised compared to patients with PH and sinus rhythm (SR).
Furthermore, the occurrence of AF in PH was associated with an
increase of right atrial pressure (RAP) and right atrial dilatation.
While no direct association was found between pulmonary artery
pressure (PAP) and AF in PH, right ventricular function was reduced in AF, indicating more advanced disease. In PH due to left
heart failure the prevalence of AF was particularly high (57.7% vs
22.8% in other forms of PH). In this subgroup, left atrial dilatation,
increase of pulmonary capillary wedge pressure, PAP and RAP
were more pronounced in AF than in SR, suggesting that more
marked backward failure led to AF in this setting.
Discussion PH is associated with increased prevalence of AF.
Occurrence of AF in PH indicates clinical deterioration and more
advanced disease. Clinical trials to identify a beneficial therapy for
AF in PH are warranted.
Factors Determining Outcome in Patients with
Heart Failure and Normal Ejection Fraction
C. Tufaro, J. Mascherbauer, B. Marzluf, Th. Binder, I. M. Lang, D. Bonderman
Division of Cardiology, Department of Internal Medicine II, Medical University
Background Patients with heart failure and normal left ventricular ejection fraction (HFNEF) face an adverse outcome. The aim of
the present study was to identify factors that determine prognosis.
Methods Consecutive patients with HFNEF diagnosed according
to current ESC guidelines were recruited in our prospective Viennese
registry. Death and/or hospitalization for heart failure were defined
as primary outcome variables. Outcome groups were compared with
Table 11: C. Tufaro et al. Independent predictors of outcome in
heart failure with normal ejection fraction
95 %-CI
BMI (kg/m2)
PVR (dynes.s/cm5)
Results of the multivariable logistic regression model of factors determining outcome in patients with heart failure and normal ejection fraction. Data
are listed as Odds Ratios (ORs), 95%-CI and p-values in the final model.
DMII: Diabetes mellitus; BMI: Body mass index; PVR: pulmonary vascular
J KARDIOL 2012; 19 (5–6)
ÖKG-Jahrestagung 2012 – Abstracts
respect to potential prognostic predictors using the Student’s t-test.
Multivariable logistic regression analysis was applied to determine
whether parameters of interest were associated with adverse outcome. P < 0.05 indicated statistical significance.
Results Between December 2010 and January 2012, 49 HFNEF
patients (34 f, 15 m, mean age 70 ± 8 years) were registered. After a
mean follow-up of 5 ± 9 months, 14 (29 %) patients were hospitalized or died. Patients in the adverse outcome group were characterized by higher body mass index (BMI, 35 ± 7 vs 29 ± 5, p = 0.004),
higher systolic pulmonary pressure on echo (sPAP in mmHg, 69 ±
15 vs 55 ± 14, p = 0.004), shorter 6-minute walk distance (6-MWD
in m, 271 ± 131 vs 364 ± 100, p = 0.019), higher transpulmonary
gradient (TPG in mmHg, 15 ± 4 vs 12 ± 4, p = 0.013) and a higher
pulmonary vascular resistance (PVR in dynes.s/cm5, 257 ± 97 vs
198 ± 71, p = 0.030). Diabetes mellitus II (DM II, 75% vs 24%,
p = 0.002) and atrial fibrillation (92% vs 51%, p = 0.013) were more
prevalent among patients with adverse outcome.
In the multivariable regression model, only BMI, DM II and PVR
remained independent predictors of outcome (Table 11).
Discussion Presence of DM II, higher BMI and higher PVR
worsen prognosis in HFNEF patients.
Katheterablation bei ventrikulären Tachykardien/
Kammerflimmern mit komplexem arrhythmogenem
IX – 6
 Rhythmologie/Rhythmology
M. Derndorfer, M. Martinek, E. Sigmund, Ch. Lemes, H.-J. Nesser, J. Kautzner,
H. Pürerfellner
Abteilung für Kardiologie I, Krankenhaus Elisabethinen, Linz, Österreich;
Department für Kardiologie, IKEM, Prag, Tschechische Republik
Electroanatomic Substrate Mapping and Catheter
Ablation of Right and Left Atrial Macroreentry
VIII – 6
F. Danmayr, B. Strohmer, M. Brandt, U. Hoppe
Universitätsklinik für Innere Medizin II, PMU Klinik Salzburg
Introduction Atrial macroreentry tachycardias (AMRT) represent a spectrum of arrhythmias resulting from surgical treatment of
congenital heart disease, or as a consequence of previous surgical or
catheter ablations. The purpose of this retrospective study is to characterize the arrhythmogenic substrate and reentry circuits in patients
with drug-resistant AMRT and to report the ablation approach guided
by electroanatomic mapping.
Methods We report about a case series of 15 pts (age 56 ± 18 [21–
76] yrs; male n = 10), who presented to our institution with typical
(n = 9) or atypical (n = 6) atrial flutter refractory to antiarrhythmic
medication. Surgically corrected congenital heart disease was present
in 6 pts (ASD n = 4; VSD n = 2), a history of cardiac surgery in 3 pts
(tricuspid and/or mitral annuloplasty rings n = 2, CABG+PM n = 1),
previous catheter interventions in 4 pts (PVI n = 2, RA catheter ablations n = 2, LA surgical ablation n = 1) and no obvious structural
heart disease in 4 pts.
Results After informed consent electrophysiological study was carried out to diagnose scar-related AMRT (CL 270 ± 50 ms). Electroanatomical mapping was performed in 14/15 patients (CARTO
n = 11; NAVX n = 3). AMRT was defined to the RA in 10 pts, and
to the LA in 5 pts according to concealed entrainment pacing techniques. A PPI < 30 ms and identical intracardiac activation sequence
during pacing at critical sites were presumed to be part of the reentry
circuit. Double loop reentry was identified in the RA (n = 4) involving the atriotomy scar and in the LA (n = 3) related to electrical silent
areas or previous surgical ablations. Isolated cavotricuspid isthmus
(CTI) dependent reentry was the mechanism in 3 pts only. Temperature-controlled irrigated ablation was applied to the critical isthmus
of the proposed reentry circuit in the RA or LA with focal or linear
lesions connecting to nearby conduction barriers. RA lesions spanned
from the atriotomy scar to the IVC, SVC or TV (n = 5), LA ablations
consisted of a set of lesions incorporating the septal area (n = 2), the
roof and/or superior PV (n = 2) and the endo/epicardial isthmus
(n = 2). In addition, standard CTI ablation was performed in 10 pts
for protective reasons or due to involvement in double loop reentry.
Unmappable right AMRT forms underwent an anatomically guided
substrate ablation (n = 2). The endpoint of the procedure was defined as termination of the clinical AMRT (13/15 pts) and documen-
J KARDIOL 2012; 19 (5–6)
tation of conduction block with widely split double potentials across
the ablation line. One patient with ASD and previous RA substrate
modifications received a pacemaker due to symptomatic sinusbradycardia following ablation. During a mean follow-up of 22 ± 18 months
all pts remained free of the clinical AMRT, however 5/15 pts developed other intraatrial tachyarrhythmias, mostly atrial fibrillation.
Conclusion Patients with different pathological conditions may
demonstrate similar features with respect to arrhythmogenic substrates and reentry circuits. Conduction barriers, such as postinterventional or surgical atrial scars as well as idiopathic electrical silent
areas were identified as central obstacle for AMRT by electroanatomic 3D mapping. Our approach of ablating critical parts of the
incisional- or scar related sites together with the CTI in the majority
of patients resulted in elimination of the clinical AMRT. Over longterm we observed a moderate risk for other intraatrial tachyarrhythmias, particularly atrial fibrillation.
Einleitung Ventrikuläre Tachykardien (VT) und Kammerflimmern (VF) bei (meist) struktureller Herzerkrankung stellen komplexe Krankheitsbilder dar, die für den Patienten (Pat.) aufgrund der
potentiell lebensbedrohlichen Charakteristik inkl. adäquater bzw.
inadäquater Schocks des implantierten ICD-Systems eine besonders
belastende Situation ergeben. Die Katheterablation stellt einen überwiegend palliativen Behandlungsansatz dar und gestaltet sich je
nach zugrundeliegendem Substrat unterschiedlich komplex.
Methodik Im Krankenhaus der Elisabethinen Linz wurden in den
Jahren 2007 bis 2011 insgesamt 129 Patienten (Abbildung 35) einer
VT-Ablation unterzogen. Von diesen wurden retrospektiv 26 Pat.
analysiert, bei denen ein komplexes arrythmogenes Substrat vorlag.
Als Grunderkrankung wurde bei 11 Patienten eine ischämische CMP,
bei 3 eine dilatative CMP, 4x eine zurückliegende Myokarditis, 2×
eine ARVD und bei 6 Patienten eine idiopathische VT/VF mit rezidivierenden ICD-Schocks angegeben. Das durchschnittliche Alter
der Patienten (23 m, 3 w) betrug 57 ± 12 Jahre, die LVEF vor Ablation war 43 ± 12 %, 100 % der Patienten hatten rezidivierende VT/
VF-Episoden, 15 Patienten (57,7 %) teils multiple Schockabgaben
durch den ICD.
Zur Charakterisierung des arrhythmogenen Substrates wurde ein 3-DVoltagen-Map (CARTO, Fa. Biosense Webster) verwendet. 9 Pat.
(34,6 %) wurden in Vollnarkose untersucht, 15 in Sedoanalgesie.
Der intravasale Ultraschall kam 11× zum Einsatz, 22 Prozeduren
wurden endokardial, 2 epikardial und 2 beiderorts durchgeführt. Pro
Pat. konnten 2,38 ± 1,47 VT-Morphologien mit Zykluslängen zwischen 264 ms und 580 ms ausgelöst werden (Tabelle 12). Die Ablation erfolgte mit einem wassergekühlten Ablationskatheter
(NaviStar bzw. 4× Smart Touch, Fa. Biosense Webster). Untersucht
wurden Prozedurdauer, Durchleuchtungszeit, Strahlendosis, An-
Abbildung 35: M. Derndorfer et al. VT-Ablationen im KH Elisabeth
ÖKG-Jahrestagung 2012 – Abstracts
Tabelle 12: M. Derndorfer et al.
Pair Parameter
Prozedurdauer (min)
max Signifikanz
Durchleuchtung (s)
Strahlendosis (cGycm²)
Ablationszeit (s)
Energie gesamt (Ws)
Energie max (W)
Temperatur max
VTs ausgelöst (n)
VT-Zykluslängen (ms)
VTs vor Ablation (n)
CQ p =
VTs nach Ablation (n)
ICD-Schocks vorher (n)
CQ p =
ICD-Schocks nachher (n)
Abbildung 37: M. Derndorfer
et al. Patienten mit Notwendigkeit einer Rehospitalisierung
arrhythmogener Ursache nach
HF-Ablation. Telefonische Abfrage im Februar 2012.
Abbildung 38: M. Derndorfer
et al. Vom Patienten beurteilte
Lebensqualität (QoL) nach HFAblation. Telefonische Abfrage
im Februar 2012.
Abbildung 36: M. Derndorfer et al. VTs und ICD-Schockabgaben
im Verlauf.
Abbildung 39: M. Derndorfer et al. Kardialer Kompass, Patientin.
Abbildung 40: M. Derndorfer et al. Kardialer Kompass, Patient.
zahl der Ablationspunkte, die Ablationszeiten, maximale und gesamte Energieabgabe und erreichte Temperatur (Tabelle 12). Die
Patienten wurden 02/2012 telefonisch bzgl. VT-Rezidiven, ICDSchocks und Veränderung der Lebensqualität (QoL) befragt.
Resultate Bei 5 Prozeduren war aufgrund VF oder hämodynamischer Intoleranz der ausgelösten VTs eine elektrische Kardioversion
notwendig, 2× kamen postinterventionell zur Kreislaufstabilisierung Katecholamine zum Einsatz. Schwere Komplikation (relevanter Perikarderguss, bleibende Beeinträchtigung, Tod) wurden nicht
beobachtet. Bei 18 Pat. konnte zum Prozedurende keine VT mehr
induziert werden, 7× wurde aufgrund fortgeschrittener Prozedurdauer auf eine Austestung verzichtet, 1× konnte von 2 VT-Morphologien noch 1 provoziert und aufgrund ihres epikardialen Ursprunges in einer 2. Sitzung behandelt werden.
14 Patienten (53,8 %) berichteten bei einem mittleren Follow-up
von 27,6 ± 16,5 Monaten hinsichtlich der VTs über Rezidiv-Freiheit
und 23 Patienten (88,5 %) über Freiheit von ICD-Schocks (Abbildung 36). In 19 Fällen (73,1 %) war keine Rehospitalisierung aufgrund der bekannten Arrhythmie mehr notwendig (Abbildung 37),
24 Pat. (92,3 %) schilderten eine teils deutlich gebesserte QoL
J KARDIOL 2012; 19 (5–6)
ÖKG-Jahrestagung 2012 – Abstracts
(Abbildung 38). Zwei kardiale Kompasse implantierter ICDs zeigen Langzeitverläufe (Abbildungen 39, 40).
Schlussfolgerung Ablationen bei komplexem arrhythmogenem
Substrat mit rezidiv. VT/VF bei Pat. mit meist signifikanter struktureller Herzerkrankung und teils multiplen ICD-Schocks sind aufwändige Interventionen, die jedoch für den Pat. eine deutliche klinische Verbesserung durch Reduktion von Arrhythmien und Schocks
Klinische Ergebnisse mit Dronedaron (Multaq®) bei
nicht-permanentem Vorhofflimmern anhand des
IX – 7
M. Derndorfer, M. Martinek, E. Sigmund, Ch. Lemes, H.-J. Nesser, H. Pürerfellner
Abteilung für Kardiologie I, Krankenhaus Elisabethinen, Linz
Einleitung Dronedaron (Multaq®, Fa. Sanofi-Aventis) ist ein
Mehrkanalblocker, der in Österreich bei nicht-permanentem Vorhofflimmern (VHF) seit Anfang 02/2010 als Antiarrhythmikum zur
Verfügung steht. Wir berichten über die klinischen Ergebnisse der
DEMETER-Beobachtungsstudie (prospektives Register, Laufzeit
von 02/2012 bis 12/2011).
Methodik An 6 österreichischen Zentren wurden 94 Patienten
(Pat.) (67 m, 27 w) mit einem Alter von 65 ± 11 Jahre in die Studie
aufgenommen. Als Einschlussgrund wurde bei 2 Patienten erstmaliges VHF, 68× paroxysmales VHF (72 %) und 24× persistierendes
VHF (25,5 %) vermerkt, jeweils 50 % der Pat. wurden ambulant oder
stationär auf Dronedaron umgestellt. Zur Baseline-Visite (BL) konnte
bei 75 Pat. (80 %) Sinusrhythmus (SR) und 17× VHF (18 %), sowie
2× Vorhofflattern (VHFL) dokumentiert werden (Abbildung 41),
echokardiographisch wurde bei 77 Pat. (82 %) eine normale und
17× (18 %) eine reduzierte LVEF zwischen 35 und 50 % berechnet.
Die mittlere Vorhofsgröße lag bei 43 ± 7 mm, der CHADS2-Score
bei 1,3 ± 1.
Neben EKG und Labor wurden nach 3 und 6 Monaten die NYHAStadien erfasst und die Pat. zu ihrer aktuellen Lebensqualität (QoL)
hinsichtlich des VHF befragt (0 = sehr schlecht; 10 = exzellent).
Resultate 52 von 94 Pat. (= 55 %) konnten die Studie protokollkonform abschließen, 20 Pat. waren nicht auswertbar (lost to
Follow-up), bei 14 Pat. wurde ein Abbruch dokumentiert. Grund für
das Ausscheiden waren bei 12 Pat. (75 %) VHF-Rezidive, 2× (13 %)
eine Intoleranz gegen das Medikament (Diarrhoe), 1× Verordnungsprobleme und 2× mangelnde Compliance. Proarrhythmische Effekte oder Todesfälle traten nicht auf. 8 Pat. wurden wegen eines VHFRezidivs rehospitalisiert, weitere stationäre Aufnahmen aus kardiovaskulärer Ursache waren nicht notwendig. Unter Dronedaron kam
es über 6 Monate zu keiner relevanten Progression von SR in ein
Abbildung 41: M. Derndorfer et al. Rhythmus zum Zeitpunkt des
Follow-up (%).
J KARDIOL 2012; 19 (5–6)
persistierendes VHF, dies zeigten sowohl die zum FU1 und FU2
registrierten Ruhe-EKGs (Abbildung 42) als auch die jeweils niedrigen Raten an erforderlichen Kardioversionen (62 % der Pat. in der
Anamnese, 5,3 % zum FU1, 3,8 % zum FU2). Die Leberwerte blieben über 6 Monate stabil, das Serumkreatinin stieg pharmakodynamisch erwartungsgemäß signifikant an (Tabelle 13). Relevante
EKG-Veränderungen, insbesondere eine QTc-Verlängerung kamen
nicht vor (Tabelle 13).
Die Herzinsuffizienzfälle unter Dronedaron (44,7 % zur BL, 26,7 %
zum FU1, 23,1 % zum FU2) nahmen von Visite zu Visite viel stärker
ab als zu (Abbildung 43). Statistisch konnte dafür (Kreuztabellenanalyse) eine tatsächliche Verbesserung des Zustandes der Pat. und
nicht das Ausscheiden „schlechter“ Probanden aus der Studie bestätigt werden. Entsprechend wurde von den Pat. bereits ab dem FU1
eine signifikant bessere QoL geäußert (Abbildung 44) und diese
Entscheidung bis zum Schluss beibehalten.
Abbildung 42: M. Derndorfer et al. Kreatinin im Verlauf – Boxplots
(Median – Quartile).
Tabelle 13: M. Derndorfer et al.
44,70 %
23,10 %
Std. Dev.
Pair 1
Pair 2
Pair 3
Pair 4
Pair 5
Pair 6
Pair 7
Pair 8
Pair 9
Pair 10
Pair 11
p < 0,001
ÖKG-Jahrestagung 2012 – Abstracts
Abbildung 43: M. Derndorfer et al. Anteil der Patienten mit Herzinsuffizienz.
Methods Between April 2004 and October 2011, 70 consecutive
patients (83% men, mean age 59 ± 14 years) underwent 122 catheter
ablation procedures, including 24 epicardial procedures, at our center.
Results The median number of inducible VTs was 2 (range 1–7,
cycle length 380 ± 83 msec), mean left ventricular ejection fraction
was 33.6 ± 9.95 ml. Acute complete success, defined as the lack of
inducibility of any VT at the end of procedure, was achieved in 68%
of patients. Eleven patients (15.7%) died during a median follow-up
of 420 days (range 25–2705 days) 53% of patients were free from
VT recurrence. In univariate analysis LVEF (p = 0.015), clinical VT
CL (p = 0.03), and GFR (p = 0.039) were correlated with VT free
survival. However, in multivariate logistic regression only female
gender (p = 0.005) and left ventricular end-systolic diameter
LVESD < 53 mm (0.009) were associated with VT free survival.
Conclusion VT free survival during long term follow-up in our
patients cohort Catheter ablation in patients with DCM and electrical storm due to monomorphic VT, who had an ICD, prevents further VT recurrence in 53% of the patients. Female gender and
LVESD are reliable markers to predict VT free survival.
Erhöhte Strahlenexposition bei Substratablation
ventrikulärer Tachykardien
VIII – 8
B. Frey, N. Doruska, Ch. Wollmann, M. Pribyl, P. Schlossnagl, H. Mayr
Abteilung für Kardiologie, Klinik für Innere Medizin 2, Landeskrankenhaus,
St. Pölten
Abbildung 44: M. Derndorfer et al. Lebensqualität quantitativ – Boxplots (Median – Quartile).
Schlussfolgerung Unter Beobachtung von Klinik, EKG sowie
Labor (Serumkreatinin, Leberwerte) zeigte sich Dronedaron bei
nicht-permanentem VHF ohne rezente kardiale Dekompensation
nebenwirkungsarm und sicher in der Anwendung. Zudem kam es zu
einer signifikanten Abnahme an klinischer Herzinsuffizienz (p = 0,001)
und einer signifikant gebesserten QoL der Pat. (p = 0,013, BL vs.
FU1 bzw. 0,027, BL vs. FU2) (Tabelle 13, Abbildung 43, 44). Anhand eines stabilen Verhältnisses an Patienten mit VHF und SR
konnte unter Dronedaron über 6 Monaten keine relevante Progression von paroxysmalem in persistierendes VHF beobachtet werden.
Long-Term Outcome of Catheter Ablation of Electrical Storm Due to Monomorphic Ventricular Tachycardia in a Large Cohort of Patients with
Nonischemic Cardiomyopathy
L. Fiedler, B. Dinov, R. Schönbauer, A. Bollmann, P. Sommer, T. Gaspar,
D. Husser-Bollmann, Ch. Piorkowski, G. Hindricks, A. Arya
Abteilung für Rhythmologie, Herzzentrum Leipzig, Deutschland
Introduction This study aimed to assess the predictors of long
term outcome in patients with idiopathic dilated cardiomyopathy
undergoing catheter ablation. Electrical storm due to recurrent ventricular tachycardia (VT) can adversely affect their long-term survival. This study evaluates the efficiency of the radiofrequency
catheter ablation of electrical storm due to monomorphic VT in patients with idiopathic dilated cardiomyopathy and assesses predictors for recurrence.
Einleitung Strahlendosen > 5 Gy am Referenzpunkt (Air Kerma)
erhöhen das Risiko eines Strahlenschadens der Haut. Gesamtkörperdosen > 100 mSv, errechnet aus dem Dosisflächenprodukt (DFP),
erhöhen nachweislich das Risiko, an einer Leukämie oder einem
Lymphom oder Karzinom zu erkranken. Bezüglich der Substratablation ventrikulärer Tachykardien (VT) inklusive Mapping mittels CARTO gibt es noch kaum Daten bezüglich der zu erwartenden
Methode Wir evaluierten die Strahlendosis in allen unseren Patienten (n = 27), bei denen von 9/2009 bis 12/2011 eine VT-Ablation
(n = 28) durchgeführt wurde und verglichen die Dosis zu den letzten
28 Ablationen 2011, bei denen kein CARTO-Mapping-System verwendet wurde (Kontrollen). Indikationen zur VT-Ablation waren
St. p. Herzinfarkt (n = 13), dilatative Kardiomyopathie (n = 10),
arrhythmogene rechtsventrikuläre Dysplasie (ARVD) (n = 2) und
idiopathische VT (n = 2). Die Kontrollen waren eine Ablation des
„slow pathway“ (n = 13), des rechts atrialen Isthmus (n = 10), einer
fokalen atrialen Tachykardie (n = 2), einer akzessorischen Bahn
(n = 2) und einer Tachykardie aus dem Ausflusstrakt bei ARVD
(n = 1). In Erwartung langer Prozeduren wurde vor Beginn des VTAblationsprogramms das Strahlenschutzkonzept optimiert.
Ergebnisse siehe Tabelle 14.
Diskussion Die Strahlendosis und somit die Strahlenexposition
bei Substratablation von VTs ist deutlich höher im Vergleich zu
Routine-Ablationen. Kritische Werte werden nur selten erreicht,
nämlich bei einem Patienten mit kombinierter endo- und epikardialer Ablation. Dies unterstreicht die klinische Bedeutung eines Konzepts zur Optimierung des Strahlenschutzes bei VT-Ablation.
Tabelle 14: B. Frey et al.
Alter (Jahre)
64 ± 12
Geschlecht (m/w)
Untersuchungszeit (min)
308 ± 79
Durchleuchtungszeit (min)
55 ± 25
DFP (cGycm2)
19.444 ± 13.331
Air Kerma (Gy)
1,6 ± 1,07
Air Kerma (> 5 Gy)
Effektive Dosis (mSv)
41 ± 28
Effektive Dosis (> 100 mSv)
58 ± 16
163 ± 71
30 ± 30
11.793 ± 11.605
0,94 ± 0,93
25 ± 25
n. s.
n. s.
< 0,01
< 0,01
< 0,05
< 0,05
< 0,05
J KARDIOL 2012; 19 (5–6)
ÖKG-Jahrestagung 2012 – Abstracts
Endogenous tPA is an Independent Predictor of
Adverse Cardiovascular Events and All Cause
Mortality in Patients with Atrial Fibrillation Treated
According to Guidelines
VIII – 7
M. Freynhofer, S. Gruber, V. Bruno, T. Höchtl, S. Farhan, J. Wojta, K. Huber
3rd Med. Department of Internal Medicine, Cardiology and Emergency Medicine,
Wilhelminenhospital, Vienna
Background Tissue plasminogen activator (tPA) is the major activator of plasminogen, which is responsible for thrombus resolution. Patients with atrial fibrillation (AF) exhibit higher levels of
endogenous tPA, suggesting a hyperfibrinolytic state due to endothelial dysfunction and clinically silent thrombus generation. tPA
might help to estimate the thromboembolic risk of patients with AF.
We therefore investigated whether high levels of endogenous tPA,
independently of the CHADS2-score, predict major adverse cardiovascular events (MACE) in patients with AF treated according to
current guidelines.
Methods This prospective, longitudinal single center study included 269 patients with AF. Blood samples were analyzed for tPAantigen concentration by means of enzyme-linked immunoassay kits.
Results Patients were followed for a median duration of 1933
(1517–2277) days. After adjustment for all univariable predictors
for MACE and all-cause mortality (p ≤ 0.1), tPA above the median
of 4.22 ng/ml (HR 3.003 [95%-CI: 1.688–5.341]; p < 0.001 and HR
2.525 [95%-CI: 1.440–4.428]; p = 0.001, respectively) remained independently associated with outcome. In patients with low and intermediate risk for cardiovascular events according to the CHADS2score the addition of high tPA plasma levels (> 4.22 ng/ml) had significant impact on the patients outcome (HR 3.254 [1.129–9.378];
p = 0.029 and HR 2.330 [1.273–4.264]; p = 0.006, respectively).
Conclusion High values of endogenous tPA independently predict MACE and all-cause mortality in patients with AF. Therefore,
tPA and the hyperfibrinolytic state in AF might represent an important biomarker for the development and perpetuation of vascular
disease in AF patients. This might be an additional help to risk stratification in AF patients.
Renal Function, P-Glycoprotein-Affecting Drugs and
Stroke Prevention in Atrial Fibrillation
XVII – 1
F. Höllerl, C. Stöllberger, J. Finsterer, F. Weidinger
2. Medizinische Abteilung, Krankenanstalt Rudolfstiftung, Wien
Introduction Dabigatran is an oral thrombininhibitor which
showed similar efficacy as warfarin for stroke prevention yet a
lower bleeding rate in patients with atrial fibrillation (AF) in the RELY study. The serum concentration of dabigatran is influenced by
renal function as well as the P-glycoprotein-(P-gp)-system. The aim
of this cross-sectional study was to assess renal function and prescription frequency of P-gp-affecting drugs in hospitalized AF patients.
Methods P-gp-affecting drugs were searched from the literature.
Consecutive patients with AF hospitalized between December 2009
and January 2010 were included. The CHADS2-score was assessed,
the medication was registered and screened for P-gp-affecting
drugs. The glomerular filtration rate (GFR) was calculated by the
“modification of diet in renal disease” formula.
Results In 100 patients (47 females, mean age 74 ± 12 y), the
mean CHADS2-score was 2.4 ± 1.4. GFR was < 30 ml/min/1.73 m2
in 9 patients, 30–45 in 12 patients, 46–59 in 21 patients, 60–89 in 42
patients and ≥ 90 ml/min/1.73 m2 in 16 patients. Forty-two patients
took at least one, and 4 patients 2 P-gp-affecting drugs: Simvastatin
(n = 22), amiodarone (n = 8), vitamin E (n = 8), carvedilol (n = 4),
diltiazem (n = 2), dipyridamole (n = 1), propranolol (n = 1), verapamil (n = 1). P-gp-affecting drugs were prescribed to 3 patients with
GFR < 30 ml/min/1.73 m2, 4 patients with GFR 30–45, 9 patients
with GFR 60–89, 18 patients with GFR 60–89 and 7 patients with
GFR ≥ 90. Only 9 patients had a normal renal function as well as no
prescription of P-gp-affecting drugs.
J KARDIOL 2012; 19 (5–6)
Conclusion Normal renal function was present in only 16% of
hospitalized AF-patients. P-gp-affecting drugs were prescribed to
42% of hospitalized AF patients. Only 9% of hospitalized AF patients have a normal renal function and do not receive P-gp-affecting
drugs. More information about the relevance of impaired renal function and drug interactions is warranted before dabigatran may be
widely used for stroke prevention.
Significant Reduction of Procedure Time and
Fluroscopy Exposure Using the Achieve Mapping
Wire for Pulmonary Vein Isolation with the
Cryocath Ballon
XVII – 4
S. Hönig, C. Steinwender, A. Kypta, K. Saleh, T. Lambert, F. Leisch
I. Medizinische Abteilung mit Kardiologie, Allgemeines Krankenhaus, Linz
Purpose The aim of our examination was to figure out whether
there was an advantage in using the novel mapping wire (Achieve,
Medtronic) performing pulmonary vein isolation (PVI) in combination with the Cryocath Ballon (Medtronic) in a paroxysmal atrial fibrillation (AF) population.
Methods We performed PVI with the Cryo-Ballon in a total
population of 105 patients. In the first group a conventional mapping catheter (Lasso, St. Jude) was used to check pulmonary vein
isolation after application of Cryo-energy. In the second group the
new Achieve mapping wire was used for mapping the PV-potentials during Cryo-ablation. Procedure time, fluoroscopy time and
clinical follow-up were analysed in a retrospective manner. Clinical follow-up consisted of repetitive 48-hr-Holter-ECGs and a personal log of duration and frequency of symptoms in terms of palpitations at 1 month, 3 months and 12 months after PVI. Clinical
success was proven by freedom of atrial arrhythmias longer than
30 sec.
Results Significant reduction of procedure time (conventional
group: mean 180,7 min vs 146,8 min in the Achieve-group, p > 0.01)
and fluoroscopy exposure (conventional group: mean 35.3 min. vs
30.9 min Achieve-group, p > 0.001) were reached by using the new
achieve mapping wire. These differences showed high significance
already after a small cohort of patients suggesting avoidance of a
learning curve as supposed for every new technique. No safety issues appeared and efficacy was shown as high as in the conventional
group with a trend towards the Achieve group (free of AF: 75% in
the conventional and 81% in the Achieve-group, p = n. s.) with a
mean follow-up of 16 months (3–24 months).
Conclusion Using the Achieve during Cryo-Ablation for paroxysmal AF showed significant reduction in procedure and fluoroscopy time with the same efficacy as the standard approach and
without decrease in safety profile. The Achieve may be a tool for
increasing the number of ablations by making the intervention
easier and faster, but further studies are needed to prove this hypothesis.
Voltagegeführte Katheterablation der Pulmonalvenen (PV) bei Vorhofflimmern
XVII – 7
E. Gatterer, M. Wurm, H. Keller, Ch. Steger, F. Weidinger
2. Medizinische Abteilung, Krankenanstalt Rudolfstiftung, Wien; St. Jude
Einleitung Die antrale Pulmonalvenenisolation (PVI) hat sich in
den vergangenen Jahren als die effektivste Ablationsmethode von
paroxysmalem Vorhofflimmern herausgestellt. 3D-Mapping-Systeme werden zur Darstellung des linken Atriums und der Lungenvenen und zur Markierung der Ablationsläsionen verwendet. Mit
dem Ensite NavX Velocity System von St. Jude Medical kann simultan mit dem anatomischen Map ein sogenanntes Voltage-Map (VM)
erstellt werden. Aber nur wenige Zentren nutzen die Möglichkeit
der farblichen Darstellung der Voltage. Die voltagegeführte Ablationsstrategie wird anhand von zwei Beispielen demonstriert.
Methode Unsere Methode der PVI umfasst das gleichzeitige Erstellen einer anatomischen 3D-Karte und des VM (automatische
ÖKG-Jahrestagung 2012 – Abstracts
Abbildung 45: E. Gatterer et al. Voltage-Map vor Energieabgaben
Abbildung 46: E. Gatterer et al. Voltage-Map nach der posterioren
Linie. Die Energieabgabe erfolgt nur mit 15–20 Watt, weil es wiederholt zu Alarmen der Ösophagustemperatursonde kommt.
Abbildung 47: E. Gatterer et al. Signifikante Änderung der Voltage
posterior nach Energieabgaben am Dach der Vene (LSPV )
Abbildung 48: E. Gatterer et al. Voltage-Map nach Isolation aller
Venen (anterior posterior)
LSPV: linke oberen PV; LIPV: linke unteren PV; RSPV: rechte obere
PV; RIPV: rechte untere PV
Abbildung 49: E. Gatterer et al. Voltage-Map nach Isolation aller Venen (LAO-Projektion)
Quantifizierung der elektrischen Potenziale und Farbkodierung:
Signalgröße > 0,5 mV violett, < 0,2 mV grau, dazwischen Farbspektrum blau bis rot), die Darstellung der akuten Veränderungen
der Voltage während der Ablation, Erstellen eines neuen Maps nach
Fertigstellung einer Linie bzw. nach Umkreisen eines Venenpaares,
Lokalisation von Gaps im Ablationsring (AR) und abschließende
Darstellung der Voltage des übrigen Vorhofs nach Isolation aller
Venen. Am Ende der Prozedur muss der Bereich innerhalb der ARe
(Venen und Antrum) grau sein. Abschließend wird der graue Bereich mit dem Ablationskatheter abgetastet und es wird mit 20 Volt
stimuliert. Bei Capture des Sinus Coronarius wird Energie appliziert
bis kein Capture mehr vorliegt.
Beispiel 1 70-jähriger Mann mit paroxysmalem Vorhofflimmern.
Abbildung 45 zeigt das VM vor den Energieabgaben und man sieht,
wie weit erregbares Gewebe in die großen Lungenvenen hineinreicht.
Abbildung 46 zeigt den nur geringen Effekt der ersten posterioren
Linie links auf die Voltage, Abbildung 47 die signifikante Änderung
der Voltage nach den Energieabgaben am Dach der Vene (orange
Punkte). Zu diesem Zeitpunkt finden sich bereits deutlich gesplittete
Signale auf dem Spiralkatheter (atriales Farfield und Venensignal).
Die Ablationslinie wird nun am Unterrand der LIPV in Richtung
Ridge fortgesetzt, danach erfolgt die Ablation anterior vom Dach
nach inferior. Die Isolation der LSPV gelingt im anterioren Zwickel
der sog. Carina zwischen den linken Venen, die Isolation der linken
unteren Vene in einer Lücke am posterioren Unterrand der LIPV.
Analoges Vorgehen bei Ablation der rechten Venen. Abbildungen 48 und 49 zeigen das VM nach Isolation aller Venen.
Beispiel 2 Redo-Prozedur: 55-jähriger Mann, primär erfolgreiche
PV-Isolation im September 2011. Abbildung 50 zeigt das AusgangsVM im Sinusrhythmus. Die LSPV und die LIPV sind antral anhaltend isoliert. Die RSPV ist nicht mehr isoliert, auch die posteriore
Linie, vorbei an der akzessor. Vene ist nicht dicht. Die RIPV ist anhaltend isoliert. Es erfolgt eine ringförmige Ablation um die RSPV
und eine zweite um die kleine akzessor. Vene. Die Isolationsstelle
der RSPV (gelber Punkt) liegt im Bereich der posterioren Carina
(Abbildung 51).
Schlussfolgerung Die Voltagegeführte PVI ist eine elegante Methode, um die akuten Veränderungen im leitfähigen Gewebe und den
Fortschritt der Prozedur zu zeigen. Die Methode ist besonders hilfJ KARDIOL 2012; 19 (5–6)
ÖKG-Jahrestagung 2012 – Abstracts
Abbildung 50: E. Gatterer et al. Voltage-Map zu Beginn der Untersuchung (oben posteriore, unten anteriore Ansicht). Die linken Venen
sind anhaltend isoliert, die rechte obere und die kleine akzessorische
Vene rechts nicht.
Abbildung 51: E. Gatterer et al. Reisolation der RSPV durch komplette Ablation um die Vene (Isolation anterior, siehe gelber Punkt)
sowie Re-Isolation der kleinen akzessorischen rechten Vene durch
zirkumferentielle Ablation um die Vene (gelber Punkt in der Carina).
reich bei Redo-Prozeduren, weil die Ablationslinien der vorangehenden Prozedur ohne zusätzlichen Zeitaufwand dargestellt werden und
sich sofort eine klare Ablationsstrategie ableiten lässt.
Methodik Von 1/2010 bis 12/2011 führten wir bei 84 Patienten
mit ungeklärten Synkopen und Präsynkopen eine Kipptischuntersuchung durch. Es wurde der Task Force Monitor von CNSystems
verwendet, die Dauer der Orthostase (60°) betrug 30 Minuten. Das
Follow-up erfolgte telefonisch, teilweise ambulant.
Ergebnisse Kriterien für POTS erfüllten 16/84 (19,0 %) Pat.
Frauen waren häufiger betroffen (9:7), das Durchschnittsalter betrug
33,3 Jahre (17–70 Jahre) für Frauen und 37,6 Jahre (22–65 Jahre)
für Männer. 14/16 Pat. hatten insgesamt 69 Synkopen (durchschn.
4,1) vor der Untersuchung (10 Pat. mit 1–4 Synkopen, 4 Pat. mit
≥ 5 Synkopen), 2/16 Patienten hatten Präsynkopen.
M. Wurm: techn. Unterstützung von der Fa. St. Jude Medical (SJM)
Das posturale orthostatische Tachykardiesyndrom
(POTS) bei Patienten mit Synkope und Präsynkope
VIII – 5
H. Keller, Ch. Steger, E. Gatterer
2. Medizinische Abteilung, Krankenanstalt Rudolfstiftung, Wien
Einleitung POTS (posturales orthostatisches Tachykardiesyndrom)
ist definiert durch Symptome einer orthostatischen Intoleranz, verbunden mit einem Frequenzanstieg von >30 Schlägen oder einem
Anstieg der Herzfrequenz (HF) auf > 120 Schläge/min innerhalb
von 10 Minuten in Orthostase (Abbildung 52). Bei 30 % der Patienten kommt es zu Synkopen. Die Pathogenese ist ungeklärt. Möglicherweise liegt eine Störung der sympathischen Vasokonstriktion
mit venösem Pooling vor. Die Prävalenz wird mit 0,2 % angenommen. Neben allgemeinen Maßnahmen wie Volumenzufuhr, Salzen
der Nahrung, Tragen von Stützstrümpfen und Ausdauertraining
werden auch Medikamente wie Fludrocortison, α-Rezeptoragonisten und Betablocker eingesetzt.
Die Kipptischuntersuchung ist die einzig etablierte Methode, POTS
zu diagnostizieren. Ziel der retrospektiven Untersuchung war es,
den Anteil von POTS bei Pat., die zur Kipptischuntersuchung zugewiesen wurden, festzustellen, die Behandlung auszuwerten und das
Ansprechen auf die Therapie zu analysieren.
J KARDIOL 2012; 19 (5–6)
Abbildung 52: H. Keller et al. POTS bei der Kipptischuntersuchung.
ÖKG-Jahrestagung 2012 – Abstracts
Bei der Untersuchung stieg die HF von 70 (50–109) auf 109 (81–
146) an; Bei 15/16 Pat. erfolgte der HF-Anstieg < 3 Minuten. 3 Pat.
entwickelten eine orthostatische Hypotonie, 4 Pat. eine vasovagale
Synkope, 1 Pat. eine Präsynkope. Die Barorezeptorsensitivität war
bei 11/16 Pat. reduziert (BRS < 7 ms/mm Hg).
Als Therapie wurden Volumenzufuhr, Stützstrümpfe, Salzen, Counter-Manöver bei Symptomen, Stehtraining sowie ein Ausdauertraining empfohlen. 3 Patienten erhielten Betablocker, 1 Patientin
Midodrin, 1 Pat. einen Loop-Recorder implantiert, 1 Pat. erhielt in
einem anderen Zentrum einen Schrittmacher implantiert.
Bei 15/16 Pat. erfolgte ein Follow-up von 54 Wochen (9–107, median 51). 47/64 Therapieempfehlungen wurden übernommen (73 %).
Während die Volumenzufuhr (15/15), Salzen (7/9), Ausdauertraining (12/14; Æ 2,3 Std./Woche), Counter-Manöver (5/7) und
Stehtraining (3/4) häufig umgesetzt wurden, haben nur 5/15 Patienten Stützstrümpfe getragen.
Insgesamt traten 15 Synkopen im Follow-up auf (78 % Reduktion).
Bei 3/4 Pat. mit ≥ 5 Synkopen kam es nur mehr 1× zu einer Synkope,
auch bei 10 Pat. mit 1–4 Synkopen trat nur mehr 1 Synkope auf. Die
Zahl reduzierte sich von 4,1 auf 1,0 pro Pat. Nur 2 Pat. hatten nach
der Kipptischuntersuchung mehr Synkopen. Die Lebensqualität
(1 für sehr gut, 10 für sehr schlecht) wurde mit 3,6 vor und 2,3 nach
der Kipptischuntersuchung angegeben.
Diskussion Die Prävalenz von POTS betrug 19 %. Die Compliance
der Pat. war gut (73 %). Die Synkopenhäufigkeit konnte durch die
Diagnosestellung, Aufklärung und Therapievorschläge reduziert
und die Lebensqualität verbessert werden. Neben einer ausführlichen Aufklärung sind die nicht-medikamentösen Therapieformen
als „First-line“-Therapie angezeigt und effektiv, ebenso wie ein
moderates Ausdauertraining.
Autonome und kardiovaskuläre Effekte von Licht
VIII – 1
S. Kohl, U. Bauer, M. Schmitt, M. Edlinger, A. Süssenbacher, O. Pachinger,
M. Stühlinger
Universitätsklinik für Innere Medizin III/Kardiologie, Medizinische Universität
Einleitung Licht ist ein bedeutender Einflussfaktor auf den menschlichen Körper, über autonome und kardiovaskuläre Auswirkungen bestimmter Lichtszenarien ist allerdings wenig
bekannt. Während rotes Licht als vorwiegend
adrenerg aktivierender Trigger wirkt, führt blaues Licht eher zu Entspannung und Aktivierung
des Parasympathikus. Wir überprüften daher die
Hypothese, dass eine kontrollierte und spezifische Licht-Exposition für 3 Stunden zur Beeinflussung der Herzfrequenz-Variabilität (HRV)
und in weiterer Folge zu Veränderungen des
Blutdruck-Verhaltens, der Endothelfunktion und
der Entwicklung von Arrhythmien führt.
Methode Zusammen mit der Bartenbach Lichtlabor GmbH entwickelten wir eine spezielle
Lichtkabine, in der sich Probanden für jeweils
4 Stunden aufhielten und verschiedenen Lichtszenarien ausgesetzt wurden. Während der Lichtszenarios wurde als Maß für die Aktivierung des
autonomen Nervensystems die HRV bestimmt,
zusätzlich wurden zur Analyse von kardiovaskulären Auswirkungen des Lichts Holter-EKGs,
Langzeit-Blutdruck-Messungen durchgeführt und
zusätzlich die Endothelfunktion (EF; Endopat®,
Itimar) gemessen. Die Untersuchungen wurden
nach 30 min Neutrallicht (NL) jeweils während
einem roten (RL) und einem blauen Lichtszenario
(BL) bei 10 trainierten Probanden (TP), 10 Patienten nach Katheterablation einer akzessorischen
Bahn (WPW) und bei 10 Patienten mit ischämischer Kardiomyopathie (CMP) durchgeführt.
Resultate Im Vergleich zu NL führte das rote Lichtszenario (RL)
zu einer signifikanten und konkordanten Verbesserung der HRV
nach 60 min (SDNN –35,2; RMSSD –19,9; SD-1 –14,1; p < 0,05)
und 120 min (SDNN –25,7; RMSSD –19,3; SD-1 –13,7; p < 0,05)
Lichtexposition, während blaues Licht (BL) keine signifikanten
Veränderungen hervorrief. Der Anstieg der HRV war in der Gruppe
der Sportler (TP) besonders stark ausgeprägt. Parallel zu diesen autonomen Veränderungen beeinflusste die Lichtexposition die Endothelfunktion (Enopat Index –0.35 RL vs. NL; p < 0,001). Auch hier
wurden die stärksten Veränderungen in der TP-Gruppe beobachtet.
Die Auswirkungen des RL-Lichtszenarios für 3 Stunden führte
allerdings nicht zu Veränderungen des Blutdruck-Verhaltens während oder 24 Stunden nach der Exposition. Auch Messungen der
Herzfrequenz und der Häufigkeit von ventrikulären oder supraventrikulären Extrasystolen wurden durch die Lichtszenarien nicht
beeinflusst (alle p = n. s.).
Zusammenfassung Durch eine Lichtexposition über 2 Stunden
mit rotem, aber nicht mit blauem Licht kann unter kontrollierten Bedingungen die Herzfrequenz-Variabilität und die Endothelfunktion
signifikant beeinflusst werden. Diese kurzfristigen Effekte führen
aber nicht zur Veränderung von Blutdruck-Verhalten oder Neigung
zu ventrikulären oder supraventrikulären Arrhythmien.
Asymptomatic Cerebral Lesions in Pulmonary Vein
Isolation Under Therapeutic Anticoagulation
M. Martinek, E. Sigmund, Ch. Lemes, M. Derndorfer, H.-J. Nesser, H. Pürerfellner
Abteilung für Kardiologie, Krankenhaus der Elisabethinen, Linz
Background Left atrial radiofrequency ablation has been shown
to carry a risk of asymptomatic cerebral lesions. No data exists in
patients under full anticoagulation throughout the ablation procedure. The aim of this study was to quantify the amount of silent cerebral lesions assessed by preprocedural and postprocedural MRI in
these patients and to identify clinical or procedural parameters that
increase the risk
Methods A total of 80 consecutive patients undergoing catheter
ablation for paroxysmal (n = 53; 66.3%) or persistent (n = 27;
33.8%) atrial fibrillation were included in the study. Pulmonary vein
antrum isolation, roofline, mitral isthmus line, and CFAE ablation
using 3.5 mm open-irrigated tip catheters were performed, as
Table 15: M. Martinek et al. Clinical and procedural parameters in univariate analysis
No. of patients
(Congestive) Heart failure
Mean age, y
Diabetes mellitus
Previous stroke or TIA
Coronary heart disease
Male gender
CHADS-VASc score
Type of AF
Left ventricular ejection fraction, %
Left atrial parasternal diameter, mm
Mean ACT value during procedure, s
INR at the day of ablation procedure
Type of procedure
PV isolation (only)
Linear lesions
Linear lesions + CFAE
Radiofrequency time, min
Total energy delivered, Ws
Electrical cardioversion
Patients with
silent cerebral lesion
Patients without
silent cerebral lesion
9 (69)
62,6 ± 7,8
1 (8)
2 (15)
2 (15)
9 (69)
8 (61)
1,9 ± 1,0
4 (6)
39 (58)
58,9 ± 8,5
3 (5)
6 (9)
3 (16)
44 (66)
32 (48)
1,3 ± 1,2
5 (39)
8 (61)
53 ± 3
42 ± 4
330 ± 52
2,2 ± 0,5
48 (72)
19 (28)
53 ± 4
40 ± 5
343 ± 36
2,4 ± 0,6
4 (31)
7 (54)
4 (31)
2 (15)
54 ± 16
84,013 ± 31,365
9 (69)
48 (72)
19 (28)
6 (9)
6 (9)
50 ± 18
79,195 ± 28,453
19 (28)
J KARDIOL 2012; 19 (5–6)
ÖKG-Jahrestagung 2012 – Abstracts
needed. All patients underwent preprocedural and postprocedural
cerebral MRI.
Results Postprocedural MRI revealed new embolic lesions in 13 patients (16.3%), all of them asymptomatic. The only clinical parameter
showing a significant correlation with cerebral embolism was the type
of atrial fibrillation (5/53 paroxysmal – 9.4% vs 8/27 persistent
– 29.6%; p = 0.021). Procedural parameters contributing to an increased
risk were electrical cardioversion (p = 0.009) and additional linear
(p = 0.07) or CFAE lesions (p = 0.05). The only factor showing a trend
to significance in multivariate analysis remained electrical cardioversion with an increased risk of 3.98 (95%-CI: 0.83–19; p = 0.08).
Conclusion Radiofrequency ablation in patients under therapeutic anticoagulation is associated with a substantial risk of silent embolism detected by cerebral MRI. Risk factors for cerebral lesions
are the type of atrial fibrillation, additional linear of CFAE lesions
and, in particular, electrical cardioversion during the ablation procedure (Table 15).
Impact of a New Contact Force Sensing Catheter on
Procedural Parameters in Radiofrequency Ablation
of Atrial Fibrillation
IX – 2
M. Martinek, Ch. Lemes, E. Sigmund, M. Derndorfer, H.-J. Nesser, H. Pürerfellner
Abteilung für Kardiologie, Krankenhaus der Elisabethinen, Linz
Background Left atrial radiofrequency ablation has been established for the treatment of atrial fibrillation. New catheter material
with the unique opportunity to directly visualize catheter contact
force and direction as well as integration of this information into a
3D electro-anatomic System (CARTO 3) have recently been released. The aim of this study was to assess the impact of this new
technique on procedural parameters.
Methods A total of 29 consecutive patients (65% male, 59.6 ±
10.5 years) undergoing catheter ablation for paroxysmal atrial fibrillation were included in the study. Pulmonary vein antrum isolation
with documented entry and exit block was performed using either
the standard NaviStar® ThermoCool® catheter (n = 17) or the new
ThermoCool® SmartTouchTM (n = 12) contact force sensing catheter
(both Biosense Webster). Both catheters are mounted with equal
3.5 mm open-irrigated tips. A maximum of 25 W was delivered at
the left atrial posterior wall, 30 W were used in other positions with
an irrigation flow rate of 2 ml/min at baseline and 20 ml/min during
radiofrequency application.
Results Procedural data showed a remarkable decline in ablation
time (radiofrequency time needed to isolate all pulmonary veins)
from 56.2 ± 16.1 to 40.9 ± 9.5 minutes (p = 0.007) with a reduction
in overall procedure time of 25.5 ± 11.8 minutes (p = 0.003). In parallel the total energy delivered could be significantly reduced from
78,051 ± 18,239 to 63,421 ± 13,511 Ws (p = 0.026).
Conclusion The use of novel contact force sensing technology
was able to significantly reduce ablation and procedure times in
atrial fibrillation ablation in this small pilot study. Energy delivery
was substantially reduced by avoiding radiofrequency ablation in
positions with insufficient surface contact.
CHA2DS2-VASc als Risikomarker für Vorhofflimmern
VIII – 2
R. Riedlbauer, M. Gruber, H. Forstner, F. M. Fruhwald, K. Horvath, T. Pieber,
B. Pieske, F. R. Heinzel
Klinische Abteilung für Kardiologie; Klinische Abteilung für Endokrinologie,
Medizinische Universität Graz
Einleitung Die CHA2DS2-VASc-Score wurde 2010 aktualisiert,
um das Risiko von Thromboembolien bei bestehendem Vorhofflimmern (VHF) besser beurteilen zu können. Die Diagnose VHF erfordert gewöhnlich die EKG-Dokumentation und ist bei asymptomatischem paroxysmalem VHF erschwert. Die meisten der in der
CHA2DS2-VASc-Score zusammengefassten Begleitfaktoren (chronische Herzinsuffizienz, Hypertonus, fortgeschrittenes Alter, Diabetes, stattgehabter Schlaganfall, Gefäßerkrankungen) begünstigen
J KARDIOL 2012; 19 (5–6)
Abbildung 53: R. Riedlbauer et al.
für sich das erstmalige Auftreten von VHF. CHA2DS2-VASc könnte
daher geeignet sein, das Risiko für das Auftreten von VHF mit
thromboembolischen Komplikationen insgesamt zu beurteilen. Wir
untersuchten den Zusammenhang zwischen der CHA2DS2-VAScScore und der Prävalenz von VHF in einem kardiologisch engmaschig überwachten Patientenkollektiv.
Methoden Wir verglichen die Prävalenz von VHF in diesem Kollektiv mit einer Patientenkohorte einer nicht-kardiologischen Ambulanz. Es wurden fortlaufend 501 Patienten der KardiomyopathieAmbulanz (CMP-Amb) und 473 Patienten der diabetischen Ambulanz (Diab-Amb) unserer Klinik retrospektiv eingeschlossen und
die Patientendaten bzgl. der CHA2DS2-VASc-Risikofaktoren, der
Prävalenz der Diagnose VHF und zusätzlicher Begleiterkrankungen
und medikamentösen Therapie analysiert.
Ergebnisse Bei den Patienten mit engmaschiger kardiologischer
Kontrolle (CMP-Amb) fand sich eine signifikante positive Korrelation zwischen CHA2DS2-VASc-Score und der Prävalenz von VHF
(p < 0,05; Chi-Quadrat). Beim Vergleich von DM-Amb und CMPAmb reflektierten Unterschiede in der Häufigkeit von Herzinsuffizienz (2 % in DM-Amb vs. 61 % in CMP-Amb) und Diabetes (99 %
vs. 29 %) die Auswahl der Kollektive. Das Diab-Amb-Kollektiv
umfasste mehr Frauen (38 % vs. 28 %; p < 0,001). Patienten aus der
Diab-Amb litten häufiger an Hypertonus (83 % vs. 68 % ), seltener
an vaskulären Manifestationen (41 % vs. 57 %) und Niereninsuffizienz (21 % vs. 29 %; für alle p < 0,01).
Die Verteilung der CHA2DS2-VASc-Scores war in beiden Patientenkollektiven vergleichbar (Abbildung 53). Der Anteil der Patienten mit bekanntem VHF war in der Diab-Amb signifikant geringer
als in der CMP-Amb (8 % vs. 32 %; p < 0,001). Der Anteil der Patienten mit zerebrovaskulärem Ereignis war jedoch nicht unterschiedlich (15 % in Diab-Amb vs. 12 % in CMP-Amb). Der Anteil
der Patienten mit sehr hoher CHA2DS2-VASc-Score (≥ 5) ohne orale Antikoagulation (unabh. von dem Vorliegen von VHF) war signifikant höher in der DM-Amb (77 % vs. 60 %).
Diskussion Das Risiko für das Vorliegen von VHF korreliert mit
der CHA2DS2-VASc-Score. Die geringe Prävalenz der Diagnose
VHF bei gleicher CHADS-VASc-Score und gleicher SchlaganfallsPrävalenz in dem nicht-engmaschig kardiologisch kontrollierten
Kollektiv könnte auf eine höhere Prävalenz von klinisch nichtapparentem VHF bei diesen Patienten zurückzuführen sein.
Circumferential Pulmonary Vein Ablation with One
or Two Eyes Opened: A Retrospective Comparison
of Single vs Double Transseptal Approach
VIII – 3
R. Schönbauer, B. Dinov, L. Fiedler, P. Sommer, T. Gaspar, Ch. Piorkowski,
G. Hindricks, A. Arya
Abteilung Rhythmologie, Herzzentrum Leipzig, Deutschland
Introduction Pulmonary vein isolation is the cornerstone of catheter ablation of atrial fibrillation. The perfect method to achieve this
goal is still under debate. For this reason we analyzed whether the
ÖKG-Jahrestagung 2012 – Abstracts
concomitant or alternating use of circular mapping catheter and ablation catheter is the better approach.
Methods 95 consecutive patients with atrial fibrillation (38%
male, 42% paroxysmal, age 61 ± 10 years) were analyzed retrospectively. In all patients complete bidirectional circumferential pulmonary vein isolation was the endpoint. Patients were divided into two
groups. In single transseptal group (STSP) (n = 48) one transseptal
puncture was performed with alternating use of ablation catheter
and circular mapping catheter. In the double transseptal group
(DTSP) (n = 47) 2 transseptal punctures were performed, allowing
the use of circular mapping catheter during ablation.
Results Baseline patients’ characteristics were comparable between the 2 groups. Comparing procedure related data there was no
significant difference in procedure time, radiation time and radiation
dose, but there was a trend towards longer ablation time in the
STSP-group (37,8 vs 32,0 minutes; p = 0.07). Severe procedure related complications occurred in two patient in the DTSP-group and
in no patient in the STSP-group (p = n. s.). After a median follow-up
of 9.8 months 34 (70.8%) patients in the STSP-group and 37 (78.7%)
patients in the DTSP-group were free of recurrence of atrial fibrillation and/or atrial flutter (p = 0.259).
Conclusion DTSP and concomitant use of circular mapping and
ablation catheter does not lead to superior ablation success however,
there is a trend toward shorter ablation time compared to STSPGroup. Further randomized studies are warranted to clarify this issue.
Left Atrial Flutter in Absence of Previous Left Atrial
Ablation or Heart Surgery: Mapping, Ablation and
One-Year Follow-up
VIII – 4
R. Schönbauer, B. Dinov, L. Fiedler, G. Hindricks, Ch. Piorkowski, A. Bollmann
Abteilung für Rhythmologie, Herzzentrum Leipzig, Deutschland
Background In days of routinely performed left atrial ablation
procedures (mainly for atrial fibrillation) the incidence of left atrial
flutter has strongly increased. Savety and feasibility of ablation of
these, obviously iatrogenic induced arrhythmias is well known and
described in detail before.
Objective In this present retrospective study we describe the arrhythmia-findings, -management and ablation results of patients
presenting with highly symptomatic left atrial flutter but in absence
of previous left atrial ablation or heart surgery.
Methods From 01/2009 to 12/2010, 30 patients (18 male) with
recurrent highly symptomatic left atrial flutter without previous left
atrial ablation or heart surgery presented for catheter ablation. 24 patients also had documented episodes of atrial fibrillation. The diagnose of left atrial flutter was based on body surface ecg and additionally required characteristic findings in biatrial entrainment maneuvers. Using a nonfluoroscopic electroanatomic mapping system
(CARTO [n = 6] or NavX [n = 24]) the left atrium was reconstructed
and integrated in its previously acquired computer tomography image. Then the documented arrhythmia was mapped by entrainmentand/or activation-mapping. Additionally pulmonary vein isolation
was performed. Bidirectional block of ablation lesions and non-inducibility of any tachycardias were procedure endpoints. The primary study endpoint was cumulative freedom from any arrhythmia
6 and 12 months after a single ablation procedure.
Results In 30 patients a total of 54 tachycardias was documented
(1–4/patient). 39 tachycardias (72%) could be mapped and ablated
successfully. 13 patients (43.3%) reached the study endpoint at
6 months and 9 (30.0%) at 12 months post ablation procedure. In
9 patients a second ablation procedure was done.
Conclusion Ablation of atypical left atrial tachycardias without
previous left atrial ablation are challenging procedures with an
eventually poor outcome. So these arrhythmias might be a sign of a
an already more diseased left atrium with multiple possibilities of
reentry circuits.
Outcome of Left Atrial Radiofrequency Catheter Ablation in Patients with Paroxysmal and Persistent
Atrial Fibrillation
IX – 8
A. Schratter, R. Achleitner, St. Oblin, St. Fritsch, M. Brunner
4. Medizinische Abteilung mit Kardiologie, Krankenhaus Hietzing, Wien
Background Atrial fibrillation (AF) is the most common arrhythmia and may lead to substantial symptoms and loss of quality of life.
Left atrial radiofrequency catheter ablation is a therapeutic alternative when antiarrhythmic drugs fail in maintaining stable sinus
rhythm (SR). At our department, catheter ablation is used since 2009
in patients with symptomatic AF (either paroxysmal or persistent)
that can not be controlled by antiarrhythmic drugs. We wanted to
evaluate the efficacy of catheter ablation of AF in this new centre.
Methods We conducted follow-ups at 3, 12 and 24 months after
left atrial radiofrequency catheter ablation performed since 2009 in
71 patients suffering from symptomatic AF. Catheter ablation was
performed as follows: after anatomical and electrical 3D-reconstruction of the left atrium, either only pulmonary veins were isolated by
circumferential lesions (first procedure), or pulmonary vein isolation was combined with roofline and anterior line lesions placed in
the left atrium (second procedure). In addition, in patients where
pulmonary veins were shown to be isolated in the second procedure,
we looked for complex fractionated electrograms (CFE) and ablated
at the site of their appearance, if appropriate.
At each follow-up, ECG at rest as well as holter-ECG-recordings
(48 hours) were analyzed; furthermore, symptoms and current medications were assessed. Patients presenting with relapse of AF at follow-up received a second procedure, if appropriate.
Results 71 patients were followed up, 32 women and 39 men.
Mean age was 60 years. 58 patients presented with paroxysmal and
13 with persistent AF (i. e. 82% and 18%, respectively). 3-month
follow-up was conducted in 71, 12-month follow-up in 40 and 24month follow-up in 15 patients. At 3 months, 54 patients presented
with SR (76%) and 27 with AF (24%). 81% of patients with formerly paroxysmal AF and 54% of patients with formerly persistent
AF showed SR at follow-up. At 12 months, 35 patients showed SR
(87.5%; 88% of formerly paroxysmal and 83% of persistent AF) and
5 showed AF (12.5%). At 24 months, 14 patients presented with SR
(93%; 93% of formerly paroxysmal and 100% of persistent AF) and
1 with AF (7%). All patients with SR were without any further arrhythmia-related symptoms.
13 patients (18%) underwent a second procedure due to recurrent
AF, which results in an average of 1.2 procedures per patient. After
the second procedure, 11 patients showed stable SR (85%) and
2 patients presented with AF (15%).
Procedure-related complications occurred in 5 out of 71 patients
(7%): 3 aneurysma spuria and 2 pericardial tamponades, all of them
non fatal.
Figure 54: A. Schratter et al.
J KARDIOL 2012; 19 (5–6)
ÖKG-Jahrestagung 2012 – Abstracts
Robotic Navigation for Catheter Ablation of Paroxysmal and Persistent Atrial Fibrillation: A SingleCenter Experience After 165 Cases
XVII – 2
C. Steinwender, S. Hönig, T. Lambert, A. Kypta, F. Leisch
I. Medizinische Abteilung mit Kardiologie, Allgemeines Krankenhaus, Linz
Figure 55: A. Schratter et al.
Conclusion In a collective of 71 patients treated by catheter ablation for AF in a newly implemented centre, 13 patients (18%) presented with AF at follow-up and received a second procedure. Non
fatal complications occurred in 5 patients (7%). Catheter ablation
showed to be a feasible and efficient method in our centre for patients suffering from symptomatic AF when drug therapy failed
(Figures 54, 55).
Vernakalant: Medikamentöse Kardioversion bei Vorhofflimmern – Erfahrungen am eigenen Patientengut
XVII – 5
E. Sigmund, M. Martinek, M. Derndorfer, H.-J. Nesser, H. Pürerfellner
Abteilung für Kardiologie, Krankenhaus der Elisabethinen, Linz
Einleitung Seit Jänner 2011 ist Vernakalant (Brinavess®, Fa. MSD),
welches zur Substanzgruppe ARDA („atrial repolarization-delaying
agents“) angehört, in Österreich erhältlich und wird bei Vorhofflimmern von kurzer Dauer (< 7 Tage) eingesetzt. Wir berichten über
unsere Erfahrungen im Rahmen des klinischen Routinebetriebs bei
individuell körpergewichtsadaptierter Zubereitung als intravenöse
Infusion unter stationären Bedingungen bei adäquater Hydrierung.
Methodik 25 Patienten (Pat.) (12 weiblich/13 männlich) im Alter
von 66,3 ± 14,7 Jahren wurden bislang behandelt. Die Arrhythmiedauer lag bei 18 Pat. (72 %) < 12 Stunden, bei 3 Pat. (12 %) < 24
Stunden und bei 4 Pat. (16 %) bei < 48 Stunden.
Resultate Die Gesamtkonversionsrate lag bei 14 Pat. (56 %),
davon konvertierten 11 Pat. (78,6 %) bereits nach der Initialdosis in
den Sinusrhythmus, bei 3 Pat. (21 %) war die Gabe einer 2. Dosis
erforderlich. Die Konversionszeit lag zwischen 10 und 35 Minuten
nach Beginn der Infusion.
An unerwünschten Wirkungen (UAW) waren Hustenanfall mit Niesen (17,4 %), Dysgeusie (13 %), Hitzegefühl (13 %), Flush-Symptomatik (4,3 %) sowie einmalig VES in Salvenform (4,3 %) zu dokumentieren. Alle UAW waren nach wenigen Minuten selbstlimitierend.
Entgegen der in den klinischen Studien berichteten Hypotonie-Neigung konnten wir eher die Tendenz einer Blutdrucksteigerung von
10–30 mmHg systolisch im Rahmen der Anwendung mit Vernakalant verzeichnen (8 Patienten; 32 %). Relevante Hypotensionen
wurden (bei adäquater Hydrierung) nicht beobachtet.
Diskussion Vernakalant konnte bislang seine Effizienz im Ausmaß der in den klinischen Studien beobachteten Konversionsrate
von knapp über 50 % bestätigen. Auch die Sicherheit konnte bezüglich maligner ventrikulärer Arrhythmien bzw. Hypotonien verifiziert werden. Somit kommt diesem Medikament bei der Auswahl
des adäquaten Patientengutes und unter Einhaltung einer ausreichenden Hydrierung durchaus ein Stellenwert zur medikamentösen
Kardioversion von Vorhofflimmern in der klinischen Routine zu.
J KARDIOL 2012; 19 (5–6)
Introduction Remote navigation systems represent a novel method
for catheter ablation of atrial fibrillation (AF). The Sensei robotic
navigation system (Hansen Medical, Mountain View, USA) enables
remote catheter navigation via a robotic steerable sheath (Artisan™,
Hansen Medical). The aim of this study is to report the first Austrian
experience with the Sensei™ system for the treatment of patients (P)
with paroxysmal and persistent AF.
Materials and Methods Between November 2009 and September 2011, 165 P (59 ± 7 years, 109 males) underwent robotic circumferential pulmonary vein isolation (PVI) for paroxysmal AF (87
P, 53%) or robotic circumferential PVI plus robotic creation of a left
atrial roof line for persistent AF (78 P, 47%). The EnSite NavX™
system (St. Jude Medical, Minneapolis, USA) was used for 3-dimensional mapping. For ablation, a 3.5 mm open-irrigated cooledtip ablation catheter (Therapy Cool Path ns™, St. Jude Medical) was
used. PVI was confirmed by a multipolar spiral catheter (Optima™,
St. Jude Medical) as second left atrial catheter. Completeness of
block along the roof line was confirmed by appropriate left atrial
pacing maneuvers. All procedures were performed during deep
sedo-analgesia after left atrial thrombi had been excluded by transesophageal echochardiography.
Follow-up consisted of 48-hour ECG monitoring at 3, 6, and 12
months after ablation plus additional ECGs recorded during episodes of suspicious symptoms. Freedom from atrial arrhythmias
≥ 30 seconds was counted as clinical success.
Results PVI of all pulmonary veins was achieved in 158 P (96%).
In 7 P (4%), one pulmonary vein could not be isolated, respectively.
Block along the roof line could be achieved in all cases. The mean
procedure time was 229 ± 47 minutes (224 ± 48 minutes in paroxysmal AF versus 239 ± 35 minutes in persistent AF, p = n. s.). The
mean fluoroscopic time was 24 ± 8 minutes (23 ± 9 minutes in paroxysmal AF versus 24 ± 8 minutes in persistent AF, p = n. s.). The
mean operator’s fluoroscopy exposure was 12 ± 8 minutes. As complications, two groin hematoma requiring transfusion and two pericardial tamponades requiring pericardiocentesis occurred, respectively.
After a median follow-up of 16 months (range 5–28 months), the
success rate after a single procedure was 66% for P with paroxysmal
AF and 51% for P with persistent AF, respectively.
Success rates increased to 79% in paroxysmal AF and 72% in persistent AF, respectively, after a second procedure (in 29% of P with
paroxysmal and in 42% of P with persistent AF).
Discussion Remote navigation with the Sensei™ robotic system
is effective, safe and requires limited fluoroscopy. For the first 165 P,
mid-term success rates for P with paroxysmal and persistent AF
were comparable to other technologies.
Evaluierung eines zirkulären Kryoablationskatheters
zur Isolation von Pulmonalvenen im Schweinemodell
IX – 1
M. Stöger, M. Stühlinger, K. Spuller, D. Pehböck, G. Klima, H. Rabl, C. N. Nowak,
G. Fischer, F. Hintringer
Abteilung für Kardiologie, Universitätsklinik für Innere Medizin III; Universitätsklinik für Anästhesie und Intensivmedizin; Department für Anatomie, Histologie
und Embryologie, Medizinische Universität Innsbruck; AFreeze GmbH Innsbruck;
UMIT – Private Universität für Gesundheitswissenschaften; Medizinische Informatik und Technik, Institut für Elektrotechnik und Biomedizinische Technik, Hall in Tirol
Einleitung Die Isolation der Pulmonalvenen (PVs) ist eine etablierte
Strategie der Behandlung von Vorhofflimmern (VHF) mittels Katheterablation. Rezidive durch elektrische Rekonnektion sind aber häufig. Zudem können durch alleinige Isolation der PVs nicht alle für das
VHF verantwortlichen Mechanismen behandelt werden. Daher wurde
ÖKG-Jahrestagung 2012 – Abstracts
Isolation of the Entire Substrate: A Novel Ablation
Strategy for Treatment of Multiple Ventricular Tachycardias After Anterior Wall Myocardial Infarction
IX – 5
R. Tilz, A. Rillig, Y. Yoshiga, A. Metzner, E. Wissner, K.-H. Kuck, F. Ouyang
Abteilung für Kardiologie, Asklepios Klinik St. Georg, Hamburg, Deutschland
Abbildung 56: M. Stöger et al.
ein neuartiger zirkulärer Kryoablationskatheter für die Erzeugung periostialer linearer Läsionen entwickelt und im Tierversuch validiert.
Material und Methoden Der Prototyp eines zirkulären Kryoablationskatheters (CoolLoop; AFreeze GmbH, Österreich) wurde entwickelt und im Tiermodell getestet. Nach Einführung des Katheters in
die Vorhöfe wurde am Antrum der PVs und am Ostium der oberen
Hohlvene (SVC) von insgesamt 14 Hausschweinen (50–
70 kg) eine Kryoablation durchgeführt. Nach einer Woche wurden die
Tiere sakrifiziert, die Atria entnommen und die mit Azan gefärbten
Läsionen hinsichtlich Größe, Tiefe und Transmuralität untersucht.
Ergebnisse Während der Analyse der insgesamt 76 Läsionen an
PVs und SVC stellte sich heraus, dass die mit dem Prototyp erzeugten
Läsionen kaum transmural bzw. kontinuierlich waren. Deshalb wurde
unter anderem die Anzahl der Mikrolochpaare zur Emission des Kühlmittels in die Siedekammer von 6 auf 12 erhöht, was zu einer verbesserten effektiven Kühlleistung bei gleich bleibendem Kühlmittelfluss führte. Nach diesen Anpassungen konnten 7,65 ± 5,15 mm lange
durchgehende Läsionen mit einer mittleren Tiefe von 1,4 ± 0,62 mm
erzeugt werden. Dabei waren 87 % der Läsionen transmural.
Diskussion Nach Optimierung der Siedekammer können mit unserem neuen Kryoablationskatheter im Tierversuch lange, lineare,
transmurale Läsionen erzeugt werden (Abbildung 56).
Implantable Loop Recorders are Useful to Eventually Indicate Antiarrhythmic Devices in Myotonic
Dystrophy 1
IX – 3
C. Stöllberger, Ch. Steger, W.-B. Winkler, J. Finsterer, F. Weidinger
2. Medizinische Abteilung, Krankenanstalt Rudolfstiftung, Wien
Since implantable cardioverters/defibrillators and pacemakers prevent fatal outcomes of arrhythmias in myotonic dystrophy1, the
proper selection is crucial. Implantable loop-recorders are developed to detect arrhythmias. Seven patients with myotonic dystrophy1, aged 34–64 years, with inconclusive findings on 24-hourHolter recording, received implantable loop recorders. Implantable
loop-recorders detected arrhythmias which resulted in implantation
of pacemakers in 3 and of cardioverter/defibrillator in 1 patient.
Only 1 of these patients reported symptoms suggestive of arrhythmias. In a further patient with symptoms suggestive of arrhythmia,
implantable loop-recorder disclosed no rhythm disturbance. We
conclude that implantable loop-recorders are useful in detecting
arrhythmias in myotonic dystrophy1 patients.
Background Ventricular tachycardia (VT) with multiple morphologies originating in the anterior wall may occur after anterior
wall myocardial infarction. At present time, there is no consensus
about the best ablation strategy. We report about three patients in
whom isolation oft the entire substrate was performed.
Methods Three patients (pts, 66 ± 5 years, 3 male, LVEF 29 ±
14%) with ischaemic cardiomyopathy after anterior wall myocardial
infarction underwent catheter ablation for sustained VT. All pts had
recurrent ICD shocks (VT storm in 2) despite amiodarone and betablocker therapy. Mean VT Cl was CL 440 ± 127 ms and demonstrated a right-bundle-branch morphology.
During electrophysiological study, 4 ± 2 VTs were induced. Clinical
VT occurred spontaneously in 1 pt and was inducible in 2 pts.
CARTO mapping of the left ventricle (LV) was performed in SR
(n = 2) or during RV pacing (n = 1) and revealed a low voltage
(< 1.5 mV) area with fractionated electrograms and late potentials in
the antero-apical LV (mean area of 90 ± 34 cm2). Perfect pace map
of the clinical VTs was obtained in this area. The entire low voltage
area was isolated with a circumferential isolation line along the low
voltage area border-zone with a mean of 30 ± 9 RF applications. No
RF application was applied within the area. Isolation of the areas
was defined as absence of all potentials within the isolated area demonstrated by detailed point-by-point mapping. Automaticity was
demonstrated in 2/3 pts.
Procedure and fluoroscopy time was 155 ± 22 min and 10.3 ± 0.7
min, respectively. At the end oft the procedure, there was no (n = 2)
or one fast non-clinical VT (n = 1) inducible. No complications occurred. No clinical VT occurred during a follow-up of 5 ± 7 months.
Conclusion Isolation of the entire substrate appears to be feasible
in patients with antero-apical wall myocardial infarction.
Persistierendes Vorhofflimmern: Nicht-invasive
Evaluierung der mittleren linksatrialen Zykluslänge
und Vergleich mit EPU-Daten
XVII – 6
S. Winter, H. Pürerfellner, M. Martinek, J. Aichinger
Abteilung für Kardiologie, Krankenhaus der Elisabethinen, Linz
Einleitung Bei Patienten mit persistierendem Vorhofflimmern ist
die mittlere atriale Zykluslänge des linken Herzohres (LAACL)
nach den Arbeiten von Haïsaguerre und seiner Arbeitsgruppe aus
Bordeaux eine wichtige Determinante für die Erfolgswahrscheinlichkeit einer Ablationsprozedur mit kurativer Intention. Eine
LAACL unter 130 Millisekunden gilt dabei als Prädiktor für besonders schlechte Erfolgsraten. Diese LAACL wurde in den Originalarbeiten aus Bordeaux invasiv im Rahmen der elektrophysiologischen Prozedur im Katheterlabor bestimmt. Unsere Intention war es
hingegen, auch eine nicht-invasive Möglichkeit zur Bestimmung
dieses Messwertes zu finden – der Vorteil einer derartigen Methode
wäre darin zu sehen, dass diese Kenngröße mit prognostischer Implikation schon in der Vorfelddiagnostik im Rahmen der Therapiestratifizierung zur Verfügung stehen würde. Dies wäre eine zusätzliche potenzielle Möglichkeit, um damit Patienten mit persistierendem Vorhofflimmern und besonders schlechten Erfolgsaussichten
hinsichtlich der Ablationstherapie schon frühzeitig identifizieren zu
können. Da in unserer Institution vor jeder Vorhof-Flimmer-Prozedur standardmäßig eine transösophageale Echokardiographie (TEE)
durchgeführt wird, bot sich dieses bildgebende Verfahren an, um
damit nicht-invasive Daten über die linksatriale Zykluslänge zu gewinnen und diese mit den intraprozeduralen und somit invasiv gewonnenen intrakardialen EKG-Daten zu vergleichen.
Material und Methode Untersucht wurden 11 Patienten mit
persistierendem Vorhofflimmern bzw. 3 Pt. mit atypischem VorhofJ KARDIOL 2012; 19 (5–6)
ÖKG-Jahrestagung 2012 – Abstracts
flattern und geplanter linksatrialer Ablationsprozedur. Mittels
transösophagealer Echokardiographie wurde das linke Herzohr dargestellt und das Sample-Volume des gepulsten Dopplers im Bereich
des Herzohr-Ostiums positioniert. Aufgezeichnet wurde der zeitliche Verlauf der Blutflussgeschwindigkeit des Herzohres mit einem
zeitlichen Maßstab von zumindest 100 mm/sec: 10 konsekutive
„mechanische“ atriale Zykluslängen des linken Herzohres wurden
vermessen und als Mittelwert dokumentiert. Die elektrischen Daten
hingegen wurden invasiv im Rahmen der Ablationsprozedur gewonnen. Ein zirkulärer Multipolar-Katheter („Lasso“) wurde in das
Herzohr positioniert und ein intrakardiales EKG mit 100 mm/sec
aufgezeichnet. Auch in diesem Falle wurden 10 konsekutive „elektrische“ atriale Zykluslängen vermessen und als Mittelwert dokumentiert. Die Messwerte beider Methoden wurden gegenübergestellt und die Korrelation bzw. die Signifikanz berechnet.
Ergebnisse Die Pearson-Korrelation zwischen den mittels TEE
gemessenen linksatrialen Zykluslängen und den entsprechenden
intraprozedural gewonnenen elektrischen Daten beträgt 0,837 auf
einem Signifikanzniveau von p < 0,01. Die entsprechende lineare
Regressionsgleichung lautet: Zykluslänge_EPU = (Zykluslänge_TEE
× 0,845) + 27,6 [ms].
Diskussion Unsere vorläufigen Daten zeigen, dass bei persistierenden Flimmerarrhythmien das TEE potenziell eine Methode ist,
mit der die LAACL nicht-invasiv gemessen werden kann. Die Anzahl der gemittelten atrialen Zyklen muss bei Einsatz von Echokardiographie aus Praktikabilitätsgründen auf etwa 10 limitiert werden.
Potenzielle Fehlerquellen der Echomessungen sind Dropouts der
Dopplerkurve bei niedrigen Flussgeschwindigkeiten bzw. suboptimale Schallbedingungen bei der Einstellung des linken Herzohres.
Safety of RFID Gates at Ski Resorts for Patients
with Implanted Cardioverter-Defibrillators XVII – 3
T. Wolber, I. Fauchere, A. Moini, L. Haegeli, F. Duru
Universitätsspital Zürich, Schweiz
Background Recently published in vitro tests with radiofrequency identification readers (RFID) revealed clinically significant
electromagnetic interference with implantable pacemakers and implantable cardioverter-defibrillators (ICDs). Incidents in patients
with pacemakers and ICDs have not been reported yet. The aim of
this clinical study was to evaluate the risk of electromagnetic interference (EMI) during use of RFID-based access control systems
used in ski resorts in patients with ICDs and cardiac resynchronization therapy-defibrillators CRT-Ds).
Methods 34 patients implanted with an ICD or CRT-D were included in the study. Tests were performed using two commercially
available RFID access control systems (gates) used at ski resorts
operating on different frequencies of 125 kHz and 13 mHz. After
initial device interrogation, patients were standing upright within
each gate for a minimum of 30 seconds both at a random position as
well as with the ICD positioned at the closest possible distance from
the RF source, simulating a worst case scenario. Electrocardiographic and telemetric real-time monitoring of devices and patients’
heart rhythm was performed throughout the study.
Results ECG monitoring by body surface ECG demonstrated RF
artifacts in all patients. However, real-time telemetry of intracardiac
electrograms did not show artifacts or evidence of EMI causing inappropriate pacing, changes in pacing rate, or delivery of
antitachycardia pacing. Interrogation of devices after the test revealed no inappropriate tachycardia detection, programming changes,
oversensing or ICD malfunction during all tests in all patients.
Conclusion Although in vitro test demonstrated the ability of
RFID systems to interfere with the function of ICDs, this clinical
study showed no evidence of EMI during use of RFID-based accesscontrol systems used in ski resorts simulating a real-world setting.
Therefore, the use of these access-control systems seems to be safe
for patients implanted with an ICD or CRT-D. However, patients
J KARDIOL 2012; 19 (5–6)
should be advised to avoid prolonged standing in close proximity to
RFID antennas.
 Risikofaktoren – Stoffwechsel – Lipide/
Risk Factors – Metabolism – Lipids
Myokardinfarkt als Auswirkung der angeborenen
Stoffwechselstörung Kearns-Sayre-Syndrom
S. Gasser, B. Gissing, H. Mächler, H. Brussee
Abteilung für Kardiologie; Abteilung für Experimentelle Kardiologie, LKH Graz;
MEDUK Kardiologie, Graz
Das Kearns-Sayre-Syndrom stellt einen seltenen Symptomkomplex
dar, der verschiedene Körpersysteme betrifft und auf einer Störung
des Muskelstoffwechsels, bedingt durch partielle Deletionen im
mitochondrialen Erbgut (delta-mtDNA), die manchmal auch mit einer Duplikation (dup-mtDNA) assoziiert sein können, basiert. Als
Folge dieser strukturellen Veränderungen der mitochondrialen
DNA manifestiert sich eine schwere, vor allem neuromuskulär betonte Erkrankung, die aber auch Störungen im kardialen Reizleitungssystem, die bis hin zum kompletten AV-Block zeigt. Koronare Herzkrankheit oder Myokardinfarkt sind in diesem Zusammenhang bislang noch nicht beschrieben.
Bei dem hier im Mittelpunkt stehenden Patienten handelt es sich um
einen 45-jährigen Mann. Die ersten Manifestationen des KearnsSayre-Syndroms zeigten sich zwischen dem 35. und 38. Lebensjahr.
In diesem Zeitraum wurden seine Symptome dieser Erkrankung
erstmals zugeschrieben und die Diagnose gesichert. Der Patient
wurde mit Thoraxschmerz unter notärztlicher Begleitung in die
Erstaufnahme der Universitätsklinik für Innere Medizin gebracht.
Relevante Vorerkrankungen: bekanntes Kearns-Sayre-Syndrom,
CPEO im Rahmen der Grunderkrankung (regelmäßige Kontrollen
an der Augenklinik), Niereninsuffizienz im Stadium der kompensierten Retention, rezidivierende Synkopen, Nikotinabusus (53 py),
Nykturie 2–3×, Depression, Kontrastmittelallergie.
Status und Allgemeinsymptome: 43-jähriger Patient in stark reduziertem Allgemeinzustand, wach, orientiert. Größe: 182 cm, Gewicht: 85 kg, RR: 137/104, Puls: 77, Caput/Collum: Augenmuskelparese; Pulmo: hochstehende Lungenbasen, sonst Vesikuläratmung.
Cor: rhythmisch, normokard. Abdomen/Extremitäten: Abdomen
gebläht, Darmgeräusche lebhaft in allen 4 Quadranten, kein Druckschmerz, keine Beinödeme; Grob-Neurologisch: Schwäche des linken Armes, Augenmuskellähmung rechts > links. Ruhe-EKG:
Sinusrhythmus, Frequenz 77/min, Linkstyp, PQ-Zeit von 0,2 ms,
R/S-Umschlag in V3, ST-Streckenhebungen in II, III und AVF. Im
Katheterlabor wurde eine Notfalluntersuchung mit Koronarangiographie durchgeführt. Es erfolgte eine Sofort-PTCA nach diagnostischer Sitzung (Eingefäß-PTCA) mit Rekanalisation und folgender
Zweifachimplantation (Genous; Antikörper-beschichtete Stents) in
der RCA. Das Delay war < 3 Stunden. Während der Untersuchung
traten keine Komplikationen auf.
Procedere: Hochdosierte Statingabe für 2 Wochen (bis zur Stenteinheilung), danach weiterführende Statin-Normaldosis, Plavix 1 Tablette täglich für 28 Tage und T-ASS 100 mg als Dauertherapie.
Im Rahmen dieser Fallbesprechung stehen sich 2 Krankheitsbilder
gegenüber, die sich in ihrer Ätiologie und Pathogenese deutlich von
einander unterscheiden. Einerseits eine mitochondrial vererbte, neuromuskuläre Erkrankung, die auf Basis von Defekten in der DNA
zur Manifestation kommt und zu den eher selteneren Varianten des
menschlichen Genoms zu zählen ist. Auf der anderen Seite findet
sich die koronare Herzkrankheit. Es wird die Frage diskutiert, ob die
Manifestation einer KHK in diesem speziellen Fall des 46-jährigen
Patienten eine noch nicht beschriebene Facette des Kearns-SayreSyndroms sein könnte.
ÖKG-Jahrestagung 2012 – Abstracts
Welche Bedeutung besitzen Von-Willebrand-Faktor,
Faktor VIII, PAI-1 und t-PA als Prädiktoren der kardiovaskulären Mortalität? Ergebnisse der Ludwigshafen
Risk and Cardiovascular Health Study
M. E. Kleber, R. Siekmeier, T. B. Grammer, B. R. Winkelmann, B. O. Boehm, W. März
Abteilung Medizinprodukte, Bundesinstitut für Arzneimittel und Medizinprodukte,
Bonn; Institute of Public Health, Social and Preventive Medicine, Medical Faculty
of Mannheim, Universität Heidelberg; Cardiology Group, Frankfurt-Sachsenhausen,
Frankfurt/Main; Division of Endocrinology, Department of Medicine, University
Hospital, Ulm, Deutschland
Fragestellung In den Industrieländern stellen kardiovaskuläre Erkrankungen eine wesentliche Ursache der Morbidität und Mortalität
dar. Neben den Plasmalipiden sind auch Faktoren der Blutgerinnung
als Risikofaktoren dieser Erkrankung von Bedeutung. In der vorliegenden Studie wurde die Rolle von Von-Willebrand-Faktor (vWF-AG),
Faktor VIII, PAI-1-Antigen (AG) und t-PA-Antigen (AG) als Prädiktoren der Gesamtmortalität und der kardiovaskulären Mortalität bei
zur Koronarangiographie vorgestellten Patienten der Ludwigshafen
Risk and Cardiovascular Health Study (LURIC) untersucht.
Methoden Bei insgesamt 3286 Patienten mit Indikation zur Koronarangiographie, die in der Ludwigshafen Risk and Cardiovascular
Health Study eingeschlossen waren, erfolgte eine Bestimmung der
Plasmakonzentrationen bzw. -aktivitäten von Von-Willebrand-Faktor (vWF-AG), Faktor VIII, PAI-1-Antigen und t-PA-Antigen.
Während des medianen Beobachtungszeitraums von 10 Jahren verstarben 982 Patienten.
Ergebnisse Die Analysen erfolgten nach Aufteilung in Quartile
(vWF-AG: Q1: ≤ 120 U/dl, Q2: 121–158 U/dl, Q3: 159–202 U/dl
und Q4: > 203 U/dl; Faktor VIII: Q1: ≤ 128 U/dl, Q2: 129–168 U/dl,
Q3: 169–215 U/dl und Q4: > 216 U/dl; PAI–1: Q1: ≤ 15,8 µg/l, Q2:
15,81–24,7 µg/l, Q3: 24,71–36,9 µg/l und Q4: > 36,91 µg/l; t-PA:
Q1: ≤ 9,4 µg/l, Q2: 9,41–11,9 µg/l, Q3: 11,91–15,4 µg/l und Q4:
>15,41 µg/l). Es fand sich ein Anstieg der Gesamtmortalität mit zunehmender Konzentration bzw. Aktivität von vWF-AG, Faktor VIII
und t-PA (jeweils p for Trend: p ≤ 0,001) sowie PAI-1 (p for Trend:
p = 0,005) (Tabelle 16). Vergleichbare Werte von HR und 95 %-CI
fanden sich auch für die kardiovaskuläre Mortalität vor Adjustierung auf Alter und Geschlecht. Eine zusätzliche Adjustierung auf
die Parameter Alter und Geschlecht führte zu keiner relevanten Änderung der erhaltenen Ergebnisse.
Schlussfolgerungen Die gewonnenen Daten zeigen, dass vor
allem die Parameter vWF-AG, Faktor VIII und t-PA-Antigen bei
Patienten mit koronararterieller Erkrankung als Prädiktoren zur Abschätzung des individuellen Risikos für Gesamtmortalität und
kardiovaskuläre Mortalität geeignet sind. Demgegenüber weist
PAI-1 im Vergleich zu diesen Parametern eine etwas geringere Bedeutung auf. Eine Bestimmung der genannten Parameter sollte daher ergänzend zur Bestimmung der Plasmalipide (einschließlich
Lp[a]) und weiterer Prädiktoren (z. B. Homocystein) sowie persönlicher Faktoren (Rauchen, Lebensstil) erfolgen, um eine möglichst
genaue Abschätzung des individuellen Risikos zu erhalten.
Tabelle 16: M. E. Kleber et al.
Kardiovaskuläre Mortalität
HR (95 %-CI)
Q4 vs. Q1
HR (95 %-CI)
Q4 vs. Q1
HR (95 %-CI)
Q4 vs. Q1
3,20 (2,65–3,86)
3,36 (2,64–4,29)
2,19 (1,71–2,81)
Faktor VIII
2,68 (2,22–3.13)
2,89 (2,29–3,65)
2,08 (1,64–2,65)
1,36 (1,14–1,63)
1,45 (1,15–1,83)
1,57 (1,24–1,98)
2,38 (1,98–2,87)
2,21 (1,76–2,79)
1,64 (1,30–2,07)
Die Pulswellenanalyse im Rahmen der ambulanten
Blutdruckmessung korreliert mit der linksventrikulären Muskelmasse
C. Kos, K. Ablasser, T. Weber, A. Schmidt, B. Pieske, R. Zweiker
Abteilung für Kardiologie, Landeskrankenhaus, Medizinische Universität Graz;
Paracelsus Medizinische Privatuniversität Salzburg
Hintergrund In der Diagnostik und Therapie der arteriellen Hypertonie nimmt die ambulante 24-Stunden-Blutdruckmessung die
zentrale Stellung ein. Die Gefäßsteifigkeit, die durch die Pulswellenanalyse bestimmt werden kann, ist ein unabhängiger Risikofaktor für das Auftreten von kardiovaskulären Ereignissen. Die neuesten Generationen der ambulanten Blutdruckmonitorgeräte ermöglichen neben den oszillographischen Blutdruckmessungen auch die
Pulswellengeschwindigkeitsanalysen mit Bestimmung der arteriellen Gefäßsteifigkeit. Für die Abschätzung des gesamten kardiovaskulären Risikos ist zusätzlich die Bestimmung der linksventrikulären Hypertrophie erforderlich, da die linksventrikuläre Muskelmasse (LVMM) ein wichtiger Prädiktor für kardiovaskuläre Ereignisse
bei Hypertonikern ist.
Hypothese Die linksventrikuläre Muskelmasse (LVMM) korreliert mit der ambulanten Pulswellengeschwindigkeitsanalyse aus
der 24-Stunden-Blutdruckmessung.
Methodik Bei 32 Probanden ohne antihypertensive Therapie wurde echokardiographisch die linksventrikuläre Muskelmasse aus dem
M-Mode nach der Penn-Cube-Methode (LVMM) bestimmt, sowie
eine ambulante 24-Stunden-Blutdruckmessung mit Bestimmung
des Mittelwertes des systolischen und diastolischen Blutdrucks, des
zentralen aortalen Blutdrucks, der Pulswellengeschwindigkeit, des
Augmentationsindex, des peripheren Widerstandes, des Reflexionsindex und des Pulsdrucks durchgeführt. Statistisch wurde eine multiple Regressionsanalyse durchgeführt, wobei ein p < 0,05 als signifikant angesehen wurde.
Ergebnisse Sowohl die Pulswellengeschwindigkeit (p = 0,024)
als auch der Augmentationsindex (p = 0,049) korrelieren unabhängig vom gemessenen Blutdruck hochsignifikant mit der LVMM.
Für den mittleren systolischen und diastolischen Blutdruck konnte
in dieser Studie keine Signifikanz erreicht werden.
Beurteilung Die Pulswellengeschwindigkeit und der Augmentationsindex aus der ambulanten 24-Stunden-Blutdruckmessung korrelieren hochsignifikant mit der LVMM bei Patienten ohne antihypertensive Therapie. Daher bietet die ambulante Pulswellengeschwindigkeitsanalyse zusätzliche Information zur 24-StundenBlutdruckmessung für die Diagnostik und Therapie der arteriellen
Oxygen Administration Improves Peripheral Endothelial Function in Young Healthy Adults
L. Leitner, J. Doerler, C. Trost, M. Wanitschek, H. F. Alber, Ch. Kaehler,
O. Pachinger, M. Frick, A. Suessenbacher
Universitätsklinik für Innere Medizin III/Kardiologie, Medizinische Universität
Background Long term oxygen treatment decreases cardiovascular risk in patients with severe chronic obstructive pulmonary
disease (COPD). Peripheral endothelial dysfunction is associated
with COPD. In patients with atherosclerotic disease an improvement in peripheral endothelial function was related to a decrease in
cardiovascular risk. Whether oxygen administration reduces cardiovascular risk by an improvement in peripheral endothelial
function is unknown. The aim of the present project was to test the
short-term effect of oxygen inhalation in young healthy adults as a
feasibility and pilot study before investigating this issue in patients with COPD.
Methods In 32 young healthy adults (14 women, mean age 27.5 ±
5.1 years) peripheral endothelial function was measured using the
EndoPATTM device: a plethysmographic record of the finger arterial
pulse wave amplitude (PWA) was captured for 5 minutes at rest,
followed by 5 minutes occlusion of the right upper arm using a
sphygmomanometer cuff inflated to suprasystolic levels. After deJ KARDIOL 2012; 19 (5–6)
ÖKG-Jahrestagung 2012 – Abstracts
flation reactive hyperaemia was measured for 5 minutes. Endothelial function was calculated using the reactive hyperaemia peripheral arterial tonometry (RH-PAT) index as the ratio between the
magnitude of the average post occlusive PWA and an average of
5 minutes of the preocclusion PWA. RH-PAT index was assessed at
baseline and after 30 minutes of 4 liters/minute oxygen administration via a non-rebreather oxygen mask. Arterial partial pressure of
oxygen (PaO2) was obtained by arterialized earlobe capillary sampling before and after oxygen administration.
Results Cardiovascular risk factors: smoking (n = 10), positive
family history for premature cardiovascular disease (n = 4), hypercholesterolemia (n = 3), arterial hypertension (n = 3). Oxygen administration increased the mean PaO2 from 90 ± 15 to 158 ± 25 mmHg
(p < 0.001). After oxygen administration the mean RH-PAT index
increased from 2.21 ± 0.54 to 2.54 ± 0.52 (p < 0.001). A bivariate
correlation was found between the absolute increase of RH-PAT
index and the absolute PaO2 increase (r = 0.537; p = 0.026). Additionally, a correlation was found between HDL cholesterol and the
absolute increase of RH-PAT index (r = 0.663; p = 0.01).
Conclusion Endothelial function measurement during oxygen inhalation is feasible. Short term oxygen administration improves peripheral endothelial function in young healthy individuals. Whether
the reduction of cardiovascular risk by oxygen treatment, in patients
with COPD can be explained by an improvement in peripheral endothelial function, will be investigated in further studies.
Regulation L-Arginine-Glycine Amidotransferase in
Normoxia and Hypoxia
S. Pätzold, E. Holzwart, D. von Lewinski, H. Mächler
Klinische Abteilung für Kardiologie, Universitätsklinik für Innere Medizin,
Medizinische Universität Graz
Many genes and pathways have been screened in myocardial tissue
of patients with congestive heart failure (CHF) and ischemia in order to provide insight into mechanisms of recovery brought about
pharmacologically. In a recent paper, Cullen and co-workers (Circulation 2006) have shown that myocardial arginine-glycine amidotransferase (AGAT) gene expression showed a significant decrease
during improvement of heart failure under beta-blockade. This was
an unexpected finding, as AGAT is the rate-limiting enzyme that
catalyzes formation of guanidinoacetate (GAA), the immediate precursor of creatine. It has been suggested that the return of AGAT
expression from its elevated level to normal levels in remodelling
may be a consequence of beta-blocker therapy that the patients in
this study have undergone. The authors could verify that there is
indeed creatine synthesis in myocardial tissue, whereas until then it
has been thought that creatine be mainly produced only in liver and
kidney. Its myocardial expression seems to be increased in CHF and
ischemia as an attempt to preserve contractile integrity, as a result of
the number of functional myocytes being decreased in CHF or ischemia.
We found that, without the influence of beta-blockers, there is no
significant regulation of AGATM-expression during myocardial ischemia. There is, however a significant difference between the expression of AGATM during myocardial ischemia in the presence of
atenolol (1546 ± 0.05) and nebivolol (1.10 ± 0.04; +SEM; p < 0.05).
Table 17: S. Pätzold et al. AGAT is more than 3 times down-regulated in nebivolol under hypoxia as well as under normoxia, with
atenolol less than 2 times
Nebivolol : Control
Atenolol : Control
Nebivolol : Control
Atenolol : Control
J KARDIOL 2012; 19 (5–6)
In the microarray preliminary (Table 17) analyses, we found that
the gene expression of AGATM is down-regulated by both
nebivolol and atenolol. This regulation seemingly constitutes a class
effect of beta-blockers.
Using real-time PCR, we could confirm the above data. While there
is just a trend of down-regulation under atenolol in ischemia, there is
a strong, statistically significant down-regulation of AGATM gene
expression in the nebivolol group during experimental ischemia.
In fact, the excessive adrenergic drive both in untreated heart failure
and likewise in ischemic heart failure as well as the increase in cellular
Ca levels and creatine production ultimately lead the heart into a vicious circle resulting in progressive heart failure. Research of the last
two decades tells us that beta-blockers not only are excellent antihypertensive drugs but also successfully counteract this deleterious spiral in CHF and ischemia. As to myocardial ischemia, O2-consumption
correlates with the amount of cytoplasmic creatine available. The synthesis of high energy phosphate and thus oxygen consumption will be
decreased in myocardial tissue prone to a lesser creatine synthesis.
Thus, down-regulation of myocardial AGATM by beta-blockers will
certainly be beneficial in myocardial protection of hypertensive patients at risk for ischemic heart disease an CHF.
Coronary Artery Disease as a Risk for Developing
Type-2 Diabetes Mellitus
Ch. H. Saely, A. Vonbank, P. Rein, St. Beer, H. Drexel
Abteilung für Innere Medizin, Landeskrankenhaus, Feldkirch
Background Diabetes mellitus is a major risk factor for coronary
artery disease (CAD); whether conversely CAD confers an increased risk for diabetes has not been studied so far.
Methods We prospectively recorded incident diabetes over 7.5
years in 506 consecutive non-diabetic Caucasian patients undergoing coronary angiography for the evaluation of stable CAD, covering 3795 patient years.
Results During follow-up, diabetes was newly diagnosed in 107
patients, i. e. in 21.1% of the study population or in 2.8% per year.
Patients with significant CAD (n = 293) when compared to subjects
who did not have significant CAD at the baseline angiography were
at a 33% (p = 0.027) increased diabetes risk. However, the relationship between CAD and incident diabetes was attenuated and no
longer statistically significant after adjustment for potential confounders including metabolic syndrome (MetS) status. The MetS as
diagnosed according to the current consensus definition in turn was
strongly predictive of diabetes, in particular when the more selective
NCEP-ATP-III waist cut-off values were applied for its diagnosis
(OR = 2.91 [1.83–4.64]; p < 0.001).
Conclusion We conclude that albeit apparently not causally related to diabetes incidence, the presence of CAD indicates a strongly
increased risk for incident diabetes. Repeated diabetes screening of
coronary patients and targeted programs to prevent diabetes in these
high-risk patients are warranted.
Serum Omentin is Neither Associated with the
Metabolic Syndrome Nor with Angiographically
Determined Coronary Artery Disease
Ch. H. Saely, A. Muendlein, A. Vonbank, K. Geiger, P. Rein, H. Drexel
VIVIT-Institute, Landeskrankenhaus, Feldkirch
Background Some recent small studies have described associations of the new adipocytokine omentin with the metabolic syndrome (MetS) and with cardiovascular disease. However, data still
are very scarce.
Methods We therefore measured serum omentin in 395 patients
undergoing coronary angiography for the evaluation of established
or suspected stable CAD; the MetS was defined according to NCEPATPIII criteria; significant CAD was diagnosed when coronary
stenoses ≥ 50% were present.
Results Omentin was positively correlated with age (r = 0.170;
p < 0.001) but did not show significant correlations with waist cir-
ÖKG-Jahrestagung 2012 – Abstracts
cumference, fasting glucose, HDL cholesterol, triglycerides, systolic blood pressure, or diastolic blood pressure; it was similar in
MetS patients (n = 118) as in subjects without the MetS (15 ± 21 vs
14 ± 15 ng/ml; p = 0.460). Omentin also did not differ significantly
between patients with significant CAD (n = 190) and those without
significant CAD (14 ± 19 vs 15 ± 15 ng/ml; p = 0.233). When both,
MetS and CAD status were considered, chemerin similar in MetS
patients as in subjects without the MetS both among those who had
significant CAD (15 ± 13 vs 15 ± 13 ng/ml; p = 0.482) and among
those who did not have significant CAD (16 ± 30 vs 14 ± 15 ng/ml;
p = 0.876); it further did not differ significantly between patients
with significant CAD and subjects without significant CAD
among MetS patients (p = 0.321) nor among subjects without
MetS (p = 0.452).
Conclusion We conclude that omentin is neither associated with
the MetS nor with angiographically determined CAD. Omentin therefore does not appear to be a useful marker of cardiometabolic disease.
Influence of Age and Smoking on Venous Endostatin
Levels: Gender Aspects
M. Sponder, St. Kampf, M. Priglinger, Ch. Reuter, A.-M. Braas, J. Voitl,
M. Mittlböck, R. Marculescu, M. Fritzer-Szekeres, A. Zimmermann, J. StrametzJuranek
Division of Cardiology, Department of Internal Medicine II, Medical University
Vienna, Austria; Medical University Heidelberg, Germany
Background Endostatin inhibits proliferation and migration of
endothelial cells and therefore is an important angiostatic factor.
Additionally, it stimulates endothelial nitric oxide synthase (e-NOS).
Smoking impairs e-NOS, induces endothelial dysfunction, inflammation and subsequent atherosclerosis. Aging is associated with
impaired endothelium-derived NO release and alterates angiogenesis by structural and hormonal reasons. Therefore, the aim of the
study was to investigate the impact of gender, age and smoking on
venous endostatin levels.
Material and Methods Venous endostatin levels were measured
(ng/ml) at rest in 165 healthy individuals without concomitant medication divided into 4 groups: 43 elderly smoker (es; mean age: 51.81 ±
6.61 yrs), 45 elderly non-smoker (ens; mean age: 54.02 ± 7.04 yrs),
38 young smoker (ys; mean age: 24.82 ± 3.79 yrs) and 39 youngnon-smoker (yns; mean age: 23.10 ± 3.88 yrs).
Results The yns-group showed the lowest endostatin levels (91.28 ±
15.11) followed by the ens-group (114.21 ± 20.68) with no genderspecific difference in non of these both groups. Female ys (94.30 ±
19.23) showed similar amounts of endostatin as yns but male ys
(157.25 ± 33.04) had significantly higher levels than all other
groups. In contrary, in the es-group female es (136.31 ± 34.44) had
significantly higher levels (p = 0.001) than male es (103.32 ±
1. In non-smoking individuals aging is associated with a significant
increase in resting venous endostatin (p < 0.001).
2. Moreover, smoking increases significantly the endostatin release
in female (but not in male) elderly smoker (p = 0.001) and vice versa
in young smoker (p = 0.001).
3. Future studies are warranted to investigate the influence of sexsteroid on endostatin release.
Influence of Gliptins on Endostatin and Intima
Media Thickness in 35 NIDDM Patients
M. Sponder, D. Dangl, A. Sabri, L. Kosi, A. Kautzky-Willer, St. Kampf, A. Hammer,
M. Fritzer-Szekeres, B. Litschauer, J. Strametz-Juranek
Division of Cardiology, Department of Internal Medicine II, Medical University
Background Gliptins are complete inhibitors of dipeptidyl-peptidase-4 (DPP4) and therefore increase the blood levels and bioavailability of glucagon-like peptide 1 (GLP-1). Consequently, the insulin production and release rises, glucagon release decreases and
Table 18: M. Sponder et al.
30.74 ± 5.00
30.37 ± 5.02
65.03 ± 14.67
67.62 ± 12.98
126.15 ± 35.43
145.71 ± 54.67
140.00 ± 18.78
113.47 ± 25.26
< 0.001
< 0.001
7.70 ± 1.06
6.53 ± 0.73
IMT left
0.069 ± 0.01
0.068 ± 0.01
IMT right
0.070 ± 0.01
0.070 ± 0.001
blood glucose level recede. Endostatin, a potent angiostatic factor,
inhibits endothelial cell proliferation and migration and stimulates
endothelial nitric oxide synthase (e-NOS).
Material and Methods The study population consisted of 35
NIDDM-patients (15 female, mean age: 60.13 ± 10.80; 20 male,
mean age: 58.10 ± 7.32) who could not reach a HbA1c < 7% by a
metformin monotherapy. The patients obtained 50 mg Vildagliptin
+ 1000 mg Metforminhydrochlorid 2x/d (1-0-1) in tablet-form for
6 months. BMI (kg/m2), blood glucose (mg/dl), HbA1c (%), endostatin (ng/ml), intima media thickness (IMT; cm) and physical performance (by ergometry; %) were measured before and after treatment for 6 months.
Results Gliptin treatment was associated with significant decrease
in glucose (p < 0.01) and HbA1c (p < 0.01). HbA1c decreased from
7.70 ± 1.06 to 6.53 ± 0.73% resp. glucose from 140.00 ± 18.78 to
113.47 ± 25.26 mg/dl. Endostatin levels increased significantly
from 126.15 ± 35.43 to 145.71 ± 54.67 ng/ml (p < 0.04).
Conclusion A 6-month gliptin treatment is associated with a significant increase in venous endostatin levels in patients suffering
from NIDDM. If this gliptin-mediated endostatin up-regulation can
be interpreted as an additional vasoprotective property it should be
elucidated more closely (Table 18).
Influence of High-Dose Highly Efficient Statins
(Atorvastatin and Rosuvastatin) on Long-Term
Clinical Outcome in Patients Undergoing Percutaneous Coronary Interventions plus Coronary
I. Tentzeris, M. Rohla, R. Jarai, S. Farhan, M. Freynhofer, E. Samaha, E. Wessely,
A. Geppert, M. Nürnberg, G. Unger, J. Wojta, K. Huber
3rd Med. Department of Internal Medicine, Cardiology and Emergency Medicine,
Wilhelminenhospital Vienna; Division of Cardiology, Department of Internal
Medicine II, Medical University Vienna
Background Statins are recommended for prevention of progression of cardiovascular disease after coronary PCI and stenting and a
dose-dependent improvement of the lipid profile is observed with all
statins. Despite the fact that high-dose, highly efficient statins
(atorvastatin 80 mg or rosuvastatin 20 mg) are recommended especially in high-risk patients (i. e. ACS patients and/or diabetics),
clinical data are scarce and further investigation in “real-world” settings are needed.
Methods In a retrospective analysis medical therapy, cardiovascular risk factors, co-morbidities and coronary morphology were
evaluated in 2,405 prospectively registered patients undergoing PCI
and coronary stenting at our institution between January 2003 and
March 2009. Basal circulating lipid variables (total cholesterol (T-C);
LDL-cholesterol (LDL-C); were measured. Moreover, all-cause
mortality after a mean follow-up period of 52.27 ± 22.82 months
was evaluated. Results were compared between patients receiving
high-dose, highly effective statins, normal-dose statins and in patients without lipid-lowering therapy.
Results From 2,405 unadjusted patients undergoing PCI plus coronary stenting, 858 (35.7%) received high-dose atorvastatin or
rosuvastatin, 1,240 (51.6%) received other (normal) statin therapy
and 307 (12.8%) patients were not on statins at discharge. Their
J KARDIOL 2012; 19 (5–6)
ÖKG-Jahrestagung 2012 – Abstracts
mean plasma levels of lipid variables were for T-C: High-dose
statin:193 ± 60 mg/dl; low-dose statin: 172 ± 42 mg/dl; p-value for
high-dose versus low-dose = 0.056; no statin: 191 ± 43 mg/dl;
p-value for high-dose versus no statin = 0.4. The mean plasma levels
of lipid variables were for LDL-C: High-dose statin: 118 ± 55 mg/dl;
low-dose statin: 96 ± 34; p-value for high-dose versus low-dose =
0.005; no statin 114 ± 37 mg/dl; p-value for high-dose versus no
statin = 0.2.
Clinical characteristics in terms of current smoking (p < 0.001) diabetes (p = 0.028), hypertension (p = 0.026), cerebrovascular disease
(p = 0.002), peripheral vascular disease (p < 0.001), previous PCI
(p < 0.001), previous MCI (p < 0.001), previous CABG (p < 0.001)
and atrial fibrillation (p < 0.001) were significantly different between the study groups.
Eighty-one (9.4%) patients under high-dose statin therapy, 164
(13.2%) patients on low-dose statins (p-value for high-dose versus
low-dose = 0.06), and 71 (23.1%) patients without statins at discharge died during the follow-up (p-value for high-dose versus no
statin < 0.001).
After adjustment with propensity score no significant reduction in
mortality could be seen: HR for high-dose versus low-dose 0.94,
95%-CI: 0.66–1.34; p = 0.73, HR for high-dose versus no statin
0.72, 95%-CI: 0.44–1.16, p = 0.2.
Conclusion In this small single-center series of 2,405 “real
world” patients undergoing PCI and coronary stenting no significant reduction in long-term all-cause mortality was seen in patients
under high dose, highly-efficient statins compared to patients receiving normal-dose statins or no lipid lowering therapy at all. Accordingly, risk factors and co-morbidities and not the dose and selection of statins at discharge influenced mortality. A potential influence of the duration of high-dose statin therapy on these results
cannot be excluded.
Plasma Renin and Cardiovascular Mortality in Patients with Type 2 Diabetes: A 10-Year Cohort Study
A. Tomaschitz, K. Kienreich, St. Pilz, E. Ritz, T. Grammer, B. Pieske, B. O. Boehm,
W. März
Klinische Abteilung für Kardiologie; Klinische Abteilung für Endokrinologie und
Stoffwechsel, Medizinische Universität Graz; Abteilung für Nephrology, Universität
Heidelberg; Mannheim Institute of Public Health, Ruperto Carola University
Heidelberg; Medical Faculty Mannheim; Division of Endocrinology, Diabetes and
Metabolism, Graduate School of Molecular Diabetology and Endocrinology, Ulm
University; Synlab Centre of Laboratory Diagnostics, Heidelberg, Germany
Introduction Diabetes mellitus is a major risk factor for cardiovascular disease (CVD) mortality worldwide and is strongly linked
to the activation of renin-angiotensin systems. Insight into the corresponding impact of circulating renin on cardiovascular-related mortality in patients with diabetes is however lacking. This study sought
to evaluate the association between plasma renin concentration
(PRC) and CVD mortality in patients with type-2 diabetes after
long-term follow-up of almost 10 years.
Material and Methods We studied participants with type-2 diabetes of the Ludwigshafen RIsk and Cardiovascular health (LURIC)
study (29.6% females).
Results PRC (median: 12.6 [6.0–27.0] pg/mL) was measured in
1319 patients (mean age: 64.0 ± 9.8 years) referred to coronary angiography. After a median follow-up of 9.9 years, 372 participants
(28.1%) with PRC measurement at baseline had died due to fatal
cardiovascular events. Multivariable adjusted Cox analysis revealed
that compared to subjects in the lowest PRC quartile, those in the
highest quartile were at increased risk of cardiovascular mortality
(Hazard ratio: 1.71, 95%-CI: 1.19–2.46; p = 0.004). Analyses of
specific causes of cardiovascular death showed that for each SD increase in log-PRC there was a 47% (p < 0.001) increase in risk of
death due to heart failure. The relationship between PRC and cardiovascular mortality remained stable after adjustment for established
cardiovascular risk factors, ongoing antihypertensive, antidiabetic
medication and angiotensin II levels.
J KARDIOL 2012; 19 (5–6)
Discussion High PRC is a strong and independent predictor of
fatal cardiovascular events and death due to heart failure in a stable
population of patients with diabetes. Our results indicate that PRC
represents a promising cardiovascular risk marker in a broad range
of high CVD risk patients with type 2 diabetes.
The Metabolic Syndrome Significantly Affects the
Association Between Resting Heart Rate and All
Cause as Well as Cardiovascular Mortality
A. Vonbank, F. Schmid, P. Rein, Ch. H. Saely, H. Drexel
VIVIT-Institute, Landeskrankenhaus, Feldkirch
Background Epidemiological studies suggest that the resting heart
rate (RHR) is an independent predictor of cardiovascular and all cause
mortality. However, the power of the RHR to predict cardiovascular
events in patients with the metabolic syndrome (MetS) is not known.
Methods We prospectively investigated the relationship between
RHR and cardiovascular events in 756 consecutive patients undergoing coronary angiography for the evaluation of coronary artery
disease (CAD) over a follow-up period of 7.1 ± 0.1 years. The MetS
was defined according to NCEP-ATPIII criteria.
Results In the total study population, both all cause and cardiovascular mortality were increased with an increasing RHR (standardized adjusted HRs 1.03 [1.01–1.04]; p = 0.001 and 1.15 [1.03–
1.47]; p = 0.001, respectively). From our patients, 357 (47.2%) had
the MetS and 399 did not have the MetS. Among patients without
the MetS, a higher baseline RHR indicated a significantly higher
risk of total mortality (HR = 1.14 [111–1.16], p = 0.001) and cardiovascular mortality (HR = 1.13 [1.12–1.16], p = 0.001) after multivariate adjustment. However, the RHR did not significantly affect
total mortality (p = 0.120) or cardiovascular mortality (p = 0.244) in
patients with the MetS. Interaction terms RHRxMetS were significant for both total and cardiovascular mortality (p = 0.027 and
p = 0.037, respectively), indicating that the respective risks conferred by a high RHR were significantly higher in patients without
the MetS than in patients with MetS.
Conclusion We conclude that among angiographically characterized coronary patients, the metabolic syndrome status significantly
affects the association of the RHR with total and cardiovascular mortality: RHR is a strong predictor of both total and cardiovascular mortality among subjects without the MetS, but not among MetS patients.
Adipose Tissue Pro-Inflammatory Gene Expression
is Associated with Cardiovascular Disease
T. Weiss, I. Seljeflot, H. Arnesen
3rd Med. Department of Internal Medicine, Cardiology and Emergency Medicine,
Wilhelminenhospital, Vienna, Austria; Oslo University Hospital, Ulleval, Oslo,
Background Obese patients are at high risk of developing cardiovascular disease. Several studies suggest obesity as an independent
risk factor. Adipose tissue is now accepted as an endocrine organ that
produces and secretes a variety of cytokines, hormones and other
metabolic players involved in the pathogenesis of atherosclerosis.
Among this versatile group of mediators and effectors of inflammation and atherothrombosis, we have studied the expression of matrix
metalloproteinase-9 (MMP-9), tissue inhibitor of metalloproteinase-1
(TIMP-1), plasminogen activator inhibitor-1 (PAI-1), interleukin-18
(IL-18) and interleukin-6 (IL-6). All these markers have in their circulatory form been associated with cardiovascular disease. However,
there is not much data available on their expression in adipose tissue
in human subjects with and without cardiovascular disease.
Material and Methods We successfully isolated RNA from subcutaneous fat biopsies of 61 patients with or without cardiovascular
disease. We then measured the RNA expression of MMP-9, TIMP1, PAI-1, IL-18 and IL-6 with Real-Time PCR, using relative quantification.
Results Albeit not statistically significant, all inflammatory mediators – except IL-18 – were higher expressed in patients with car-
ÖKG-Jahrestagung 2012 – Abstracts
diovascular disease (n = 16) compared to those without (n = 45).
Pooling the gene expression data, trying to capture the overall inflammatory activity in adipose tissue in a score system, we observed
a highly significant association with CVD.
Conclusions Trying to capture the overall inflammatory activity,
in addition to the mass of adipose tissue, could provide useful hints
towards a pathogenetic link between obesity and presence of cardiovascular disease.
Components of the Interleukin-6 Transsignalling
System are Associated with the Metabolic Syndrome,
Endothelial Dysfunction and Arterial Stiffness X – 2
T. Weiss, H. Arnesen, I. Seljeflot
3rd Med. Department of Internal Medicine, Cardiology and Emergency Medicine,
Wilhelminenhospital, Vienna, Austria; Oslo University Hospital, Ulleval, Oslo,
Introduction The metabolic syndrome (MetS) is an increasing epidemiologic challenge and cardiovascular risk factor. Interleukin-6
(IL-6) is a cytokine that exerts its biological function via a complex
orchestration of soluble and membrane bound receptors. We have investigated associations between IL-6 and its soluble receptors, soluble
IL-6 receptor (sIL-6r) and soluble glycoprotein 130 (sGP130) and the
metabolic syndrome. Furthermore, we have investigated possible associations with endothelial dysfunction and arterial stiffness.
Methods A total of 563 subjects were included in this study.
Adult treatment panel III criteria of the national cholesterol education program were used for the definition of MetS. We used commercially available ELISA to analyze circulating levels of the markers. Pulse wave propagation time (PWP) was determined to assess
arterial stiffness.
Results The criteria for having MetS were filled by 221 subjects.
sGP130, sIL-6r and IL-6 levels were elevated in subjects with MetS (p
< 0.05 for all markers), and are associated with increasing components of MetS. Particularly hypertriglyceridaemia, hypertension and
fasting plasma glucose (FPG) seem to carry this association. sGP130
(p < 0.01), IL-6 (p < 0.05) and partially sIL-6r (p < 0.05) correlated
with markers of endothelial function (E-selectin, I-CAM-1, V-CAM1) and inversely with PWP after adjustment for relevant covariates.
Discussion sGP130, sIL-6r and IL-6 were significantly elevated
in subjects with MetS. In addition, sGP130, IL-6 and partially sIL6r were associated with markers of endothelial function and arterial
stiffness. This finding sheds new light on the role of these inflammatory cytokines in subjects with MetS and the development and progression of clinically silent atherosclerosis.
 Vitien/Cardiac Defects
Implementation of TAVI Procedures as aTeam Approach.
The Innsbruck Experience of Using a New Generation
Mobile c-Arm in the Cardiac OR
XIX – 4
N. Bonaros, S. Müller, G. Feuchtner, N. Fischler, A. Heinz, F. Plank, T. Schachner,
G. Friedrich, M. Grimm, L. Müller, T. Bartel
Abteilung für Herzchirurgie, Medizinische Universität Innsbruck
The implementation of a TAVI (Trancsatheter Aortic Valve Intervention) program in an interdisciplinary fashion has been recommended by several scientific societies. However the number of centers with multidisciplinary TAVI programs seems to be very limited.
The aim of the study was to evaluate the need of a close cooperation
between interventional cardiologists, cardiac surgeons, echocardiographers and radiologists in an institutional TAVI program.
Between February 2008 and March 2012 93 patients received TAVI
at the University Hospital Innsbruck. Transapical (n = 43, %), transfemoral (n = 42, %), transaxillary (n = 5, %), and transaortic (n = 3, %)
implantations were performed on an intend to treat basis. The decision
for intervention, preoperative planning, procedure conduction and
postoperative management were performed in consensus of the responsible team consisting of interventional cardiologists, echocardiographers, cardiac surgeons, and radiologists. The vast majority
of the patients (n = 85, %) were treated in the cardiac OR using a new
generation mobile c-arm (Ziehm RFD, OEC 9800, Phillips Veradius).
The observed success rate of implantation was 96%. There were 6
conversions to larger thoracic incisions, 2 of them as a result of apical
bleeding, and two conversions from the transfemoral to the transapical approach. One patient underwent minimally invasive aortic
valve replacement after a non-reversible c-arm crash (old generation)
before the beginning of the procedure and one patient had redo aortic
valve replacement (AVR) because of valve embolization. There were
three bail-out conversions from surgical to TAVI because of intraoperative contraindications. Cardiopulmonary bypass was used in 6 patients (7%). The majority of the transfemoral cases (27/42, 65%) required an extensive reconstruction of the femoral vessels. In two cases
an endoluminal treatment was needed. In 42 patients (45%) a low
volume contrast agent technique was applied after combining diagnostic information gathered by preoperative CT scan, and intracardiac
echocardiography. As a result 61/93 patients have a substantial profit
from the implementation of an interdisciplinary approach.
Conclusions Two thirds of the patients treated in an interdisciplinary model of TAVI have profited from the approach. The expertise
provided by different disciplines can offers significant advantages
for the preoperative planning as well as the intra and postoperative
Transaortic Catheter Valve Implantation: The Solution for Intraoperative Contraindications for Conventional Surgery?
XIX – 7
N. Bonaros, S. Müller, G. Feuchtner, A. Heinz, N. Fischler, F. Plank, G. Friedrich,
T. Schachner, M. Grimm, L. Müller, T. Bartel
Abteilung für Herzchirurgie, Medizinische Universität Innsbruck
Transcatheter valve implantation (TAVI) via transaortic approach
has been previously described for patients in whom a transfemoral
or transapical approach is not desirable or possible. We describe our
experience in three patients with intraoperatively diagnosed contraindications to conventional aortic valve replacement, who underwent transaortic TAVI as a bail-out procedure.
A 68-year-old patient, out of vessels and with previous history of kidney transplantation and peripheral vascular disease, assigned for aortic valve replacement due to severe aortic stenosis (ΔPmax = 85 mmHg)
decompensated during anesthesia induction and required a high
dose vasoconstrictor therapy. Because of the high risk for conventional surgery a transaortic approach to allow central cannulation for
extracorporeal circulation was performed. A 26 mm Edwards Sapien
prosthesis crimped upside-down was successfully implanted without the use of extracorporeal circulation. The patient had a prolonged
recovery period after early extubation, mainly because of pneumonia complicated by acute renal failure, but left the hospital 3 weeks
after the procedure in a good condition.
A 77-year-old male with isolated aortic stenosis (ΔPmax = 79 mmHg)
was assigned for minimally invasive aortic valve replacement via
upper partial sternotomy. A severe calcification of the proximal ascending aorta and the aortic root not affecting the distal part of the
aorta was found intraoperatively. Because of the high risk conventional surgery, the strategy was changed to TAVR via transaortic
access. A 26 mm Edwards Sapien prosthesis was implanted after
echocardiographic evaluation of the aortic annulus without the use
of extracorporeal circulation. The patient had an uneventful postoperative course and was discharged home 6 days after the procedure.
The third patient had severely calcified regurgitant aortic root prosthesis, who underwent open TAVI via aortotomy in cardiopulmonary bypass and cardioplegic arrest.
All procedures were monitored by transesophageal echocardiography and fluoroscopy using a new generation mobile C-arm.
This access allows external marking of the coronary ostia in order to
avoid coronary obstruction, as well as immediate repair of complicaJ KARDIOL 2012; 19 (5–6)
ÖKG-Jahrestagung 2012 – Abstracts
tions during the procedure. Closing of the aortic entry site is a very
common procedure in cardiac surgery, which can be easily managed.
In conclusion, transaortic TAVR can be performed as a minimally
invasive bail-out procedure in unexpectedly inoperable patients
without alternative peripheral access.
Minimally Invasive Double Valve Surgery: 5-Year
XIX – 5
J. Dumfarth, A. Heinz, H. Hangler, J. Kilo, S. Semsroth, M. Grimm, L. Müller
Universitätsklinik für Herzchirurgie, Medizinische Universität Innsbruck
Introduction Minimally invasive techniques for valve surgery have
emerged as a safe and efficient approach in many institutions. Based
on data and growing experience of minimally invasive mitral valve
procedures, the technique was extended to double valve surgery. Aim
of this study was to evaluate immediate and mid-term outcome in patients receiving minimally invasive double valve surgery.
Methods After implementation of a minimally invasive valve
program and the first 54 successful isolated mitral valves, double
valve surgery was started through this approach. Additional tricuspid annuloplasty was indicated for severe tricuspid regurgitation or
tricuspid annular dilatation > 40 mm. Intraoperative and follow-up
data of all patients undergoing double valve surgery from 2006 to
2011 were analyzed.
Results From 2006 to 2011, a total of 93 patients underwent minimally invasive double valve surgery through a mini-thoracotomy.
Mean patients age was 67.5 years (range 38–86), 52% were female.
In 76 patients (81%) mitral valve repair could be performed, all patients received tricuspid valve repair. Intraoperative conversion to
full sternotomy was necessary in two cases (2%) due to pleural adhesion and bleeding. In hospital mortality was 2%. During a mean
follow-up of 26 ± 12 months reoperation was performed in two patients due to endocarditis and significant tricuspid regurgitation.
Conclusion Minimally invasive tricuspid valve repair indicated
for severe tricuspid regurgitation can be added safely to mitral valve
surgery. Neither mortality nor major complications related to the
combined procedures were increased. Follow-up data show convincing results.
Experience with the Mitraclip System in Patients with
Significant Mitral Regurgitation, Distinct Impairment
of LV-Function and Multiple Co-Morbidities XIX – 2
Ch. Ebner, T. Sturmberger, W. Tkalec, J. Aichinger, R. Steringer-Mascherbauer,
V. Eder, G. Kabicher, J. Niel, H.-J. Nesser
Abteilung für Kardiologie, Krankenhaus der Elisabethinen, Linz
Introduction Mitral regurgitation (MR) is the second most common valvular disease and symptomatic patients should undergo
valve surgery. A part of these patients were refused by cardiac surgeons because of impaired LV-function, older age or multiple comorbidities. Edge-to-edge repair using the MitraClip system was
introduced as an alternative treatment option in this group of patients.
Methods and Results So far we treated 32 patients as the first
department in Austria, starting in August 2009. Indication for percutaneous catheter-based mitral valve repair with the MitraClip system
was significant MR ≥ grade 3. 31/32 patients were refused by cardiac
surgeons, 1 had failed surgical mitral repair. 22 patients (68.8%)
presented with functional MR, 4 patients (12.5%) with degenerative
disease and 6 patients (18.8%) had a mixed pathology. Patients median age was 72.5 years (IQR; 59–80) and 50% were male. The
EuroScore of the total group was 21.62 ± 12.5% and increased in the
group with a LVEF ≤ 35% up to 23.3 ± 13.6%. 14/32 patients had a
LVEF ≤ 35% and 9 further patients (28.1%) of even ≤ 25%. A single
clip was successfully implanted in 25 patients (78.1%), 5 patients
(15.6%) received two clips and 1 patient received 3 clips. In one
patient the clip could not be positioned successfully and in another
patient we had a partial leaflet detachment of the second clip. The
mean device implantation time was 109 ± 56 minutes. Only one pa-
J KARDIOL 2012; 19 (5–6)
tient developed cardiac tamponade treated successfully by conservative means, all the other procedures were uncomplicated. In-hospital and 30 days mortality was zero. ICU median duration was
2 days and total hospitalization was 11.2 ± 6.8 days (median 9, 7–
11,75 days). In the very high surgical risk group (LVEF ≤ 35%) including multiple co-morbidities the 12 month mortality was 23.1%.
In the 31/32 successful treated patients NTproBNP levels could be
reduced from mean 7614 ± 8107 to 4767 ± 4835 pg/ml and mitral
regurgitation intensity from grade 3.6 ± 0.3 to grade 1.56 ± 0.54.
Conclusion Mitral valve repair using the MitraClip system was
shown to be feasible with high success rate in patients with significant mitral regurgitation. Particularly patients with distinct impaired
LV-function in combination with multiple co-morbidities have a
low periinterventional risk and may improve but have to be selected
very carefully.
Evaluation of Changes in Geriatric Symptoms and
MRI- or CT-Determined Cerebral Embolic Lesions
Among Patients Undergoing Transcatheter Aortic Valve
Implantation Before and After Procedure
XIX – 1
V. Eder, Ch. Ebner, H. Koller, T. Schickmaier, T. Sturmberger, J. Aichinger,
W. Tkalec, R. Steringer-Mascherbauer, H.-J. Nesser
Abteilung für Kardiologie, Krankenhaus der Elisabethinen, Linz
Background Transcatheter aortic valve implantation (TAVI) is an
alternative treatment option in elderly patients with symptomatic
severe aortic valve stenosis who are not eligible for conventional
aortic valve replacement. A geriatric assessment is a multidisciplinary diagnostic approach designed to collect data on the medical,
psychosocial and functional capabilities and limitations of elderly
patients. Goal of this study was to assess changes in geriatric assessment parameters and MRI or CT determined cerebral embolic
lesions after TAVI procedure and its correlation with changes of
B-Type natriuretic peptide (BNP) levels and peak systolic gradient.
Methods and Results Between October 2007 and December
2011, 87 patients underwent TAVI with the CoreValve system for
severe symptomatic aortic valve stenosis in our institution. In 12
consecutive patients (83.8 ± 2.9 years, 4 men and 8 women, mean
aortic valve area 0.64 ± 0.16 cm2, mean peak systolic gradient of
98.8 ± 21.15 mmHg, mean LVEF 50.4 ± 8.9% ) with a logistic
EuroScore of 23.7 ± 9.6% and NT pro BNP of 1137 pg/ml (IQR
605–2521), a comprehensive geriatric assessment as well as a cerebral diffusion weighted MRI or CT scan was performed before and
within one year after TAVI. Geriatric assessment included the
MNA©, ADLs, IADLs, GDS, Timed Get up&Go, Chair Rising Test,
the Mini Cog©, Frieds Frailty criteria and the Carlson Morbidity
score. Based on the geriatric assessment patients were stratified into
functional performance categories defined as healthy/‘GoGo’ (n = 3),
vulnerable/‘SlowGo’ (n = 7) or Frail/’NoGo’ (n = 2).
After a follow-up period of 12 ± 5 months, 10 of our 12 patients
showed no changes in functional performance category or other geriatric assessment parameters (e. g. frailty), while 1 patient deteriorated and 1 patient improved to a better functional performance category. New (clinically silent) perfusion deficits, presumably due to
atherothrombotic emboli, occurred in 2 patients, but these findings
were not associated with deteriorations in geriatric performance
category. No patient suffered a clinical cerebral stroke. Overall,
BNP levels and peak systolic aortic gradients decreased after TAVI
(2040 ± 2370 vs 789 ± 704 pg/ml; p = 0.055; 89.7 ± 21.5 vs 22.5 ±
6.6 mmHg; p < 0.0001)
Conclusion and Discussion Our preliminary results of 12 patients undergoing TAVI indicate that successful TAVI, illustrated
by a significant reduction of peak systolic aortic gradient and lower
BNP levels after the procedure, is not associated with improvements
in geriatric outcome parameters e. g. functional performance categories. There was no correlation between new cerebral embolic lesions
and geriatric assessment status. Although in previous studies TAVI
demonstrates better clinical outcomes than standard medical treatment, our report does not support improvements in typical geriatric
ÖKG-Jahrestagung 2012 – Abstracts
Root Replacement for Excavating Aortic Valve EndoXIX – 10
carditis With the Freestyle® Xenograft
A. Heinz, J. Dumfarth. M. Grimm, L. Müller
Universitätsklinik für Herzchirurgie, Medizinische Universität Innsbruck
Introduction The choice of the optimum conduit for aortic root
replacement in destructive endocarditis depends on technical considerations, resistance to infection and longevity of the graft. Since
1998 we systematically used the Freestyle® xenograft instead of
Material and Methods Patients requiring left ventricular outflow tract (LVOT) and/or aortic root replacement for severe, excavating native or prosthetic valve endocarditis (NVE or PVE) who
received a xenograft full root from 1998 to 2012 were studied. Outcome analysis was performed for perioperative complications, mortality and technical success of the operation.
Results In 31 patients a Freestyle® porcine aortic root (21–29 mm)
was implanted. 17 patients had additional procedures: CABG
(n = 9), mitral valve repair or replacement (n = 3), tricuspid valve
repair (n = 1), LVOT patch repair (n = 6), ascending aorta replacement (n = 2) and ascending aorta reduction plasty (n = 4). 22 patients
were operated for PVE with annulus destruction. 30 days and hospital mortality was 6 (19.4%). There were no instances of technical
failure requiring reoperation for bleeding or replacement of the xenograft by a different conduit. 3 patients needed postoperative mechanical circulatory support, 3 patients had a pacemaker implantation for new heart block, and 7 patients required hemofiltration for
acute renal failure. Median ICU stay was 5 days (1–136), median
intubation time 2 days (1–115). Hospital stay was 26 days (8–36).
Conclusion The Freestyle® aortic root xenograft can be used technically successful instead of a homograft in the most severe cases of
excavating aortic valve endocarditis.
Impact of Tricuspid Regurgitation Late After LeftHeart Valve Surgery
XIX – 3
A. Kammerlander, B. Marzluf, D. Bonderman, M. Nikfardjam, A. Bachmann,
A. Graf, G. Maurer, J. Mascherbauer
Department of Cardiology; Department of Medical Statistics, Medical University
Background Significant tricuspid regurgitation (TR) occurring
late after left-heart surgery is frequent and associated with decreased
exercise tolerance and quality of life. Reoperative tricuspid valve
(TV) surgery has been reported to result in early mortality rates as
high as 10–25%.
The aim of the study was to evaluate whether significant TR late
after left-heart valve surgery impacts on prognosis.
Methods 647 consecutive patients who were seen in our outpatient
clinic of valvular heart disease at least 6 months after successful surgery of the aortic or/and the mitral valve were prospectively followed.
The severity of TR was assessed by echocardiography. Significant TR
was defined as TR ≥ moderate. Multivariable logistic and Cox regression models were used to determine the impact of TR on survival.
Results From 647 patients, 399 (61.7%) presented with prior aortic valve replacement (AVR); 138 (21.3%) patients had previous
surgery of the mitral valve (MV) (78 (12.1%) MV replacement; 60
(9.3%) MV repair). 63 (9.7%) patients had both AVR and MV surgery. 47 (7.3%) had previous tricuspid surgery in addition to leftsided procedure. Significant TR was present in 161 (24.9%) patients.
Patients with significant TR were predominantly female (68% vs
45%; p < 0.001), had a higher EuroSCORE at the time of last surgery (8.2 ± 3.1 vs 5.5 ± 2.4: p < 0.001); and a higher number of previous cardiac surgeries (1.2 ± 0.5 vs 1.1 ± 0.3; p = 0.007). They presented with a higher frequency of atrial fibrillation (52% vs 17%;
p < 0.001), diabetes (20% vs 13%; p = 0.030), and pulmonary hypertension (31% vs 13%; p < 0.001); and were more symptomatic
(NYHA functional class 1.97 ± 0.75 vs 1.47 ± 0.62; p < 0.001). They
furthermore had more dilated right ventricles (37.5 ± 7.9 mm vs
J KARDIOL 2012; 19 (5–6)
ÖKG-Jahrestagung 2012 – Abstracts
32.7 ± 5.0 mm; p < 0.001), more dilated left and right atria (both
p < 0.001) and presented with worse left ventricular function (LVEF
< 50% 20,5% vs 11,1%; p = 0.005).
Patients were followed for 698 ± 124 days (TR ≥ 2: 681 ± 147 days
vs TR < 2: 703 ± 116 days; p = 0.08).
In total, 54 patients died during follow-up (13,7% of patients with
TR ≥ 2 vs 6,6% patients with TR < 2, p = 0.034). By Kaplan-Meier
analysis, survival rates were significantly worse in patients with significant TR (1- and 2-year survival rates 92.6% and 87.6% in significant TR versus 96.1% and 93.4% in non-significant TR; log rank
p = 0.005).
By multivariable Cox regression analysis, significant TR (p = 0.002),
atrial fibrillation (p = 0.001), and age (p < 0.001) were found to independently predict mortality.
Conclusion Significant TR late after left-sided heart valve surgery is frequent and predicts outcome in addition to age and atrial
A New Concept for Aortic Valve Repair
XIX – 9
L. Müller, A. Heinz, J. Dumfarth, S. Semsroth, M. Grimm
Universitätsklinik für Herzchirurgie, Medizinische Universität Innsbruck
Background Repair of the aortic valve for severe regurgitation is
still a matter of debate since results are equivocal. Introduction of a
systematic approach to aortic valve repair similar to the proven concept of mitral valve repair, however, made results much more predictable. The new concept addresses simultaneously all three components of the aortic root: the annulus, the cusps and the sino-tubular junction, since alteration of each of them influences form and
function of the other two components.
Materials and Methods Since December 2011, 9 patients with
severe aortic valve regurgitation have been operated with the intention to repair the valve. Indication for valve surgery was derived
from clinical symptoms, progressive ventricular dilatation or reduction of ejection fraction. Valve analysis included anatomical classification (tricuspid, biscuspid, quadricuspid), geometrical height and
effective height of the cusps as well as diameter of the aorto-ventricular and the sino-tubular junction. Repair aimed at correction of
cusp prolaps by plication of the free margin, subvalvular annuloplasty and corresponding reconstruction of the sino-tubular junction.
Results Median age of the patients was 33 (21–53 years), 7 patients were male. Valve morphology included bicuspid AV Type I
L-R in 5, Type 0 in 1, tricuspid AV in 2 and quadricuspid AV in
1 patient. In 1 patient the intraoperative decision was for AV plus
ascending aorta replacement due to unfavorable anatomy in 1 and
the valve had to be replaced for an unsatisfactory repair result in 1
other patient. 7 valves were repaired successfully. Subvalvular suture annuloplasty was performed in 5 patients, 2 received reconstruction of the sino-tubular junction. Echo control before discharge
revealed no regurgitation (grade 0) in 3 and trace to mild (grade I) in
4 patients.
Conclusion Implementation of a new concept of aortic valve repair for severe aortic regurgitation which addresses all components
of the aortic root has led to very satisfying short term results promising long lasting freedom from valve replacement in this young
cohort of patients.
Perkutaner Aortenklappenersatz (TAVI) bei Patienten
mit inoperabler Aortenklappenstenose
XIX – 6
E. Zeindlhofer, K. Höllinger, A. Winter, Ch. Steiner, M. Schmid, D. Kiblböck,
L. Pilgerstorfer, F. Rausch, J. Reisinger, P. Siostrzonek
Interne II/Kardiologie, Krankenhaus der Barmherzigen Schwestern, Linz
Einleitung Der perkutane Aortenklappenersatz (TAVI) hat sich in
den vergangenen Jahren als neue erfolgversprechende Behandlungsmöglichkeit bei inoperablen Patienten mit Aortenklappenstenose
(AS) etabliert. Wir führen die TAVI seit Februar 2011 in multidisziplinärer Kooperation durch und berichten über unsere Ergebnisse.
J KARDIOL 2012; 19 (5–6)
Material und Methode Bisher wurden 52 Patienten (32 Männern, 20 Frauen; Alter: 82,0 ± 5,4 Jahre) mit inoperabler AS behandelt. Bei allen Patienten lag eine signifikante symptomatische AS
(Mittlerer Gradient: 58,6 ± 17,9 mm, NYHA III: 45 Pat., NYHA IV:
7 Pat.) vor, der logistische EuroSCORE betrug 28,2 ± 11,3. Bei
9 Patienten lag eine linksventrikuläre Auswurffraktion < 40 % vor.
20 Pat. hatten eine koronare Herzkrankheit, bei 14 war eine koronare Intervention vorangegangen.
Ergebnisse Die Klappenimplantation wurde durchwegs transfemoral unter Verwendung des CorValve-Systems (Medtronic,
Minneapolis, MN, USA) durchgeführt. Die Implantation erfolgte
perkutan unter Sedoanalgesie, nur bei 2 Pat. mit vorbestehender
Lungenstauung wurde eine Intubationsnarkose vorgenommen. Die
Einbringung der Klappe war in allen Fällen erfolgreich, bei einem Pat.
mit Aorteninsuffizienz musste eine zweite Klappe (Valve in Valve) implantiert werden. Die Gesamtdauer des Eingriffs betrug 80 ± 28 min,
die Durchleuchtungsdauer 23 ± 9 min. Bei keinem Pat. musste eine
Konversion zur Herzchirurgie vorgenommen werden. Nach Implantation reduzierte sich der mittlere Gradient auf 10,2 ± 5,8 mm (p < 0,001),
die Aorteninsuffizienz nach Implantation wurde bei 36 Pat. als gering
(Grad 0/I) und bei 6 Pat. als mäßig (Grad II) eingeschätzt.
Bei 10 (19 %) Pat. trat nach Schleusenentfernung eine periphere
Gefäßkomplikation auf, die bei 8 Pat. (15,2 %) gefäßchirurgisch
versorgt werden musste. Drei Pat. (5,7 %) erlitten ein reversibles
neurologisches Defizit. Bei 14 Pat. (26,9 %) musste ein permanenter
Schrittmacher implantiert werden. Die Aufenthaltsdauer auf der
Intensivstation betrug 4,8 ± 3,6 Tage, die Krankenhausaufenthaltsdauer 16,3 ± 6,5 Tage.
Ein Monat nach TAVI hatte sich das NYHA-Stadium bei allen bis
auf einen Pat. verbessert (NYHA I: 4 Pat., NYHA II: 35 Pat. und
NYHA III: 2 Pat.). Das BNP war von 1347 ± 929 auf 745 ± 541
gesunken (p < 0,001). Die 30-Tage-Mortalität betrug 2/52 (3,8 %),
die Mortalität nach einem Jahr 4/24 (16,7 %).
Diskussion Unsere Ergebnisse sind in Anbetracht der Multimorbidität der behandelten Patienten ermutigend und durchaus mit den
Ergebnissen aus größeren Studien und Registern vergleichbar.
Vergleich von 2 femoralen Verschlusssystemen
nach perkutanem Aortenklappenersatz
XIX – 8
E. Zeindlhofer, K. Höllinger, A. Winter, Ch. Steiner, A. Gierlinger, M. Schmid,
D. Kiblböck, F. Rausch, J. Reisinger, P. Siostrzonek
Interne II/Kardiologie, Krankenhaus der Barmherzigen Schwestern, Linz
Einleitung Der perkutane Aortenklappenersatz (TAVI) hat sich in
den vergangenen Jahren als erfolgversprechende Behandlungsmöglichkeit bei inoperablen Patienten mit Aortenklappenstenose
(AS) etabliert. Gefäßkomplikationen an der femoralen Punktionsstelle stellen eine typische Komplikation nach TAVI dar. Wir berichten über die Ergebnisse bei Verwendung von zwei unterschiedlichen perkutanen Verschlusssystemen.
Material und Methode Bei 51 Pat. (Alter: 82 ± 5,4 Jahre, 32
Frauen, 20 Männer, logistischer EuroSCORE: 28,2 ± 11,3) wurde in
perkutaner Technik erfolgreich eine CoreValve-Klappe (Medtronic,
Minneapolis, MN, USA) über einen femoralen Zugang implantiert.
Der Gefäßverschluss nach Entfernung der 18F-Schleuse erfolgte bei
den ersten 31 Pat. mit dem Prostar-XL- (PS-) System (Abbott Vascular, Redwood, California, USA) und bei den weiteren 20 Pat. unter Verwendung von 2 ProGlide- (PG-) Systemen (Abbott Vascular,
Redwood, California, USA). Patientenalter, Geschlechtsverteilung
und logistischer EuroSCORE waren in beiden Gruppen vergleichbar. Der präinterventionelle Gefäßdurchmesser an der Punktionsstelle betrug in der PS-Gruppe 7,9 ± 0,7 mm und in der PG-Gruppe
8,1 ± 1,2 mm (p = n. s.).
Ergebnisse Der residuale Stenosegrad an der Verschlussstelle betrug nach PS 26,5 ± 11,6 % und nach PG 15,5 ± 10,9 % (p < 0,005).
Bei 10 (19 %) Pat. trat nach Schleusenentfernung eine periphere
Gefäßkomplikation auf, die bei 8 Pat. (15,2 %) gefäßchirurgisch
und bei 2 Pat. (2,8 %) interventionell versorgt werden musste.
Gefäßchirurgische Revisionen an der 18F-Insertionsstelle waren bei
6/31 Pat. (19,4 %) nach PS und bei 0/20 Pat. (0 %) nach PG notwen-
ÖKG-Jahrestagung 2012 – Abstracts
dig (p = 0,041). Erythrozytenkonzentrate waren nach PS bei 9/31
Pat. (29 %) und nach PG bei 2/20 Pat. (10 %) erforderlich (p = 0,09).
Ein Pat. mit PS verstarb am Tag 20 nach einer chirurgischen Revision wegen einer Nachblutung. Die 30-Tage-Mortalität (PS: 3.2 %,
PG: 0 %) und die Aufenthaltsdauer auf der Intensivstation (PS: 4,8 ±
4,0 Tage, PG: 4,7 ± 2,2 Tage) waren nicht-signifikant unterschiedlich.
Diskussion Der Verschluss der femoralen Punktionsstelle mittels
PG anstelle von PS geht nach unserer Erfahrung mit weniger Blutungskomplikationen, einer reduzierten Notwendigkeit einer gefäßchirurgischen Korrektur und mit einer geringeren residualen Gefäßstenose einher.
Severe Asymptomatic Aortic Stenosis in an Elderly
R. Zilberszac, H. Gabriel, G. Maurer, R. Rosenhek
Klinische Abteilung für Kardiologie, Universitätsklinik für Innere Medizin,
Medizinische Universität Wien
Background The aim of the present study was to assess the natural
history of severe asymptomatic AS in a large cohort of elderly patients
older than 70 years. As life expectancy in the western world climbs,
calcific aortic stenosis (AS) has become more frequent since its prevalence continuously increases with age. This results in large numbers
of elderly patients receiving aortic valve interventions. However,
these patients are underrepresented in most natural history studies on
AS where the average age of patients is between 60 and 70 years.
Methods 103 consecutive elderly patients (51 female, age 77 ±
5 yrs) with asymptomatic severe AS defined by a peak aortic jet ve-
 Nachträglich erhalten
Multiple Arterial Revascularization in CABG Surgery
– Investigation of Long-Term Benefit in a Consecutive Cohort of 3129 Patients
E. Ruttmann, H. Ulmer, A. Sakic, N. Fischler, H. Alber, M. Wanitschek,
O. Pachinger, R. Schistek, M. Grimm, O. Chevtchik
Department of Cardiac Surgery; Department of Cardiology, Innsbruck Medical University, Department of Medical Statistic, Informatics, and Health Economy Innsbruck
Objective Lacking utilization of accompanying arterial grafts to a
left internal thoracic artery (LITA) in CABG surgery appear to be
based on the lack of conviction regarding any long-term benefit.
Aim of our study was to investigate whether multiple arterial
revascularization (MAR) has an impact on survival after CABG.
Methods A consecutive series of 3129 patients undergoing first,
isolated, non-emergent multivessel CABG procedure receiving at
least 2 arterial grafts from 2001 to 2010 was investigated. MAR was
performed in 1068 patients (34.1%) using radial artery in 791 patients (25.3%) and a second ITA graft in 344 patients (11%). The
remaining 2061 patients received single ITA and concomitant SVG
(conCABG group). Proportional hazard model was performed to
estimate independent predictors for survival.
Results Median follow up was 56.9 months in the MAR group and
44.5 months in the conCABG group (p < 0.001). Baseline characteristics were different regarding age, gender, smoking, cerebro- and
peripheral vascular (all < 0.001), and pulmonary disease (p = 0.04).
Actuarial survival at 1, 3, and 5 years was 98.3%, 97.7%, and 96.5%
in the MAR group compared to 97.1%, 93,1%, and 92.1% in the
conCABG group.
MAR remained a strong independent predictor for long term survival (Hazard Ratio HR: 0.65; 0.45–0.95; p = 0.02). Additionally
cerebro-vascular events (HR: 2.1; 1.3–3.5; p = 0.003) and peripheral
arterial disease (HR:2.5; 1.9–3.5; p < 0.001) revealed significant
factors for survival beside age (3.2% increase/year; 1.01–1.05;
p < 0.001). Multivariate analysis revealed an absolute mortality reduction of MAR of 2.5% and 4% at 5 and 8 years after CABG.
locity (Vmax) ≥ 4.0 m/s (average peak Vmax 4.75 ± 0.57 m/s, mean gradient 58 ± 17 mmHg, valve area 0.70 ± 0.20 cm2) were included and
followed at regular intervals. Patients with other significant valve
lesions or concomitant aortic regurgitation were excluded. Outcome
was assessed and event-free survival with events defined as development of criteria warranting aortic valve replacement or cardiac
death was determined. All of the patients in this series had moderately-to-severely calcified aortic valves.
Results During a mean follow-up of 19.4 (IQR 9.8–36.4) months,
82 patients developed criteria warranting aortic valve replacement
and 15 patients died. Event-free survival rates after 1, 2, 3 and 4
years were 72%, 44%, 23%, and 16% respectively and were not significantly different for patients younger or older than 80 years.
Event-free survival was significantly worse for patients with an AVVel ≥ 5.0 m/s with respective event-free survival rates of 51 ± 8%,
21 ± 6%, 12 ± 5% and 3 ± 3% at 1, 2, 3 and 4 years respectively, as
compared to 83 ± 5%, 55 ± 6%, 37 ± 6% and 23 ± 8% for patients
with an AV-Vel < 5.0 m/s. 7 cardiac deaths (2 myocardial infarction
and 5 cardiac decompensation) occurred after a mean of 6.3 ± 5.1
months after the last follow-up visit where the patients were reportedly asymptomatic. 3 of these pts had a restricted mobility due to
comorbidities. There were five perioperative deaths among 72 patients who underwent aortic valve replacement, while 10 patients
refused surgery. Postoperative survival rates were 89%, 81%, 77%
and 66% after 1, 2, 3 and 4 years respectively.
Conclusion In elderly asymptomatic patients with severe aortic
stenosis, a very high event rate can be expected. Symptomatic status
is often difficult to assess due to comorbidities and patients are at
high risk of rapid deterioration and death. Surgical outcomes are
good and risk stratification based on peak aortic jet velocity may
also be helpful in elderly patients with severe AS.
Conclusion The result of our study implies that MAR should be
the standard-of-care and survival benefit seems to widen over time.
Spontaneous Gross Hematuria During Dabigatran
Therapy for Secondary Stroke Prevention
C. Stöllberger, St. Rakusan, E. Sehnal, F. Wimpissinger, J. Finsterer
2. Medizinische Abteilung, Krankenanstalt Rudolfstiftung, Wien
Background Dabigatran is an oral thrombin inhibitor, approved
in several countries for prevention of stroke/embolism in atrial fibrillation as an alternative to vitamin-K-antagonists (VKAs) although important issues have not been clarified, as illustrated by the
following case.
Case Report An 85-year old man with gross hematuria had a history of hypertension, atrial fibrillation, chronic obstructive pulmonary disease, renal failure, metastatic prostate cancer and non-disabling stroke. Despite well-controlled VKA-therapy, two further
non-disabling ischemic strokes occurred, and anticoagulation
therapy was switched from phenprocoumon to dabigatran assuming
that dabigatran would be indicated in a case of “VKA-failure”. Since
the glomerular filtration rate was 38 ml/min/1.73 m2 dabigatran 110
mg/bid was prescribed.
Following antibiotic therapy of an urinary tract infection, the patient
suffered from diarrhea and loperamide 2 mg bid for 2 days was prescribed. Two days later gross hematuria started. Dabigatran was
stopped after the patient had taken the last dose in the morning of
day 1. Hematuria persisted, necessitating 2 blood transfusions. On
cystoscopy no bleeding source was identified. The thrombin time
was 75 sec even 31 hours after intake of the last dabigatran dose. To
stop bleeding, 4 units of fresh frozen plasma were given. On day 3,
hematuria ceased and eventually the patient was discharged with
Dabigatran in patients with carcinoma and P-gp-affecting drugs may cause major bleeding. There is a need for monitoring tools of the anticoagulant status of patients receiving
dabigatran in bleeding situations, an antidote and research about
drug-drug interactions and urological side effects.
J KARDIOL 2012; 19 (5–6)
(nur Erstautoren)
Ablasser K. ........................................... 130
Jarai R. .......................................... 124 (2×)
Bader K. ............................................... 131
Badr Eslam R. ...................................... 143
Beer L. .................................................. 131
Blessberger H. ...................................... 160
Bonaros N. ................................... 189 (2×)
Brandt M. C. ........................................ 160
Christ G. ............................................... 161
Colantonio C. ............................... 149 (2×)
Kammerlander A. ................................. 191
Kaulfersch C. ....................................... 125
Keller H. ............................................... 178
Kleber M. E. ......................................... 185
Klug G. ................................. 144, 146 (2×)
Kohl S. .................................................. 179
Köllerer Ch. .......................................... 163
Kos C. ................................................... 185
Krenn L. C. ........................................... 164
Krychtiuk K. A. .................................... 134
Danmayr F. ........................................... 172
Darabi T. ............................................... 131
Demyanets S. ............................... 123 (2×)
Derndorfer M. .............................. 172, 174
Dolliner P. ............................................. 154
Dörler J. ................................................ 123
Dumfarth J. ........................................... 190
Leibl M. ................................................ 164
Leitner L. .............................................. 185
Lichtenauer M. ..................................... 134
Ebner Ch. ............................. 155, 161, 190
Eder V. .................................................. 190
Fandl T. .................................................
Fiedler L. ..............................................
Freudenthaler B. ...................................
Frey B. ..................................................
Freynhofer M. ......................................
Frick M. ................................................
Friedrich G. ..........................................
Friedrich O. ..........................................
Fruhwald F. ..........................................
Furtner M. ............................................
Gangl C. ...............................................
Gasser R. ..............................................
Gasser S. ...............................................
Gatterer E. ............................................
Gieseking E. .........................................
Gyöngyösi M. ......................................
Hammerer M. ....................................... 162
Haubner B. J. ................................ 133 (2×)
Heinz A. ................................................ 191
Hemetsberger R. ................................... 163
Holfeld J. ...................................... 133, 134
Höllerl F. .............................................. 176
Hönig S. ............................................... 176
Hörmann P. ........................................... 151
J KARDIOL 2012; 19 (5–6)
Scherzer S. ................................... 166 (2×)
Schickmaier Th. ................................... 151
Schoenleitner P. .................................... 139
Schönbauer R. .............................. 180, 181
Schratter A. ........................................... 181
Schreiber C. .......................................... 139
Schwarzl M. ................................. 140 (2×)
Siekmeier R. ................................. 152 (2×)
Sigmund E. ........................................... 182
Sipötz J. ................................................ 166
Sponder M. ........................... 153, 187 (2×)
Steinacher R. ........................................ 126
Steinwender C. ..................................... 182
Steringer-Mascherbauer R. .................. 153
Stöger M. .............................................. 182
Stöllberger C. ....................... 153, 183, 193
Strobl M. S. .......................................... 141
Sturmberger Th. ................................... 158
Mahr St. ........................................ 148, 156
Mangold A. ................................... 125 (2×)
Martinek M. ................................. 179, 180
Marzluf B. ............................................ 146
Mayr A. ................................................ 147
Mitterbauer A. ...................................... 136
Motloch L. J. ................................ 136, 165
Muendlein A. ........................................ 137
Müller L. .............................................. 192
Tajsic M. ............................................... 127
Tentzeris I. ............................................ 187
Tilz R. ................................................... 183
Tomaschitz A. ............................... 158, 188
Tscherner M. ........................................ 154
Tufaro C. .............................................. 171
Ucar-Altenberger H. ............................. 128
Unterhuber M. ...................................... 168
Niebauer J. ........................................... 170
Niederau M. ......................................... 157
Pätzold S. .............................................
Petener D. .............................................
Pilgerstorfer L. .....................................
Plass C. .................................................
Platzer V. ..............................................
Preis N. .................................................
Rammer M. .......................................... 170
Reda S. ................................................. 166
Reiner M. .............................................. 137
Riedlbauer R. ....................................... 180
Rottländer D. ........................ 138 (2×), 171
Ruisz W. ............................................... 151
Ruttmann E. ................................. 170, 193
van Tulder R. ................................ 128, 154
Verderber J. .......................................... 159
Von der Heidt A. .................................. 159
Vonbank A. ................................... 129, 188
Wallner M. ............................................ 141
Watzke L. ............................................. 141
Weihs W. ............................................... 147
Weiler H. ...................................... 142 (2×)
Weiss T. ........................................ 188, 189
Winter A. .............................................. 168
Winter S. ............................................... 183
Wolber T. .............................................. 184
Wolf St. ................................................ 142
Wurm R. ............................................... 130
Sacherer M. .......................................... 138
Saely Ch. H. ................. 171 (2×), 186 (2×)
Santer D. ............................................... 139
Saurer G. .............................................. 157
Zechner P. ............................................. 147
Zeindlhofer E. ...................... 168, 192 (2×)
Zilberszac R. ........................................ 193
Zweiker D. .................................... 143, 169
Zweimüller M. ..................................... 195
Beziehen Sie die elektronischen Ausgaben unserer Zeitschriften kostenlos.
Die Lieferung umfasst 4–6 Ausgaben pro Jahr zzgl. allfälliger Sonderhefte.
Unsere e-Journale stehen als PDF-Datei zur Verfügung und sind auf den meisten
der marktüblichen e-Book-Readern, Tablets sowie auf iPad funktionsfähig.
Bestellung kostenloses e-Journal-Abo
Besuchen Sie unsere zeitschriftenübergreifende Datenbank
Besuchen Sie unsere Rubrik Medizintechnik-Produkte
Führungsdraht Radifocus
Glidewire Advantage &
Supportkatheter Navicross
Terumo Deutschland GmbH
Siemens AG Österreich
IntelliSpace Cardiovascular
Philips Austria GmbH,
boso ABI-system 100
Boso GmbH & Co KG
Itrevia 7-Serie
BIOTRONIK Vertriebs-GmbH
Die neue Rubrik im Journal für Kardiologie: Clinical Shortcuts
In dieser Rubrik werden Flow-Charts der Kardiologie kurz und bündig vorgestellt
Bisher erschienen:
 Diagnose und Therapie der
 Interventionelle kathetergestützte
 Diagnose und Therapie der
 Einsatz einer perioperativen Blockertherapie
chronischen Herzinsuffizienz
J Kardiol 2014; 21 (1–2): 50–55.
J Kardiol 2014; 21 (5–6): 154–60.
Aortenklappenimplantation (TAVI)
J Kardiol 2014; 21 (11–12): 334–7.
zur Reduktion von Morbidität und Mortalität
J Kardiol 2015; 22 (1–2): 38–40.